<?xml version="1.0" encoding="Windows-31J"?>
<ArticleSet xmlns="http://www.openarchives.org/OAI/2.0/">
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0309-0167</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinicopathological and transcriptomic profiles of 101 patients with diffuse large B-cell lymphoma/high-grade B-cell lymphoma with double-hit MYC and BCL2 or BCL6 and triple hit</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Miyaoka</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joaquim</FirstName>
        <LastName>Carreras</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yara Yukie</FirstName>
        <LastName>Kikuti</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruka</FirstName>
        <LastName>Ikoma</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Nagase</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Pathology, School of Medicine Tokai University  Isehara Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Orita</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Hematology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Medical Oncology, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Tsukasaki</LastName>
        <Affiliation>Department of Hematology, International Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuji</FirstName>
        <LastName>Momose</LastName>
        <Affiliation>Department of Pathology, Saitama Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Kameoka</LastName>
        <Affiliation>Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Hematology, Osaka City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Satou</LastName>
        <Affiliation>Department of Surgical Pathology, Aichi Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiichi</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Center for Clinical Pathology, Fujita Health University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Oishi</LastName>
        <Affiliation>Department of Pathology, University of Yamanashi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akio</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Hematology, NHO Shibukawa Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Division of Hematology, Kawasaki Municipal Kawasaki Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Masugi</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathology, School of Medicine, Tokai University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims: Diffuse large B-cell lymphoma/high-grade B-cell lymphoma (DLBCL/HGBCL) with MYC and BCL2 rearrangements (double-hit lymphoma with BCL2, DHL-BCL2) is a mature aggressive B-cell lymphoma that also includes concurrent triple hit with BCL6 translocation (TH). DHL with MYC and BCL6 (DH-BCL6) can also occur. The differences among these three DLBCL/HGBCL subtypes have not yet been definitively determined.&lt;br&gt;
Methods and Results: This study characterized the clinicopathological features and transcriptomic profiles of a series of 101 cases of DLBCL/HGBCL that were subclassified according to MYC, BCL2 and BCL6 FISH data, including cell-of-origin (COO)-like, molecular high-grade (MHG)-like and double-hit/dark-zone (DHIT/DZsig)-like signatures. DLBCL/HGBCL-DH-BCL2 was characterized by higher HGBCL morphology, CD10 positivity, GCB Hans's, GCB COO and MHG molecular subtype. DLBCL/HGBCL-TH had higher LDH levels and worse overall survival. DLBCL/HGBCL-DH-BCL6 had higher MUM1 expression, non-GCB Hans', ABC/Unclassified COO, non-MHG and low DHIT/DZ signatures. Transcriptomic analysis showed that DLBCL/HGBCL-DH-BCL2 and DLBCL/HGBCL-TH were close but separated from DLBCL/HGBCL-DH-BCL6. Gene set enrichment analysis (GSEA) revealed different levels of enrichment between the subtypes.&lt;br&gt;
Conclusions: DLBCL/HGBCL-DH-BCL6 differs from the DLBCL/HGBCL-DH-BCL2, and the DLBCL/HGBCL-TH is associated with the worst survival. Analysis of all three genes of MYC, BCL2 and BCL6 is recommended in the context of DLBCL/HGBCL diagnosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">BCL2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">BCL6</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">high-grade B-cell lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecular profile</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MYC</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rearrangements</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2688-4046</Issn>
      <Volume>6</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>PPy]Coated Wire Actuators for the Micromechanostimulation of Cells: Fabrication and Characterization</ArticleTitle>
    <FirstPage LZero="delete">e202500639</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Amaia B.</FirstName>
        <LastName>Ortega]Santos</LastName>
        <Affiliation>Sensor and Actuator Systems, Department of Physics Chemistry and Biology (IFM), Link&#246;ping University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Hayano</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emilio Satoshi</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Advanced Research Center for Oral and Craniofacial Sciences Dental School, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jose G.</FirstName>
        <LastName>Mart&#237;nez</LastName>
        <Affiliation>Sensor and Actuator Systems, Department of Physics Chemistry and Biology (IFM), Link&#246;ping University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kamioka</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Edwin W. H.</FirstName>
        <LastName>Jager</LastName>
        <Affiliation>Sensor and Actuator Systems, Department of Physics Chemistry and Biology (IFM), Link&#246;ping University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cellular mechanotransduction signals play a crucial role in physiological and pathological conditions, including skeletal disorders. Although various systems exist to mechanically stimulate cultured cells, most are constrained by incubator incompatibility, limited physiological relevance, nonuniform stimulation, or complexity. The objective of this article is to develop and validate a compact, incubator-compatible tool capable of delivering localized and physiologically relevant mechanical stimulation to small cell populations. Here, we introduce a polypyrrole-based wire-shaped microactuator designed to induce localized mechanical stress to adjacent cells. These wire-shaped microactuators are biocompatible, easy-to-use, and compact for use within standard in vitro cell culture systems. Using a noncontact optical method, we characterize the actuation of polypyrrole-coated wires in an aqueous NaDBS electrolyte, showing radial expansion of 1.5&#8211;8&#8201;&#181;m depending on the deposited polypyrrole film thickness, comparable to cellular dimensions. Next, the actuation is confirmed to be robust and stable to use in cell culture media at physiological temperature. To evaluate biological relevance, osteoblastic KUSA-A1 cells are mechanically stimulated inside the incubator and transcriptomic changes are assessed. Mechanical stimulation resulted in upregulation of genes previously associated with mechanotransduction, including Fos and Fosb. Additionally, several uncharacterized long noncoding RNAs are differentially expressed, suggesting potential novel players in the mechanotransduction pathway.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">conducting polymers</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mechanotransduction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osteoblasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">polypyrrole</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RNA sequencing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">soft-microactuators</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1467-5463</Issn>
      <Volume>27</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>SGCRNA: spectral clustering-guided co-expression network analysis without scale-free constraints for multi-omic data</ArticleTitle>
    <FirstPage LZero="delete">bbag021</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsunori</FirstName>
        <LastName>Osone</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Takao</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeo</FirstName>
        <LastName>Otake</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Takarada</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Weighted gene co-expression network analysis (WGCNA) is among the most widely employed methods in bioinformatics. WGCNA enables the identification of gene clusters (modules) exhibiting correlated expression patterns, the association of these modules with traits, and the exploration of candidate biomarker genes by focusing on hub genes within the modules. WGCNA has been successfully applied in diverse biological contexts. However, conventional algorithms manifest three principal limitations: the assumption of scale-free topology, the requirement for parameter tuning, and the neglect of regression line slopes. These limitations are addressed by SGCRNA. SGCRNA provides Julia functions for the analysis of co-expression networks derived from various types of biological data, such as gene expression data. The Julia packages and their source code are freely available at https://github.com/C37H41N2O6/SGCRNAs.jl.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">co-expression network analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multi-omics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spectral clustering</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0923-1811</Issn>
      <Volume>119</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Big data-driven target identification by machine learning: DRD2 as a therapeutic target for psoriasis</ArticleTitle>
    <FirstPage LZero="delete">9</FirstPage>
    <LastPage>17</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Dermatology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusuke</FirstName>
        <LastName>Sawada</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Otoha</FirstName>
        <LastName>Ichinose</LastName>
        <Affiliation>Department of Bioscience and Bioinformatics, Faculty of Computer Science and Systems Engineering, Kyushu Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Terabayashi</LastName>
        <Affiliation>Department of Pharmacology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Hatano</LastName>
        <Affiliation>Department of Dermatology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Yamanishi</LastName>
        <Affiliation>Department of Complex Systems Science, Graduate School of Informatics, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshimasa</FirstName>
        <LastName>Ishizaki</LastName>
        <Affiliation>Department of Pharmacology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: The development of medical treatments has traditionally relied on researchers leveraging scientific knowledge to hypothesize disease mechanisms and identify therapeutic agents. However, the depletion of novel therapeutic targets has become a significant challenge, resulting in stagnation within pharmaceutical research.&lt;br&gt;
Objective: To address the scarcity of therapeutic targets, we developed a machine learning (ML)-based system capable of predicting therapeutic target molecules for diseases. To validate its utility, we applied this system to psoriasis, aiming to identify novel treatment strategies.&lt;br&gt;
Methods: Our approach utilized a large clinical database to calculate reporting odds ratios for all drugs associated with the prevention of diseases of interest. We identified target proteins by analyzing large chemical structure databases to discover proteins commonly associated with preventive drug candidates. Experimental validation was conducted by administering a predicted therapeutic candidate in an imiquimod-induced psoriasis mouse model.&lt;br&gt;
Results: The ML-based predictions identified drugs for Parkinsonfs disease as potential preventive candidates for psoriasis. Further analysis highlighted dopamine receptor D2 (DRD2) as a therapeutic target. Administration of a DRD2 agonist alleviated psoriasis symptoms in mice, evidenced by the downregulation of mRNA expression in the IL-17 pathway and reduced serum tumor necrosis factor-ƒ¿ levels.&lt;br&gt;
Conclusion: This study demonstrates the utility of a novel ML-based system for identifying therapeutic targets, as shown by its successful application in uncovering the role of DRD2 in psoriasis. Beyond psoriasis, this system offers significant potential for exploring pathological mechanisms and discovering therapeutic targets across various diseases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">big data</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dopamine receptor D2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psoriasis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Chemical Society (ACS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2470-1343</Issn>
      <Volume>11</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Water-Resistant Antibacterial Coatings Using Cetylpyridinium Chloride - Graphene Oxide Composites</ArticleTitle>
    <FirstPage LZero="delete">14570</FirstPage>
    <LastPage>14577</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Okubo</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Field of Medical Development, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gen</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Komoda</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology - Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Nishina</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology - Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hospital-acquired infections remain a persistent threat in healthcare settings, especially with the increasing number of elderly and immunocompromised patients. In situations where the use of disposable materials is difficult, durable antibacterial surface coatings are essential. In this study, we report the structural characterization of cetylpyridinium chloride-graphene oxide (CPC&#8211;GO) hybrid materials and the sustainability of their antibacterial effects, aiming at washable antibacterial coatings for medical applications. Graphene oxide (GO) has a large surface area and numerous functional groups, while cetylpyridinium chloride (CPC) is a quaternary ammonium compound with well-documented antibacterial activity. We hypothesized that the stable incorporation of CPC through the functional groups of GO could improve surface retention and provide long-term antibacterial performance. The structural properties of the CPC&#8211;GO composites were characterized by UV&#8211;vis spectroscopy, X-ray diffraction, thermogravimetric analysis, scanning electron microscopy, and atomic force microscopy. These analyses confirmed the formation of a complex through ionic bonds and the maintenance of a planar composite structure. The antibacterial performance of the CPC&#8211;GO coatings was examined using representative bacteria. Notably, the CPC&#8211;GO coatings maintained their antibacterial activity significantly better than the negative controls even after multiple washings. The excellent surface retention of the CPC&#8211;GO composite suggests its potential as a next-generation antibacterial coating for areas where disinfection and sterilization are impossible, such as the interior of complex medical devices. This study suggests a strategy to extend the efficacy of existing antibacterial agents through the application of nanomaterials. Future studies will focus on the controlled release, long-term stability, and biocompatibility of CPC to realize clinical applications.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2211-7156</Issn>
      <Volume>18</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development of FTase inhibitors inspired by the structures of andrastins</ArticleTitle>
    <FirstPage LZero="delete">102828</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fumino</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Tanioka</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayano</FirstName>
        <LastName>Kosaka</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Matsuzawa</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Obita</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Sakajiri</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Department of Complex Systems Science, Graduate School of Informatics, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusuke</FirstName>
        <LastName>Sawada</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Kohyama</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Yamanishi</LastName>
        <Affiliation>Department of Complex Systems Science, Graduate School of Informatics, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mineyuki</FirstName>
        <LastName>Mizuguchi</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Matsuya</LastName>
        <Affiliation>Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We designed and synthesized structurally simple farnesyl transferase (FTase) inhibitors (1a&#8211;1d) by leveraging andrastin, a natural product with FTase inhibitory activity. 1a&#8211;1d possess a cyclopentane-1,3-dione core, which is critical for FTase recognition; a farnesyl moiety, which is a simplified motif of A to C rings of andrastin; and a carboxylic acid or methoxycarbonyl group, which enables multipoint hydrogen bonding interactions with FTase. Competitive inhibition experiments revealed that 1d has the most potent FTase inhibitory activity. Docking simulation analysis of 1a&#8211;1d with FTase suggested that the multipoint hydrogen bonding interactions between the cyclopentane-1,3-dione moiety and the carboxyl group play an important role in FTase recognition.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Andrastin analogs</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Farnesyl transferase (FTase) inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hydrogen bonding interactions</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cyclopentane-1,3-dione</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Molecular docking</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0012-1592</Issn>
      <Volume>68</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Simple Method for RNA-Seq of Manually Isolated Chromatophores in Oryzias Fishes</ArticleTitle>
    <FirstPage LZero="delete">e70044</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Goda</LastName>
        <Affiliation>Institute of Photonics Medicine, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asuka</FirstName>
        <LastName>Miyagi</LastName>
        <Affiliation>Institute of Photonics Medicine, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Sugiwaka</LastName>
        <Affiliation>Department of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakatsu</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Cellular and Structural Physiology Institute (CeSPI) and Graduate School of Pharmaceutical Sciences, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Bessho]Uehara</LastName>
        <Affiliation>Frontier Research Institute for Interdisciplinary Science, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiko</FirstName>
        <LastName>Hibi</LastName>
        <Affiliation>Department of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Comparative Genomics Laboratory, National Institute of Genetics</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rieko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>World Medaka Aquarium, Nagoya Higashiyama Zoo and Botanical Gardens</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kawilarang W. A.</FirstName>
        <LastName>Masengi</LastName>
        <Affiliation>Faculty of Fisheries and Marine Science, Sam Ratulangi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazunori</FirstName>
        <LastName>Yamahira</LastName>
        <Affiliation>Tropical Biosphere Research Center, University of the Ryukyus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Ansai</LastName>
        <Affiliation>Ushimado Marine Institute, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Biological Science, Division of Natural Science, Graduate School of Science, Nagoya University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>RNA sequencing (RNA-seq) has become an essential tool for analyzing gene expression and exploring cell type&#8211;specific transcriptomes. However, sample preparation and quality control remain challenging, as current approaches typically rely on dissecting tissues containing mixed cell populations or using flow cytometry to isolate fluorescently labeled cells. Here we present a simple and reliable method for RNA-seq of chromatophores (pigment cells) by manually isolating cells based on their natural pigmentation. We analyzed four chromatophore types\melanophores, xanthophores, iridophores, and leucophores\in medaka (Oryzias latipes). Remarkably, as few as 100 cells per type yielded reasonably high-quality transcriptomes sufficient to identify differentially expressed genes (DEGs). Furthermore, this method was successfully applied to a non-model medaka species, O. woworae, which shares the same four chromatophore types. Our approach enables efficient, low-cost, and cross-species transcriptome analysis of chromatophores without requiring transgenic markers or flow cytometry.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2572-1143</Issn>
      <Volume>9</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mechanosensitive Ion Channel PIEZO1 Suppresses BMP2-Induced Ossification of the Annulus Fibrosus Cells</ArticleTitle>
    <FirstPage LZero="delete">e70168</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hisakazu</FirstName>
        <LastName>Shitozawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nakamichi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Uotani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Takatori</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutaka</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Science of Functional Recovery and Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Major cause of low-back pain is intervertebral disc degeneration (IVDD), with mechanical stress playing a crucial role in its progression. A mechanosensitive ion channel, PIEZO1, is involved in various musculoskeletal tissues, but its role in the annulus fibrosus (AF) remains unclear. This study aimed to elucidate the function of PIEZO1 in AF cells under mechanical stimulation.&lt;br&gt;
Methods: Primary rat AF cells were subjected to cyclic tensile strain (CTS) at low (2%) and high (12%) strain levels to investigate strain-dependent effects on osteogenic gene expression. We evaluated the effects of Piezo1, Piezo2, and Trpv4 knockdown by RNA interference to identify the upstream mechanotransducer. Furthermore, PIEZO1 was activated using the agonist Yoda1, followed by RNA-sequencing analysis and evaluation of its effects on BMP2-induced osteogenesis in rat AF cells. We also examined the effects of Yoda1 in primary human AF cells.&lt;br&gt;
Results: Low-strain CTS significantly suppressed osteogenic marker expression, which was not observed with high strain. Piezo1 knockdown reversed this suppression, whereas Piezo2 and Trpv4 had no effect. Piezo1 activation by Yoda1 produced similar anti-osteogenic effects in both rat and human AF cells. RNA sequencing revealed the enrichment of ossification and calcineurin signaling pathways in rat cells. Furthermore, Piezo1 activation inhibited BMP2-induced osteogenesis and nuclear translocation of p-Smad1/5/9.&lt;br&gt;
Conclusions: Piezo1 maintains AF cell homeostasis under mechanical stress by suppressing osteogenic changes via calcineurin-mediated inhibition of BMP signaling, which may represent a novel therapeutic target for IVDD.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">annulus fibrosus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">calcification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ossification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PIEZO1</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1547-5271</Issn>
      <Volume>22</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Aging of the tricuspid valve annulus detected by photon-counting detector computed tomography: Importance of aortic root compression on occurrence of arrhythmias</ArticleTitle>
    <FirstPage LZero="delete">e772</FirstPage>
    <LastPage>e780</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Nagase</LastName>
        <Affiliation>Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihisa</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuro</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Ueoka</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saori</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norihisa</FirstName>
        <LastName>Toh</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiro</FirstName>
        <LastName>Nishii</LastName>
        <Affiliation>Department of Cardiovascular Therapeutics, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine and Dentistry</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background The aortic root compresses the heart in elderly patients, potentially influencing the conduction system and causing atrial tachyarrhythmias. However, actual anatomic alterations in the right side of the heart because of aortic root compression have not yet been fully evaluated.&lt;br&gt;
Objective This study aimed to elucidate the alterations in the tricuspid valve annulus (TVA) caused by aortic root compression using a 3-dimensional endoscopic view of the heart constructed by photon-counting detector computed tomography, an emerging medical technology.&lt;br&gt;
Methods We analyzed 147 consecutive patients who underwent photon-counting detector computed tomography at our institute after excluding those with diseases that directly influenced the right side of the heart.&lt;br&gt;
Results Aortic root compression caused significant TVA deformation. We defined severe TVA compression as the length of the TVA compressed by the aortic root &#8805;80% of the major axis of the TVA. Severe compression was more prevalent in elderly patients (age &#8805;75 years [44%]; P &lt; .01). The distance between the membranous septum and ostium of the coronary sinus was shortened, whereas the cavotricuspid isthmus was elongated in older patients. The regression analysis identified aging as a significant contributor to TVA compression. The short minor and long major axes of the TVA, incidence of atrial tachyarrhythmias (74% vs 45%; P &lt; .01), and atrioventricular conduction disturbances (35% vs 15%; P &lt; .01) were more frequently observed in patients with severe compression.&lt;br&gt;
Conclusion Aortic root compression deforms the TVA and alters the anatomic relationship between the atrioventricular conduction system and the cavotricuspid isthmus. Therefore, aortic root compression may contribute to the occurrence of atrial tachyarrhythmias and conduction disturbances in older patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Tricuspid valve annulus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Aortic root</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Photon-counting detector computed tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Atrial tachyarrhythmia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Conduction abnormality</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1478-811X</Issn>
      <Volume>24</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>MMP-3 cleavage of Lamin A induces pro-migratory nuclear deformity, nucleophagy, and their autophagic secretion with extracellular vesicles in metastatic cancer</ArticleTitle>
    <FirstPage LZero="delete">146</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eman A.</FirstName>
        <LastName>Taha</LastName>
        <Affiliation>Department of Biochemistry, Faculty of Science, Ain Shams University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vikas</FirstName>
        <LastName>Tiwari</LastName>
        <Affiliation>Council of Scientific &amp; Industrial Research-Indian Institute of Toxicological Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuki</FirstName>
        <LastName>Takebe</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lizi</FirstName>
        <LastName>Xing</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiharu</FirstName>
        <LastName>Sogawa</LastName>
        <Affiliation>Department of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniaki</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Dental Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stuart K.</FirstName>
        <LastName>Calderwood</LastName>
        <Affiliation>Division of Molecular and Cellular Biology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that cleave a plethora of substrates, including components of the extracellular matrix and cell-surface-associated proteins, as well as intracellular targets. MMPs have also been found in extracellular vesicles (EVs), such as exosomes. MMP-3 promotes tumor growth, epithelial-to-mesenchymal transition, genome instability, migration, invasion, and metastasis of cancer cells, and nuclear MMP-3 controls gene transcription. Intranuclear proteolysis by MMPs may significantly alter cancer progression. However, the nuclear substrates of MMP-3 have not been well investigated. In this study, we performed proteomic analyses to identify the nuclear substrates and EV proteins regulated by MMP-3. While rabidly metastatic colon cancer (LuM1) three-dimensionally cultured tumoroids secreted EVs containing 30 protein types, including Lamin A (LMNA), MMP-3, fibronectin (FN1), HSPA8 (Hsc70), ƒÀ-actin (ACTB), and vimentin (VIM), CRISPR/Cas9-based knockout of MMP-3 reduced the secretion of these proteins in EVs. Notably, EV-bound cleaved Lamin secretion was confirmed by immunoelectron microscopy. Also, MMP-3 formed proteolytic dimers via its hemopexin-like repeat domains in nuclei. Many nuclear MMP-3-binding proteins, including Lamin A/C, histones, topoisomerases, and hnRNPs, were screened by co-immunoprecipitation followed by proteomics. Proteolytic MMP-3 overexpression generated a C-terminal 30-kDa fragment of Lamin A, whose cleavage site was defined via structural analysis. MMP-3 digestion of Lamin A induced nuclear deformity (atypia) required for cell migration in confined space. The cleaved Lamin A and MMP-3 were transported with autophagosomes (LC3B+), nucleophagosomes, and amphisomes (CD63&#8201;+&#8201;LC3B+) and co-secreted with EVs. Proteolytic MMP-3 also induced nuclear speckles of Lamin A, suggesting their roles in transcription and splicing. Clinical analysis revealed that high expressions of MMP3 and LMNA were significantly seen in head and neck squamous cell carcinoma (HNSC) than in the other 16 cancer types, and predicted poor prognosis of patients suffering from HNSC, pancreatic, rectum and lung adenocarcinomas at specific stages. Immunohistochemistry revealed that nuclear MMP-3 and cleaved Lamin were significantly higher expressed in stage IV metastatic HNSC cases than in stage I non-metastatic cases. Taken together, MMP3-cleavage of Lamin A induces nuclear deformity, nucleophagy, and their autophagic co-secretion with EVs in metastatic cancer. Also, high expression of MMP-3 and secretion of Lamin A can predict poor prognosis in multiple cancer types at specific stages.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Lamin A (LMNA)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Matrix metalloprotease (MMP)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteolysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Extracellular vesicle (EV)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exosome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Autophagy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Amphisome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nuclear deformity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Migration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metastatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Head and neck squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Colorectal cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2056-5933</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dental infection is associated with early relapse in patients with ANCA-associated vasculitis</ArticleTitle>
    <FirstPage LZero="delete">e006392</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Nawachi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Katsuyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshia</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Moe</FirstName>
        <LastName>Sakamoto-Tokunaga</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuki</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Terajima</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Hirose</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takato</FirstName>
        <LastName>Nakadoi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manami</FirstName>
        <LastName>Hirata-Watanabe</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keigo</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruki</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eri</FirstName>
        <LastName>Katsuyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mariko</FirstName>
        <LastName>Takano-Narazaki</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigetomo</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-Ei</FirstName>
        <LastName>Sada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic autoimmune disease where infections can trigger relapses. Dental infections, being common and associated with systemic inflammation, may play a role in AAV relapse, though their impact remains unclear. We aimed to evaluate the association between severe dental infections and early relapse in patients with AAV.&lt;br&gt;
Methods This retrospective cohort study included patients newly diagnosed with AAV between January 2011 and July 2022. Patients with severe dental infections requiring tooth extraction were placed in the dental infection group, while the remaining patients were assigned to the control group. The primary outcome was defined as either vasculitis relapse or all-cause mortality within 1 year of treatment initiation. Adjusted HRs (aHRs) and 95% CIs were estimated using Cox proportional hazards models.&lt;br&gt;
Results A total of 93 patients were enrolled with a median age of 74 years. 41 patients (44.1%) had severe dental infections in this cohort. Over the 1-year follow-up period, 13 patients experienced a relapse and two died, resulting in a composite event rate of 20.9 per 100 person-years. Dental infection was independently associated with the composite outcome (aHR, 3.78 (95% CI 1.13 to 12.66); p=0.031). Exploratory analysis indicated that composite outcome rates were similar regardless of tooth extraction among patients with dental infections.&lt;br&gt;
Conclusions Severe dental infections were associated with increased risk of early relapse or mortality in AAV. These findings highlight the importance of early dental evaluation in AAV management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>JMIR Publications Inc.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2369-3762</Issn>
      <Volume>12</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prescription Support Practice for Pharmacy Students: Pre-Post Educational Intervention Study</ArticleTitle>
    <FirstPage LZero="delete">e79545</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuka</FirstName>
        <LastName>Aizawa</LastName>
        <Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Higashionna</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shimon</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuaki</FirstName>
        <LastName>Shinomiya</LastName>
        <Affiliation>Department of Pharmaceutical Care and Clinical Pharmacy, Tokushima Bunri University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Niimura</LastName>
        <Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Goda</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Ishizawa</LastName>
        <Affiliation>Clinical Research Center for Developmental Therapeutics, Tokushima University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: In the field of team-based care, pharmacists are vital for optimizing medication therapy. However, many medical professionals lack the opportunity to learn how to propose prescription changes with precision.&lt;br&gt;
Objective: This study aimed to address this knowledge gap by developing and assessing a new educational program for pharmacy students focused on prescription support and interprofessional collaboration.&lt;br&gt;
Methods: We recruited 191 fifth-year pharmaceutical students during the 2022]2024 academic years. The program featured a 7-day intensive curriculum that included learning how to assist with prescriptions, analyzing clinical data, and engaging in role-playing exercises. A web-based questionnaire and a paper test were used to evaluate studentsf awareness and knowledge both before and after the program. Statistical analyses were performed to verify the significance of changes; we utilized the Wilcoxon signed-rank test for the ordinal data derived from the specific behavioral objectives and 2-tailed paired t tests for the interval data from the knowledge tests. The magnitude of change was quantified using r for Wilcoxon tests and Cohen dz for 2-tailed t tests, with 95% CI calculated to ensure the stability and reliability of the observed results.&lt;br&gt;
Results: Analysis of the primary outcome specific behavioral objectives revealed statistically significant effects across all items (Wilcoxon signed-rank test; P&lt;.001). Effect sizes (r=0.505]0.835) ranged from moderate to large, with particularly large effects observed in identifying contents issue (r=0.835, 95% CI 0.126-0.330; P&lt;.001). Knowledge test scores showed significant improvement in the following 3 subjects: pharmacology (r=|0.504, 95% CI &#8211;0.215 to 0.127; P&lt;.001), organic chemistry (r=0.254, 95% CI &#8211;0.148 to &#8211;0.193; P=.004), and communication (r=0.221, 95% CI &#8211;0.151 to &#8211;0.190; P=.01). No significant changes were observed in pathology or pharmacokinetics.&lt;br&gt;
Conclusions: This program provides strong evidence that practical, hands-on learning with hospital pharmacists helps improve pharmacy studentsf professional skills and optimize pharmaceutical therapies in interprofessional care. By teaching pharmacists to effectively propose prescription changes, the program equips them to become integral members of interprofessional care, ultimately leading to optimized pharmaceutical care for patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">academic detailing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pharmaceutical clinical practice</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prescription support</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">professional education</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interprofessional care</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Clinical Investigation</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-3708</Issn>
      <Volume>11</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Collagen-binding C-type natriuretic peptide enhances chondrogenesis and osteogenesis</ArticleTitle>
    <FirstPage LZero="delete">e198959</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Sawamura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusaku</FirstName>
        <LastName>Esaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusuke</FirstName>
        <LastName>Sawada</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Okusha</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Aoyama</LastName>
        <Affiliation>Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Dental School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiko</FirstName>
        <LastName>Mima</LastName>
        <Affiliation>Department of Medical Technology, Faculty of Health Sciences, Ehime Prefectural University of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Biochemistry and Molecular DentistryBacteriology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Tsukahara</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Imagama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Hosono</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>C-type natriuretic peptide (CNP) is known to promote chondrocyte proliferation and bone formation; however, CNPfs extremely short half-life necessitates continuous intravascular administration to achieve bone-lengthening effects. Vosoritide, a CNP analog designed for resistance to neutral endopeptidase, allows for once-daily administration. Nonetheless, it distributes systemically rather than localizing to target tissues, which may result in adverse effects such as hypotension. To enhance local drug delivery and therapeutic efficacy, we developed a potentially novel synthetic protein by fusing a collagen-binding domain (CBD) to CNP, termed CBD-CNP. This fusion protein exhibited stability under heat conditions and retained the collagen-binding ability and bioactivity as CNP. CBD-CNP localized to articular cartilage in fetal murine tibiae and promoted bone elongation. Spatial transcriptomic analysis revealed that the upregulation of chondromodulin expression may contribute to its therapeutic effects. Treatment of CBD-CNP mixed with collagen powder to a fracture site of a mouse model increased bone mineral content and bone volume compared with CNP-22. Intraarticular injection of CBD-CNP to a mouse model of knee osteoarthritis suppressed subchondral bone thickening. By addressing the limitations of CNPfs rapid degeneration, CBD-CNP leverages its collagen-binding capacity to achieve targeted, sustained delivery in collagen-rich tissues, offering a promising strategy for enhancing chondrogenesis and osteogenesis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1462-8910</Issn>
      <Volume>27</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>D3 lymph node dissection in colon cancer patients aged 90&#8201;years and over: Is it justified? A multi]institutional retrospective study</ArticleTitle>
    <FirstPage LZero="delete">e70269</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Setouchi Colorectal Neoplasm Registration study group collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aim: The oncological benefit of D3 lymph node dissection (D3 LND) for colon cancer in patients aged &#8805;90&#8201;years remains unclear. This study aimed to evaluate the impact of D3 LND on outcomes in this specific, vulnerable population.&lt;br&gt;
Method: This retrospective cohort study evaluated 166 patients aged &#8805;90&#8201;years with pathological Stages II&#8211;III colon cancer undergoing non-D3 or D3 LND from a multicentre database (2011&#8211;2022). Postoperative complications, overall survival and cancer-specific survival were compared between LND groups using propensity score-weighted analyses.&lt;br&gt;
Results: D3 LND group had significantly more females and laparoscopic procedures. Operation time was longer, and blood loss was lower in the D3 LND group. Postoperative complications and severe complications were significantly fewer, and postoperative hospital stay was shorter in the D3 LND group. The number of harvested lymph nodes and distal margin was significantly higher in the D3 group. While unadjusted analysis showed better overall survival with D3 LND (p&#8201;&lt;&#8201;0.001), adjusted cancer-specific survival showed no significant difference (p&#8201;=&#8201;0.10). Adjusted mortality risk was significantly higher in the non-D3 group (p&#8201;=&#8201;0.001).&lt;br&gt;
Conclusion: In nonagenarian colon cancer patients, D3 LND is safe and feasible without increasing complications, but lacks survival benefit. Careful consideration is warranted, and high-quality D2 LND must be consistently ensured when limited surgery is chosen.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colon cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lymph node dissection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nonagenarian</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">postoperative complication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">survival benefit</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0385-5600</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Overexpression of Escherichia coli yaiX Confers Multidrug Resistance and Enhances Virulence in the Silkworm Infection Model</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kinuka</FirstName>
        <LastName>Hongu</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Kosaki</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin]Ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Research Center for Intestinal Health Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Furuta</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikara</FirstName>
        <LastName>Kaito</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The emergence of bacteria with both antimicrobial resistance and high virulence has become a global health concern, underscoring the urgent need to elucidate the molecular basis underlying these traits. Here, we employed the silkworm (Bombyx mori) infection model, which is suitable for high-throughput screening, together with an Escherichia coli library containing plasmid clones of all genes from strain W3110, to identify genes whose overexpression enhances virulence. We found that overexpression of the uncharacterized protein YaiX promoted bacterial proliferation in silkworms and increased host lethality. Compared with the empty-vector control, the YaiX-overexpressing strain exhibited resistance to multiple antimicrobial agents with diverse mechanisms of action, including ƒÀ-lactams, tetracyclines, fluoroquinolones, aminoglycosides, cationic surfactants, and hydrogen peroxide. Sequence analysis revealed that amino acids 18&#8211;52 of YaiX contain a transferase hexapeptide domain predicted to form a left-handed parallel ƒÀ-helix. Overexpression of YaiX mutants lacking regions outside this domain conferred ampicillin resistance, whereas deletion of the hexapeptide domain abolished this phenotype. RNA sequencing and GO enrichment analyses further indicated that YaiX overexpression altered the expression of genes encoding RNA-binding proteins and porins. These findings suggest that YaiX overexpression, through its hexapeptide domain, modulates gene expression and contributes to both multidrug resistance and enhanced virulence in E. coli.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Escherichia coli</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hexapeptide domain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multidrug resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pseudogene function</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RNA]seq</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">silkworm infection model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">virulence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">yaiX</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2038-131X</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Early C-reactive protein as a predictive biomarker for postoperative complications following robot-assisted surgery for rectal cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusei</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Okabayashi</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Utsumi</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Miyaso</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Surgery, NHO Fukuyama Medical Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This retrospective cohort study aimed to assess the predictive value of early postoperative C-reactive protein (CRP) levels for complications following robot-assisted rectal surgery (RARS) for rectal cancer. We analyzed data from 117 consecutive patients who underwent elective RARS at Okayama University Hospital between September 2020 and January 2025. Serum CRP levels were routinely measured preoperatively and on postoperative days (POD) 1 and 4. The primary outcome was the occurrence of any postoperative complication within 30 days, classified according to the Clavien&#8211;Dindo grading system. Postoperative complications were observed in 26 patients, representing 22.2% of the cohort. Univariate analysis revealed that several factors were significantly associated with complications, including older age, higher ASA score, neoadjuvant therapy, stoma creation, prolonged operative time, and elevated CRP levels on POD1 and POD4. Notably, multivariate logistic regression analysis identified POD1 CRP as a robust independent predictor of overall postoperative complications (adjusted odds ratio 0.77, 95% confidence interval (CI) [0.63&#8211;0.93], p&#8201;&lt;&#8201;0.01). In the ROC analysis, the AUC was 0.735 (bootstrap bias-corrected 95% CI 0.544&#8211;0.848). The optimal cutoff value of POD1 CRP was 5.63 mg/dl, at which Youdenfs index, yielding a sensitivity of 0.615 and specificity of 0.868. In conclusion, early postoperative measurement of CRP on POD1 serves as a valuable and independent biomarker for predicting complications following RARS for rectal cancer. Incorporating POD1 CRP into postoperative surveillance may facilitate the early identification of high-risk patients, thereby facilitating timely interventions and ultimately improving surgical outcomes in this patient population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Robot-assisted surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Postoperative complication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">C-reactive protein</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0964-2633</Issn>
      <Volume>70</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prevalence and Modifiable Risk Factors of Dementia in People With Down Syndrome: Cross]Sectional Study of Japan in Collaboration With the Intellectual Diversity for Goodness Research Consortium (INDIGO]2019)</ArticleTitle>
    <FirstPage LZero="delete">329</FirstPage>
    <LastPage>336</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Takenoshita</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seishi</FirstName>
        <LastName>Terada</LastName>
        <Affiliation>Department of Neuropsychiatry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taku</FirstName>
        <LastName>Kurozumi</LastName>
        <Affiliation>Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Takaki</LastName>
        <Affiliation>Department of Neuropsychiatry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryozo</FirstName>
        <LastName>Kuwano</LastName>
        <Affiliation>Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Suemitsu</LastName>
        <Affiliation>Asahigawaso Research Institute, Social Welfare Corporation Asahigawaso</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: People with Down syndrome (DS) have a strong genetic predisposition to Alzheimer's disease (AD). However, the clinical burden and associated risk factors in diverse, non-Western populations remain less understood. This study aimed to investigate the prevalence of dementia in Japanese adults with DS and to identify modifiable clinical factors associated with dementia.&lt;br&gt;
Methods: This cross-sectional multicentre study surveyed 133 adults with DS (mean age 50.1&#8201;years) residing in 45 welfare facilities across Japan in 2019. Dementia was diagnosed by a consensus panel of physicians using established criteria (DSM-5, ICD-10, DC-LD) after comprehensive assessments, including the Japanese version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID-J). Logistic regression analysis was performed to identify factors independently associated with dementia.&lt;br&gt;
Results: Forty-six participants (34.6%) were diagnosed with dementia. The prevalence rose sharply with age: 0% in their 30s, 30.8% in their 40s, 31.6% in their 50s and 65.5% in their 60s. After adjusting for covariates, older age, female sex, dyslipidaemia and visual impairment were independently associated with dementia.&lt;br&gt;
Conclusions: This study, the largest of its kind in Asia, confirms a high prevalence of dementia in institutionalized Japanese adults with DS. Crucially, this study is the first to identify dyslipidaemia and visual impairment as independent and potentially modifiable risk factors in this population. These findings highlight tangible targets for clinical interventions aimed at mitigating dementia risk in people with DS.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1863-9941</Issn>
      <Volume>52</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Preferential sacral fracture sites in fragility fractures of the pelvis type IVb and comparison of internal fixation methods: CT-based morphological mapping and finite element analysis</ArticleTitle>
    <FirstPage LZero="delete">72</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Naniwa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Yorimitsu</LastName>
        <Affiliation>Department of Musculoskeletal Traumatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsubasa</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruhiko</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Section of Medicine, Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Fukuoka</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Mochizuki</LastName>
        <Affiliation>Department of Emergency Health Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Yamakawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Hanakawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama Saidaiji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Fragility fractures of the pelvis (FFP) classified as Rommens-Hoffman type IVb are associated with spinopelvic dissociation and are generally considered to require surgical intervention. This study aimed to clarify the localization patterns of FFP type IVb and compare the biomechanical stability of different internal fixation techniques.&lt;br&gt;
Methods In this retrospective study, morphologic mapping of sacral fracture lines was performed in 36 patients with FFP type IVb. Based on the mapping results, a finite element (FE) model of FFP type IVb was developed to evaluate the biomechanical stability of ilio-sacral screw (ISS) fixation, trans-sacral screw (TSS) fixation, spinopelvic fixation (SPF; On each side, L5 pedicle screw was connected to two iliac screws with a rod, and the bilateral constructs were linked using a cross-connector.), and bilateral triangular fixation (one TSS at S1 combined with SPF mentioned above) using finite element analysis (FEA).&lt;br&gt;
Results Morphologic mapping showed that the sacrum fracture transverse line tended to pass between the S1-2 transverse lines. Although bilateral triangular fixation and SPF provided the highest stability in both U-type and H-type fractures, a TSS for U-type and two TSSs for H-type also demonstrated comparable levels of stability. ISS-based methods showed greater displacements.&lt;br&gt;
Conclusion TSS-based fixation may provide stability comparable to bilateral triangular fixation and SPF in FFP type IVb, with less invasiveness when anatomy permits. Further studies are needed to optimize treatment strategies for this complex injury.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Fragility fractures of the pelvis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Spinopelvic dissociation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Finite element analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Internal fixation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1471-2261</Issn>
      <Volume>25</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prognostic value of right atrial strain in patients with chronic heart failure</ArticleTitle>
    <FirstPage LZero="delete">908</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichi</FirstName>
        <LastName>Takaya</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsutaka</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Nishihara</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norihisa</FirstName>
        <LastName>Toh</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miyoshi</FirstName>
        <LastName>Toru</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims Right ventricular dysfunction is a well-established prognostic marker in patients with heart failure (HF). However, the prognostic significance of right atrial (RA) function remains unclear. Given its sensitivity to systemic congestion, RA function may provide additional insights into HF disease progression and management. This study aimed to investigate whether RA reservoir function serves as an independent prognostic indicator in patients with chronic HF.&lt;br&gt;
Methods A total of 613 patients with chronic HF and a left ventricular (LV) ejection fraction of less than 50% who underwent echocardiographic assessment at Okayama University Hospital between January 2018 and March 2023 were included (median age: 68 (58&#8211;76) years; 69% male). RA reservoir function was quantified using two-dimensional speckle-tracking echocardiography. The primary endpoint was cardiovascular death or HF-related hospitalization. Kaplan&#8211;Meier survival analysis was performed to examine the association between RA reservoir function and clinical outcomes.&lt;br&gt;
Results During a median follow-up period of 41 months (range: 12&#8211;91 months), 119 patients experienced cardiac events. Compared with event-free patients, those with cardiac events exhibited a significantly larger RA maximum volume index (38 mL/m2 vs. 31 mL/m2, P&#8201;&lt;&#8201;0.001) and a significantly lower RA reservoir longitudinal strain (RASr) (17% vs. 22%, P&#8201;&lt;&#8201;0.001). Kaplan&#8211;Meier analysis demonstrated that patients with RASr&#8201;&#8804;&#8201;20% had significantly poorer event-free survival than those with RASr&#8201;&gt;&#8201;20%, even without RA volume enlargement (log-rank test, P&#8201;&lt;&#8201;0.001). Multivariate Cox regression analysis identified RASr as an independent predictor of cardiac events (hazard ratio: 0.95, 95% confidence interval: 0.93 to 0.97, P&#8201;&lt;&#8201;0.001).&lt;br&gt;
Conclusions In patients who experienced adverse cardiac events, a reduced RASr and an increased RA maximum volume were observed. Furthermore, a reduced RASr was independently associated with an increased risk of cardiovascular death and HF-related hospitalization in patients with chronic HF and LV dysfunction. These findings indicate that RASr may serve as a valuable prognostic marker for the risk stratification and management of chronic HF.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Right atrial function</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Right atrial strain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chronic heart failure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Echocardiography</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1364-6753</Issn>
      <Volume>27</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Compound heterozygosity of a novel missense variant and exonic deletion in hypomyelinating leukodystrophy 15</ArticleTitle>
    <FirstPage LZero="delete">16</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Orimo</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonari</FirstName>
        <LastName>Seki</LastName>
        <Affiliation>Department of Neurology, Tokyo Teishin Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Shiio</LastName>
        <Affiliation>Department of Neurology, Tokyo Teishin Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Harushi</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Radiology, School of Medicine, Jichi Medical University,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Department of Neurology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hypomyelinating leukodystrophy 15 (HLD15) results from biallelic pathogenic variants in EPRS1, but exonic deletions have not been reported. We describe a 40-year-old woman with mild intellectual disability, ataxia, dystonia, and MRI showing hypomyelination. Whole-exome sequencing identified a heterozygous missense variant in the prolyl-tRNA synthetase domain of EPRS1 (c.3430 C&#8201;&gt;&#8201;G; p.Leu1144Val, NM_004446.3), without second variant. Whole-genome sequencing revealed a heterozygous 220-bp deletion spanning exon 15 (c.1743-30_1932del), and segregation analysis confirmed compound heterozygosity. RT-PCR from lymphoblastoid cells demonstrated exon-15 skipping leading to a frameshift (p.Asn582Serfs*10) and nonsense-mediated decay, leaving predominant expression of the paternally inherited missense allele. These findings support loss-of-function for the deletion and classify c.3430 C&#8201;&gt;&#8201;G as likely pathogenic under ACMG/AMP criteria (PM1, PM2, PM3, PP3). This case represents the first exonic deletion reported in EPRS1. The relatively mild, adult-onset phenotype broadens both mutational and clinical spectra of HLD15 and highlights the importance of structural-variant anal</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Hypomyelinating leukodystrophy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EPRS1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Structural variant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exon deletion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nonsense&#8209;mediated decay</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Whole&#8209;genome sequencing</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2688-4526</Issn>
      <Volume>7</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Safety and efficacy of Rez&#363;m water vapour energy therapy in BPH patients receiving antithrombotic therapy: A Japanese single]centre experience</ArticleTitle>
    <FirstPage LZero="delete">e70170</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takatoshi</FirstName>
        <LastName>Moriwake</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruki</FirstName>
        <LastName>Kaku</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kasumi</FirstName>
        <LastName>Yoshinaga</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Yamanoi</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okamura Isshindo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: The objective of this study is to evaluate the safety and efficacy of Rez&#363;m water vapour energy therapy (WAVE) in Japanese patients with benign prostatic hyperplasia (BPH) continuing antithrombotic therapy and to validate the Okayama University Modified Clavien-Dindo classification (OU-mCD) for perioperative hematuria.&lt;br&gt;
Patients and Methods: We retrospectively analysed 80 consecutive patients who underwent WAVE from August 2023 to July 2024, including 37 (46.2%) continuing antithrombotic therapy perioperatively. Hematuria within 30&#8201;days was graded using conventional Clavien-Dindo classification and the OU-mCD, a novel classification focusing on intervention necessity. We assessed clinically significant hematuria (Grade &#8805; Ib), catheter-free rate, prostate volume reduction and haemoglobin change.&lt;br&gt;
Results: Clinically significant hematuria occurred in 21.6% (8/37) of patients continuing antithrombotic therapy versus 4.7% (2/43) without (p&#8201;=&#8201;0.038). All 10 Grade &#8805; Ib cases occurred during hospitalization with the catheter in place and were managed conservatively with continuous bladder irrigation (median 1 day); none required transfusion or surgical reintervention. Only one patient required temporary drug discontinuation. Treatment efficacy did not differ by antithrombotic status: 86.2% achieved PVR&#8201;&lt;&#8201;50&#8201;ml with 44% mean prostate volume reduction. Multivariate analysis identified antithrombotic therapy as the sole independent risk factor for Grade &#8805; Ib hematuria (OR 5.46, 95% CI 1.06&#8211;28.16, p&#8201;=&#8201;0.042).&lt;br&gt;
Conclusion: WAVE can be safely performed with continued antithrombotic therapy. Whereas Grade &#8805;Ib hematuria occurred in 25% of antiplatelet/anticoagulant users (vs. 5% without), 75% had no significant bleeding, and all complications were managed conservatively without transfusion. The OU-mCD provides precise complication stratification. These findings suggest outpatient procedures may be feasible with appropriate patient selection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">benign prostatic hyperplasia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hematuriaantithrombotic therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japanese</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OU-mCD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">water vapour energy therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Medical Association (AMA)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2574-3805</Issn>
      <Volume>8</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non&#8211;Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials</ArticleTitle>
    <FirstPage LZero="delete">e2543107</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Pasi A.</FirstName>
        <LastName>J&#228;nne</LastName>
        <Affiliation>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Planchard</LastName>
        <Affiliation>Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, Medical Oncology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, Nation Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Egbert F.</FirstName>
        <LastName>Smit</LastName>
        <Affiliation>Department of Pulmonary Diseases, Leiden University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Adrianus Johannes</FirstName>
        <LastName>de Langen</LastName>
        <Affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maurice</FirstName>
        <LastName>P&#233;rol</LastName>
        <Affiliation>Department of Medical Oncology, Centre L&#233;on B&#233;rard</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Enriqueta</FirstName>
        <LastName>Felip</LastName>
        <Affiliation>Department of Medical Oncology, Vall dfHebron University and Vall dfHebron Institute of Oncology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Thoracic Oncology, Aichi Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misako</FirstName>
        <LastName>Nagasaka</LastName>
        <Affiliation>Division of Hematology-Oncology, Department of Medicine, University of California Irvine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaline</FirstName>
        <LastName>Pereira</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Daiichi Sankyo Co Ltd</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ahmed</FirstName>
        <LastName>Ali</LastName>
        <Affiliation>Daiichi Sankyo Europe GmbH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maha</FirstName>
        <LastName>Karnoub</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Yonemochi</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Leung</LastName>
        <Affiliation>Daiichi Sankyo Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bob T.</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Thoracic Oncology and Early Drug Development Service, Global Research Program, Memorial Sloan Kettering Cancer Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Importance  Brain metastases reduce overall survival rates of patients with non&#8211;small cell lung cancer (NSCLC); patients with epidermal growth factor receptor 2 (ERBB2 [formerly HER2])&#8211;mutant NSCLC are more likely to have baseline brain metastases. Trastuzumab deruxtecan (T-DXd) is an approved ERBB2-directed treatment for previously treated unresectable or metastatic ERBB2-mutant NSCLC.&lt;br&gt;
Objective  To assess the clinical effectiveness and safety of T-DXd 5.4 mg/kg and 6.4 mg/kg doses in patients with previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases.&lt;br&gt;
Design, Setting, and Participants  This post hoc secondary analysis pooled patients from the DESTINY-Lung01 (data cutoff date: December 3, 2021) and DESTINY-Lung02 (data cutoff date: December 23, 2022) clinical trials by T-DXd dose (5.4 mg/kg and 6.4 mg/kg). DESTINY-Lung01 was a multicenter, open-label, 2-cohort, nonrandomized phase 2 study, while DESTINY-Lung02 was a dose-blinded, multicenter, 2-cohort, randomized phase 2 study. Participants had a previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases at baseline. All statistical analyses were performed from April 2023 to October 2024.&lt;br&gt;
Intervention  Patients received a T-DXd dose of either 5.4 mg/kg or 6.4 mg/kg intravenously every 3 weeks.&lt;br&gt;
Main Outcome and Measure  Systemic and intracranial effectiveness by blinded independent central review using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1, sites of progression, and safety.&lt;br&gt;
Results  This analysis included 102 patients in the T-DXd 5.4-mg/kg dose group (65 females [64%]; median [range] age, 57.5 [37.0-83.0] years and 59.5 [30.0-79.0] years in patients with and without brain metastases, respectively) and 141 patients in the T-DXd 6.4-mg/kg dose group (94 females [67%]; median [range] age, 62.5 [29.0-88.0] years and 59.0 [27.0-83.0] years in patients with and without brain metastases, respectively). In each group, 31% (32 of 102) and 38% (54 of 141) of patients, respectively, had baseline brain metastases and 53% (17 of 32) and 44% (24 of 54), respectively, received prior brain metastasis treatment. In patients with and without brain metastases, systemic confirmed objective response rates (ORRs) were 47% (15 of 32; 95% CI, 29%-65%) and 50% (35 of 70; 95% CI, 38%-62%), respectively, with the T-DXd 5.4-mg/kg dose, and 50% (27 of 54; 95% CI, 36%-64%) and 59% (51 of 87; 95% CI, 48%-69%) with the T-DXd 6.4-mg/kg dose. Median progression-free survival was 7.1 (95% CI, 5.5-9.7) months in the T-DXd 5.4-mg/kg dose group and 7.1 (95% CI, 4.5-9.6) months in the T-DXd 6.4-mg/kg dose group of patients with baseline brain metastases. Among patients with measurable baseline brain metastases, intracranial confirmed ORRs were 50% (7 of 14; 95% CI, 23%-77%) with the T-DXd 5.4-mg/kg dose and 30% (9 of 30; 95% CI, 15%-49%) with the T-DXd 6.4-mg/kg dose. At both doses, the safety profile of T-DXd was generally manageable, regardless of baseline brain metastases, favoring the T-DXd 5.4 mg/kg dose.&lt;br&gt;
Conclusions and Relevance  In this secondary analysis, T-DXd at the approved dose of 5.4 mg/kg showed antitumor activity in patients with previously treated ERBB2-mutant metastatic NSCLC with or without brain metastases. This finding supports T-DXd 5.4 mg/kg use in this population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1556-0864</Issn>
      <Volume>20</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02\A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC</ArticleTitle>
    <FirstPage LZero="delete">1814</FirstPage>
    <LastPage>1828</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Pasi A.</FirstName>
        <LastName>J&#228;nne</LastName>
        <Affiliation>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sang-We</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Oncology Department, Asan Medical Center, Seoul, and University of Ulsan College of Medicine, Ulsan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David</FirstName>
        <LastName>Planchard</LastName>
        <Affiliation>Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, and Faculty of Medicine, Paris-Saclay University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Myung-Ju</FirstName>
        <LastName>Ahn</LastName>
        <Affiliation>Department of Hematology and Oncology, Samsung Medical Center Sungkyunkwan, and University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Egbert</FirstName>
        <LastName>Smit</LastName>
        <Affiliation>Department of Pulmonary Diseases, Leiden University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Adrianus</FirstName>
        <LastName>Johannes de Langen</LastName>
        <Affiliation>Department of Thoracic Oncology, Netherlands Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maurice</FirstName>
        <LastName>P&#233;rol</LastName>
        <Affiliation>Department of Medical Oncology, L&#233;on Berard Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Elvire</FirstName>
        <LastName>Pons-Tostivint</LastName>
        <Affiliation>Centre Hospitalier Universitaire Nantes, Nantes University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Silvia</FirstName>
        <LastName>Novello</LastName>
        <Affiliation>Department of Oncology, University of Turin, Turin, and Azienda Ospedaliero-Universitaria San Luigi Gonzaga</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Thoracic Oncology, Aichi Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dong-Wan</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaline</FirstName>
        <LastName>Pereira</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fu-Chih</FirstName>
        <LastName>Cheng</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yingkai</FirstName>
        <LastName>Cheng</LastName>
        <Affiliation>Daiichi Sankyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyle</FirstName>
        <LastName>Dunton</LastName>
        <Affiliation>Daiichi Sankyo UK</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ahmed</FirstName>
        <LastName>Ali</LastName>
        <Affiliation>Daiichi Sankyo Europe GmbH</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Thoracic Oncology, National Cancer Center Hospital East</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Trastuzumab deruxtecan (T-DXd) demonstrated strong and durable responses in patients with previously treated HER2 (ERBB2) mutant (HER2m) metastatic NSCLC (mNSCLC) in the DESTINY-Lung02 primary analysis (December 23, 2022, data cutoff). This final analysis evaluated T-DXd efficacy and safety after 8 additional months of follow-up, including clinically relevant subgroups and patient-reported outcomes.&lt;br&gt;
Methods: DESTINY-Lung02 was a randomized, dose-blinded, multicenter, phase 2 trial. Patients with previously treated HER2m mNSCLC were randomized 2:1 to receive T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. Primary end point was confirmed objective response rate by blinded independent central review.&lt;br&gt;
Results: As of August 25, 2023, 102 and 50 patients had received T-DXd 5.4 or 6.4 mg/kg, respectively. Median follow-up (Q1&#8211;Q3) was 15.8 (8.2&#8211;20.7) months and 16.5 (9.4&#8211;20.8) months, respectively. Confirmed objective response rate (95% confidence interval) was 50.0% (51/102; 39.9%&#8211;60.1%) and 56.0% (28/50; 41.3%&#8211;70.0%), respectively. Safety profile was acceptable and generally manageable. Accordingly, median treatment duration (Q1&#8211;Q3) was 7.7 (3.7&#8211;14.4) months and 8.3 (2.8&#8211;13.1) months; drug-related grade 3 or higher treatment-emergent adverse events occurred in 39.6% (40/101) and 60.0% (30/50), with nausea most common (67.3% [68/101], 82.0% [41/50]). Adjudicated drug-related interstitial lung disease occurred in 14.9% (15/101) and 32.0% (16/50), mostly grade 1 or 2 with one grade 5 in each arm. Health-related quality of life was preserved for the duration of T-DXd treatment while sample size was sufficient for analysis, with no adverse effects on health-related quality of life observed at either dose.&lt;br&gt;
Conclusions: T-DXd demonstrated strong and durable responses at both doses, with no clinically significant changes in toxicity. The approved 5.4-mg/kg dose demonstrated a more favorable benefit-risk profile, including lower adjudicated drug-related interstitial lung disease incidence.&lt;br&gt;
ClinicalTrials.gov identifier: NCT04644237</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">HER2-directed therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HER2-mutant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HER2-targeted</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Non&#8211;small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trastuzumab deruxtecan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Association for Cancer Research (AACR)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2767-9764</Issn>
      <Volume>6</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical Characteristics and Spatial Transcriptome Analysis of Non&#8211;Small Cell Lung Cancers Exhibiting Early Alectinib Resistance: A Retrospective OLCSG Study</ArticleTitle>
    <FirstPage LZero="delete">284</FirstPage>
    <LastPage>293</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tadahiro</FirstName>
        <LastName>Kuribayashi</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihide</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Respiratory Medicine, Ohara Healthcare Foundation, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Kuyama</LastName>
        <Affiliation>Department of Respiratory Medicine, NHO Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Thoracic Oncology and Medicine, National Hospital Organization, Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichiro</FirstName>
        <LastName>Kudo</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naokatsu</FirstName>
        <LastName>Horita</LastName>
        <Affiliation>Department of Respiratory Medicine, Kure Kyosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroe</FirstName>
        <LastName>Kayatani</LastName>
        <Affiliation>Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Chest Surgery, Shimonoseki City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Some anaplastic lymphoma kinase (ALK) gene rearrangement&#8211;positive lung cancers show early resistance, within 3 months, to alectinib. This study investigated the clinical and molecular characteristics of these patients. We analyzed patients with unresectable stage III/IV disease without indications for radical radiotherapy and recurrent ALK-positive lung cancer who received alectinib as the primary ALK tyrosine kinase inhibitor between 2013 and 2021 at nine hospitals. In total, 103 patients were included. The median age was 65 years; 44 were male and 22 had brain metastases. The median progression-free survival and overall survival (OS) were 28.7 and 80.6 months. Nineteen patients treated for &#8804;3 months and 84 treated for &gt;3 months were categorized into the early resistance and responder groups, respectively. The early resistance group had significantly shorter OS (8.4 months vs. not estimable, P &lt; 0.001) and was significantly more likely to have brain metastases (42% vs. 17%, P = 0.027). They also showed elevated inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR). Univariate analysis identified brain metastases and high NLR as significant predictors of early resistance. Spatial transcriptome analysis and immunohistochemical staining revealed upregulation of annexin A1 (ANXA1), a calcium-dependent phospholipid-binding protein involved in inflammation and cancer progression, in the early resistance group. Interleukin 6 stimulation, prompted by elevated inflammatory markers, increased ANXA1 expression and reduced alectinib sensitivity. Knockdown of ANXA1 improved alectinib sensitivity in alectinib-resistant cells. In conclusion, brain metastases and high NLR are associated with early resistance. ANXA1 may play an important role in mediating early resistance. New treatment options for the early resistance group are required.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0916-9636</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Distinct associations of blood pressure phenotypes with subclinical cerebrovascular disease and coronary artery calcification in Japanese men</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nomin</FirstName>
        <LastName>Bayaraa</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Kadota</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nazar Mohd</FirstName>
        <LastName>Azahar</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tran Ngoc Hoang</FirstName>
        <LastName>Phap</LastName>
        <Affiliation>National Institutes of Biomedical Innovation, Health and Nutrition</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sayuki</FirstName>
        <LastName>Torii</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Fujiyoshi</LastName>
        <Affiliation>Department of Hygiene, School of Medicine, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Ohkubo</LastName>
        <Affiliation>Department of Hygiene and Public Health, Teikyo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Shiino</LastName>
        <Affiliation>Molecular Neuroscience Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nozaki</LastName>
        <Affiliation>Department of Neurosurgery, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hypertension, encompassing white-coat hypertension (WCH), masked hypertension (MH), and sustained hypertension (SH), is an established risk factor for cardiovascular diseases (CVDs), including atherosclerosis. However, among the general population, findings on which target organ is affected by the different phenotypes of hypertension remain unclear. In this community-based observational study of Shiga Epidemiological Study of Subclinical Atherosclerosis, 740 Japanese men underwent brain magnetic resonance imaging to assess the presence of lacunar infarction, white-matter hyperintensities, microbleeds, and intracranial artery stenosis (ICAS) between 2012 and 2015. They also underwent office blood pressure (BP) measurements, home BP monitoring for at least five consecutive days, and coronary artery calcification (CAC) assessments between 2010 and 2014. The final analysis included 686 participants without a history of CVDs. Of the 686 participants, the mean age (&#8201;}&#8201;SD) was 68.0 (&#8201;}&#8201;8.3) years, and 39.3% were taking antihypertensive medication. In multivariable-adjusted models, each of WCH, MH, and SH was significantly associated with a higher risk of microbleeds compared to normotension. However, the association of WCH with microbleeds was evident only among those on antihypertensive medication (adjusted odds ratio [OR] 6.75 [95% CI 1.83&#8211;24.86]) and absent in those not on such medication (adjusted OR 1.20 [95% CI 0.31&#8211;4.73]). SH was associated with lacunar infarction, ICAS, and CAC. Among Japanese men, WCH, MH, SH were associated with subclinical cerebrovascular diseases, whereas only SH was associated with CAC. Moreover, any elevated BP phenotype increased the risk of microbleeds. Our findings suggest that different hypertension phenotypes distinctly affect target organs, particularly the brain and heart.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Blood pressure phenotypes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Morning hypertension</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Home blood pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Subclinical cerebrovascular disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Coronary artery calcification</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1123-6337</Issn>
      <Volume>29</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Safety and feasibility of D3 lymph node dissection in oldest-old patients undergoing colorectal cancer surgery: a multi-institutional, retrospective analysis</ArticleTitle>
    <FirstPage LZero="delete">146</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F.</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">N.</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Department of Surgery, Tottori Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">K.</FirstName>
        <LastName>Shigemitsu</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Surgery, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Surgery, Kobe Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Surgery, Onomichi City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Nobuhisa</LastName>
        <Affiliation>Department of Surgery, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F.</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">W.</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Umeoka</LastName>
        <Affiliation>Department of Surgery, Matsuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Setouchi Colorectal Neoplasm Registration Study Group Collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Colorectal cancer (CRC) is a significant health burden, with lymph node dissection (LND) playing a critical role in staging and guiding treatment. However, the optimal extent of LND for the oldest-old population (aged&#8201;&#8805;&#8201;90 years) remains undefined because of insufficient targeted clinical data. This study aimed to compare the short-term outcomes of D3 versus non-D3 LND in Stage II&#8211;III CRC in oldest-old patients.&lt;br&gt;
Methods This retrospective cohort study utilized data from the Setouchi Colorectal Neoplasm Registration database, including 282 oldest-old patients with CRC treated between 2011 and 2022. Patients were stratified into D3 and non-D3 LND groups, with inverse-probability-weighted regression adjustment implemented to address potential confounding factors. Postoperative complications and hospital stays were analyzed using regression models and descriptive statistics.&lt;br&gt;
Results D3 LND resulted in significantly higher lymph node harvests in both Stage II and Stage III patients (p&#8201;&lt;&#8201;0.01). There were no significant differences in overall or major postoperative complications between D3 and non-D3 groups. Hospital stays were comparable for Stage II patients but shorter for Stage III patients in the D3 group (p&#8201;&lt;&#8201;0.01). Complication rates ranged from 28% to 47.7%, with surgical site infections and pneumonia being the most common.&lt;br&gt;
Conclusions D3 LND can be safely performed in oldest-old patients with CRC without increasing postoperative complications or extending hospital stays. These findings support the feasibility of extensive LND in this age gr</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Lymph node dissection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oldest-old patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Postoperative complication</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1757-2215</Issn>
      <Volume>19</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pan-cancer profiling links C1orf50 to DNA repair and immune modulation in ovarian cancer</ArticleTitle>
    <FirstPage LZero="delete">13</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Anna</FirstName>
        <LastName>Rogachevskaya</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Ohtsu</LastName>
        <Affiliation>Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vanessa D.</FirstName>
        <LastName>Chin</LastName>
        <Affiliation>UMass Chan Medical School, UMass Memorial Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tirso</FirstName>
        <LastName>Pe&#241;a</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Arai</LastName>
        <Affiliation>Department of Urology, Gunma University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Molecular Physiology, Faculty of Medicine, Graduate School of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background C1orf50 encodes a small, evolutionarily conserved protein, the function of which remains unclear. Its significance across various human cancers, particularly its specific role in ovarian cancer within an immunogenomic context, is not yet fully understood. Utilizing The Cancer Genome Atlas and single-cell RNA sequencing (scRNA-seq) public datasets, we conducted a comprehensive profiling of C1orf50 across multiple cancer types, with a particular focus on ovarian cancer, to investigate its associations with copy-number status, genomic instability, tumor programs, and the immune microenvironment.&lt;br&gt;
Results Across cancer types, copy-number gain or amplification of C1orf50 was most frequent in ovarian cancer and closely tracked with higher messenger RNA levels. Higher C1orf50 expression was associated with a greater tumor mutational burden and homologous recombination deficiency, as indicated by gene-set patterns that suggested heightened cell-cycle and cellular stress responses accompanied by reduced oxidative phosphorylation, enrichment of regulatory T cells, and depletion of resting memory CD4 T cells. In ovarian cancer, focal events at chromosome 1p34.2 were accompanied by stepwise increases in C1orf50 expression by clinical stage and were linked to higher tumor mutational burden, homologous recombination deficiency, and greater loss of heterozygosity, together with more frequent gene alterations in BRCA1 or BRCA2. Immune composition clustered into profiles consistent with an immunosuppressive context in tumors with higher C1orf50 expression. The scRNA-seq data further revealed that cancer cells enhanced immune-suppressive interactions with various immune cell populations and diminished antigen-presentation signals. Analyses of genomic instability in ovarian cancer suggested mutational processes compatible with base-substitution patterns associated with cytidine deaminase activity and with insertion-deletion patterns characteristic of homologous recombination failure, while transcript-level patterns pointed to a broad downshift of canonical DNA repair activity with apparent compensatory adjustments in related pathways rather than a uniform change in any single pathway.&lt;br&gt;
Conclusions The overexpression of C1orf50 characterizes an aggressive immunogenomic phenotype in ovarian cancer, distinguished by genomic instability, impaired DNA repair mechanisms, and extensive immunosuppression. These findings indicate that C1orf50 warrants consideration as a potential biomarker and a prospective target for therapeutic investigation. Furthermore, they advocate for the progression to prospective validation and functional studies to ascertain its clinical significance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">C1orf50</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pan-cancer analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DNA repair</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gene expression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor microenvironment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune evasion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Single-cell RNA-seq</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1880-6546</Issn>
      <Volume>76</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of systemic ventricular assist combined with fenestration in failing Fontan: A theoretical analysis</ArticleTitle>
    <FirstPage LZero="delete">100065</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shuji</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Kotani</LastName>
        <Affiliation>Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Horio</LastName>
        <Affiliation>Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiri</FirstName>
        <LastName>Kisamori</LastName>
        <Affiliation>Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Miyahara</LastName>
        <Affiliation>Pediatric Heart Disease and Adult Congenital Heart Disease Center, Showa Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Uemura</LastName>
        <Affiliation>Department of Research Promotion and Management, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Shishido</LastName>
        <Affiliation>Department of Research Promotion and Management, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Kasahara</LastName>
        <Affiliation>Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Biventricular assist for failing Fontan circulation remains challenging. Because fenestration effectively reduces stressed blood volume and central venous pressure in Fontan patients with increased pulmonary vascular resistance (PVR), systemic ventricular assist device (VAD) combined with fenestration may improve hemodynamics in failing Fontan patients with increased PVR who would require biventricular assist. To validate this hypothesis, we performed a computational hemodynamic simulation of the failing Fontan circulation using a lumped parameter model. We compared hemodynamic variables between the models with and without fenestration while the PVR index was increased sequentially from 3.01 to 6.81 Wood Units m2. Following VAD initiation and stressed blood volume reduction, central venous pressure was maintained at a lower level in the fenestration models. This positive effect was greater in the model with larger fenestration diameter. However, excessive fenestration caused significant desaturation. In failing Fontan circulation with elevated PVR, systemic VAD combined with fenestration significantly improved hemodynamics.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Fontan circulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hemodynamic simulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ventricular assist device</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fenestration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pulmonary vascular resistance</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume>30</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>How to report and discuss subgroup analyses in clinical practice guidelines? Evaluation procedure of the clinical and statistical relevancy</ArticleTitle>
    <FirstPage LZero="delete">1259</FirstPage>
    <LastPage>1267</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>Department of Internal Medicine, Niigata Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Oya</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergy, Fujita Health University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Graduate School of Medical Sciences, Research Institute for Diseases of the Chest, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Teraoka</LastName>
        <Affiliation>Internal Medicine III, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Morise</LastName>
        <Affiliation>Department of Respiratory Medicine, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The results of subgroup analyses of clinical trials are important reference information when considering the generalizability of a study treatment, i.e., providing the best treatment for each individual patient. The results of subgroup analyses are often presented in publications, etc. as forest plots focusing on patient backgrounds. However, it is important to fully understand and grasp some of the issues involved in subgroup analyses and to interpret the results carefully to apply them in clinical practice. Although the literature includes some reports on how subgroup analyses should be evaluated and handled for the purpose of establishing medical practice guidelines, most of the papers have mainly evaluated the reliability of subgroup analyses from a statistical perspective; few of them have incorporated clinical importance in their evaluations. Therefore, in December 2019, we established a Subgroup Analysis Review Committee consisting of oncologists specializing in lung cancer treatment and statistical experts among the members of the Guidelines Review Committee of the Japanese Lung Cancer Association, with the aim of appropriately reflecting subgroup analysis in Japanese lung cancer practice guidelines. We developed a new evaluation strategy to incorporate clinical aspects as well as reliability assessment. Specifically, on the basis of a clinical and statistical review of the problems with subgroup analyses presented as clinical trial results, we developed criteria and procedures to ensure consistency and fairness in the citation of clinical guidelines.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Subgroup analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Guideline</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lung cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>64</Volume>
      <Issue>14</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Myeloid Sarcoma in the Small Intestine</ArticleTitle>
    <FirstPage LZero="delete">2155</FirstPage>
    <LastPage>2159</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Kamio</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsunori</FirstName>
        <LastName>Matsueda</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Kametaka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Myeloid sarcoma is a rare extramedullary tumor of immature myeloid cells that is often associated with acute myeloid leukemia (AML). We herein report an 81-year-old man who presented with intestinal obstruction due to myeloid sarcoma of the small intestine. Diagnostic challenges were overcome using double-balloon enteroscopy and a biopsy, which confirmed the diagnosis of myeloid sarcoma. The patient subsequently developed AML but responded well to chemotherapy. This case underscores the importance of considering myeloid sarcoma in the differential diagnosis of small-bowel tumors. Highlighting the significance of a histological analysis, even in patients presenting with small bowel obstruction, the early diagnosis and treatment are crucial for improving outcomes, particularly in patients without a history of hematologic malignancies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acute myeloid leukemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">double-balloon enteroscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">myeloid sarcoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">small intestine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ovid Technologies (Wolters Kluwer Health)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2639-8028</Issn>
      <Volume>8</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association Between Positive End-Expiratory Pressure at Venovenous Extracorporeal Membrane Oxygenation Initiation and Liberation Outcomes in Acute Respiratory Distress Syndrome: A Multicenter Retrospective Study</ArticleTitle>
    <FirstPage LZero="delete">e1375</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Kosaki</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuaki</FirstName>
        <LastName>Nishikimi</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichiro</FirstName>
        <LastName>Ohshimo</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Shime</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>IMPORTANCE: The optimal level of positive end-expiratory pressure (PEEP) during venovenous extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome (ARDS) remains uncertain.&lt;br&gt;
OBJECTIVES: This study aimed to evaluate the association between initial PEEP settings at ECMO initiation and the rate of successful ECMO liberation in patients with severe ARDS.&lt;br&gt;
DESIGN, SETTING, AND PARTICIPANTS: We conducted a post hoc analysis of the multicenter Japan Chest CT for ARDS Requiring Venovenous ECMO (J-CARVE) registry. Adult patients with severe ARDS treated with venovenous ECMO between 2012 and 2022 at 24 institutions were included. Participants were categorized into three groups according to PEEP at ECMO initiation: low (&lt; 8&#8201;cm H2O), middle (8&#8211;10&#8201;cm H2O), and high (&gt; 10&#8201;cm H2O).&lt;br&gt;
MAIN OUTCOMES AND MEASURES: The primary outcome was successful liberation from ECMO within 30 days. Multivariable Cox proportional hazards models were used to evaluate associations. Secondary outcomes included 60-day mortality, duration of ECMO support, and duration of mechanical ventilation.&lt;br&gt;
RESULTS: Among 683 patients analyzed, the overall ECMO liberation rate at 30 days was 69.2%. Liberation rates were 57.8% (103/178), 73.5% (259/352), and 72.5% (111/153) in the low, middle, and high PEEP groups, respectively. After adjustment, the low group had a significantly lower likelihood of successful ECMO liberation (hazard ratio [HR], 0.56; 95% CI, 0.39&#8211;0.81) compared with the middle group. No significant difference was observed between the high and middle groups (HR, 0.80; 95% CI, 0.58&#8211;1.10). The low group had longer ECMO duration; however, 60-day mortality and hospital length of stay did not differ significantly among groups.&lt;br&gt;
CONCLUSIONS AND RELEVANCE: Lower PEEP levels at ECMO initiation were associated with reduced likelihood of successful ECMO liberation compared with moderate PEEP, whereas estimates for high vs. moderate PEEP were not statistically significant. These findings support avoiding insufficiently low PEEP and underscore the need for prospective studies to refine optimal PEEP strategies in patients with severe ARDS.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acute respiratory distress syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">extracorporeal membrane oxygenation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mechanical ventilation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">respiratory therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">weaning</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2730-664X</Issn>
      <Volume>6</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of an oral exercise intervention on pre-frailty or frailty in older people: a randomized clinical trial</ArticleTitle>
    <FirstPage LZero="delete">96</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Preventive Dentistry, Division of Dentistry, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Sawada</LastName>
        <Affiliation>Section of Preventive and Public Health Dentistry, Division of Oral Health, Growth and Development, Faculty of Dental Science, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakura</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Division of Health Promotion, Okayama-City Health Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Oral Health Sciences, Faculty of Health Care Sciences, Takarazuka University of Medical and Health Care</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ekuni</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Frailty is often experienced by older adults, which can lead to long-term health problems. We aimed to examine associations with improvements in nutritional status, sarcopenia (age-related loss of skeletal muscle mass and strength), and frailty in four groups with different oral exercise frequencies.&lt;br&gt;
Methods: We conducted a prospective, parallel multi-arm randomized controlled trial (Japan Registry of Clinical Trials (jRCT) 1062210063) to test the effects of oral exercise on frailty in older adults. Each intervention consisted of a standardized oral exercise protocol including neck exercises, lip exercises, and tongue movements, designed to improve oral function and reduce frailty. The primary outcome was the change in the number of frailty criteria from baseline to follow-up. Individuals aged &#8805;60 years were screened for frailty status using standardized criteria at the Department of Preventive Dentistry at Okayama University Hospital between October 2022 and December 2023. Those identified as pre-frailty or frailty were eligible and enrolled in the study. After screening 60 individuals, 58 eligible participants were randomly assigned using block randomization to one of four oral exercise frequency groups: 3 times/day &amp; everyday, 3 times/day &amp; 3 days/week, once/day &amp; everyday, and once/day &amp; 3 days/week. A two-way repeated measures analysis of variance was used to evaluate the impact of the four frequencies of oral exercise methods on frailty in older adults. Outcome assessors were blinded; participants were not.&lt;br&gt;
Results: Here we show the results of the 58 participants. Group sizes are: 3 times/day &amp; everyday (n&#8201;=&#8201;14), 3 times/day &amp; 3 days/week (n&#8201;=&#8201;15), once/day &amp; everyday (n&#8201;=&#8201;14), once/day &amp; 3 days/week (n&#8201;=&#8201;15). The trial is completed as planned, and all randomized participants are analyzed. The main effect of time is significant for the number of frailty criteria (F&#8201;=&#8201;14.803, p&#8201;&lt;&#8201;0.001, partial eta squared = 0.215). The mean changes from baseline to follow-up are |0.357 (95% Confidence Interval |0.787 to 0.073) in the 3 times/day &amp; everyday group, |0.600 (95% Confidence Interval |1.255 to 0.055) in the 3 times/day &amp; 3 days/week group, |0.571 (95% Confidence Interval |1.379 to 0.236) in the once/day &amp; everyday group, and |0.600 (95% Confidence Interval |1.008 to |0.192) in the once/day &amp; 3 days/week group. The main effect of time is also significant for the number of oral hypofunction criteria (F&#8201;=&#8201;16.456, p&#8201;&lt;&#8201;0.001, partial eta squared = 0.234). No important adverse events or side effects related to the intervention were observed.&lt;br&gt;
Conclusions: After conducting oral exercises for 3 months on older adults with pre-frailty or frailty, improvements in frailty are observed. Overall, these exercises could be a simple, low-cost way to support healthy aging in the community.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-321X</Issn>
      <Volume>32</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tick-borne pathogens in ticks collected from Humans: A prospective clinical pilot study</ArticleTitle>
    <FirstPage LZero="delete">102931</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaomi</FirstName>
        <LastName>Sumida</LastName>
        <Affiliation>Numakuma Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kawamata</LastName>
        <Affiliation>Numakuma Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimi</FirstName>
        <LastName>Hidani</LastName>
        <Affiliation>Numakuma Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Tick-borne diseases (TBDs), particularly Japanese spotted fever, are an increasing public health concern in Japan. Data on pathogens carried by ticks removed directly from patients and their associated clinical outcomes remain limited. This prospective study investigated pathogen carriage in patient-derived ticks and evaluated the clinical risk of TBDs. Between April and October 2025, ticks were collected from patients presenting with tick bites at two medical institutions in Western Japan. Ticks were morphologically identified and spotted fever group rickettsiae (SFGR) was detected by nested PCR targeting the 17-kDa antigen gene, followed by sequence analysis. Clinical data, including patient background, antibiotic prescriptions, and outcomes, were reviewed. Clinical information was available for 70 patients (median age; 75 years), of whom 88.6% were prescribed prophylactic antibiotics. Ticks were collected from 60 patients (85.7%), and seven adults without antibiotic prophylaxis were followed for disease onset. Sixty-two ticks, predominantly Amblyomma testudinarium (88.7%), were analyzed. SFGR was detected in eight ticks (12.9%), including seven A. testudinarium and one Ixodes nipponensis, collected from seven patients. Two patients bitten by Rickettsia tamurae&#8211;carrying ticks were observed for one month without antibiotics and remained asymptomatic. In this prospective analysis, no clinically apparent rickettsiosis was observed following bites from R. tamurae&#8211;positive ticks without antibiotic prophylaxis; however, subclinical infection could not be excluded. Despite the small sample size, our findings suggest that the clinical risk associated with R. tamurae infection may be low. Direct analysis of removed ticks from patients may help characterize pathogen reservoirs and inform targeted approaches to TBDs.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Epidemiology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japanese spotted fever</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Spotted fever group rickettsiae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tick bite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tick-borne disease</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ovid Technologies (Wolters Kluwer Health)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1743-9159</Issn>
      <Volume>112</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Total thymectomy is oncologically superior to partial thymectomy in patients with thymic carcinoma: insights from a multicenter real-world data analysis</ArticleTitle>
    <FirstPage LZero="delete">2301</FirstPage>
    <LastPage>2310</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center of Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Habu</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromasa</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mototsugu</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Kurosaki</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eisuke</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsurou</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiya</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makio</FirstName>
        <LastName>Hayama</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Tao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaomi</FirstName>
        <LastName>Yamane</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Inokawa</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Hirami</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiko</FirstName>
        <LastName>Misao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshifumi</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kawamata</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group (OUTSSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Although total thymectomy has been the standard surgical approach for thymic epithelial tumors, an increasing number of recent reports suggest that partial thymectomy for early-stage thymomas may yield outcomes comparable to those of total thymectomy. However, whether partial thymectomy is a viable alternative for thymic carcinoma remains unclear.&lt;br&gt;
Materials and methods: A total of 106 patients with thymic carcinoma underwent curative intended resection at 19 institutions between January 2010 and December 2021. Excluding 14 patients with incomplete resection, 92 patients with thymic carcinoma who underwent total (n = 73) or partial thymectomy (n = 19) were compared. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan&#8211;Meier curves and Cox proportional hazard models. Overlap weighting was applied to adjust for potential confounding factors.&lt;br&gt;
Results: Among patients with clinical stage I disease, 79.3% were upstaged to stage II or higher postoperatively. Unadjusted analyses revealed no statistically significant differences in OS and RFS between the total and partial thymectomy groups, although a trend toward poorer outcomes in the partial thymectomy group was observed. After overlap weighting, partial thymectomy was associated with significantly poorer OS (P = 0.0027) and higher recurrence risk (P &lt; 0.0001). Early postoperative recurrence occurred more frequently in the partial thymectomy group.&lt;br&gt;
Conclusion: Partial thymectomy was associated with significantly worse survival and recurrence outcomes in thymic carcinoma. Given the limitations of preoperative diagnosis, total thymectomy should remain the preferred surgical approach for undiagnosed thymic epithelial tumors to achieve optimal oncologic control and minimize the risk of recurrence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">partial thymectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">real-world data analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">retrospective comparative cohort study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thymic carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thymic epithelial tumors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">total thymectomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Metastatic Intraocular Tumor Likely from Hepatocellular Carcinoma Mimicking Panuveitis</ArticleTitle>
    <FirstPage LZero="delete">63</FirstPage>
    <LastPage>67</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Eri</FirstName>
        <LastName>Takasu</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Shiode</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Kindo</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mio</FirstName>
        <LastName>Hosokawa</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Matoba</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kanzaki</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuro</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Adachi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70074</ArticleId>
    </ArticleIdList>
    <Abstract>A 77-year-old man undergoing treatment for hepatocellular carcinoma (HCC) presented with blurred vision in his right eye, persisting for 2 months. Slit-lamp microscopy and fundus examination revealed inflammatory cells in the anterior chamber, severe vitreous opacities, and retinal vasculitis in the right eye. The patient underwent vitreous surgery with biopsy, and vitreous cytology confirmed a metastatic intraocular tumor originating from the HCC. Radiotherapy was administered to the right eye, with no recurrence of intraocular inflammation observed at 10 months post-irradiation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">metastatic intraocular tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatocellular carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">panuveitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">uveitis masquerade syndrome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes in Prescribing Patterns of Antiviral Drugs before and after Public Coverage Termination among Hospitalized COVID-19 Patients in Regional Hospitals in Japan: A Retrospective, Multicenter Study</ArticleTitle>
    <FirstPage LZero="delete">55</FirstPage>
    <LastPage>62</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70073</ArticleId>
    </ArticleIdList>
    <Abstract>In Japan, antiviral agents for COVID-19 were freely available until September 2023 as part of national policy. This study evaluated changes in these agentsf prescribing patterns and the patient outcomes following the policy shift. We conducted a multicenter retrospective study at four hospitals in Japanfs Okayama and Kagawa prefectures from January 2022 to March 2024. The study period was divided into the public-expenditure phase (January 2022 to September 2023) and the post-expenditure phase (October 2023 to March 2024). We extracted the hospitalized patientsf clinical data from the electronic database. The studyfs primary outcome was the antiviral prescription rate; the secondary outcome was in-hospital mortality. Among the 302 hospitalized patients (median age 85 years), 52.0% were classified as having a mild condition. Of the patients with mild conditions, 37.7% were diagnosed in outpatient settings prior to hospitalization. During the public-expenditure phase, 47.4% of the patients received antivirals as outpatients, mainly molnupiravir (80.9%). In the post-expenditure period, 80.0% of the patients were prescribed antivirals, mostly molnupiravir (91.7%). The antiviral prescription rate was significantly higher after the policy change. The overall in-hospital mortality was 15.8%, with no significant difference between the two periods (17.0% vs. 10.5%). Despite the termination of government funding, antiviral prescriptions remained frequent at community hospitals located in highly aging regions of western Japan such as Okayama and Kagawa prefectures. Mortality remains high among the elderly, highlighting the need for continued antiviral therapy and booster vaccinations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">coronavirus disease 2019</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">public expenditure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prescribing pattern</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prognosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0001-690X</Issn>
      <Volume>153</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of Schizophrenia Spectrum Disorders on the Receipt of Invasive and Systemic Therapy for Colorectal Cancer: A Nationwide Multicenter Retrospective Cohort Study in Japan</ArticleTitle>
    <FirstPage LZero="delete">191</FirstPage>
    <LastPage>199</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Neuropsychiatry, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisuke</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomone</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maiko</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Division of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nakaya</LastName>
        <Affiliation>Tohoku Medical Megabank Organization, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Department of Medical Informatics, Shimane University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Otsuki</LastName>
        <Affiliation>Department of Psychiatry, Faculty of Medicine, Shimane University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Shimazu</LastName>
        <Affiliation>Division of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Hinotsu</LastName>
        <Affiliation>Department of Biostatistics and Data Management, Sapporo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Uchitomi</LastName>
        <Affiliation>Department of Cancer Survivorship and Digital Medicine, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Psychiatry, Faculty of Medicine, Shimane University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: This study examined treatment disparities for colorectal cancer among patients diagnosed with schizophrenia spectrum disorders (SSD), focusing on invasive treatments and stage-appropriate systemic therapy within a universal healthcare system.&lt;br&gt;
Method: In this nationwide retrospective cohort study (2018&#8211;2021), we identified 248,966 colorectal cancer patients, including 2337 diagnosed with SSD, using linked cancer registry and insurance claims data in Japan. The presence of SSD was classified according to ICD-10 codes F20&#8211;29. We used multivariable logistic regression to compare the odds of receiving stage-appropriate adjuvant chemotherapy and systemic therapy, as well as the odds of receiving surgical or endoscopic treatments, between the two groups. The analysis adjusted for age, sex, clinical stage, and scores on the Charlson Comorbidity Index and Barthel Index.&lt;br&gt;
Results: The clinical stage distribution at diagnosis for colorectal cancer differed significantly between patients with SSD and those without psychiatric disorders (p&#8201;&lt;&#8201;0.001). After adjusting for clinical stage and other covariates, patients with SSD demonstrated significantly lower odds of receiving surgical or endoscopic treatment (adjusted odds ratio [aOR], 0.83; 95% CI, 0.73&#8211;0.94). The disparities were more pronounced for systemic therapy; patients with SSD had substantially lower odds of receiving adjuvant chemotherapy for stage III disease (aOR, 0.33; 95% CI, 0.26&#8211;0.41) and systemic therapy for stage IV disease (aOR, 0.23; 95% CI, 0.17&#8211;0.31).&lt;br&gt;
Conclusion: Patients with SSD encounter substantial disparities in accessing standard colorectal cancer care, particularly systemic therapies. These findings highlight the urgent need for interventions to ensure equitable cancer treatment for this vulnerable population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">healthcare disparities</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psycho-oncology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">schizophrenia spectrum disorders</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2950-3299</Issn>
      <Volume>33</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Collagen depletion by pirfenidone enhances antitumor effect of oncolytic adenovirus against peritoneal metastases of gastric cancer</ArticleTitle>
    <FirstPage LZero="delete">201045</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Okura</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Mikane</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ema</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Une</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Noma</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Ohtsuka</LastName>
        <Affiliation>Laboratory of Fundamental Oncology, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rieko</FirstName>
        <LastName>Ohki</LastName>
        <Affiliation>Laboratory of Fundamental Oncology, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Urata</LastName>
        <Affiliation> Oncolys BioPharma, Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cancer-associated fibroblasts (CAFs) play a crucial role in collagen accumulation, which develops and promotes peritoneal metastasis (PM) in gastric cancer (GC). In addition, the abundant stromal collagens in the tumor microenvironment function as a physical barrier against penetration of antitumor drugs and oncolytic viruses. This study investigated whether collagen depletion by pirfenidone (PFD), an antifibrotic drug, enhances the antitumor effects of oncolytic adenoviruses. Analysis of the clinical samples revealed a significant association of high expression of collagen 1 and ƒ¿-smooth muscle actin (ƒ¿-SMA) with PM development and poor prognosis of advanced GC. Human and murine GC cells enhanced collagen production by fibroblasts, which was suppressed by PFD. Abundant fibroblasts and collagen inhibited the penetration of OBP-702, which reduced the antitumor effects of OBP-702 in the spheroid model. Intraperitoneal co-injection of GC cells and fibroblasts promoted the development of collagen-rich PM and reduced the antitumor effects of OBP-702 in vivo model. PFD suppressed collagen production in PM and improved viral penetration into the tumors, which enhanced the antitumor effects of OBP-702 against PM of GC. Collagen depletion by PFD enhances the penetration of OBP-702 into PM of GC, in turn enhancing the antitumor effects of OBP-702 against PM of GC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">MT: Regular Issue</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oncolytic virotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peritoneal metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">collagen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pirfenidone</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1349-0079</Issn>
      <Volume>68</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Insights into the taste of organic acids via TAS1Rs</ArticleTitle>
    <FirstPage LZero="delete">100731</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Yamase</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuki</FirstName>
        <LastName>Takebe</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kengo</FirstName>
        <LastName>Horie</LastName>
        <Affiliation>Department of Oral Physiology, Graduate School of Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Mitoh</LastName>
        <Affiliation>Department of Oral Physiology, Graduate School of Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuko</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Institute for Protein Research, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Oral Physiology, Graduate School of Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: Organic acids contribute significantly to the flavor of fermented foods by imparting sourness. Although mice generally avoid sour taste, previous studies have reported greater consumption of l-lactic acid than its d-enantiomer, suggesting enantiomer-specific recognition. This behavior is hypothesized to involve TAS1Rs, which consists of sweet/umami receptors. However, it remains unclear whether TAS1Rs additionally contribute to the recognition of other chiral organic acids. This study aimed to evaluate the role of TAS1Rs, particularly TAS1R3, in the modulation of enantiomer-dependent behavioral responses to organic acids in mice.&lt;br&gt;
Methods: Behavioral responses were evaluated using 48-h and 1-h 2-bottle tests. Binding of organic acids to TAS1Rs was investigated by differential scanning fluorimetry (DSF) with the ligand-binding domain (LBD) of medaka Tas1r2a/Tas1r3.&lt;br&gt;
Results: Wild-type mice consumed more d-malic acid than l-malic acid in the 48-h test, whereas Tas1r3-KO mice showed no such difference. This pattern was not observed in the short-term 1-h test, which minimized the contribution of post-ingestion and learned effects. DSF analysis revealed no binding of any of the tested organic acids to the LBD of medaka Tas1r2a/Tas1r3.&lt;br&gt;
Conclusions: Organic acids may elicit TAS1R3-dependent post-ingestion signals that contribute to enantiomer-selective consumption in mice. Electrostatic interactions and hydrogen-bonding networks within the orthosteric pocket of TAS1Rs may account for the differences in binding affinity to the LBD of medaka Tas1r2a/Tas1r3 between organic acids and L-alanine, a known ligand.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Taste detection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Organic acid preference</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">G-protein coupled receptor (GPCR)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Knockout mice</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surface electrostatic potential</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1757-4749</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sodium butyrate augments the antibacterial activity of tetracycline against clinical isolates of multidrug-resistant Vibrio cholerae</ArticleTitle>
    <FirstPage LZero="delete">9</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sushmita</FirstName>
        <LastName>Kundu</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sourin</FirstName>
        <LastName>Alu</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Abhishek</FirstName>
        <LastName>Singh</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Animesh</FirstName>
        <LastName>Gope</LastName>
        <Affiliation>Division of General Medicine, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ranjan Kumar</FirstName>
        <LastName>Nandy</LastName>
        <Affiliation>Division of Bacteriology, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asish K.</FirstName>
        <LastName>Mukhopadhyay</LastName>
        <Affiliation>Division of Bacteriology, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Division of Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nabendu Sekhar</FirstName>
        <LastName>Chatterjee</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sushmita</FirstName>
        <LastName>Bhattacharya</LastName>
        <Affiliation>Division of Biochemistry, ICMR- National Institute for Research in Bacterial Infections</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Antibiotic resistance poses a major challenge in treating Vibrio cholerae infections. One promising method to counter resistance is the co-administration of antibiotics with non-antibiotic adjuvants to enhance their efficacy. This study investigated the combined action of sodium butyrate (SB) and tetracycline on tetracycline-resistant V. cholerae strains.&lt;br&gt;
Results The combined activity of SB and antibiotics was assessed on eight V. cholerae clinical isolates using the Fractional Inhibitory Concentration Index (FICI), with SB-Tetracycline showing strong synergy (FICI: 0.09&#8211;0.5). Functional and mechanistic studies, including time-kill kinetics, live/dead staining, SEM-based morphological analysis, and fluorometric assays, demonstrated a synergistic antibacterial effect of SB and Tetracycline. This effect was associated with increased membrane permeability, disruption of membrane integrity, dissipation of the proton motive force, and suppression of efflux activity. These changes collectively led to membrane damage, enhanced intracellular accumulation of Tetracycline, decreased intracellular ATP levels, and ultimately, bacterial cell death. Moreover, GM1-CT ELISA and fluorescence microscopy revealed the synergistic anti-virulence activity of the SB- Tetracycline combination. Finally, the combination of SB and Tetracycline showed enhanced efficacy in animal models compared with monotherapy.&lt;br&gt;
Conclusion: The observed SB-Tetracycline synergy provides a promising therapeutic approach to overcome tetracycline resistance in V. cholerae, offering a potential adjunct strategy for the management of antibiotic-resistant cholera infections.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">V. cholerae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sodium butyrate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tetracycline</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Synergy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Antibiotic adjuvant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0041-1132</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Pediatric autologous peripheral blood stem cell collection without heparin using a highly concentrated sodium citrate anticoagulant: A retrospective comparison with standard ACD-A</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Ikeuchi</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Shimono</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Division of Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Heparin combined with sodium citrate has been used in leukocytapheresis for pediatric patients. Since 2022, we have performed leukocytapheresis using a highly concentrated sodium citrate solution (HSC, 5.32%) instead of acid citrate dextrose solution A (ACD-A). We conducted this study to determine whether HSC use reduces run time and the total amount of anticoagulant solution in children.&lt;br&gt;
Study Design and Methods: We retrospectively analyzed data from consecutive autologous peripheral blood stem cell harvests (auto-PBSCHs) between June 2012 and May 2025, including patient characteristics, mobilization methods, protocol used, anticoagulant type, run time, total anticoagulant solution volume, and collection efficiency.&lt;br&gt;
Results: Auto-PBSCH was performed using the mononuclear cell collection (MNC) protocol in 28 procedures and the continuous MNC protocol in 20 procedures. ACD-A was used in 35 procedures and HSC in 13. The run time was significantly shorter (204 [range, 117&#8211;302] vs. 157&#8201;min [range, 103&#8211;227], p&#8201;=&#8201;.02) in the HSC group and also confirmed in multivariable regression analysis (coefficient, |55.6; 95% confidence interval, |106.2 to |5.04; p&#8201;=&#8201;.03). In a subgroup analysis of cMNC procedures, CD34+ collection efficiency showed a strong negative correlation with the proportion of run time devoted to establishing the initial interface (r&#8201;=&#8201;|.73, p&#8201;=&#8201;.0003).&lt;br&gt;
Conclusion: Delays in establishing the initial interface can reduce the duration of the effective MNC collection phase and may negatively affect collection efficiency. Careful attention to the initial interface phase is therefore warranted when using HSC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acid citrate dextrose solution</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">autologous</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">continuous mononuclear cell collection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">highly concentrated sodium</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pediatric</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peripheral blood stem cells</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1349-4147</Issn>
      <Volume>54</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mycobacterium mageritense-associated refractory cutaneous infection and lymphadenitis in an immunocompetent adult: insights from genomic sequencing</ArticleTitle>
    <FirstPage LZero="delete">19</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Bacteriology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Kawakami</LastName>
        <Affiliation>Department of Dermatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Matsuura</LastName>
        <Affiliation>Konohana Dermatology Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Dermatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Dermatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Poowadon</FirstName>
        <LastName>Muenraya</LastName>
        <Affiliation>Department of Bacteriology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Nontuberculous mycobacteria are increasingly recognized as causes of chronic and refractory skin and soft tissue infections, even in individuals without immunodeficiency. Among them, Mycobacterium mageritense is a rare, rapidly growing species that can lead to persistent lesions requiring prolonged antimicrobial therapy. Reports of M. mageritense infections involving both the skin and regional lymph nodes are limited, and this case adds new clinical and genomic insights.&lt;br&gt;
Case presentation A 48-year-old previously healthy man presented with a slowly enlarging cutaneous lesion on his lower leg and ipsilateral inguinal lymphadenitis. Empirical antibacterial therapy with ƒÀ-lactams and macrolides was ineffective. Wound cultures subsequently grew M. mageritense, confirmed by whole-genome sequencing. Several antimicrobial regimens were attempted, and the final successful therapy consisted of oral levofloxacin and minocycline for 4 months, leading to complete clinical resolution. Genomic analysis identified resistance-related genes, including erm(40), aac(2Œ)-Ib, tet(V), and RbpA, although in vitro minimum inhibitory concentrations showed variable susceptibility. Phylogenetic comparison revealed that the isolate was closely related to previously reported M. mageritense strains from Japan.&lt;br&gt;
Conclusions This case demonstrates that M. mageritense can cause cutaneous infection with secondary lymphadenitis in an immunocompetent host. Accurate species identification using molecular or genomic methods and selection of appropriate combination antibiotic therapy based on susceptibility testing are crucial for successful management of such infections.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Genome sequence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lymphadenitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mycobacterium mageritense</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Skin and soft tissue infections</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rapidly growing mycobacteria</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-3492</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A retrospective cohort study comparing periodontal regeneration using fibroblast growth factor]2 versus autologous bone graft</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshiki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ito]Shinoda</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mai</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuki</FirstName>
        <LastName>Nonomura</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Ideguchi</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Okubo</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazu</FirstName>
        <LastName>Takeuchi]Hatanaka</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>The Center for Graduate Medical Education (Dental Division), Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology&#8211;Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Fibroblast growth factor-2 (FGF-2) is a novel agent utilized in periodontal regeneration therapy. However, its clinical efficacy compared with autologous bone graft (ABG), a long-established treatment, remains unclear. This study aimed to compare the clinical outcomes of FGF-2 and ABG and to assess the impact of patient background factors on outcomes when using FGF-2.&lt;br&gt;
Methods: We collected the subjects from January 2013 to September 2023. Clinical outcomes included the vertical bone defect improvement rate (VBDIR) and the probing pocket depth improvement (PPDI). Clinical outcomes between the two groups were compared using analysis of covariance (ANCOVA), adjusting for age, sex, smoking history, and hypertension. Additionally, a multilevel linear analysis was performed to assess factors influencing outcomes in FGF-2.&lt;br&gt;
Results: A total of 180 sites from 141 patients (FGF-2: 150 sites; ABG: 30 sites) were evaluated. Both VBDIR and PPDI significantly improved postoperatively in both groups. There were no significant differences in clinical outcomes between FGF-2 and ABG. In FGF-2, smoking history was positively associated, while the preoperative bone defect angle (BDA) was negatively associated with clinical outcomes.&lt;br&gt;
Conclusions: FGF-2 might exhibit clinical outcomes comparable to those of ABG, suggesting it is a clinically viable alternative for vertical bone defects. When using FGF-2, patient-specific factors such as smoking history and preoperative BDA should be considered carefully.&lt;br&gt;
The name in the trial registry: A survey of clinical practice and evaluation of treatment outcomes of periodontal regenerative therapy using REGROTH at Okayama University Hospital</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">autologous bone graft</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibroblast growth factor-2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontal pocket</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontal regeneration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vertical bone defect</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1687-8728</Issn>
      <Volume>2026</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Experimental Analysis of Automatic Discrimination Performance Between Simulated Bruxism and Non]Bruxism Under Conscious Conditions Using Electromyography and Machine Learning</ArticleTitle>
    <FirstPage LZero="delete">7874254</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Minakuchi</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Electrical Engineering and Information Systems, Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">L&#7897;c Ho&#224;ng</FirstName>
        <LastName>&#272;&#236;nh</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruna</FirstName>
        <LastName>Miki</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ko</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tazuko</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Electrical Engineering and Information Systems, Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuo</FirstName>
        <LastName>Kuboki</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Minematsu</LastName>
        <Affiliation>Department of Electrical Engineering and Information Systems, Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: This study aimed to evaluate the potential use of machine learning to automatically classify electromyography (EMG) data into bruxism simulated movement with tooth contact (BMwTC), bruxism simulated movement without tooth contact (BMwoTC), and non-bruxism movement (non-BM).&lt;br&gt;
Methods: Twelve eligible healthy participants (female/male: 2/10, mean age: 35.3&#8201;}&#8201;8.4&#8201;years) were asked to perform the simulated movements (all the tasks were performed five times for 5&#8201;s each with a 30-s rest interval). The electrodes were placed on the masseter, infrahyoid, inframandibular, and chin muscles. A sound sensor was placed adjacent to the masseter. The EMG and sound data were sampled at 1 and 44.1&#8201;kHz, respectively. Single- and multi-stream hidden Markov models (HMMs) were used to automatically discriminate the tested behavior from the others using a hamming window with 100&#8201;ms and shift length of 50&#8201;ms. The leave-one-out method was used for training and testing the model, with data from 11 participants used for training and one for testing. Each participant was evaluated, and the final performance was measured by averaging the results of 12 classification trials. The validity of the discrimination was assessed by calculating the harmony mean values using six EMG signals and the sound data.&lt;br&gt;
Results: The masseter EMG demonstrated significantly higher discrimination accuracy in the single-stream model (p&#8201; &lt; 0.05, One-way ANOVA, Tukey HDS). The multi-stream model also demonstrated higher accuracy; however, no significant difference was observed. Notably, the accuracy of BMwoTC was less than 0.5.&lt;br&gt;
Conclusion: The machine-learning-based discriminative system accurately discriminates BMwTC from non-BM using masseter EMG.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bruxism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dentistry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">electromyography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EMG discrimination</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1873-149X</Issn>
      <Volume>33</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Bridging the Gap Between Static Histology and Dynamic Organ-on-a-Chip Models</ArticleTitle>
    <FirstPage LZero="delete">10</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Zheyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiji</FirstName>
        <LastName>Naruse</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>For more than a century, pathology has served as a cornerstone of modern medicine, relying primarily on static microscopic assessment of tissue morphology\such as H&amp;E staining\which remains the ggold standardh for disease diagnosis. However, this conventional paradigm provides only a snapshot of disease states and often fails to capture their dynamic evolution and complex functional mechanisms. Moreover, animal models are constrained by marked interspecies differences, creating a persistent gap in translational research. To overcome these limitations, we propose the concept of New Pathophysiology, a research framework that transcends purely morphological descriptions and aims to resolve functional dynamics in real time. This approach integrates Organ-on-a-Chip (OOC) technology, multi-omics analyses, and artificial intelligence to reconstruct the entire course of disease initiation and to enable personalized medicine. In this review, we first outline the foundations and limitations of traditional pathology and animal models. We then systematically summarize more than one hundred existing OOC disease models across multiple organs\including the kidney, liver, and brain. Finally, we elaborate on how OOC technologies are reshaping the study of key pathological processes such as inflammation, metabolic dysregulation, and fibrosis by converting them into dynamic, mechanistic disease models, and we propose future perspectives in the field. This review adopts a relatively uncommon classification strategy based on pathological mechanisms (mechanism-based), rather than organ-based categorization, allowing readers to recognize shared principles underlying different diseases. Moreover, the focus of this work is not on emphasizing iteration or replacement of existing approaches, but on preserving past achievements from a historical perspective, with an emphasis on overcoming current limitations and enabling new advances.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">new pathophysiology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">organ-on-a-chip/OOC</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dynamic disease modeling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">histopathology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">large-model analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">personalized medicine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>The Japanese Society of Interventional Radiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2432-0935</Issn>
      <Volume>10</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Is Saline Sealing of Needle Tract Effective to Prevent Pneumothorax after Computed Tomography-guided Lung Biopsy?</ArticleTitle>
    <FirstPage LZero="delete">e2025-0068</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuaki</FirstName>
        <LastName>Munetomo</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Umakoshi</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Iguchi</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Hiraki</LastName>
        <Affiliation>Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: To evaluate the efficacy of needle tract sealing using normal saline instillation for decreasing the risk of pneumothorax after computed tomography-guided lung biopsy.&lt;br&gt;
Material and Methods: This retrospective, single-institution study included 391 computed tomography-guided lung biopsies performed by 12 operators between January 2022 and October 2024. After exclusion, 298 biopsies were analyzed by comparing the saline seal (n = 138) and control (n = 160) groups. A 17/18-gauge or 19/20-gauge coaxial biopsy system was used, and tract sealing was performed by instilling 1-5 mL of normal saline during the withdrawal of the introducer needle in the saline seal group; tract sealing was not performed in the control group. After 1:1 propensity score matching was performed to balance baseline characteristics, the incidences of pneumothorax and chest tube placement were compared between the two groups using Fisher's exact test.&lt;br&gt;
Results: After propensity score matching, 108 pairs (mean lesion size: 17 mm) were well balanced. The incidence of pneumothorax did not differ significantly between the control and saline seal groups (50.0% vs. 60.2%, respectively; p = 0.171). Similarly, the incidence of chest tube placement was not significantly different between the two groups (7.4% vs. 13.0%, respectively; p = 0.260).&lt;br&gt;
Conclusions: According to the propensity score-matched analysis, normal saline instillation for tract sealing did not significantly reduce the incidence of pneumothorax or chest tube placement. In our cohort, which had a high prevalence of small lesions, saline sealing alone may be insufficient to reduce post-biopsy pneumothorax risk. Hence, combined strategies require further investigation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">pneumothorax</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lung biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">image-guided biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">needle tract sealing</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Royal Society of Chemistry (RSC)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-750X</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Multi-step mechanisms of early phospholipid hydrolysis and mineralisation unveiled through combined quantum chemical calculations and experimental analysis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Department of Materials Science, Waseda University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahumi</FirstName>
        <LastName>Shiotani</LastName>
        <Affiliation>Department of Resources and Environmental Engineering, Waseda University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yunhao</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Materials Science, Waseda University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reina</FirstName>
        <LastName>Kurihara</LastName>
        <Affiliation>Department of Resources and Environmental Engineering, Waseda University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsunori</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Department of Resources and Environmental Engineering, Waseda University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emilio Satoshi</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Advanced International and Information Dentistry, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">N&#237;lson</FirstName>
        <LastName>Kunioshi</LastName>
        <Affiliation>Department of Materials Science, Waseda University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Phospholipids play key roles in bone formation, with phosphatidylserine (PS) reportedly inducing more rapid mineralisation than phosphatidylcholine (PC); however, the underlying mechanisms remains unclear. This study investigated PS and PC mineralisation using experimental methods and computational chemistry. The stationary points in the potential energy surfaces of the reactions were preliminarily found using a neural network potential (PreFerred Potential in Matlantis) capable of predicting the interaction energies for arbitrary combinations of atoms, and then refined through density functional theory calculations (Gaussian16, at the B3LYP/6-31G(d,p) level of theory). When hydrolysis reactions were assumed to be the initial step in the mineralisation of phospholipids, the results were consistent with empirical analysis. PS was found to be more easily hydrolised than PC, primarily owing to the presence of a labile proton in the NH3+ group of serine that facilitates proton transfer, enhancing hydrolysis of PS at lower energy thresholds. Specifically, when a single phospholipid was considered, three distinct hydrolysis routes were identified: between serine (or choline) and phosphate, between glycerol and phosphate, and between an aliphatic carbon chain and the glycerol backbone. In particular, the initial steps of hydrolysis involved the formation of a pentavalent phosphate intermediate. When calculations were performed with two adjacent phospholipid molecules, the loosely bound proton (H+) in the NH3+ group could be readily transferred either to the P&#8211;O bond linking serine to the phosphate group; or to the P&#8211;O bond connecting the phosphate to glycerol in a neighboring PS6 molecule. These findings reveal the important roles of serine NH3+ in facilitating hydrolysis of PS, and provide insights for designing novel molecules to accelerate bone regeneration.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-321X</Issn>
      <Volume>31</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of full-time equivalent allocation on the effectiveness of antimicrobial stewardship activities: A multicenter study in Okayama, Japan</ArticleTitle>
    <FirstPage LZero="delete">102730</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shiho</FirstName>
        <LastName>Kajita</LastName>
        <Affiliation>Antimicrobial Stewardship Team, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Okita</LastName>
        <Affiliation>Department of Surgery, Setouchi City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Haruki</LastName>
        <Affiliation>Department of Pharmacy, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruto</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Antimicrobial Stewardship Team, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasurou</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Antimicrobial Stewardship Team, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Higashionna</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Satou</LastName>
        <Affiliation>Division of Pharmacy, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumihiro</FirstName>
        <LastName>Torigoe</LastName>
        <Affiliation>Division of Pharmacy, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinobu</FirstName>
        <LastName>Iwamoto</LastName>
        <Affiliation>Division of Pharmacy, Okayama Kyoritsu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mika</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Infection Control Team, National Hospital Organization Minami-Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumiko</FirstName>
        <LastName>Yamane</LastName>
        <Affiliation>Infection Control Team, National Hospital Organization Minami-Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kenmotsu</LastName>
        <Affiliation>Division of Pharmacy, Okayama Saiseikai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Sugimura</LastName>
        <Affiliation>Department of Internal Medicine, Okayama Kyoritsu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Infection Control Team, National Hospital Organization Minami-Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fusao</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Hepatology, Okayama Saiseikai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Koyama</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikamasa</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Infection Control Team, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichirou</FirstName>
        <LastName>Andou</LastName>
        <Affiliation>Infection Control Team, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshimitsu</FirstName>
        <LastName>Suwaki</LastName>
        <Affiliation>Infection Control Team, Okayama City Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Optimized administration of antimicrobial agents is critical for mitigating the emergence of antimicrobial resistance. This study aimed to elucidate the relationship between antimicrobial stewardship (AS) activities and antimicrobial prescription trends and patterns.&lt;br&gt;
Methods: This retrospective, multicenter, longitudinal study was conducted between April 2014 and March 2023 (9-year fiscal period). A structured, questionnaire survey, regarding institutional infrastructure and environmental parameters, service modalities provided by AS activities, resource allocation and systemic support, and data on the use of broad-spectrum antimicrobial agents, was distributed to co-investigators working at seven hospitals in Okayama, Japan. Full-time equivalent (FTE) allocation for each healthcare facility were calculated and subsequently compared among the hospitals. Temporal variations in the proportional distribution of broad-spectrum antimicrobial agents were statistically evaluated using joinpoint regression analysis.&lt;br&gt;
Results: Two hospitals where pharmacists were exclusively dedicated to AS activities and met the recommended FTE allocation showed a statistically significant reduction in the proportion of broad-spectrum antibiotic administration, with average annual percentage changes of |8.0 % (95 % confidence interval [CI]: |10.5 to |5.8) and |3.1 % (95 % CI: |5.5 to |0.7), respectively. In contrast, two other hospitals with full-time AS members but insufficient FTE allocation exhibited inconsistent and statistically nonuniform trends. The remaining three healthcare institutions with poorly resourced AS teams demonstrated no statistically significant trends in their broad-spectrum antimicrobial prescriptions.&lt;br&gt;
Conclusion: Our findings uncovered that hospitals with adequate FTE staffing metrics for AS activities exhibited statistically significant downward trends in the consumption of broad-spectrum antimicrobial agents.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Antimicrobial resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Antimicrobial stewardship</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Full-time equivalent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Infection prevention and control</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trend analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2328-8957</Issn>
      <Volume>13</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of Candida Care Bundle Compliance on the Prognosis of Patients With Candidemia: A Multicenter Retrospective Cohort Study With Propensity Score Matching Analysis (2016&#8211;2023)</ArticleTitle>
    <FirstPage LZero="delete">ofaf790</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshie</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of General Internal Medicine, Okayama Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Center for Medical Education and Internationalization, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukinobu</FirstName>
        <LastName>Akamatsu</LastName>
        <Affiliation>Department of General Medicine, Tottori Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Haruki</LastName>
        <Affiliation>Department of Pharmacy, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Iwamoto</LastName>
        <Affiliation>Department of General Medicine, NHO Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Fujisato</LastName>
        <Affiliation>Department of Pharmacy, Okayama Rousai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ako</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background. Candidemia is a life-threatening infection with high mortality, and appropriate management is essential to improve patient outcomes. The Candida Care Bundle aims to standardize hospital management for patients with candidemia and reduce mortality.&lt;br&gt;
Methods. This retrospective multicenter cohort study included candidemia cases from 9 hospitals in Japan between 2016 and 2023. Compliance to the Candida Care Bundle was evaluated based on 5 elements: central venous catheter removal within 24&#8197;hours, appropriate antifungal therapy, ophthalmologic examination, follow-up blood cultures, and antifungal treatment for &#8805;2 weeks after clearance. Patients were categorized into high (4&#8211;5 items) and low (0&#8211;3 items) compliance groups. The primary and secondary outcomes were defined as 30-day survival and the development of endophthalmitis, with propensity score matching used to adjust for potential confounders.&lt;br&gt;
Results. Among 230 patients, 160 (69.5%) were classified into the high compliance group, which exhibited significantly lower 30-day mortality than the low compliance group (8.8% vs 57.1%, P &lt; .01). Even after matching, the high compliance group remained independently associated with improved survival (hazard ratio [HR]: 0.15; 95% confidence interval [CI]: .08&#8211;.30). C. albicans (HR: 1.95; 95% CI: 1.01&#8211;3.52) and central line-associated bloodstream infection (HR: 2.63; 95% CI: 1.35&#8211;5.12) were associated with the fatal outcome. Endophthalmitis involved 23.6% of the patients, being associated with C. albicans (odds ratio [OR]: 8.18; 4.46&#8211;19.30) and central line-associated bloodstream infection (OR: 2.69; 1.08&#8211;6.70).&lt;br&gt;
Conclusions. Strict compliance to the Candida Care Bundle significantly improves survival, underscoring its importance in candidemia management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">candida bundle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">candidemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endophthalmitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prognosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">propensity score matching</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Pharmaceutical Society of Japan</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-6158</Issn>
      <Volume>49</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Exploratory Analysis for Development Predictive Models of Immune Checkpoint Inhibitor-Induced Myocarditis Using a Nationwide Claims Database</ArticleTitle>
    <FirstPage LZero="delete">66</FirstPage>
    <LastPage>73</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Reina</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Nakagomi</LastName>
        <Affiliation>Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miyu</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Clinical Pharmacy, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayana</FirstName>
        <LastName>Michihara</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya F.</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Clinical Pharmacy Practice, School of Pharmacy &amp;amp; Pharmaceutical Sciences, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pranav M.</FirstName>
        <LastName>Patel</LastName>
        <Affiliation>Division of Cardiology, School of Medicine, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Tanioka</LastName>
        <Affiliation>Medical AI Project, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Uehara</LastName>
        <Affiliation>Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Immune checkpoint inhibitors (ICIs), essential in cancer therapy, can cause severe immune-related adverse events (irAEs), including myocarditis with a high fatality rate. Currently, the pathogenesis, biomarkers, and risk factors of ICI-induced myocarditis (ICIM) are not fully understood. This exploratory study aimed to develop machine learning-based models to predict the onset of ICIM within 3 months of starting ICI therapy, using a large health insurance database. The models were constructed using the Light Gradient Boosting Machine (LightGBM) and Random Forest algorithms, incorporating clinical variables such as comorbidities and prior medication classifications. In this study, a strategy combining undersampling and bagging was used to minimize the impact of highly imbalanced datasets. The Random Forest model demonstrated superior performance compared with the LightGBM model, and the SHapley Additive exPlanations (SHAP) analysis for the Random Forest model revealed that the concurrent use of ICIs was the most important variable for predictions. Although predictive performance remains limited (AUROC &#8776; 0.63), this exploratory framework demonstrates the feasibility of developing data-driven risk prediction models for ICIM. Future studies with expanded datasets and integration of laboratory parameters are warranted to improve predictive accuracy and potential clinical applicability.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immune checkpoint inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">myocarditis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">adverse event</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japan Oil Chemists' Society</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1345-8957</Issn>
      <Volume>74</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Bioconversion and Metabolic Fate of the n-1 Polyunsaturated Fatty Acids, 6,9,12,15- Hexadecatetraenoic (C16:4 n-1) and 8,11,14,17- Octadecatetraenoic (C18:4 n-1) Acids, in HepG2 Cells</ArticleTitle>
    <FirstPage LZero="delete">1023</FirstPage>
    <LastPage>1032</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Faculty of Food and Nutritional Sciences, Toyo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideto</FirstName>
        <LastName>Nishiguchi</LastName>
        <Affiliation>Faculty of Chemistry, Materials, and Bioengineering, Kansai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Hosomi</LastName>
        <Affiliation>Faculty of Chemistry, Materials, and Bioengineering, Kansai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Tanizaki</LastName>
        <Affiliation>Bizen Chemical Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiro</FirstName>
        <LastName>Tsushima</LastName>
        <Affiliation>Bizen Chemical Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomichi</FirstName>
        <LastName>Baba</LastName>
        <Affiliation>Bizen Chemical Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihisa</FirstName>
        <LastName>Misawa</LastName>
        <Affiliation>Bizen Chemical Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuaki</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Hygiene and Public Health, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Department of Hygiene and Public Health, Kansai Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Fukunaga</LastName>
        <Affiliation>Faculty of Chemistry, Materials, and Bioengineering, Kansai University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Fish oil contains not only major fatty acids with double bonds at the n-3, n-6, n-7, and n-9 positions but also those with a double bond at the n-1 position, such as 6,9,12,15-hexadecatetraenoic acid (C16:4 n-1; HDTA). However, intracellular bioconversion and metabolic fate of n-1 polyunsaturated fatty acids (PUFA) remain unclear. Therefore, in this study, we aimed to assess the intracellular bioconversion and metabolic fate of HDTA and its metabolite, 8,11,14,17- octadecatetraenoic acid (C18:4 n-1; ODTA), using HepG2 cells. Based on the results of cell viability and cytotoxicity assays for HDTA and ODTA, the concentration of each fatty acid supplemented in the experiments was set at 10 ƒÊM. HepG2 cell culture with HDTA revealed C20:4 n-1 as a new HDTA metabolite, along with previously reported ODTA. Our findings suggest that the HDTA taken up by HepG2 cells undergoes elongation to form ODTA and C20:4 n-1. Following supplementation with HDTA, ODTA, and 5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; EPA), fatty acids disappeared from the culture medium within 24 h. Notably, the total relative level of HDTA and its metabolites, including ODTA and C20:4 n-1 in HDTA- and ODTA-supplemented cells were significantly lower than the total relative level of EPA and its metabolites, including 7,10,13,16,19-docosapentaenoic acid (C22:5 n-3), C24:6 n-3, and 4,7,10,13,16,19-docosahexaenoic acid (C22:6 n-3) in the EPA-supplemented cells. Except for a portion that was intracellularly elongated, most HDTA was taken up by HepG2 cells and may undergo rapid fatty acid ƒÀ-oxidation. However, RNA-sequencing and real-time polymerase chain reaction analysis revealed no significant changes in fatty acid ƒÀ-oxidation&#8211;related gene expression levels in HDTA-supplemented cells. Collectively, these results provide novel insights into the intracellular bioconversion mechanisms and metabolic fate of HDTA and ODTA in HepG2 cells, suggesting that the metabolic fate of n-1 PUFA is distinct from that of common PUFA.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">n-1 polyunsaturated fatty acids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hexadecatetraenoic acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">octadecatetraenoic acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HepG2</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Single cell spatial transcriptomics links Wnt signaling disruption to extracellular matrix development in a cleft palate model</ArticleTitle>
    <FirstPage LZero="delete">29639</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Jeremie Oliver</FirstName>
        <LastName>Pi&#241;a</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Resmi</FirstName>
        <LastName>Raju</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Evan</FirstName>
        <LastName>Stipano</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aye Chan</FirstName>
        <LastName>Myo</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Department of Molecular Biology and Biochemistry, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuaki</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Department of Molecular Biology and Biochemistry, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Parna</FirstName>
        <LastName>Chattaraj</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masae</FirstName>
        <LastName>Furukawa</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rena N.</FirstName>
        <LastName>DfSouza</LastName>
        <Affiliation>Section on Craniofacial Genetic Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH)</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Despite advances in understanding the morphological disruptions that lead to defects in palate formation, the precise perturbations within the signaling microenvironment of palatal clefts remain poorly understood. To explore in greater depth the genomic basis of palatal clefts, we designed and implemented the first single cell spatial RNA-sequencing study in a cleft palate model, utilizing the Pax9|/| murine model at multiple developmental timepoints, which exhibits a consistent cleft palate defect. Visium HD, an emerging platform for true single-cell resolution spatially resolved transcriptomics, was employed using custom bins of 2&#8201;~&#8201;2 ƒÊm spatial gene expression data. Validation of spatial gene expression was then validated using custom designed Xenium In Situ mRNA spatial profiling and RNAscope Multiplex assays. Functional enrichment analysis revealed a palate cell-specific perturbation in Wnt signaling effector function in tandem with disrupted expression of extracellular matrix genes in developing mesenchyme. As a key step toward laying the framework for identifying key molecular targets these data can be used for translational studies aimed at developing effective therapies for human palatal clefts.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Spatial biology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cleft palate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Genomics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Single cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gene expression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Profiling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Extracellular matrix</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Wnt</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Transcriptome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-321X</Issn>
      <Volume>31</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Whole-genome sequencing and in vitro characterization of a disseminated ST398 Staphylococcus aureus infection: A case report</ArticleTitle>
    <FirstPage LZero="delete">102845</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Sazumi</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Bacteriology, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuhito</FirstName>
        <LastName>Suyama</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyoshi</FirstName>
        <LastName>Gotoh</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Kutsuno</LastName>
        <Affiliation>Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junzo</FirstName>
        <LastName>Hisatsune</LastName>
        <Affiliation>Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Sugai</LastName>
        <Affiliation>Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuma</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Bacteriology, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Staphylococcus aureus potentially causes systemic infections such as disseminated abscesses and bloodstream infections, leading to high mortality rates. We herein describe a case of disseminated muscle abscesses caused by sequence type (ST) 398 methicillin-sensitive S. aureus (MSSA), along with in vitro investigation results for potential pathogenic factors. A 67-year-old healthy woman was admitted to our hospital with complaints of systemic body pain. Blood cultures identified MSSA and contrast-enhanced computed tomography revealed multiple muscle abscesses extending from her neck to her soles. She received antibiotic treatment with intravenous cephazolin and underwent repeated surgical drainage, and was finally discharged. Notably, the MSSA strain exclusively affected her muscle tissues, prompting us to perform genetic analysis to uncover the underlying reason. Short-read genome analysis revealed the isolate to be ST398, harboring chp and scn genes known for immune evasion from human immunity. However, no other known pathogenic factors were identified despite rigorous assays for biofilm formation, surface and cell wall proteins, protease production, and hyaluronidase activity. ST398 S. aureus is commonly isolated from livestock, and her prior experience of being flooded could be related to the disease onset. The present case underscores the possibility of severe ST398 MSSA infections in humans, even in the absence of direct animal exposure.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Staphylococcus aureus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sequence type 398</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Disseminated infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune evasion cluster gene</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1156-5233</Issn>
      <Volume>35</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cerebellar abscess caused by Cladophialophora bantiana involving an elderly Japanese woman</ArticleTitle>
    <FirstPage LZero="delete">101548</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Nakamoto</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukika</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichiro</FirstName>
        <LastName>Hirano</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yaguchi</LastName>
        <Affiliation>Division of Clinical Research, Medical Mycology Research Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sayaka</FirstName>
        <LastName>Ban</LastName>
        <Affiliation>Division of Clinical Research, Medical Mycology Research Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Division of Clinical Research, Medical Mycology Research Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Okunobu</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuhito</FirstName>
        <LastName>Suyama</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marina</FirstName>
        <LastName>Kawaguchi</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yousuke</FirstName>
        <LastName>Sazumi</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Phaeohyphomycosis is a rare fungal infection that presents significant challenges in diagnosis and treatment. Herein, we document a case of a cerebellar abscess caused by Cladophialophora bantiana. A 77-year-old woman with type 2 diabetes mellitus and a previous history of diffuse large B-cell lymphoma gradually developed ataxia and was transferred to an emergency department. Head imaging investigations indicated a cerebellar mass and the patient underwent an emergent endoscopic drainage. Although bacterial cultures of the drainage specimen yielded no growth, a dematiaceous fungus was isolated and subsequently identified as C. bantiana through ITS sequencing analysis. The patient received antifungal combination therapy, initially with liposomal amphotericin B and voriconazole, and finally posaconazole and 5-fluorocytosine. Brain abscesses caused by C. bantiana are rarely documented, and an optimal treatment strategy has yet to be established. Given the high fatality rate, an early surgical intervention is crucial for both diagnosis and treatment. The present case was successfully treated with minimally invasive surgical intervention alongside the antifungal combination therapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Brain abscess</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cladophialophora bantiana</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Black fungus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phaeohyphomycosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Posaconazole</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Spandidos Publications</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2049-9450</Issn>
      <Volume>23</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prolonged exposure to axitinib alters the molecular profile of Caki&#8209;2 renal cell carcinoma cells</ArticleTitle>
    <FirstPage LZero="delete">101</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Ino</LastName>
        <Affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohji</FirstName>
        <LastName>Takara</LastName>
        <Affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Hyogo Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Axitinib, an oral second&#8209;generation multitargeted tyrosine kinase inhibitor, is used as a second&#8209;line treatment for metastatic renal cell carcinoma (RCC). However, patients often develop resistance after initial responsiveness, necessitating the elucidation of the underlying resistance mechanisms. Therefore, the present study aimed to investigate the mechanisms underlying axitinib resistance using the Caki&#8209;2 human papillary RCC model cells. Cells tolerating 0.1 &#181;M axitinib were designated as Caki/AX cells. Cell viability was assessed using the water&#8209;soluble tetrazolium salt assay. Notably, the 50% inhibitory concentration (IC50) values of axitinib and sunitinib were significantly higher in Caki/AX cells than those in Caki&#8209;2 cells, indicating 2.83&#8209; and 1.2&#8209;fold resistance, respectively. By contrast, the IC50 values of sorafenib and erlotinib were decreased in Caki/AX cells. Moreover, Caki/AX cells showed resistance to everolimus, temsirolimus and rapamycin, and decreased sensitivity to vinblastine, vincristine, paclitaxel, doxorubicin and SN&#8209;38 compared with Caki&#8209;2 cells. Notably, etoposide, 5&#8209;fluorouracil, cisplatin and carboplatin sensitivities were comparable in both cell types. Reverse transcription&#8209;quantitative polymerase chain reaction (PCR) analysis revealed that the mRNA levels of the ATP&#8209;binding cassette subfamily B member 1 and subfamily G member 2 were significantly higher in Caki/AX cells than those in Caki&#8209;2 cells. A PCR array related to vascular endothelial growth factor signalling showed that the mRNA levels of FIGF (also known as vascular endothelial growth factor D) and sphingosine kinase 1 were upregulated, whereas those of Rac family small GTPase 2 were downregulated in Caki/AX cells. Overall, these findings suggested that the upregulation of the ATP&#8209;binding cassette subfamily B member 1, FIGF and sphingosine kinase 1 mRNA levels, and downregulation of the Rac family small GTPase 2 mRNA levels may contribute to acquired resistance in Caki/AX cells.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">axitinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">drug resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ABC transporter</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0732-8893</Issn>
      <Volume>113</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Time to positivity for differentiating blood culture contamination: A 20-hour cutoff for major contaminants</ArticleTitle>
    <FirstPage LZero="delete">117030</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Manabe</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Nakamoto</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Nursing, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kiguchi</LastName>
        <Affiliation>Department of Nursing, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Blood culture remains the gold standard for diagnosing bacteremia; however, contamination inevitably occurs in 2-3% of cases, requiring differentiation between true bacteremia and contamination. Although time to positivity (TTP) aids in this clinical decision, with detection after 24 hours generally indicating contamination, technological advances in blood culture systems may have shortened this threshold interval.&lt;br&gt;
Methods: This study retrospectively analyzed blood culture data in our hospital from April 2023 to January 2025 to determine the optimal TTP cutoff. Patients with positive blood cultures for major contaminating bacteria were included. Cases were classified as true bacteremia or contamination based on a comprehensive chart review conducted by the antimicrobial stewardship audit, and TTP was compared between the groups. Sensitivity, specificity, and Youden index at various TTP cutoffs were utilized to determine the optimal threshold using the receiver operating characteristic curve analysis.&lt;br&gt;
Results: Seventy-one patients were enrolled, with 34 cases classified as true bacteremia and 37 as contamination. Identified bacteria included coagulase-negative staphylococci (70.4%), viridans group streptococci (18.3%), and others (11.3%). The median TTP was significantly shorter in the true bacteremia group compared with the contamination group (18.6 vs.25.8 hours, p &lt; 0.001). In the contamination group, 43.2% of the cases demonstrated positive growth within 24 hours. Based on sensitivity, specificity, and Youden index, the optimal threshold was estimated to be 20 hours. A subgroup analysis of the CNS-only cohort yielded concordant results.&lt;br&gt;
Conclusion: This study suggests that a 20-hour TTP threshold could help effectively differentiate true bacteremia from contamination in current clinical settings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Bacteremia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Blood stream infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Contamination</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Incubation time</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Time to positivity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2050-0904</Issn>
      <Volume>13</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Experience and Insight Into Genetic Diagnosis of Infective Aortic Aneurysm</ArticleTitle>
    <FirstPage LZero="delete">e71586</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Culture-negative infected aneurysms possibly occur in various clinical situations, including prior antibiotic exposure. Accurate microbial identification is crucial for an optimal antimicrobial strategy. 16S ribosomal RNA gene sequence analysis would provide a useful tool for precise bacterial identification.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">16S rRNA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">culture-negative</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Enterobacter hormaechei</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">infected aneurysm</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>European Respiratory Society (ERS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2312-0541</Issn>
      <Volume>11</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Global trends in idiopathic pulmonary fibrosis mortality rates during 2001&#8211;2022</ArticleTitle>
    <FirstPage LZero="delete">00362-2025</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ko</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Division of Hematology/Oncology, Mayo Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Quynh Thi</FirstName>
        <LastName>Vu</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Koyama</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and ultimately fatal lung disease. Updated global mortality data, especially from underexplored countries, are limited. This study aimed to understand the current global trends in IPF-associated mortality rates.&lt;br&gt;
Methods This observational study used the World Health Organization Mortality Database to analyse data stratified by sex, age and geographic region, encompassing 64 countries between 2001 and 2022. IPF was defined according to the International Code for Diseases-10 code J84.1. Crude and age-standardised mortality rates per 100&#8201;000 individuals were calculated to estimate long-term mortality trends. Mortality rates were calculated by dividing IPF-associated deaths by the corresponding population, with age-specific rates determined for each 5-year age group. Trends in the 2001&#8211;2022 period were analysed using a locally weighted regression model, and the average annual percentage change in mortality rates between 2010 and 2022 was estimated using joinpoint regression analysis.&lt;br&gt;
Results Overall, 874&#8201;998 deaths associated with IPF were analysed. The LOESS-smoothed crude mortality rate increased from 2.10 (95% confidence interval (CI) 1.77&#8211;2.43) per 100&#8201;000 in 2001 to 3.14 (95% CI 2.71&#8211;3.57) per 100&#8201;000 by 2022. The LOESS-smoothed age-standardised mortality rates increased overall, peaking at 1.59 (95% CI 1.51&#8211;1.67) per 100&#8201;000 in 2018 and declining slightly to 1.57 (95% CI 1.35&#8211;1.79) per 100&#8201;000 in 2022. Mortality was higher among males than females; furthermore, 87.5% of deaths occurred in individuals aged &#8805;65&#8197;years. Mortality rates were highest among the American population, with a notable increase in Latin American countries.&lt;br&gt;
Conclusion IPF-associated mortality rates have increased globally, particularly in males. Significant geographical, age and sex disparities were observed, emphasising the need for targeted public health measures and improved disease management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2772-5723</Issn>
      <Volume>5</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Feasibility and Diagnostic Utility of Mucosal T-Cell Flow Cytometry for Intestinal Graft-Versus-Host Disease</ArticleTitle>
    <FirstPage LZero="delete">100820</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mai</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Division of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Araki</FirstName>
        <LastName>Hirabata</LastName>
        <Affiliation>Division of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahide</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Division of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aims: Timely diagnosis of intestinal complications after hematopoietic stem cell transplantation (HSCT), including graft-versus-host disease (GVHD), transplant-associated thrombotic microangiopathy, and cytomegalovirus infection, is essential for appropriate management. This study evaluated whether mucosal T-cell profiling from endoscopic biopsies could support the diagnosis of these post-transplant conditions.&lt;br&gt;
Methods: We prospectively analyzed 58 intestinal biopsy specimens from 21 post-HSCT patients. Paired samples were obtained from the stomach and duodenum during upper endoscopy and from the ileum and large intestine during colonoscopy. Lymphocytes were isolated from each specimen and analyzed using flow cytometry. These data were integrated with those of a previously collected cohort (35 patients, 51 samples) for comparative immunophenotypic analysis across histologically defined groups.&lt;br&gt;
Results: Duodenal biopsies yielded more lymphocytes than did gastric biopsies (mean } standard deviation: 532 } 823 vs 233 } 392 cells; P = .070), with comparable yields between the ileum and colon. Among 41 evaluable cases, the CD56+:CD3+ ratio was significantly lower in patients with GVHD (5.5 } 2.2%) than in those with nonspecific or no inflammation (28.4 } 16.3%; P = .006). A cutoff value of &lt;11% provided 85.7% sensitivity and 83.3% specificity for diagnosing GVHD (area under the curve = 0.91).&lt;br&gt;
Conclusion: Mucosal T-cell profiling using endoscopic biopsies is feasible and may aid in the diagnosis of GVHD after HSCT. A decreased CD56+:CD3+ ratio is a promising marker for distinguishing GVHD from other post-transplant intestinal conditions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cytomegalovirus infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">flow cytometry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">graft-versus-host disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hematopoietic stem cell transplantation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">T lymphocytes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Association of Rehabilitation Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2432-1354</Issn>
      <Volume>10</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Reliability and Validity of the Japanese Perme ICU Mobility Score: An Initial Psychometric Evaluation</ArticleTitle>
    <FirstPage LZero="delete">20250037</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Rehabilitation Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Rehabilitation Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuto</FirstName>
        <LastName>Nakanishi</LastName>
        <Affiliation>Department of Disaster and Emergency Medicine, Graduate School of Medicine, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Katsukawa</LastName>
        <Affiliation>Department of Scientific Research, Japanese Society for Early Mobilization</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ricardo Kenji</FirstName>
        <LastName>Nawa</LastName>
        <Affiliation>Department of Critical Care Medicine, Hospital Israelita Albert Einstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Christiane</FirstName>
        <LastName>Perme</LastName>
        <Affiliation>Department of Rehabilitation Services, Houston Methodist Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Rehabilitation Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikumi</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Academic Field of Health Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Hirohata</LastName>
        <Affiliation>Academic Field of Health Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives : The Perme ICU Mobility Score is widely used to assess functional status, but no version of this assessment tool has been validated for use in Japan. This study aimed to translate the Perme Score into Japanese and evaluate its reliability and validity.&lt;br&gt;
Methods : Following forward&#8211;backward translation, the Japanese Perme Score was tested at ICU discharge. Inter-rater reliability was examined using weighted kappa coefficient. Construct validity was assessed through correlations with the Medical Research Council Sum Score (MRC-SS), Functional Status Score for the ICU (FSS-ICU), and ICU Mobility Scale (IMS). Predictive validity for activities of daily living (ADL) independence (Barthel Index &#8805;&#8201;85) and discharge destination was evaluated using Receiver operating characteristic (ROC) analysis. Floor and ceiling effects were also analyzed.&lt;br&gt;
Results : In 69 patients, the Japanese Perme Score showed high inter-rater reliability (ƒÈ=0.83). It showed moderate correlation with FSS-ICU (rho=0.61) and IMS (rho=0.73), and it showed weak correlation with MRC-SS (rho=0.36). Predictive validity for ADL independence and home discharge yielded AUCs of 0.76 and 0.73, respectively. A ceiling effect was noted in 10% of cases, with no floor effect.&lt;br&gt;
Conclusions: The Japanese Perme Score is a reliable, valid instrument for evaluating physical function at ICU discharge.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">critical illness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intensive care unit</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">outcome assessment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">physical function</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rehabilitation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2772-7076</Issn>
      <Volume>14</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genetic variability in Neisseria meningitidis strains isolated in a Japanese hospital</ArticleTitle>
    <FirstPage LZero="delete">100511</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazuyoshi</FirstName>
        <LastName>Gotoh</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuma</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Bacteriology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: Neisseria meningitidis is a significant pathogen causing invasive meningococcal disease, posing clinical and public health concerns worldwide. This study aimed to investigate the genetic characteristics of N. meningitidis clinical isolates at Okayama University Hospital in Japan.&lt;br&gt;
Methods: Between 2018 and 2023, five clinical strains were isolated, of which three were subjected to the antimicrobial susceptibility testing and whole genetic analysis using MiSeq platform (Illumina, San Diego, CA, USA).&lt;br&gt;
Results: One non-groupable isolate, belonging to sequence types (STs)-11026 (ST-32 complex), exhibited non-susceptibility to penicillin G, with a five-mutation pattern (F504L, A510V, I515V, H541N, and I566V) in the penA amino acid sequence and additional mutations (XXXIV and N513Y) characteristic of a mosaic penA gene. The other two isolates, ST-1655 (ST-23 complex) with serogroup Y and ST-2057 with serogroup B, were susceptible to penicillin G, neither of which contained the five-mutation pattern. Levofloxacin resistance was observed in two isolates carrying the T91I mutation in the gyrA protein.&lt;br&gt;
Conclusion: Our findings suggest the presence of antimicrobial-resistant N. meningitidis in Japan, underscoring the necessity for continuous local surveillance. Additional research is crucial for clarifying the ongoing spread of resistance mechanisms and for establishing effective countermeasures to reduce the clinical burden of invasive meningococcal disease.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Antimicrobial resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Invasive meningococcal disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Drug-resistant gene</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Genome sequence</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0040-8166</Issn>
      <Volume>93</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Detection of the nuclear translocation of androgen receptor using quantitative and automatic cell imaging analysis</ArticleTitle>
    <FirstPage LZero="delete">102631</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Lanlan</FirstName>
        <LastName>Bai</LastName>
        <Affiliation>Graduate School of Science and Engineering, Iwate University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tao</FirstName>
        <LastName>Wu</LastName>
        <Affiliation>Graduate School of Science and Engineering, Iwate University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuki</FirstName>
        <LastName>Fukasawa</LastName>
        <Affiliation>Neuro-AI Integration Science Laboratory, Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sayo</FirstName>
        <LastName>Kashiwagi</LastName>
        <Affiliation>Rohto Pharmaceutical Co., Ltd., Basic Research Development Division</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruka</FirstName>
        <LastName>Tate</LastName>
        <Affiliation>Graduate School of Science and Engineering, Iwate University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taku</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Graduate School of Science and Engineering, Iwate University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Sugano</LastName>
        <Affiliation>Graduate School of Science and Engineering, Iwate University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Graduate School of Science and Engineering, Iwate University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Rohto Pharmaceutical Co., Ltd., Basic Research Development Division</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Akashi</LastName>
        <Affiliation>Neuro-AI Integration Science Laboratory, Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fukuda</LastName>
        <Affiliation>Graduate School of Science and Engineering, Iwate University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Testosterone signaling mediates diseases such as androgenetic alopecia and prostate cancer and is controlled by the activation of the androgen receptor (AR) and nuclear translocation of the ligand-receptor complex. This study established an immortalized dermal papilla cell line that stably expresses the AR labeled with a monomeric green fluorescence marker. The cells expressed the histone H2B protein as visualized using a red fluorescence marker, enabling the Detection of nuclear translocation under live cell conditions using image analysis. The AR was observed to be translocated from the cytoplasm to the nucleus of cells after stimulation with dihydrotestosterone (DHT). The signal intensity of the nuclear/cytoplasm ratio was analyzed using automatic image analysis and a newly developed algorithm. The quantitation method to detect nuclear translocation revealed that the AR nuclear signal plateaued approximately 20&#8239;min after DHT exposure. Our developed method has the potential to save human labor by the automatic process of the image.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Dermal papilla cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nuclear translocation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Androgen receptor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Live cell imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Digital image analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Quantitation algorithm</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1756-4646</Issn>
      <Volume>135</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Inhibitory effect of cyclodextran on the induction of dental caries by Streptococcus mutans</ArticleTitle>
    <FirstPage LZero="delete">107077</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Haruka</FirstName>
        <LastName>Asaumi</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakuya</FirstName>
        <LastName>Matsuura</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Tabata</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Naka</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiyo</FirstName>
        <LastName>Matsumoto-Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cyclodextrans (CIs) are cycloisomaltooligosaccharides that are known to function as dextran analogues and are possible inhibitors of dental plaque formation. CIs have a structure in which 7 to 12 glucose molecules are cyclically linked by ƒ¿-1,6 bonds. We examined the inhibitory effects of CIs on the induction of dental caries by Streptococcus mutans. The inhibitory effects for bacterial growth, anti-enzymatic activity, and biofilm formation were analyzed. Additionally, the inhibitory effect of CIs on the induction of dental caries was investigated using a rat caries model. The presence of CIs resulted in reduced bacterial growth and biofilm formation. Kinetic analysis of the results showed that the inhibitory effect of CIs on anti-enzymatic activity is competitive. Furthermore, the caries scores with CIs were lower than those without CIs in both diet and drinking experiments. These results suggest that CIs possess strong anticaries activity and may be useful as a dietary supplement.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Streptococcus mutans</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">glucosyltransferase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dental caries</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cyclodextran</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">animal experiments</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG-TOP2 Study</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kayoko</FirstName>
        <LastName>Tao</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Pathology, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Childhood Cancer Data Management, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Komatsu</LastName>
        <Affiliation>Department of Pediatrics, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Tsujimoto</LastName>
        <Affiliation>Department of Pediatrics, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Pediatrics, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Tanimura</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minako</FirstName>
        <LastName>Sugiyama</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Sekiguchi</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Yatabe</LastName>
        <Affiliation>Department of Diagnostic Pathology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Diagnostic Pathology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Okita</LastName>
        <Affiliation>Department of Pathology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Hirato</LastName>
        <Affiliation>Department of Pathology, Public Tomioka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Kohashi</LastName>
        <Affiliation>Department of Pathology, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukichi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Kanagawa Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kohsaka</LastName>
        <Affiliation>Division of Cellular Signaling, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Department of Clinical Genomics, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuniko</FirstName>
        <LastName>Sunami</LastName>
        <Affiliation>Department of Laboratory Medicine, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Genetic Medicine and Services, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Tsutsumi</LastName>
        <Affiliation>Genome Science &amp; Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Aburatani</LastName>
        <Affiliation>Genome Science &amp; Medicine Division, Research Center of Advanced Science and Technology, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Koh</LastName>
        <Affiliation>Department of Hematology and Oncology, Saitama Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Pediatrics, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Karakawa</LastName>
        <Affiliation>Department of Pediatrics, Hiroshima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukayo</FirstName>
        <LastName>Terashita</LastName>
        <Affiliation>Department of Pediatrics, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Fujisaki</LastName>
        <Affiliation>Department of Pediatric Hematology and Oncology, Osaka City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Okinawa Prefectural Nanbu Medical Center &amp; Children's Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Yoneda</LastName>
        <Affiliation>Department of Pediatric Surgery, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Mochizuki</LastName>
        <Affiliation>Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Shichino</LastName>
        <Affiliation>Department of Pediatrics, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Hematology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Takimoto</LastName>
        <Affiliation>Department of Childhood Cancer Data Management, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Ichimura</LastName>
        <Affiliation>Department of Pathology, Kyorin University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chitose</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Pediatrics, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimikazu</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Children's Cancer Center National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Clinical Genomics, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>To develop an optimized genomic medicine platform for pediatric cancers, a nationwide cancer genome profiling project was conducted from January 2022 to February 2023 in collaboration with the Japan Children's Cancer Group. This prospective observational study analyzed matched blood and FFPE tumor samples from patients aged 0&#8211;29&#8201;years with solid tumors. Genomic analysis used the TOP2 hybrid capture&#8211;enrichment system, targeting 737 and 455 genes in the DNA and RNA panels, along with allele-specific genome copy number alterations. A total of 210 patients from 50 institutions were enrolled across Japan (median age, 8&#8201;years; range, 0&#8211;25). Of these, 154 (77%) were enrolled at diagnosis or during/after initial treatment and 56 (27%) at disease progression or relapse. The TOP2 findings had great benefits in clarifying the diagnosis of pediatric solid tumors. Among the 204 patients with genomic results, 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%), respectively. Oncogenic fusions were noted in 45 (23%) patients. A copy number alteration was identified in at least one genomic region in 170 (83%) patients. Two patients exhibited a high tumor mutation burden. Seventeen (8%) patients harbored a germline pathogenic/likely pathogenic variant in cancer-predisposing genes. This study highlighted the feasibility of implementing a nationwide precision medicine platform and the clinical utility of the TOP2 system for pediatric cancers. The results support the integration of genomic data into the standard clinical care of pediatric patients with cancer, both at diagnosis and at relapse.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">genomic medicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">integrative diagnosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecularly targeted therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multigene panel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pediatric cancers</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1472-6831</Issn>
      <Volume>25</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Evaluation of Streptococcus mutans strains possessing genes encoding collagen-binding proteins in the Japanese population</ArticleTitle>
    <FirstPage LZero="delete">1908</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Suehiro</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jinthana</FirstName>
        <LastName>Lapirattanakul</LastName>
        <Affiliation>Department of Oral Microbiology, Faculty of Dentistry, Mahidol University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Naka</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiyo</FirstName>
        <LastName>Matsumoto-Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rena</FirstName>
        <LastName>Okawa</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Streptococcus mutans harbors collagen-binding protein genes, namely cnm and cbm, which are implicated in its virulence and pathogenicity in both oral and extraoral infections. Although both genes were initially identified in S. mutans isolated from Japanese populations, their geographical prevalence, distribution, and genetic relatedness within Japan remain largely unexplored. This study investigates the prevalence of S. mutans strains carrying cnm and cbm genes across Japan, correlates these findings with clinical data, and analyzes the genetic relatedness of cnm-positive and cnm-negative strains using multilocus sequence typing (MLST).&lt;br&gt;
Methods Dental plaque specimens were collected from 1248 individuals from eight Japanese cities (Hiroshima, Fukuoka, Nagasaki, Niigata, Okayama, Osaka, Tokushima, and Tokyo) and plated on selective medium for S. mutans isolation. S. mutans was confirmed in 523 subjects by colony morphology and PCR using species-specific primers, and the presence of the cnm and cbm genes was determined by PCR with gene-specific primers. Demographic (age, sex) and oral examination (caries prevalence, caries experience, number of teeth) data were recorded. MLST was employed to genotype selected cnm-positive and cnm-negative S. mutans strains to assess their clonal relationships.&lt;br&gt;
Results Among 523 subjects possessing S. mutans (aged 3&#8211;90 years), we detected cnm-positive strains in all cities; specifically, the prevalence ranged from 5.5% in Okayama to 25.0% in Tokushima. In contrast, cbm-positive strains were less common and undetectable in some regions. Furthermore, subjects harboring cnm-positive S. mutans were significantly older (p&#8201;=&#8201;0.002) and had higher caries prevalence and experience (p&#8201;&lt;&#8201;0.001). MLST revealed evolutionary relationships among cnm-positive strains across the cities but no discernible region-specific clustering. Clonal relationships partially reflected cnm gene distribution, particularly for exclusively cnm-positive or cnm-negative clonal complexes, but inconsistencies involving serotypes and cnm presence within some clonal complexes and sequence types were also noted.&lt;br&gt;
Conclusions The cnm-positive S. mutans strains are widely distributed throughout Japan and are associated with increased age and caries burden. Although core genome analysis revealed some clonal patterns, the non-uniform distribution of the non-core cnm gene is likely influenced by horizontal gene transfer, providing S. mutans with adaptive advantages irrespective of its core genetic background or serotype.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Collagen-binding protein gene</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cnm gene</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cbm gene</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multilocus sequence typing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Serotype</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Streptococcus mutans</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2399-3642</Issn>
      <Volume>8</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A genome-wide association study identifies the GPM6A locus associated with age at onset in ALS</ArticleTitle>
    <FirstPage LZero="delete">1720</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Genki</FirstName>
        <LastName>Tohnai</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Atsuta</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Keio University Regenerative Medicine Research Center, Kawasaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahisa</FirstName>
        <LastName>Katsuno</LastName>
        <Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuishin</FirstName>
        <LastName>Izumi</LastName>
        <Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuya</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Division of Neurology, Department of Internal Medicine, Jichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuko</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Yabe</LastName>
        <Affiliation>Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Nakazato</LastName>
        <Affiliation>Department of Neurology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobutaka</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Neurology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehisa</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Neurology, Toho University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Department of Neurology, Toho University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asako</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Neurology, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Aoki</LastName>
        <Affiliation>Department of Neurology, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumoto</FirstName>
        <LastName>Shibuya</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kuwabara</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Neurology, Vihara Hananosato Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rina</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Neurology, NHO Higashinagoya National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuko</FirstName>
        <LastName>Aiba</LastName>
        <Affiliation>Department of Neurology, NHO Higashinagoya National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Ishihara</LastName>
        <Affiliation>Department of Neurology, Brain Research Institute, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Onodera</LastName>
        <Affiliation>Department of Neurology, Brain Research Institute, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kota</FirstName>
        <LastName>Bokuda</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Neurological Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Neurological Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Neurology, Gunma University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuko</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Division of Neurology, NHO Sagamihara National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiaki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Yokota</LastName>
        <Affiliation>Department of Neurology and Neurological Science, NucleoTIDE and PepTIDE Drug Discovery Center (TIDE), Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuaki</FirstName>
        <LastName>Kanai</LastName>
        <Affiliation>Department of Neurology, Fukushima Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu-ichi</FirstName>
        <LastName>Noto</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuji</FirstName>
        <LastName>Kaji</LastName>
        <Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirohisa</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Neurology, Fujita Health University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Konishi</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikiko</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hozuki</FirstName>
        <LastName>Fukaya</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun-ichi</FirstName>
        <LastName>Niwa</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Doyu</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Neurology, Aichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiho</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Keio University Regenerative Medicine Research Center, Kawasaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiko</FirstName>
        <LastName>Ozawa</LastName>
        <Affiliation>Keio University Regenerative Medicine Research Center, Kawasaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Keio University Regenerative Medicine Research Center, Kawasaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Nakatochi</LastName>
        <Affiliation>Public Health Informatics Unit, Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gen</FirstName>
        <LastName>Sobue</LastName>
        <Affiliation>Division of ALS Research, Aichi Medical University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Amyotrophic lateral sclerosis (ALS) exhibits considerable clinical variability, such as differences in age at onset (AAO). Multiple factors, including genetic factors, may underlie this variability; however, the specific determinants remain unclear. To identify genes affecting AAO, we have conducted a genome-wide association study in Japanese patients with ALS (discovery cohort: n&#8201;=&#8201;1808; replication cohort: n&#8201;=&#8201;207). Here, we show that the minor A allele of rs113161727 at the ADAM29-GPM6A locus is associated with a younger AAO in the discovery cohort (effect, -4.27 years; p&#8201;=&#8201;4.60 ~ 10-8); this finding has been confirmed in the replication cohort (p&#8201;=&#8201;0.0068) and meta-analysis (p&#8201;=&#8201;1.08 ~ 10|9). Among 65 ALS patients with a SOD1 mutation, the AAO has been found to be 10.2 years younger in those with the A allele than in those without it (p&#8201;=&#8201;0.002). This variant correlates with GPM6A upregulation in iPSC-derived motor neurons, suggesting GPM6A as a candidate AAO modifier. Overall, our study highlights the impact of genetic modifiers on ALS heterogeneity and provides a potential target for delaying disease onset.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Informa UK Limited</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2167-8421</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel in-frame duplication variant of SOD1 in a Japanese family with familial amyotrophic lateral sclerosis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Naruse</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Riku</LastName>
        <Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitsugu</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shimon</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Division of Neurology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Pathology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Moro</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Kotsuki</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Tokushige</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Uchibori</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chizuko</FirstName>
        <LastName>Oishi</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yabata</LastName>
        <Affiliation>Department of Neurology, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Urushitani</LastName>
        <Affiliation>Department of Neurology, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yaeko</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Neurology, Kyorin University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: To analyze the cases of a family with a novel in-frame duplication variant (NM_000454.5:c.357_357&#8201;+&#8201;2dup, p.Val120dup) of SOD1 and a structural model of the mutated SOD1 protein. Methods: The clinical profiles of three patients in the family were analyzed, including the neuropathological findings of the probandfs mother. Genetic analyses were conducted for three patients. cDNA and in silico structural analyses were performed to evaluate the effects of duplication variants on the structure of SOD1. Results: The clinical features of the patients included predominant involvement of the lower motor neurons, asymmetric onset of motor symptoms in the lower limbs, and a relatively rapid progression of muscular weakness and respiratory insufficiency. Neuropathological findings revealed severe loss of spinal cord motor neurons, and immunohistochemistry using an anti-misfolded SOD1 antibody revealed aggregates in the spinal cord. Genetic analyses revealed a c.357_357&#8201;+&#8201;2dup at the exon 4&#8211;intron 4 boundary of SOD1 in three patients. cDNA analysis of the proband suggested the presence of a valine (p.Val120dup) duplication in the heterozygous state, and the SOD1 transcript level showed no significant differences from those of healthy controls. In silico structural analyses predicted that p.Val120dup could affect the structure of the ƒÀ-barrels and copper ion binding site of SOD1, suggesting an abnormal conformation of SOD1 that is predicted to interfere with the binding of copper ions. Conclusion: We identified a novel in-frame duplication variant in the C-terminus of ƒÀ7 of SOD1. This genotype&#8211;structure&#8211;phenotype study of SOD1 provides valuable insights into disease-causing mechanisms.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Familial amyotrophic lateral sclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SOD1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">in-frame duplication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">protein structure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">misfolded protein</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2328-9503</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dorsolateral Cervical Cord T2 Hyperintensity in KIF1C-Related Disease (Spastic Paraplegia 58): Two Long-Duration Cases</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Osaki</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Osako</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chisen</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Neurology, Tokyo Metropolitan Kita Medical and Rehabilitation Center for the Disabled</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Kurokawa</LastName>
        <Affiliation>Department of Radiology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Harushi</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Radiology, School of Medicine, Jichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pathogenic variants in KIF1C cause Spastic Paraplegia 58 (SPG58), typically presenting with cerebellar ataxia and spastic paraparesis. We report two unrelated patients with spastic paraparesis, cerebellar ataxia, and tremor. Whole-exome sequence analysis identified novel homozygous variants in the motor domain of KIF1C (NM_006612.6): c.921G&gt;A (p.Trp307Ter) and c.607C&gt;T (p.Arg203Trp). In addition to the canonical brain MRI showing leukoencephalopathy with posterior dominance and hyperintensity along the corticospinal tracts, both patients showed symmetric T2 hyperintensity confined to the lateral and dorsal columns of the cervical cord. Given the long disease durations (22 and 51&#8201;years), these findings may represent late-emerging or previously overlooked spinal cord involvement and broaden the neuroradiological spectrum of SPG58.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cerebellar ataxia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hereditary spastic paraplegia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KIF1C</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">leukoencephalopathy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>63</Volume>
      <Issue>13</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Activated CD4+ T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy</ArticleTitle>
    <FirstPage LZero="delete">1863</FirstPage>
    <LastPage>1872</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuntaro</FirstName>
        <LastName>Ikegawa</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital, Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chihiro</FirstName>
        <LastName>Kamoi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisakazu</FirstName>
        <LastName>Nishimori</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Division of Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Division of Blood Transfusion, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-ichi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective Chimeric antigen receptor (CAR) T cell therapy is an emerging and effective therapy for relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL). The characteristic toxicities of CAR T cell therapy include cytokine release syndrome (CRS) and prolonged cytopenia. We investigated the factors associated with these complications after CAR T cell therapy by analyzing lymphocyte subsets following CAR T cell infusion.&lt;br&gt;
Methods We retrospectively analyzed peripheral blood samples on days 7, 14, and 28 after tisagenlecleucel (tisa-cel) infusion by flow cytometry at our institution between June 2020 and September 2022.&lt;br&gt;
Patients Thirty-five patients with R/R DLBCL who received tisa-cel therapy were included.&lt;br&gt;
Results A flow cytometry-based analysis of blood samples from these patients revealed that the proportion of CD4+CD25+CD127+ T cells (hereafter referred to as "activated CD4+ T cells" ) among the total CD4+ T cells on day 7 after tisa-cel infusion correlated with the duration of CRS (r=0.79, p&lt;0.01). In addition, a prognostic analysis of the overall survival (OS) using time-dependent receiver operating characteristic curves indicated a significantly more favorable OS and progression-free survival of patients with a proportion of activated CD4+ T cells among the total CD4+ T cells &lt;0.73 (p=0.01, and p&lt;0.01, respectively).&lt;br&gt;
Conclusion These results suggest that the proportion of activated CD4+ T cells on day 7 after tisa-cel infusion correlates with the CRS duration and predicts clinical outcomes after CAR T cell therapy. Further studies with a larger number of patients are required to validate these observations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chimeric antigen receptor T cell therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diffuse large B cell lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">flow cytometry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cytokine release syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prolonged cytopenia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1873-9601</Issn>
      <Volume>19</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Interaction between nuclear]translocated cellular communication network factor 2 and purine]rich box 1 regulates the expression of fibrosis]related genes</ArticleTitle>
    <FirstPage LZero="delete">e70051</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Xuan Thi</FirstName>
        <LastName>Nguyen</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaharu</FirstName>
        <LastName>Takigawa</LastName>
        <Affiliation>Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences  Okayama Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cellular communication network factor 2 (CCN2) with a nuclear localization signal-like peptide is known to promote fibrosis. However, translocation of CCN2 into the nucleus and its role in fibrosis remain unclear. We hypothesized that nuclear-translocated CCN2 is associated with purine-rich box 1 (PU.1), which is a transcription factor regulating the differentiation of myofibroblasts. Western blot analysis of the cytoplasmic and nuclear fractions of cell lysate and immunofluorescence analysis revealed that CCN2 was detectable in both the cytoplasm and nuclei of murine fibroblastic NIH3T3 cells. Additionally, chromatin immunoprecipitation (IP)-PCR and an electrophoretic mobility shift assay revealed that recombinant CCN2 protein bound to the regulatory region of Spi1, which encodes PU.1. Furthermore, IP-Western blot analysis showed that CCN2 interacted with PU.1. Finally, the forced expression of both Ccn2 and Spi1 significantly promoted the production of angiotensin II, and increased fibrosis-related molecules, such as Col1a1 and Acta2, at the gene and protein levels. These findings indicate that CCN2 translocated to the nucleus interacts with PU.1 and that the complex promotes the markers of myofibroblast differentiation, suggesting that CCN2 plays an important role in fibrosis via cooperation with PU.1, as a transcription co-factor.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cellular communication network factor 2 (CCN2)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibrosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">myofibroblast</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">purine]rich box 1 (PU.1)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transcription co]factor</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1085-9489</Issn>
      <Volume>30</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Case of Retinopathy&#8211;Sensory Neuropathy Syndrome With a Novel Compound Heterozygous FLVCR1 Variant</ArticleTitle>
    <FirstPage LZero="delete">e70082</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yumiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Fukui</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Deguchi</LastName>
        <Affiliation>Department of Neurology, Okayama City General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohito</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Taira</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayaka</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Osakada</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taijun</FirstName>
        <LastName>Yunoki</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emi</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mami</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Morihara</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aims: Retinopathy&#8211;sensory neuropathy syndrome (RETSNS), also known as posterior column ataxia with retinitis pigmentosa (PCARP), is a rare neurodegenerative disorder that is caused by biallelic pathogenic variants in FLVCR1. Here, we report a case of a Japanese patient with RETSNS.&lt;br&gt;
Methods: Clinical, neuroradiological, and electrophysiological findings were documented. Whole-genome sequencing was performed. Subcloning was carried out to confirm compound heterozygosity. A functional assay was performed to assess the pathogenicity of the variants.&lt;br&gt;
Results: The patient showed retinitis pigmentosa and sensory ataxia. Over the course of the disease, autonomic dysfunction has become increasingly evident. Despite consanguinity in the family, whole-genome sequencing identified two heterozygous variants in FLVCR1 (c.369T&gt;G, p.Phe123Leu and c.733A&gt;G, p.Asn245Asp). Cloning of the PCR product followed by Sanger sequencing indicated compound heterozygosity of the variants. Immunocytochemistry of HEK293FT cells transfected with plasmids containing wild-type or variant FLVCR1 cDNA demonstrated altered subcellular localization of the variant FLVCR1 proteins, characterized by reduced membrane localization.&lt;br&gt;
Interpretation: We report a novel variant in FLVCR1 causing RETSNS. The functional assay supports the pathogenicity of the variants.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">FLCVR1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">functional analysis </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">posterior column ataxia with retinitis pigmentosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">subcellular localization</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2049-4173</Issn>
      <Volume>13</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Identification of New Repeat Expansion Diseases</ArticleTitle>
    <FirstPage LZero="delete">244</FirstPage>
    <LastPage>249</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama UniversityGraduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Through a genetic study of benign adult familial myoclonus epilepsy (BAFME) type 1, TTTCA and TTTTA repeat expansions have been identified in intron 4 of SAMD12. Lengths of expanded repeats inversely correlated with age at onset of epilepsy. Gain-of-toxic function mechanisms are suggested by the presence of UUUCA-repeat-containing RNA foci. From families with BAFME who did not have repeat expansions in SAMD12, we identified expanded TTTCA and TTTTA repeats in TNRC6A and RAPGEF2. These findings indicated a strong correlation between the repeat motif and the phenotype, leading to the identification of other types of BAFME. We then conducted genetic analysis of neuronal intranuclear inclusion disease (NIID), oculopharyngeal myopathy with leukoencephalopathy (OPML), and oculopharyngodistal myopathy (OPDM). From the observation that NIID, OPML, and OPDM, in addition to fragile X-associated tremor/ataxia syndrome, have shared clinical features, a direct search for CGG repeat expansions successfully led to the identification of the causative genes. Here, I review recent studies on repeat expansions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2452-199X</Issn>
      <Volume>57</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Robust adhesion between solid-state hydroxyapatite and bone tissue through surface demineralization</ArticleTitle>
    <FirstPage LZero="delete">632</FirstPage>
    <LastPage>645</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shichao</FirstName>
        <LastName>Xie</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Division of Biomaterials Science and Engineering, Graduate School of Dentistry, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruyuki</FirstName>
        <LastName>Aoyagi</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihisa</FirstName>
        <LastName>Otaka</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaofeng</FirstName>
        <LastName>Yang</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Division of Materials and Manufacturing Science, Graduate School of Engineering, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Current bone adhesives typically lack adequate mechanical strength, long-term stability, or biocompatibility. To address these limitations, we designed a new adhesion strategy using a solid-state hydroxyapatite (HAp) adhesive in combination with bone surface demineralization.&lt;br&gt;
Methods: Solid-state HAp adhesives were synthesized via wet chemical precipitation and heat treatment. Cortical bone specimens were partially demineralized with phosphoric acid (H3PO4) or ethylenediaminetetraacetic acid (EDTA), and characterized using scanning electron microscopy (SEM) and attenuated total reflectance&#8211;Fourier transform infrared spectroscopy (ATR-FTIR). Shear adhesion strength of HAp to demineralized bone was measured over time. In vivo fixation was assessed in rats using micro-computed tomography and histology. Statistical analysis used Tukey-Kramer tests after normality and variance checks.&lt;br&gt;
Results: Although the HAp adhesive failed to adhere to non-demineralized bone, effective adhesion was achieved on the surface-demineralized bone tissue. Shear adhesion strength was significantly higher in EDTA-treated samples (238.4 kPa at 10 h) compared to H3PO4-treated samples (102.9 kPa at 1 h), with performance correlating with demineralization depth. ATR-FTIR and SEM analyses revealed that EDTA preserved collagen's triple-helix structure and free water content, both enhancing adhesion. Animal experiments confirmed stable fixation of HAp adhesive to demineralized bone tissue.&lt;br&gt;
Conclusions: Surface demineralization enabled strong adhesion of the solid-state HAp adhesive to bone by exposing collagen swollen with water. Adhesion strength was influenced by structural changes in the demineralized layer, and the adhesive provided stable in vivo fixation, supporting its potential for bone-anchored biomedical applications.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Solid-state adhesive</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hydroxyapatite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Demineralized bone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Collagen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hydration</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Exacerbation of Proteinuria in a Patient with Beh&#231;etfs Disease and IgA Nephropathy Following Colchicine Discontinuation</ArticleTitle>
    <FirstPage LZero="delete">457</FirstPage>
    <LastPage>461</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Asakawa</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Sakurabu</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Onishi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Matsuoka-Uchiyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemi</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoko</FirstName>
        <LastName>Umebayashi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69849</ArticleId>
    </ArticleIdList>
    <Abstract>This case involves a 23-year-old male who was diagnosed with Beh&#231;etfs disease 5 years ago and managed with colchicine. Two months ago, he underwent renal biopsy due to abnormal urinalysis and kidney dysfunction, leading to a diagnosis of IgA nephropathy. He subsequently underwent tonsillectomy followed by glucocorticoid pulse therapy. However, after the tonsillectomy, discontinuing colchicine led to increased proteinuria, despite the glucocorticoid pulse therapy. Upon reintroducing colchicine, urinary protein excretion decreased, achieving incomplete remission. These findings suggest that colchicine may be effective in decreasing proteinuria in patients with Beh&#231;etfs disease complicated by IgA nephropathy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Beh&#231;etfs disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IgA nephropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">colchicine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Recurrence of FVIII Inhibitor during Surgery in a Patient with Severe Hemophilia A Receiving Emicizumab Prophylaxis</ArticleTitle>
    <FirstPage LZero="delete">451</FirstPage>
    <LastPage>455</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Moe</FirstName>
        <LastName>Hagihara</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Seike</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Hayashino</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Yasuhara</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyohei</FirstName>
        <LastName>Kin</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Division of Transfusion and Cell Therapy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69848</ArticleId>
    </ArticleIdList>
    <Abstract>Emicizumab, a bispecific monoclonal antibody, benefits patients with severe hemophilia A. It alters laboratory assessments of coagulation activity, requiring anti-idiotype monoclonal antibodies for accurate monitoring. A 64-year-old man, receiving emicizumab regularly, was admitted for laminoplasty. We planned to use FVIII replacement during the perioperative period after confirming the disappearance of inhibitors, monitoring coagulation activity with anti-idiotype monoclonal antibodies. Activated partial thromboplastin time was prolonged on postoperative day 2, prompting an immediate switch to eptacog alfa. The patient recovered without bleeding. This case underscores the necessity of anti-idiotype monoclonal antibodies for accurate monitoring.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">emicizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">eptacog alfa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hemophilia A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anti-idiotype monoclonal antibodies to emicizumab</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration in Patients Aged 85 or Older</ArticleTitle>
    <FirstPage LZero="delete">405</FirstPage>
    <LastPage>412</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chihiro</FirstName>
        <LastName>Ouchi</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mio</FirstName>
        <LastName>Morizane Hosokawa</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Shiode</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Matoba</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuro</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69842</ArticleId>
    </ArticleIdList>
    <Abstract>We investigated the treatment outcomes of patients aged &#8805;85 years with neovascular age-related macular degeneration (nAMD) who received anti-vascular endothelial growth factor (anti-VEGF) therapy using either treat-and-extend (TAE) or pro re nata (PRN) regimens for 1 year in real-world clinical practice. Eighty-five eyes from 85 patients were included. Among them, types 1, 2, and 3 macular neovascularization and polypoidal choroidal vasculopathy were present in 27.1%, 17.6%, 18.8%, and 36.5%, respectively. TAE and PRN regimens were used in 43.5% and 56.5% of patients, respectively. At baseline, the PRN group was older and had worse best-corrected visual acuity (BCVA), greater central retinal thickness, and more intraretinal fluid than the TAE group. In the TAE group, the mean number of injections was 7.6, BCVA improved significantly, and all retinal fluid rates decreased. In the PRN group, the mean number of injections was 3.9, BCVA remained unchanged, and the rates of macular fibrosis and atrophy increased. No serious adverse events were observed in either group. Anti-VEGF therapy was safe for patients aged &#8805; 85 years with nAMD, and the TAE regimen effectively improved BCVA in this population. BCVA remained unchanged in the PRN-treated patients, with baseline disease severity and/or undertreatment potentially influencing the outcomes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anti-vascular endothelial growth factor therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neovascular age-related macular degeneration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">age</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">treat-and-extend</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pro re nata</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2772-5022</Issn>
      <Volume>5</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Amelioration of Cd-induced bone deterioration by orally administered calcium phosphate</ArticleTitle>
    <FirstPage LZero="delete">101482</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ping-chin</FirstName>
        <LastName>Sung</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ahmad</FirstName>
        <LastName>Bikharudin</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Randa</FirstName>
        <LastName>Musa</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihisa</FirstName>
        <LastName>Otaka</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadaaki</FirstName>
        <LastName>Matsusaka</LastName>
        <Affiliation>Division of Materials and Manufacturing Science, Graduate School of Engineering, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aira</FirstName>
        <LastName>Matsugaki</LastName>
        <Affiliation>Division of Materials and Manufacturing Science, Graduate School of Engineering, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Division of Materials and Manufacturing Science, Graduate School of Engineering, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Biomaterials, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cadmium (Cd) is a heavy metal that accumulates in the body, primarily through daily grain intake, and has a high affinity for bone, leading to skeletal diseases such as osteomalacia and fractures. Hydroxyapatite (HAp), a major bone mineral component, is highly pH-sensitive and is known to incorporate Cd, as observed in studies of Itai-itai disease. Based on these findings, we hypothesized that HAp could serve as an effective oral detoxification material for heavy metals. This study investigated the efficacy of orally administered HAp in inhibiting Cd-induced changes in bone physical and chemical properties, comparing its effects to those of activated charcoal (AC), a common detoxifying agent. Six-week-old male ICR mice were exposed to cadmium via drinking water containing CdCl2 and subsequently given diets containing either HAp or AC for four weeks. Three-point bending tests, micro-CT analysis, and histological observations of the femurs demonstrated that mice receiving HAp exhibited improved mechanical strength and enhanced bone quality protection compared to the control and other Cd-treated groups. Activated charcoal also contributed to bone quality improvement at low concentrations, but its effect diminished at high concentrations. These results suggest that the oral administration of HAp may be a promising therapeutic strategy for suppressing cadmium-induced osteomalacia.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cadmium</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bone deterioration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Calcium phosphate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bone quality</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1473-0502</Issn>
      <Volume>64</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Factors affecting the development of hypokalemia during apheresis in healthy donors</ArticleTitle>
    <FirstPage LZero="delete">104195</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Fukumi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Ikeuchi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Division of Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Despite being generally safe, apheresis for peripheral blood stem cell collection potentially disrupts electrolyte balance owing to the use of citric acid as an anticoagulant. As prior research has primarily studied hypocalcemia, information on the kinetics of potassium levels during apheresis in healthy donors is scarce. We investigated the fluctuation in potassium levels during apheresis and the risk factors for hypokalemia. This subanalysis used data from an open-label, randomized controlled trial of goral calcium supplementation versus placebo in mitigating citrate toxicityh conducted between January 2021 and July 2022, at Okayama University Hospital. Potassium levels were significantly reduced after 5-day granulocyte colony-stimulating factor (G-CSF) administration (p&#8239;&lt;&#8239;0.0001), with seven patients (16.7&#8239;%) given oral potassium administration before apheresis because the treating physician deemed potassium levels potentially unsafe and three (7.1&#8239;%) presenting with hypokalemia at apheresis. Potassium levels after apheresis were significantly lower than those before apheresis (baseline; p&#8239;&lt;&#8239;0.0001), and 28 of 42 donors (66.7&#8239;%) experienced biochemical, clinically unapparent hypokalemia immediately after the completion of apheresis. A &gt;&#8239;15&#8239;% reduction in potassium levels from baseline was associated with age and the acid citrate dextrose solution A (ACD-A) volume in univariate analysis. In the multivariable analysis, both factors were associated (hazard ratio [HR], 11.60; 95&#8239;% confidence interval [CI], 1.60&#8211;83.70; p&#8239;=&#8239;0.02 and HR, 17.50; 95&#8239;% CI, 1.07&#8211;136.00; p&#8239;=&#8239;0.04). In conclusion, G-CSF administration and apheresis ultimately induced hypokalemia in two-thirds of the donors. Older age and higher ACD-A volume may affect potassium levels during apheresis in healthy donors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Allogeneic</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Peripheral blood stem cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypokalemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Acid citrate dextrose solution A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Healthy donors</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2399-3642</Issn>
      <Volume>8</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Single-cell and spatial transcriptomic characterization of pulmonary pleomorphic carcinoma</ArticleTitle>
    <FirstPage LZero="delete">1773</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Ohki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Ishimura</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryunosuke</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Higashihara</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Yoshichika</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiaki</FirstName>
        <LastName>Mukohara</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mao</FirstName>
        <LastName>Yoshikawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuma</FirstName>
        <LastName>Fukumoto</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Tomioka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaroh</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiichiro</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetaka</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pulmonary pleomorphic carcinoma (PPC) is a rare subtype of lung cancer that comprises both epithelial and sarcomatoid components. The molecular basis of PPC, including the cellular dynamics of its components, remains largely unknown. To elucidate potential therapeutic targets for PPC, we perform a multi-omics analysis incorporating digital spatial profiling and single-cell RNA sequencing (scRNA-seq). PPC exhibits diverse driver gene alterations, including MET exon 14 skipping mutation (METex14) and ALK fusion. In spatial transcriptomics, MET gene and protein are overexpressed exclusively within the epithelial component and not in the sarcomatoid component, even in patients harboring METex14. Epithelial-mesenchymal transition (EMT)-related transcriptional changes, along with extracellular matrix (ECM) remodeling between the epithelial and sarcomatoid components, are observed. scRNA-seq identifies cell populations within the epithelial component that contribute to the malignant transformation and differentiation of the sarcomatoid component. They are characterized by an intermediate EMT state with ECM remodeling signature, suggesting their potential as novel therapeutic targets for PPC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2468-2942</Issn>
      <Volume>45</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Neoadjuvant FOLFOXIRI for locally advanced rectal cancer: A retrospective analysis focusing on long-term anal preservation</ArticleTitle>
    <FirstPage LZero="delete">101049</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>To investigate the safety and efficacy of FOLFOXIRI as neoadjuvant chemotherapy (NAC) for locally advanced rectal cancer (LARC). The outcomes of preoperative and perioperative treatments, as well as long-term outcomes, were retrospectively compared between 26 patients who underwent FOLFOXIRI as NAC for LARC with cT3&#8211;4 and/or N+ at our institute between 2015 and 2022, and 31 patients with LARC who underwent neoadjuvant chemoradiotherapy (CAPOX-RT) at our institute between 2011 and 2022. Grade 3 or higher adverse events due to neoadjuvant treatment were significantly more common in the FOLFOXIRI group (11 cases, 42.3 %) than in the CAPOX-RT group (3 cases, 9.7 %), and most of these were neutropenia. Based on the postoperative pathological findings, the complete response rate was significantly lower in the FOLFOXIRI group (1 case, 3.8 %) than in the CAPOX-RT group (7 cases, 22.6 %), but there were no significant differences in the R0 resection rate, survival rate, or relapse-free survival rate. In the CAPOX-RT group, 17 patients (54.8 %) had anal preservation, and during the observation period, 4 patients required stoma construction due to loss of anal function in the late stage. In contrast, in the FOLFOXIRI group, there were no cases of loss of anal function among the 20 patients (76.9 %) who had anal preservation. FOLFOXIRI as NAC requires caution regarding hematological toxicity, but it can be an effective treatment option for patients with LARC who wish to preserve their anus.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Locally advanced rectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neoadjuvant chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FOLFOXIRI</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Late pelvic toxicity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2304-6767</Issn>
      <Volume>13</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of miR-128-3p on Renal Inflammation in a Rat Periodontitis Model</ArticleTitle>
    <FirstPage LZero="delete">577</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mohammad</FirstName>
        <LastName>Nurhamim</LastName>
        <Affiliation>Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yixuan</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Momoko</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Fukuhara</LastName>
        <Affiliation>Department of Preventive Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosei</FirstName>
        <LastName>Nagashima</LastName>
        <Affiliation>Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Oral Health, Takarazuka University of Medical and Health Care</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ekuni</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: The study aim was to investigate the effects of extracellular vesicles (EVs) derived miR-128-3p on renal inflammation using a rat periodontitis model. Methods: Ten-week-old male Wistar rats were divided into two groups: a control (n = 8) and a lipopolysaccharides (LPS) group (n = 8). The LPS group received LPS (Porphyromonas gingivalis) injection in the gingiva for 7 days. At the end of the experiment, plasma, gingival tissue, and kidney samples were collected. Hematoxylin and eosin staining was performed to evaluate the glomerular tissue injury score. Bioinformatic analysis was conducted to identify potential target genes of miR-128-3p. The reverse transcription-quantitative polymerase chain reaction was performed to evaluate miR-128-3p, inflammatory, pro-inflammatory cytokine, chemokine and predicting genefs expression. The control and LPS groups were compared using Welchfs t-test. p-values &lt; 0.05 were considered to indicate statistical significance. Results: The kidney glomerular tissue injury score was significantly higher in the LPS than in the control group. miR-128-3p expression in the LPS group was significantly higher in the gingival tissue and plasma. mRNAs (interleukin [IL]-1ƒÀ, tumor necrosis factor [TNF]-ƒ¿, C-X3-C motif chemokine ligand 1 [CX3CL1], and C-X-C motif chemokine ligand 7 [CXCL7]) expression was higher in the kidney of the LPS group. The potential target genes of activin A receptor type I (Acvr1), ribosomal protein S6 kinase B1 (Rps6kb1), and transforming growth factor beta receptor type 1 (Tgfbr1) were significantly lower in the kidneys of the LPS group. Conclusions: EVs-derived miR-128-3p in LPS induced periodontitis may cause kidney inflammation which may be mediated by, Rps6kb1, Tgfbr1, and Acvr1.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">extracellular vesicles</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">miR-128-3p</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mRNA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lipopolysaccharide</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0915-5635</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>EUS-Guided Versus Percutaneous Transhepatic Drainage of Liver Abscesses: A Multicenter Endohepatology Study in Western Japan (EPIC-LA Study)</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ogura</LastName>
        <Affiliation>Pancreatobiliary Advanced Medical Center, Osaka Medical and Pharmaceutical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taira</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Gastroenterology Center, Ehime Prefectural Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Matsuura</LastName>
        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kitadai</LastName>
        <Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koh</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>Department of Gastroenterology, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Itonaga</LastName>
        <Affiliation>Second Department of Internal Medicine, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotaro</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Department of Gastroenterology, Tane General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Matsumori</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Emori</LastName>
        <Affiliation>Department of Gastroenterology, Wakayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Takenaka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Imai</LastName>
        <Affiliation>Department of Gastroenterology, Okanami General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Mandai</LastName>
        <Affiliation>Department of Gastroenterology, Kyoto Second Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Shintani</LastName>
        <Affiliation>Department of Gastroenterology, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Shiomi</LastName>
        <Affiliation>Division of Hepatobiliary and Pancreatic Diseases, Department of Gastroenterology, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Sagami</LastName>
        <Affiliation>Department of Gastroenterology, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotsugu</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Ikeura</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Kansai Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Shimatani</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kansai Medical University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidefumi</FirstName>
        <LastName>Nishikiori</LastName>
        <Affiliation>Department of Gastroenterology, Oita San-ai Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Endoscopy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahito</FirstName>
        <LastName>Kokubu</LastName>
        <Affiliation>Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Kamada</LastName>
        <Affiliation>Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akitoshi</FirstName>
        <LastName>Hakoda</LastName>
        <Affiliation>2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Kitano</LastName>
        <Affiliation>Second Department of Internal Medicine, Wakayama Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Percutaneous transhepatic liver abscess drainage (PTAD) and endoscopic ultrasound-guided liver abscess drainage (EUS-LAD) have several limitations. Recently, because of technical improvements in echoendoscope maneuvers, EUS-guided access for the right hepatic lobe has been reported. The aim of this multicenter, retrospective study was to compare clinical outcomes of PTAD and EUS-LAD including the right hepatic lobe in West Japan.&lt;br&gt;
Method: This retrospective, multicenter study included consecutive patients with liver abscesses between January 2019 and November 2024. The primary outcome in this study was the clinical success rate compared between EUS-LAD and PTAD.&lt;br&gt;
Results: During the study period, 1012 consecutive patients developed liver abscesses. Of them, 734 patients were excluded, 43 underwent EUS-LAD and 235 patients underwent PTAD. After propensity score-matched analysis, the clinical success rate was significantly higher in the EUS-LAD group (97.7%, 42/43) than in the PTAD group (79.1%, 34/43) (p&#8201;=&#8201;0.007). After a propensity score-matched analysis, 25 patients were included in each group. The clinical success rate was significantly higher in the EUS-LAD group (100%, 25/25) than in the PTAD group (84%, 21/25) (p&#8201;=&#8201;0.037). Adverse events were also significantly higher in the PTAD group (16%, 5/25) than in the EUS-LAD group (p&#8201;=&#8201;0.025). In addition, the median length of hospital stay was significantly shorter in the EUS-LAD group (15&#8201;days) than in the PTAD group (22&#8201;days) (p&#8201;=&#8201;0.005).&lt;br&gt;
Conclusions: EUS-LAD using a metal stent might be one of the options, but further randomized, controlled trials are needed.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">drainage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endoscopic ultrasound-guided liver abscess drainage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EUS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">liver abscess</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">percutaneous transhepatic liver abscess drainage</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1424-3903</Issn>
      <Volume>25</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy of diagnosing intraductal papillary mucinous neoplasm with mural nodules by contrast-enhanced endoscopic ultrasound using time&#8211;intensity curve analysis with a new support program: A multicenter retrospective study (with video)</ArticleTitle>
    <FirstPage LZero="delete">1103</FirstPage>
    <LastPage>1108</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Saragai</LastName>
        <Affiliation>Department of Internal Medicine, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuneyoshi</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Internal Medicine, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Ueki</LastName>
        <Affiliation>Department of Internal Medicine, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisuke</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Terasawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Tsutsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Uemoto</LastName>
        <Affiliation>Business Strategy Division, Ryobi Systems Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayoshi</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Business Strategy Division, Ryobi Systems Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akimitsu</FirstName>
        <LastName>Ohto</LastName>
        <Affiliation>Business Strategy Division, Ryobi Systems Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/objectives: Preoperative diagnosis of the pathological grade of intraductal papillary mucinous neoplasms (IPMN) is challenging. This study aimed to evaluate the accuracy of contrast-enhanced endoscopic ultrasound (CE-EUS) using time&#8211;intensity curve (TIC) analysis with a newly developed support program to differentiate between low-grade dysplasia (LGD) and high-grade dysplasia (HGD)/invasive carcinoma (IC) in IPMN.&lt;br&gt;
Methods: This study retrospectively analyzed 32 patients who underwent CE-EUS using the support program for TIC analysis and IPMN resection (LGD: 17, HGD/IC: 15) at two medical centers. The TIC parameters of mural nodules (MN) were compared between the LGD and HGD/IC groups, and the diagnostic accuracies of the TIC parameters were evaluated.&lt;br&gt;
Results: The MN/pancreatic parenchyma contrast ratio was significantly higher in the HGD/IC group than in the LGD group (1.53 vs. 0.99; P &lt; 0.0001), and the diagnostic abilities of the contrast ratio were as follows: sensitivity, 67 %; specificity, 100 %; and accuracy, 84 %. There were no differences in the echo intensity reduction rate of the MNs between the two groups (HGD/IC, 61.6 vs. 61.2, 0.99; P = 0.421), and the diagnostic abilities of the reduction rate were as follows: sensitivity, 93 %; specificity, 41 %; and accuracy, 66 %.&lt;br&gt;
Conclusions: The contrast ratio calculated using TIC analysis with the support program is potentially useful for differentiating between IPMNs with LGD and those with HGD/IC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Endoscopic ultrasonography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pancreatic intraductal papillary mucinous neoplasm</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neoplasm grading</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Contrast agent</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-8076</Issn>
      <Volume>51</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Short]Term Impacts of Japan's 2024 Physician Working]Hour Limits on Labor Conditions, Self]Directed Professional Development, and Happiness Among Obstetrician]Gynecologists</ArticleTitle>
    <FirstPage LZero="delete">e70112</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Public Health, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Nakanishi</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Asahikawa Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eri</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Aiiku Maternal and Child Health Center, Aiiku Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, University of Fukui</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Kido</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Kido</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Japanese Red Cross Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Koga</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Reproductive Medicine Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Nippon Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukio</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Gynecology, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Haraga</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiko</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Healthcare Administration, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Umazume</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihito</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Iwase</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Gunma University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Saiseikai Matsusaka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, University of Fukui</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiki</FirstName>
        <LastName>Kudo</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Sugiyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Ehime University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyonori</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Nagasaki University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Yahata</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuya</FirstName>
        <LastName>Unno</LastName>
        <Affiliation>Center for Perinatal Medicine, JCHO Sagamino Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Kurasawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahide</FirstName>
        <LastName>Maenaka</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Higashiosaka City Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Etsuko</FirstName>
        <LastName>Miyagi</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoko</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhito</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Asahikawa Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: To examine the short-term impacts of Japan's newly implemented physician working-hour limits (April 2024) on working conditions, self-directed professional development (SDPD), defined as activities undertaken outside working hours to enhance one's professional skills, and work-related happiness among obstetrician-gynecologists (OB-GYNs).&lt;br&gt;
Methods: An online survey was conducted between July 8 and July 31, 2024, targeting 867 Japan Society of Obstetrics and Gynecology members. Five hundred and fourteen full-time practitioners who had not changed workplaces around April 2024 and had no missing data were analyzed. Participants were stratified by regulation levels (A, B, C, discretionary labor system, those who don't know their own level), and their working hours, anticipated income, SDPD satisfaction, and happiness (0&#8211;10 scale) were assessed. We used multivariate linear regression to evaluate the influence of labor condition changes on happiness and explored interactions involving unpaid overtime, income changes, and SDPD satisfaction.&lt;br&gt;
Results: Compared with level A (up to 960&#8201;h of overtime per year), participants at levels B and C (up to 1860&#8201;h of overtime per year) reported significantly lower happiness (p&#8201;&lt;&#8201;0.001). Most respondents observed no major shifts in working conditions since March 2024, yet about 40% did not record SDPD hours that meet the working hour requirement as official work time. Adjusted analyses revealed that decreased income and unsatisfactory SDPD significantly lowered happiness, whereas higher SDPD satisfaction increased it (ƒÀ: |0.64 [|1.07, |0.21], |0.98 [|1.46, |0.50], and 0.90 [0.44, 1.35], respectively). Subgroup analysis indicated that rising unpaid overtime further reduced happiness among those dissatisfied with SDPD (|1.43 [|2.41, |0.45]).&lt;br&gt;
Conclusions: The new working-hour limits had minimal impact on labor conditions in the short run. However, satisfaction with SDPD was positively associated with happiness, whereas anticipated decreases in income were correlated with lower happiness.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">gynecologists</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">happiness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">obstetrician</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">work style reform</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">working-hour limits</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0941-4355</Issn>
      <Volume>33</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Factors associated with period of sick leave after gynecologic cancer treatment: a prospective cohort study</ArticleTitle>
    <FirstPage LZero="delete">1087</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Tani</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanako</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Shirakawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoyuki</FirstName>
        <LastName>Ida</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Haraga</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Eto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Nagao</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Gynecologic cancer is one of the most common malignancies in working-age women. This study aimed to investigate factors associated with period of sick leave after gynecologic cancer treatment in Japan.&lt;br&gt;
Methods A prospective cohort study on period of sick leave was conducted among 207 cancer survivors who returned to work at the same workplace. Questionnaires were randomly distributed to patients aged under 65 years and more than one-year post-treatment. Clinical information was extracted from medical records, and the factors influencing the period of sick leave were analyzed using the Mann&#8211;Whitney U test and logistic regression analysis.&lt;br&gt;
Results Surgery plus more than six courses of chemotherapy (number (n)&#8201;=&#8201;41, 166.02&#8201;}&#8201;146.84 days) led to a significantly longer period of sick leave than surgery without lymph node dissection (n&#8201;=&#8201;64, 31.15&#8201;}&#8201;30.47 days), surgery with lymph node dissection (n&#8201;=&#8201;41, 55.56&#8201;}&#8201;85.90 days), surgery plus less than six courses of chemotherapy (n&#8201;=&#8201;21, 72.42&#8201;}&#8201;56.07 days), and radiotherapy alone (n&#8201;=&#8201;21, 58.85&#8201;}&#8201;84.24 days) (OR: 2.63, 2.95, 2.67, and 2.08; 95% CI: 7.71&#8211;54.59, 18.17&#8211;92.94, 18.22&#8211;126.63, and 2.38&#8211;115.33; p&#8201;=&#8201;0.009, p&#8201;=&#8201;0.004, p&#8201;=&#8201;0.009, and p&#8201;=&#8201;0.041). gynecologic cancer survivors who experienced adverse effects after treatment had a significantly longer period of sick leave (OR: 8.50; CI: 52.98&#8211;84.98; p&#8201;&lt;&#8201;0.001). In univariate and multivariate analyses, patients who received surgery plus more than six courses of chemotherapy were most involved in long period of sick leave than other factors (OR: 11.20, and 16.997; CI: 4.86&#8211;25.08, and 5.51&#8211;52.35; p&#8201;&lt;&#8201;0.001, and p&#8201;&lt;&#8201;0.001).&lt;br&gt;
Conclusion Patients with gynecologic cancer requiring long-term treatment required the most time to return to work.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Period of sick leave</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surgery plus chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Six or more cycles of chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gynecologic cancer survivors</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1078-8174</Issn>
      <Volume>32</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Optimization of the reconstruction kernel for temporal bone imaging using photon-counting detector CT: A combined physical and visual evaluation</ArticleTitle>
    <FirstPage LZero="delete">103274</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Nishii</LastName>
        <Affiliation>Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Asahara</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Morimitsu</LastName>
        <Affiliation>Division of Radiological Technology, Medical Support Department, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Kajisaki</LastName>
        <Affiliation>Division of Radiological Technology, Medical Support Department, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">N.</FirstName>
        <LastName>Akagi</LastName>
        <Affiliation>Division of Radiological Technology, Medical Support Department, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">M.</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Division of Radiological Technology, Medical Support Department, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">H.</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>College of Transdisciplinary Sciences for Innovation, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A.</FirstName>
        <LastName>Sugaya</LastName>
        <Affiliation>Department of Otolaryngology, Head &amp; Neck Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">K.</FirstName>
        <LastName>Munetomo</LastName>
        <Affiliation>Department of Radiology, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">F.</FirstName>
        <LastName>Higaki</LastName>
        <Affiliation>Department of Radiology, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Hiraki</LastName>
        <Affiliation>Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Iguchi</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Photon-counting detector CT (PCD-CT) offers superior spatial resolution and noise characteristics compared to conventional CT. However, optimal reconstruction parameters for temporal bone imaging, especially kernel selection, remain unclear. This study aimed to identify the optimal reconstruction kernel using both objective physical image quality metrics and subjective expert assessments.&lt;br&gt;
Methods: In phantom experiments, the system performance function (SPF) based on the task-based transfer function (TTF) and noise power spectrum (NPS) was calculated across 11 reconstruction kernels (Hr60&#8211;Hr98). Based on the results of the physical evaluation and clinical considerations from clinical practice, a subset of kernels was selected for visual assessment. For clinical images, two diagnostic radiologists evaluated three fine anatomical structures (i.e., stapes footplate, incudomalleolar joint, and cochlea) and overall image quality using both a ranking method and a 5-point Likert scale.&lt;br&gt;
Results: TTF analysis indicated that Hr96 had the highest spatial resolution, while Hr60 showed the lowest noise in the NPS. SPF analysis identified Hr72 as providing the optimal balance between resolution and noise. Visual assessment using four reconstruction kernels (Hr60, Hr72, Hr76, and Hr84) showed that Hr76 consistently received the highest preference for overall image quality and visualization of fine structures. Statistically significant differences were observed among the kernels, with Hr60 consistently rated the lowest (p &lt; 0.05).&lt;br&gt;
Conclusion: The kernel Hr76 was found suitable for middle and inner ear diagnoses using PCD-CT, providing a good balance between spatial resolution and image noise. This finding provides a foundation for standardized reconstruction protocols in high-resolution temporal bone imaging.&lt;br&gt;
Implications for practice: These findings support the use of Hr76 as a standard kernel for high-resolution temporal bone imaging and may contribute to protocol optimization in clinical PCD-CT practice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Photon-counting CT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Temporal bone imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Reconstruction kernel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Image quality</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2666-5204</Issn>
      <Volume>26</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Characteristics of out-of-hospital cardiac arrest due to cerebrovascular disorders: a nationwide, retrospective, observational study</ArticleTitle>
    <FirstPage LZero="delete">101145</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Tsukahara</LastName>
        <Affiliation>Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Department of Epidemiology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Department of Emergency, Critical Care, and Disaster Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Data on out-of-hospital cardiac arrest (OHCA) due to cerebrovascular disorders is limited. This study aimed to describe the characteristics, outcomes, and annual trends of outcomes for OHCA originating from cerebrovascular disorders.&lt;br&gt;
Methods: This study was a retrospective analysis using an Utstein-style Japanese National Registry. Adult patients with OHCA due to cerebrovascular disorders and transported to the hospital between 2005 and 2021 were included. The primary outcome was a favorable neurological outcome at 30-day. We analyzed factors associated with outcomes using a multivariable logistic regression model, then evaluated annual trends of outcomes for cerebrovascular-induced OHCA.&lt;br&gt;
Results: Among 2,081,023 OHCA patients, 52,969 had cerebrovascular-induced cardiac arrest. Of these, 1903 (3.5 %) achieved a favorable neurological outcome. In the multivariable logistic regression model, male sex (adjusted odds ratio [aOR] 1.41, 95 % confidence interval [CI] 1.20&#8211;1.61), initial shockable rhythm (aOR 3.10, 95 % CI 2.18&#8211;4.40), witnessed cardiac arrest (aOR 1.92, 95 % CI: 1.57&#8211;2.34), and prehospital return of spontaneous circulation (ROSC) (aOR 11.1, 95 % CI: 9.09&#8211;13.5) were associated with favorable neurological outcomes. Prehospital adrenaline administration was negatively associated with favorable neurological outcomes (aOR 0.22, 95 % CI: 0.16&#8211;0.30). The proportion of patients with favorable neurological outcomes increased over time, rising from 3.14 % in 2005 to 4.12 % in 2021.&lt;br&gt;
Conclusions: Although OHCA due to cerebrovascular disorders is generally associated with poor neurological outcomes, 3.5 % of the patients with cerebrovascular-induced OHCA in this study had favorable neurological outcomes, with a yearly trend improving over decades. Patient characteristics associated with a higher likelihood of a favorable neurological outcome included prehospital ROSC, initial shockable rhythm, and witnessed cardiac arrest.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cardiac arrest</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cardiopulmonary resuscitation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cerebral hemorrhage </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Stroke</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Subarachnoid hemorrhage</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of Use of GRADE, Protocol Registration, and Journal Impact Factor With Reporting and Methodological Quality of Systematic Reviews Published in Rehabilitation Journals: A Meta-Epidemiological Study</ArticleTitle>
    <FirstPage LZero="delete">e95695</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tsuge</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Physical Therapy, Faculty of Health Care, Takasaki University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akikazu</FirstName>
        <LastName>Hagiyama</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daijo</FirstName>
        <LastName>Shiratsuchi</LastName>
        <Affiliation>Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatsugu</FirstName>
        <LastName>Okamura</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Rehabilitation, Yamagata Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Rehabilitation, Yamagata Saisei Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Taito</LastName>
        <Affiliation>Systematic Reviewers, Scientific Research WorkS Peer Support Group (SRWS-PSG)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study aimed to identify factors associated with the reporting and methodological quality of systematic reviews (SRs) published in rehabilitation journals. We conducted a meta-epidemiological study as a secondary analysis of a previous study. The study protocol was registered in the Open Science Framework. We analyzed 219 SRs from rehabilitation journals published since 2020. We assessed reporting quality using the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 and methodological quality using A MeaSurement Tool to Assess systematic Reviews (AMSTAR) 2. Multiple linear regression and Spearman's correlation were used to identify factors associated with quality, including Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and the Journal Impact Factor (JIF). Multivariate analysis revealed PRISMA 2020 adherence was significantly associated with use of GRADE (ƒÀ = 4.33; 95% confidence interval (CI): 3.24-5.42), protocol registration (ƒÀ = 3.40; 95% CI: 2.32-4.47), and the JIF (2023) (ƒÀ = 0.69; 95% CI: 0.42-0.95). AMSTAR 2 adherence was also significantly associated with use of GRADE (ƒÀ = 2.52; 95% CI: 1.88-3.17), protocol registration (ƒÀ = 2.07; 95% CI: 1.44-2.70), and the JIF (2023) (ƒÀ = 0.29; 95% CI: 0.14-0.45). Weak positive correlations were observed between the JIF (2023) and both PRISMA 2020 and AMSTAR 2 adherence (ƒÏ = 0.27 and ƒÏ = 0.22, respectively; both P &lt; 0.01). It should be noted that these findings reflect associations and do not imply causality. To enhance the quality of SRs in rehabilitation, researchers should prioritize adherence to PRISMA 2020, particularly the use of GRADE and protocol registration, which this study identified as key associated factors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">citation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">grade</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">journal impact factor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">methodological and reporting quality</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prisma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-5042</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Analysis of the drug target of the anti-tuberculosis compound OCT313: phosphotransacetylase is a potential drug target for anti-mycobacterial agents</ArticleTitle>
    <FirstPage LZero="delete">e00463-25</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takemasa</FirstName>
        <LastName>Takii</LastName>
        <Affiliation>Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saotomo</FirstName>
        <LastName>Itoh</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Graduate School of Pharmaceutical Sciences, Hokkaido University of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Microbiology, Graduate School of Human Life and Ecology, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Horita</LastName>
        <Affiliation>Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Bacteriology, Niigata University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sohkichi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Bacteriology, Niigata University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Oral Microbiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aoi</FirstName>
        <LastName>Kimishima</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, &#332;mura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Asami</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, &#332;mura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeaki</FirstName>
        <LastName>Hida</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kikuo</FirstName>
        <LastName>Onozaki</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Tuberculosis (TB) is one of the most common infectious diseases caused by bacteria worldwide. The increasing prevalence of multidrug-resistant TB (MDR-TB) and latent TB infection (LTBI) has intensified the global TB burden. Therefore, the development of new drugs for MDR-TB and LTBI is urgently required. We have reported that the derivative of dithiocarbamate sugar derivative, 2-acetamido-2-deoxy-ƒÀ-D-glucopyranosyl N,N-dimethyldithiocarbamate (OCT313), exhibits anti-mycobacterial activity against MDR-MTB. Here, we identified the target of OCT313. In experimentally generated OCT313-resistant bacteria, adenine at position 1,092 in the metabolic enzyme phosphotransacetylase (PTA) gene was replaced with cytosine. This mutation is a nonsynonymous mutation that converts methionine to leucine at position 365 in the PTA protein. OCT313 inhibited the enzymatic activity of recombinant wild-type PTA, but not of the mutant PTA (M365L). PTA is an enzyme that produces acetyl-coenzyme A (acetyl-CoA) from acetyl phosphate and CoA and is involved in metabolic pathways; therefore, it was expected to also be active against dormant Mycobacterium tuberculosis bacilli. OCT313 exhibits antibacterial activity in the Wayne model of dormancy using Mycobacterium bovis BCG, and overexpression of PTA in OCT313-resistant bacilli restored sensitivity to OCT313. Collectively, the target of OCT313 is PTA, and OCT313 is a promising antimicrobial candidate for MDR-TB and LTBI.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">phosphotransacetylase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">acetyl coenzyme A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dithiocarbamate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">N-acetyl glucosamine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anti-mycobacterial agents</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">latent tuberculosis infection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Long intervals between repetitive concussions reduce risk of cognitive impairment and limit microglial activation, astrogliosis, and tauopathy in adolescent rats</ArticleTitle>
    <FirstPage LZero="delete">40522</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyohei</FirstName>
        <LastName>Kin</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Nagase</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Sasada</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Sugahara</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hayato</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Saijo</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Masai</LastName>
        <Affiliation>Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Yasuhara</LastName>
        <Affiliation>Yasuhara Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Although previous studies have demonstrated the effects of concussions do not accumulate as the time interval between injuries increases, little is known about the relationship between this interval and the effects of repetitive concussions. The objective of this study is to explore the relationship between the time interval and changes in behavior and histology following repetitive concussions. Male adolescent rats received concussions by weight drop and were randomly assigned to one of five experimental groups, receiving concussions three times either daily, every other day, once per week, once every 2 weeks, or receiving sham procedures. Only rats that received daily concussions exhibited cognitive impairment, while the other groups did not. No groups showed motor or anxiety-like impairments. Histological analysis revealed accumulation of microglia, as well as astrogliosis, in the prefrontal cortex, corpus callosum, dentate gyrus, and cornu Ammonis 1 region of the hippocampus in rats subjected to daily concussions. Accumulation of phosphorylated tau was also observed in the prefrontal cortex and cornu Ammonis 1. Longer intervals between concussions may reduce the risk of cognitive impairment and limit microglial activation, astrogliosis, and phosphorylated tau accumulation. These findings may help guide decisions on the appropriate timing for return to play in humans.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Concussion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Return to play</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sports-related head injury</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microglia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Astrocyte</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tauopathy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1349-0079</Issn>
      <Volume>68</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dynamin 2 is involved in osteoblast migration by regulating the organization of F-actin</ArticleTitle>
    <FirstPage LZero="delete">100720</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Moriya</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A.</FirstName>
        <LastName>Surong</LastName>
        <Affiliation>Department of Neuroscience, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Tatsumi</LastName>
        <Affiliation>Department of Neuroscience, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Neuroscience, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiko</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kamioka</LastName>
        <Affiliation>Department of Orthodontics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirohiko</FirstName>
        <LastName>Okamura</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mika</FirstName>
        <LastName>Ikegame</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: Dynamin, a GTPase that regulates membrane dynamics, has recently been implicated in actin cytoskeletal remodeling. This study aimed to elucidate the role of dynamin in osteoblast migration by examining the effects of dynamin inhibition on the localization and organization of F-actin and dynamin 2 in MC3T3-E1 cells.&lt;br&gt;
Methods: MC3T3-E1 cells were treated with dynamin inhibitors (Dyngo 4a and Dynole 34-2), and cell migration was assessed using a wound-healing assay. Fluorescent staining was performed to analyze the intracellular localization of F-actin and dynamin 2.&lt;br&gt;
Results: Dynamin inhibition significantly reduced the migration of MC3T3-E1 cells. Fluorescence analysis revealed a marked decrease in the accumulation and colocalization of F-actin and dynamin 2 at the protrusion edge. Additionally, dynamin inhibition suppressed the formation of lamellipodia and stress fibers while promoting the appearance of abnormal F-actin clusters in the cytoplasm.&lt;br&gt;
Conclusions: These findings suggest that dynamin plays an essential role in osteoblast migration by regulating actin cytoskeletal remodeling, particularly through the formation of lamellipodia and stress fibers.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Dynamin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cell migration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Osteoblasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">F-actin</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1478-6362</Issn>
      <Volume>27</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Does perioperative discontinuation of anti-rheumatic drugs increase postoperative complications in orthopedic surgery for rheumatoid arthritis?</ArticleTitle>
    <FirstPage LZero="delete">219</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiromu</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Rheumatology, Niigata Rheumatic Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeyoshi</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Osaka Minami Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Locomotive Pain Center, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Mochizuki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kamagaya General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Ebina</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Osaka University Faculty of Medicine Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihisa</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Toho University Omori Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Arata</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Department of Orthopaedic Surgery and Rehabilitation, Toho University Sakura Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nagoya Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isao</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Rehabilitation Medicine, Kanazawa Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>The Center for Rheumatic Diseases, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Sakuraba</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyushu Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukio</FirstName>
        <LastName>Akasaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Matsubara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Matsubara Mayflower Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Mochida</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Yokohama City University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuaki</FirstName>
        <LastName>Kanbe</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nippori Orthopaedics and Rheumatic Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuko</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kakogawa Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Momohara</LastName>
        <Affiliation>Endowed Course for Advanced Therapy for Musculoskeletal Disorders, Keio University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective This study aimed to investigate whether discontinuation of biological or targeted synthetic antirheumatic disease-modifying drugs (bDMARDs or tsDMARDs) influences the incidence of postoperative complications in patients with rheumatoid arthritis (RA) undergoing orthopedic surgery.&lt;br&gt;
Methods A retrospective multicenter cohort study including patients receiving bDMARDs or tsDMARDs who underwent orthopedic surgery was conducted. Data collected encompassed the duration of drug discontinuation and postoperative adverse events, such as delayed wound healing, surgical site infection (SSI), disease flare-ups, and mortality. The association between drug discontinuation and these outcomes was analyzed. Multivariate analyses were conducted to identify potential risk factors for these events.&lt;br&gt;
Results A total of 2,060 cases were initially enrolled. After applying inclusion and exclusion criteria, data from 1,953 patients were analyzed. No significant differences were observed between the groups regarding delayed wound healing, SSI, or mortality. However, the incidence of disease flare-ups was substantially higher in the drug discontinuation group and in the interleukin (IL)-6 inhibitor group. Multivariate analysis identified that tumor necrosis factor ƒ¿ and IL-6 inhibitor use was associated with a higher risk of delayed wound healing relative to T-cell function modifiers.&lt;br&gt;
Conclusion In orthopedic surgery for patients with RA, maintaining the standard or the half of administration interval of bDMARD appears safe in the preoperative period. However, the drug discontinuation may increase the risk of postoperative flare-ups, particularly with IL-6 inhibitors. In addition, T-cell function modifiers may be associated with a lower risk of delayed wound healing, suggesting their safety profile in this context.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rheumatoid arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Orthopaedic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DMARD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Perioperative complications</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0305-182X</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Is Pain Intensity Related to Psychosocial Factors in Chronic Non]Nociceptive Orofacial Pain Patients?</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Kawase</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumika</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukiko</FirstName>
        <LastName>Nishioka</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitomi</FirstName>
        <LastName>Ujita</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Kawauchi</LastName>
        <Affiliation>Department of Dental Anesthesiology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Dental Anesthesiology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: In order to understand the psychological aspects of chronic pain, it is important to consider the relationships between pain and psychosocial factors in patients with chronic pain. While psychosocial factors are known to affect pain intensity in temporomandibular disorders, few studies have evaluated them in patients with other types of chronic orofacial pain.&lt;br&gt;
Objective: The purpose of the present study was to evaluate the relationships between pain intensity and patient characteristics, diagnostic categories and psychosocial factors in chronic non-nociceptive orofacial pain patients.&lt;br&gt;
Methods: In a retrospective, cross-sectional study, we collected information from the medical records of 123 patients with chronic non-nociceptive orofacial pain. Pain intensity was measured using the Brief Pain Inventory (BPI) total score. Analysis of the correlations among the variables revealed several strong correlations. Principal component analysis identified two components: the psychological distress and self-efficacy/quality of life (QOL) components. Multiple linear regression analyses of the overall study population and each ICOP pain category were also performed.&lt;br&gt;
Results: In the overall sample, higher BPI scores were significantly associated with a greater psychological distress component and lower self-efficacy/QOL component. The pain category was not a significant predictor of the BPI score. In the subgroup analyses, both components were significant predictors of the BPI score in myofascial orofacial pain; whereas, only the self-efficacy/QOL component was in idiopathic orofacial pain.&lt;br&gt;
Conclusion: The results indicated that pain intensity in chronic non-nociceptive orofacial pain is related to the self-efficacy/QOL psychosocial factor component. These findings suggest that assessing psychosocial factors may be clinically important for the diagnosis and treatment of chronic orofacial pain.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chronic pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">International Classification of Orofacial Pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">orofacial pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psychological distress component</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psychosocial factors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">self-efficacy/ QOL component</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1473-0502</Issn>
      <Volume>64</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel leukocytapheresis method using highly concentrated sodium citrate solution for the manufacturing of tisagenlecleucel</ArticleTitle>
    <FirstPage LZero="delete">104265</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Ikeuchi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Division of Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>For the manufacturing of tisagenlecleucel (tisa-cel) requires the non-mobilized mononuclear cell collection (MNC). CD3+ cell collection is performed using the same protocol as autologous peripheral blood stem cell harvest (auto-PBSCH), but this procedure necessitates the same target CD3+ cell yields regardless of age or body weight, which may take several days especially in pediatric and small female patients with low white blood cell counts. We previously demonstrated a novel method using highly concentration sodium citrate (HSC), which reduced the need for an anticoagulant (AC) solution and shortened the procedure time in auto-PBSCH. This novel method was expected to offer advantages for smaller patients, prompting us to investigate its application in leukocytapheresis for the manufacturing of tisa-cel. We retrospectively analyzed consecutive leukocytapheresis data obtained using Spectra Optia continuous MNC mode between November 2022 and June 2024 at our institution (n&#8239;=&#8239;9). In six of nine patients, pre-leukocytapheresis CD3+ cell counts were less than 500 /ƒÊL, but all could obtain the target CD3+ cell yields in one day upon processing blood volume adjustment. When we compared patients who had received CD3+ cell collection using normal-concentration sodium citrate (NSC) as our previously reported using propensity score-matched pair analysis, the total AC solution volume was significantly lower (1168 vs. 316&#8239;mL, p&#8239;&lt;&#8239;0.001) and procedure time was significantly shorter (254 vs. 228&#8239;min, p&#8239;=&#8239;0.04) in the HSC group compared to the NSC group. In conclusion, this procedure was also useful for non-mobilized MNC. Our findings warrant validation in a larger patient cohort.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Chimeric antigen receptor T cell therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anticoagulant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Acid citrate dextrose solution A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Highly concentrated sodium citrate</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Risk Stratification for the Prediction of Skeletal-Related Events in Patients With Bone Metastases From Non-small Cell Lung Cancer</ArticleTitle>
    <FirstPage LZero="delete">e95808</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Orthopedic Surgery, Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Skeletal-related events (SREs) frequently occur in patients with bone metastases from non-small cell lung cancer (NSCLC). This study aimed to identify risk factors for SREs in patients with NSCLC. Based on these factors, we also aimed to stratify patients into subgroups to facilitate the assessment of SRE risk. This retrospective analysis used medical records of 139 patients with NSCLC bone metastases who received treatment at our institution between 2011 and 2014. The incidence of SREs was assessed, and SRE-free survival was analyzed using the Kaplan-Meier method. Clinical information collected at registration was assessed to identify factors associated with the onset of SREs within six months. Univariate analysis was performed using Fisherfs exact test, and multivariate analysis was performed using Cox regression. Of the 139 patients, 36 (26%) developed SREs after registration. The SRE-free survival rates were 80% and 64% at 6 and 12 months, respectively. The univariate and multivariate analyses revealed that the absence of epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangement (hazard ratio (HR): 4.51, 95% confidence interval (CI): 1.32-15.7, p = 0.017) and a lactate dehydrogenase (LDH) level &#8805;400 U/L (HR: 8.08, 95% CI: 1.78-36.6, p = 0.0067) were risk factors for SRE presentation within six months. Patients were classified into the following three subgroups: with EGFR mutation or ALK rearrangement and LDH level &lt;400 U/L; without EGFR mutation or ALK rearrangement and LDH level &lt;400 U/L; with/without EGFR mutation or ALK rearrangement and LDH level &#8805;400 U/L. The corresponding six-month SRE-free survival rates were 92%, 69%, and 34%, respectively, showing significant differences (p &lt; 0.001). Close monitoring is recommended for patients with LDH levels &#8805;400 U/L in daily clinical practice, particularly with the help of the proficiency of orthopedic and radiological experts, to prevent complications such as pathological fractures and paraplegia.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anaplastic lymphoma kinase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bone metastases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">epidermal growth factor receptor-tyrosine kinase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lactate dehydrogenase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">skeletal related events</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mid-term Clinical and Radiographic Outcomes of the Actis Total Hip System: A Retrospective Study</ArticleTitle>
    <FirstPage LZero="delete">e77632</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Masada</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Koura</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction&lt;br&gt;
Implant technology for total hip arthroplasty (THA) was developed to improve hip function and patient satisfaction. Actis (DePuy Synthes, Warsaw, IN, USA) is a short fit-and-fill titanium stem, with a medial-collared and triple-taper (MCTT) geometry, that is fully coated with hydroxyapatite (HA). We evaluated the radiographic and clinical outcomes of the Actis Total Hip System during a mean follow-up of five years.&lt;br&gt;
Patients and methods&lt;br&gt;
We retrospectively analyzed data from 80 patients (14 male and 66 female, mean age: 65 } 8.4 years) who underwent primary THA using Actis stems (anterolateral approach, 60 hips; posterior approach, 20 hips). Radiographs were obtained postoperatively and at the time of the final examination. Radiographic assessments included the alignment of the femoral stem, spot welds, stress shielding, cortical hypertrophy, subsidence (&gt;2 mm), radiolucent line, pedestal formation, Dorr type, canal fill ratio (CFR), and stem fixation. Clinical evaluation included the Japanese Orthopaedic Association Hip-Disease Evaluation Questionnaire (JHEQ) and Harris Hip Score (HHS).&lt;br&gt;
Results&lt;br&gt;
The mean follow-up period was 64.0 } 6.0 months. No significant differences were observed in the alignment of the femoral components between approaches. Of the 80 hips, 53 (66.3%) showed radiographic signs of stem osseointegration, predominantly in the mid-distal region of the stem at the final follow-up. Multiple logistic regression analysis revealed that younger age and a higher CFR (20 mm proximal to the lesser trochanter) were associated with the presence of spot welds. Mild stress shielding occurred in 25 hips (31.3%), and no patient experienced severe stress shielding. All stems were fixed by bone on growth. The JHEQ and HHS significantly improved at the final assessment.&lt;br&gt;
Conclusion&lt;br&gt;
At the five-year follow-up, patients who received the Actis Total Hip System during THA had good radiographic and clinical outcomes.&lt;br&gt;</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">actis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hydroxyapatite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mid-term outcome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spot welds</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stem</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">total hip arthroplasty</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0020-1383</Issn>
      <Volume>56</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Risk factors for extensor pollicis longus tendon rupture following non-displaced distal radius fractures</ArticleTitle>
    <FirstPage LZero="delete">112454</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Furutani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nakamichi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasunori</FirstName>
        <LastName>Shimamura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kousei Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junya</FirstName>
        <LastName>Imatani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Saiseikai General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Distal radius fractures (DRFs) are common, with an increasing incidence, particularly among the elderly. Rupture of the extensor pollicis longus (EPL) tendon, essential for thumb extension, is a notable complication, especially in non-displaced DRFs. Several mechanisms, such as local adhesion, ischemic atrophy, and tendon laceration, are associated with EPL tendon rupture. This multicenter retrospective study aims to identify risk factors for EPL tendon rupture in non-displaced DRFs.&lt;br&gt;
Materials and methods: The study reviewed 20 cases of EPL tendon rupture and 52 control cases from 2005 to 2022, excluding those who underwent surgery or had incomplete computed tomography (CT) data. We investigated age, sex, location of fracture line, and the morphology of Listerfs tubercle as variables. Logistic regression and decision tree analyses were employed to determine the risk factors for EPL tendon rupture based on these variables.&lt;br&gt;
Results: Fracture lines distal to Listerfs tubercle and specific shapes of Listerfs tubercle, characterized by shallow peak height and a higher radial peak than the ulnar peak, increased the risk of EPL tendon rupture. Decision tree analysis confirmed them as major risk factors. There was a significant difference in the predicted probability rate of tendon rupture between the case with these factors and those without them (P &lt; 0.001). Conversely, the location and size of Listerfs tubercle did not affect the incidence of EPL tendon rupture.&lt;br&gt;
Conclusion: The location of fracture line and the shape of Listerfs tubercle are key factors influencing EPL tendon rupture in non-displaced DRFs. Understanding these factors can help orthopedic surgeons predict and prevent EPL tendon ruptures, improving patient outcomes following these fractures.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Distal radius fracture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Extensor pollicis longus tendon</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Risk factor</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1434-3916</Issn>
      <Volume>145</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Changes in the anatomical positions of the femoral nerve and artery in the lateral and supine positions: a multicenter retrospective study</ArticleTitle>
    <FirstPage LZero="delete">373</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryuichiro</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Medical Materials for Musculoskeletal Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Tetsunaga</LastName>
        <Affiliation>Department of Sports Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Koura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Masada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisanori</FirstName>
        <LastName>Ikuma</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Komatsubara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction Femoral nerve palsy and femoral artery injury are serious complications of total hip arthroplasty. However, few studies have compared the anatomical positions of these structures in different patient positions. This study aimed to compare the anatomical positions of the femoral nerve and artery in the lateral and supine positions.&lt;br&gt;
Materials and methods This multicenter retrospective study included 111 patients who underwent lateral and supine computed tomography (CT) from 2016 to 2023. CT images were reconstructed in the anterior pelvic plane. The horizontal distance from the anterior margin of the acetabulum to the femoral nerve (Distance N) and femoral artery (Distance A) was measured. The difference in Distance N between the two positions (ƒ¢Lateral&#8211;supine Distance N) was calculated by subtracting the supine value from the lateral value.&lt;br&gt;
Results The average Distance N was 26.5&#8201;}&#8201;5.1 mm in the lateral position and 21.1&#8201;}&#8201;4.4 mm in the supine position, with the nerve located significantly closer to the acetabulum in the supine position (P&#8201;&lt;&#8201;0.001). Similarly, the average Distance A was 26.8&#8201;}&#8201;5.4 mm in the lateral position and 20.4&#8201;}&#8201;4.9 mm in the supine position (P&#8201;&lt;&#8201;0.001). Multiple regression analysis showed that Distance N in the lateral position was significantly shorter in female patients and those with low body weight. In addition, low body weight correlated with a smaller ƒ¢Lateral&#8211;supine Distance N.&lt;br&gt;
Conclusions The femoral nerve and artery are located closer to the anterior margin of the acetabulum in the supine position than in the lateral position. Low body weight was an independent predictor of shorter Distance N in both positions and a smaller ƒ¢Lateral&#8211;supine Distance N. These findings underscore the importance of considering patient positioning during total hip arthroplasty, particularly in patients with low body weight, to reduce neurovascular risks.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Total hip arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Femoral artery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Femoral nerve</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Computed tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lateral position</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Supine position</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1465-3621</Issn>
      <Volume>55</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review</ArticleTitle>
    <FirstPage LZero="delete">313</FirstPage>
    <LastPage>326</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Itonaga</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiro</FirstName>
        <LastName>Kaku</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery , Science of Functional Recovery and Reconstruction, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Oita University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In recent years, pembrolizumab has demonstrated significant efficacy in treating tumors characterized by a high tumor mutational burden and high microsatellite instability. Tropomyosin receptor kinase (TRK) inhibitors have shown considerable efficacy against tumors harboring neurotrophic receptor tyrosine kinase (NTRK) fusion genes, highlighting the growing importance of personalized medicine in cancer treatment. Advanced sequencing technologies enable the rapid analysis of numerous genetic abnormalities in tumors, facilitating the identification of patients with positive biomarkers. These advances have increased the likelihood of providing effective, tailored treatments. NTRK fusion genes are present in various cancer types, including sarcomas, and the TRK inhibitors larotrectinib and entrectinib have been effectively used for these malignancies. Consequently, the treatment outcomes for NTRK fusion-positive tumors have improved significantly, reflecting a shift toward more personalized therapeutic approaches. This review focuses on NTRK fusion-positive sarcomas and comprehensively evaluates their epidemiology, clinical features, and radiological and histological characteristics. We also investigated the treatment landscape, including the latest methodologies involving TRK inhibitors, and discussed the long-term efficacy of these inhibitors, and their optimal order of use. Notably, larotrectinib has demonstrated a high response rate in infantile fibrosarcoma, and its efficacy has been confirmed even in advanced cases. However, further research is warranted to optimize treatment duration and subsequent management strategies. The accumulation of clinical cases worldwide will play a pivotal role in refining the treatment approaches for tumors associated with NTRK fusion genes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">NTRK fusion-positive sarcoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">larotrectinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">entrectinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">infantile fibrosarcoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">NTRK-rearranged spindle cell neoplasms</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>17</Volume>
      <Issue>19</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Utility of Same-Modality, Cross-Domain Transfer Learning for Malignant Bone Tumor Detection on Radiographs: A Multi-Faceted Performance Comparison with a Scratch-Trained Model</ArticleTitle>
    <FirstPage LZero="delete">3144</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Joe</FirstName>
        <LastName>Hasei</LastName>
        <Affiliation>Department of Medical Informatics and Clinical Support Technology Development, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yujiro</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Radiology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Graduate School of Environmental, Life Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Plusman LCC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Ikuta</LastName>
        <Affiliation>Department of Orthopedic Surgery, Graduate School of Medicine, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Osaki</LastName>
        <Affiliation>Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironari</FirstName>
        <LastName>Tamiya</LastName>
        <Affiliation>Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Miwa</LastName>
        <Affiliation>Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shusa</FirstName>
        <LastName>Ohshika</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Hirosaki University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunji</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kindai University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoaki</FirstName>
        <LastName>Kahara</LastName>
        <Affiliation>Department of Orthopedic Surgery, Mizushima Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Science of Functional Recovery and Reconstruction, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Developing high-performance artificial intelligence (AI) models for rare diseases like malignant bone tumors is limited by scarce annotated data. This study evaluates same-modality cross-domain transfer learning by comparing an AI model pretrained on chest radiographs with a model trained from scratch for detecting malignant bone tumors on knee radiographs. Methods: Two YOLOv5-based detectors differed only in initialization (transfer vs. scratch). Both were trained/validated on institutional data and tested on an independent external set of 743 radiographs (268 malignant, 475 normal). The primary outcome was AUC; prespecified operating points were high-sensitivity (&#8805;0.90), high-specificity (&#8805;0.90), and Youden-optimal. Secondary analyses included PR/F1, calibration (Brier, slope), and decision curve analysis (DCA). Results: AUC was similar (YOLO-TL 0.954 [95% CI 0.937&#8211;0.970] vs. YOLO-SC 0.961 [0.948&#8211;0.973]; DeLong p = 0.53). At the high-sensitivity point (both sensitivity = 0.903), YOLO-TL achieved higher specificity (0.903 vs. 0.867; McNemar p = 0.037) and PPV (0.840 vs. 0.793; bootstrap p = 0.030), reducing ~17 false positives among 475 negatives. At the high-specificity point (~0.902&#8211;0.903 for both), YOLO-TL showed higher sensitivity (0.798 vs. 0.764; p = 0.0077). At the Youden-optimal point, sensitivity favored YOLO-TL (0.914 vs. 0.892; p = 0.041) with a non-significant specificity difference. Conclusions: Transfer learning may not improve overall AUC but can enhance practical performance at clinically crucial thresholds. By maintaining high detection rates while reducing false positives, the transfer learning model offers superior clinical utility. Same-modality cross-domain transfer learning is an efficient strategy for developing robust AI systems for rare diseases, supporting tools more readily acceptable in real-world screening workflows.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">malignant bone tumors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transfer learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">YOLO</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiographs</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cross-domain learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diagnostic imaging</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0916-9636</Issn>
      <Volume>48</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy and safety of esaxerenone with and without sodium&#8211;glucose cotransporter-2 inhibitor use in hypertensive patients with type 2 diabetes mellitus: a pooled analysis of five clinical studies</ArticleTitle>
    <FirstPage LZero="delete">2924</FirstPage>
    <LastPage>2937</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hirohiko</FirstName>
        <LastName>Motoki</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Kuwahara</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuomi</FirstName>
        <LastName>Kario</LastName>
        <Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Katsuya</LastName>
        <Affiliation>Katsuya Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Shimosawa</LastName>
        <Affiliation>Department of Clinical Laboratory, School of Medicine, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Tsujita</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Data Intelligence Department, Daiichi Sankyo Co. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Suedomi</LastName>
        <Affiliation>Primary Medical Science Department, Daiichi Sankyo Co. Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Primary Medical Science Department, Daiichi Sankyo Co. Ltd.</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This pooled subanalysis of five multicenter, prospective, open-label, single-arm studies on esaxerenone aimed to evaluate the efficacy, organ-protective effects, and safety of esaxerenone in hypertensive patients with type 2 diabetes mellitus (T2DM), with and without concomitant sodium&#8211;glucose cotransporter-2 inhibitor (SGLT2i) therapy. In total, 283 and 279 patients were included in the safety (with SGLT2i, 148; without, 135) and full analysis sets (with SGLT2i; 145; without, 134), respectively. Significant changes in morning home systolic/diastolic blood pressure (SBP/DBP) from baseline to Week 12 were shown in the overall population (mean change: |11.9/|5.2&#8201;mmHg, both P&#8201;&lt;&#8201;0.001) and both SGLT2i and non-SGLT2i subgroups (|11.3/|4.8 and |12.5/|5.7&#8201;mmHg, respectively, all P&#8201;&lt;&#8201;0.001). Similar findings were observed in bedtime home and office SBP/DBP. The proportions of patients who achieved target home SBP/DBP&#8201;&lt;&#8201;135/85&#8201;mmHg were 71.2% (overall population) and 70.5% and 71.9% in the SGLT2i and non-SGLT2i subgroups, respectively. The urine albumin-to-creatinine ratio significantly improved from baseline to Week 12 in the overall population and SGLT2i subgroups (percentage change in geometric mean from baseline: |42.8%, |43.0%, and |42.6%, respectively, all P&#8201;&lt;&#8201;0.001). N-terminal pro-B-type natriuretic peptide levels improved in all groups. The incidence of serum potassium &#8805;5.5&#8201;mEq/L was 2.0% vs 5.2% in the SGLT2i vs non-SGLT2i subgroups. Esaxerenone demonstrated significant BP-lowering effects, and improved renal and cardiovascular parameters, regardless of SGLT2i use. Safety was consistent across groups, with the numerically lower incidence of serum potassium &#8805;5.5&#8201;mEq/L in the SGLT2i subgroup suggesting a potential mitigating effect of SGLT2is on the risk of hyperkalemia.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Esaxerenone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypertension</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Morning home blood pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sodium&#8211;glucose cotransporter-2 inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Type 2 diabetes mellitus</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0916-9636</Issn>
      <Volume>48</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy and safety of esaxerenone in hypertensive patients with chronic kidney disease, with or without type 2 diabetes mellitus: a pooled analysis of five clinical studies</ArticleTitle>
    <FirstPage LZero="delete">2413</FirstPage>
    <LastPage>2426</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirohiko</FirstName>
        <LastName>Motoki</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Kuwahara</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shinshu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuomi</FirstName>
        <LastName>Kario</LastName>
        <Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Katsuya</LastName>
        <Affiliation>Katsuya Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Shimosawa</LastName>
        <Affiliation>Department of Clinical Laboratory, School of Medicine, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Tsujita</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Data Intelligence Department, Daiichi Sankyo Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Suedomi</LastName>
        <Affiliation>Primary Medical Science Department, Daiichi Sankyo Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>Primary Medical Science Department, Daiichi Sankyo Co., Ltd.</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Effective management of blood pressure (BP) and albuminuria are crucial for suppressing chronic kidney disease (CKD) progression and cardiovascular risks in hypertension. This pooled analysis evaluated the antihypertensive effects, organ-protective effects, and safety of esaxerenone in hypertensive patients with CKD by integrating five clinical studies of esaxerenone. Patients were divided based on type 2 diabetes mellitus (T2DM) status (with or without T2DM) and creatinine-based estimated glomerular filtration rate (eGFRcreat) (30 to &lt;60 and &#8805;60&#8201;mL/min/1.73 m2). Significant changes in morning home BP from baseline at Week 12 were observed in the overall population (mean change |12.8/&#8201;|&#8201;5.4&#8201;mmHg), T2DM subgroups (&#8201;|&#8201;12.2/&#8201;|&#8201;4.5 and |14.5/&#8201;|&#8201;7.8&#8201;mmHg), and eGFRcreat subgroups (&#8201;|&#8201;12.5/&#8201;|&#8201;4.7 and |14.0/&#8201;|&#8201;6.9&#8201;mmHg) (all P&#8201;&lt;&#8201;0.001). Bedtime home and office BP showed similar tendencies. Urine albumin-to-creatinine ratio significantly improved from baseline at Week 12 in the overall population (mean change: |55.2%), T2DM subgroups (&#8201;|&#8201;56.5% and |52.0%), and eGFRcreat subgroups (&#8201;|&#8201;54.6% and |55.4%) (all P&#8201;&lt;&#8201;0.001). N-terminal pro-B-type natriuretic peptide levels significantly decreased in the overall population (percent change: |14.1%) and subgroup without T2DM (&#8201;|&#8201;25.3%). The incidence of serum potassium &#8805;5.5 mEq/L was lower in the subgroup with T2DM vs without T2DM (3.1% and 11.3%), potentially related to the use of sodium&#8211;glucose cotransporter 2 inhibitors. These findings highlight the sustained BP-lowering effect of esaxerenone throughout the day in hypertensive patients with CKD, irrespective of T2DM status, and its significant reduction in albuminuria. The data support the safety and efficacy of esaxerenone in this patient population, underscoring its potential as a valuable therapeutic option.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">albuminuria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chronic kidney disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esaxerenone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">morning hypertension</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">type 2 diabetes mellitus</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1664-3224</Issn>
      <Volume>16</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A pilot transcriptomic study of a novel multitargeted BRT regimen for anti&#8211;MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy</ArticleTitle>
    <FirstPage LZero="delete">1568338</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Moe</FirstName>
        <LastName>Tokunaga</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>DNA Chip Research Inc., Medical Laboratory</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitori</FirstName>
        <LastName>Hiratsuka</LastName>
        <Affiliation>DNA Chip Research Inc., Medical Laboratory</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Nakatsue</LastName>
        <Affiliation>Division of Rheumatology and Nephrology, Department of Internal Medicine, Nagaoka Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Saeki</LastName>
        <Affiliation>Division of Rheumatology and Nephrology, Department of Internal Medicine, Nagaoka Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takatsune</FirstName>
        <LastName>Umayahara</LastName>
        <Affiliation>Division of Dermatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Koyama</LastName>
        <Affiliation>Division of Rheumatology, Center for Autoimmune Diseases, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is associated with severe outcomes, primarily due to rapidly progressive interstitial lung disease (RP-ILD), which is often refractory to standard therapies such as calcineurin inhibitors (e.g., tacrolimus) combined with cyclophosphamide (TC-Tx). This study evaluated the efficacy of a novel multitargeted regimen combining baricitinib, rituximab, and tacrolimus (BRT-Tx) in improving survival outcomes for MDA5-DM patients with poor prognostic factors.&lt;br&gt;
Methods: Fourteen MDA5-DM patients with multiple adverse prognostic factors were studied. Seven received the BRT-Tx regimen, and the remaining seven, previously treated with TC-Tx, served as historical controls. Twelve-month survival was assessed. Transcriptome analysis was performed for six patients (BRT=3, TC=3), beginning with cluster analysis to evaluate whether changes in peripheral blood gene expression varied according to treatment or prognosis. Gene ontology analysis characterized expression profiles in survivors and distinguished treatment effects. Alterations in the type I, II, and III interferon signatures were also assessed.&lt;br&gt;
Results: In the TC-Tx group, four of seven patients succumbed to RP-ILD, whereas all seven BRT-Tx patients survived the 12-month observation period. Only one BRT-Tx patient required combined rescue therapies, including plasma exchange, and one case of unexplained limbic encephalitis (LE) occurred. Cytomegalovirus reactivation was observed in both groups (BRT: 5/7; TC: 6/7). Transcriptomic analysis revealed no treatment-specific clustering of differentially expressed genes (DEGs) before and after therapy. However, survivors and nonsurvivors formed distinct clusters, with survivors showing significant posttreatment suppression of B-cell-related gene expression. Moreover, interferon signature scores were significantly lower after treatment in survivors than in nonsurvivors. BRT-Tx effectively suppressed B-cell-mediated immune responses and maintained a low interferon signature, while TC-Tx resulted in nonspecific gene suppression, and in nonsurvivors, an elevated interferon signature was observed.&lt;br&gt;
Conclusion: BRT-Tx has the potential to improve survival in MDA5-DM patients by effectively targeting hyperactive immune pathways. The combination of rituximab and tacrolimus is expected to disrupt B-cell&#8211;T-cell interactions and reduce autoantibody production, whereas baricitinib may suppress both IFN and GM-CSF signaling, regulating excessive autoimmunity mediated by cells such as macrophages. Unlike TC-Tx, BRT-Tx avoids cyclophosphamide-associated risks such as infertility and secondary malignancies. Future randomized controlled trials are warranted to validate its efficacy and safety.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anti-MDA5 antibody-positive dermatomyositis (MDA5-DM)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">JAK inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">baricitinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rituximab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multitargeted treatment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">IFN signature</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transcriptome analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>14</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex)</ArticleTitle>
    <FirstPage LZero="delete">27481</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Shimamoto</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takako</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Nagasu</LastName>
        <Affiliation>Department of Nephrology and Hypertension, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kishi</LastName>
        <Affiliation>Department of Nephrology and Hypertension, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Medical Informatics, Graduate School of Medical Science, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Tsuruya</LastName>
        <Affiliation>Department of Nephrology, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Nephrology, Faculty of Medicine, Saitama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kouichi</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Medical Science and Cardiorenal Medicine, Graduate School of Medicine, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiei</FirstName>
        <LastName>Narita</LastName>
        <Affiliation>Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Nephrology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of General Medicine, Juntendo University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yokoo</LastName>
        <Affiliation>Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology and Rheumatology, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiichiro</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Department of Health Data Science, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromi</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Medical Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaomi</FirstName>
        <LastName>Nangaku</LastName>
        <Affiliation>Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Kashihara</LastName>
        <Affiliation>Department of Nephrology and Hypertension, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Chronic kidney disease-mineral and bone disorder (CKD-MBD) are recognized as a systemic disease affecting the prognosis of patients with CKD. Proper management of CKD-MBD is important to improve the prognosis of patients with CKD. Although proteinuria is recognized as a poor prognostic factor in these patients, few reports have examined its association with CKD-MBD. We examined the association between proteinuria and CKD-MBD using data from the Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex). Among the patients registered in the J-CKD-DB-Ex, 30,977 with CKD stages G2&#8211;G5 who had serum creatinine, albumin, calcium, and phosphate concentrations measured at least once and urinalysis performed were included. The patients were divided into four groups (negative, 1+, 2+, and 3+) according to the degree of proteinuria. The association between proteinuria and CKD-MBD was examined by a logistic regression analysis. In a model adjusted for age, sex, diabetes, and the estimated glomerular filtration rate (eGFR), the odds ratio of the 3&#8201;+&#8201;group compared with the negative group significantly increased to 2.67 (95% confidence interval, 2.29&#8211;3.13) for hyperphosphatemia, 2.68 (1.94&#8211;3.71) for hypocalcemia, and 1.56 (1.24&#8211;1.98) for hypomagnesemia. Proteinuria is associated with hyperphosphatemia, hypocalcemia, and hypomagnesemia in patients with CKD independently of eGFR.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CKD-MBD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteinuria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hyperphosphatemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypocalcemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypomagnesemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">J-CKD-DB-Ex</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1471-230X</Issn>
      <Volume>25</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Neoadjuvant chemotherapy strategies for optimizing safety and efficacy in elderly patients with locally advanced gastric cancer</ArticleTitle>
    <FirstPage LZero="delete">670</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Kakiuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunya</FirstName>
        <LastName>Hanzawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Kashima</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Kagawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background The completion rate of adjuvant chemotherapy for gastric cancer (GC) is suboptimal, particularly in elderly patients. While neoadjuvant chemotherapy (NAC) for locally advanced GC has shown promise, data on elderly patients remain limited. Given the considerable physical burden of NAC, optimizing its administration is crucial. This study evaluates the safety and efficacy of a modified approach for elderly patients.&lt;br&gt;
Methods A retrospective analysis was conducted on 38 patients with cStage II/III GC who received NAC between November 2015 and December 2023. Additionally, 25 patients aged&#8201;&#8805;&#8201;75 years with cStage III who underwent upfront surgery during the same period were analyzed.&lt;br&gt;
Results The NAC group was divided into non-elderly (&lt;&#8201;75 years, n&#8201;=&#8201;27) and elderly (&#8805;&#8201;75 years, n&#8201;=&#8201;11) groups. The elderly group had poorer ECOG-PS (p&#8201;=&#8201;0.016). While all non-elderly patients completed&#8201;&#8804;&#8201;3 cycles, more elderly patients underwent 4 cycles (p&#8201;=&#8201;0.0047). However, per-cycles of S-1 (p&#8201;=&#8201;0.0003) and oxaliplatin (p&#8201;=&#8201;0.0018) were lower in the elderly group. Importantly, adverse events and treatment efficacy were comparable between groups. Among patients aged&#8201;&#8805;&#8201;75 years, the upfront surgery group had poorer ECOG-PS (p&#8201;=&#8201;0.017) and underwent more frequent distal gastrectomy (p&#8201;=&#8201;0.014).&lt;br&gt;
Conclusions NAC can be safely administered to elderly patients by increasing cycles while reducing per-cycle dosage. It may also serve as a viable alternative to upfront surgery.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Neoadjuvant chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Elderly</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Adverse events</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparative Analysis of a Dual DNA&#8211;RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsunori</FirstName>
        <LastName>Osone</LastName>
        <Affiliation>Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mashu</FirstName>
        <LastName>Futagawa</LastName>
        <Affiliation>Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Hirasawa</LastName>
        <Affiliation>Department of Clinical Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Next-generation sequencing-based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor-only DNA panels from single institutions. In 2023, Japan introduced an insurance-covered cancer genomic profiling test\the GenMine TOP Cancer Genome Profiling System\a dual DNA&#8211;RNA panel with matched tumor&#8211;normal testing. This study evaluated its utility compared to a conventional DNA-only test (FoundationOne CDx) in managing sarcoma patients using a nationwide genetic profiling database provided by the Center for Cancer Genomics and Advanced Therapeutics. This study included 1046 patients registered between August 2023 and October 2024. The dual DNA&#8211;RNA test identified significantly more fusion genes (20.3% vs. 7.4%, p&#8201;&lt;&#8201;0.001) and therapeutically targetable kinase fusions (3.5% vs. 1.2%, p&#8201;=&#8201;0.019) than the DNA-only test. Among patients with translocation-related sarcomas, histology-specific fusion genes were identified in 77.5% using the dual panel, compared to 40.0% with the DNA-only panel (p&#8201;&lt;&#8201;0.001). In non-gastrointestinal stromal tumor sarcomas, the dual test showed a trend toward higher rates of genotype-matched therapy (4.3% vs. 2.6%, p&#8201;=&#8201;0.25) and a significantly higher rate of molecular targeted therapy (4.3% vs. 1.5%, p&#8201;=&#8201;0.03). Additionally, 5.7% of patients had pathogenic germline variants identified through tumor&#8211;normal matched analysis. These findings suggest that a dual DNA&#8211;RNA panel with matched tumor&#8211;normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">comprehensive cancer genomic profiling (CGP)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fusion genes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gene alterations</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genotype-matched therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">potential germline variants (PGVs)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1618-1247</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of CT-assessed sarcopenia on the severity of odontogenic deep neck infections: a retrospective cohort study</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Kikuta</LastName>
        <Affiliation>Dental and Oral Medical Center, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chizuru</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kinisada</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Tachibana</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jingo</FirstName>
        <LastName>Kusukawa</LastName>
        <Affiliation>Dental and Oral Medical Center, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Akashi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Sarcopenia is increasingly recognized as a key predictor of adverse health outcomes. This study aimed to evaluate the impact of computed tomography-assessed sarcopenia (CT&#8211;SP) on the clinical severity and hospitalization duration of odontogenic deep neck infections (DNIs). Total of 119 patients admitted for odontogenic DNI treatment were included. Patients were divided into two groups by DNI clinical severity (severe or mild) and the patients' characteristics, including CT&#8211;SP based on skeletal muscle index (SMI), were compared between two groups. Multivariable logistic regression analysis was performed to identify independent risk factors for severe DNI. The correlation between SMI and hospitalization duration was assessed using Spearmanfs rank correlation coefficient. Of the 119 patients, 60 (50.4%) presented with severe DNIs, including deep neck abscesses and necrotizing soft tissue infections. After adjusting for potential confounders, multivariable analysis identified CT&#8211;SP as the sole independent risk factor associated with severe DNI (Odds Ratio&#8201;=&#8201;3.04; 95% Confidence Interval, 1.20&#8211;7.71; p&#8201;=&#8201;0.019). Furthermore, SMI demonstrated a significant, weak negative correlation with the hospitalization duration (r&#8201;=&#8201;| 0.331, p&#8201;&lt;&#8201;0.001). CT&#8211;SP is a powerful, independent risk factor associated with severity in patients with odontogenic DNIs. This finding underscores the critical role of systemic host factors in the clinical course of maxillofacial infections and highlights the potential of opportunistic CT screening as a factor to consider in risk stratification in this vulnerable population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CT-assessed sarcopenia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Odontogenic deep neck infections</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Severity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hospitalization duration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Skeletal muscle index</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1999-4923</Issn>
      <Volume>17</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development of Propofol-Encapsulated Liposomes and the Effect of Intranasal Administration on Bioavailability in Rabbits</ArticleTitle>
    <FirstPage LZero="delete">1446</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hitomi</FirstName>
        <LastName>Ujita</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukiko</FirstName>
        <LastName>Nishioka</LastName>
        <Affiliation>Department of Dental Anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Riko</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Miyawaki</LastName>
        <Affiliation>Department of Dental Anesthesiology and Special Care Dentistry, Okayama University Graduate of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Propofol is frequently used as an intravenous anesthetic and is rapidly metabolized. Therefore, if it could be administered non-invasively (e.g., orally) as premedication, it might hasten emergence from anesthesia, thereby improving patient safety. However, it undergoes extensive first-pass metabolism in the liver and intestines, limiting the route for premedication. We evaluated whether intranasal delivery of a propofol-encapsulated liposome solution improves systemic exposure and bioavailability in rabbits. Methods: A propofol-encapsulated liposome solution was administered to rabbits via the intravenous, oral, and intranasal routes. Blood propofol concentrations were measured for up to 60 min after administration and the area under the concentration&#8211;time curve (AUC0&#8211;60) and bioavailability of the propofol-encapsulated liposome solution were compared with those of the non-encapsulated propofol formulation. The differences were tested by two-way analysis of variance (ANOVA) with &#352;id&#225;kfs post hoc multiple-comparisons test and the Mann&#8211;Whitney test (ƒ¿ = 0.05). Results: The AUC0&#8211;60 for blood propofol concentrations after intravenous administration was significantly higher with the propofol-encapsulated liposome solution than with the non-encapsulated propofol formulation (3038.8 } 661.5 vs. 1929.8 } 58.2 ng&#183;min/mL; p = 0.0286). By contrast, no increase in blood propofol concentrations was observed after oral administration, whereas intranasal administration increased blood propofol concentrations and yielded significantly higher bioavailability compared with the non-encapsulated propofol formulation (16.4 } 7.3% vs. 2.0 } 1.2%; p = 0.0286). Conclusions: The findings of the present study suggest that intranasal liposomal propofol increased systemic availability compared with a non-encapsulated formulation, supporting further evaluation as a candidate premedication approach for propofol.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">liposome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">propofol</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bioavailability</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intranasal administration</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0276-3478</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>DSOK-0011 Potentially Regulates Circadian Misalignment and Affects Gut Microbiota Composition in Activity-Based Anorexia Model</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Sumitomo Pharma Co. Ltd</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taro</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Sumitomo Pharma Co. Ltd</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Horiuchi</LastName>
        <Affiliation>Sumitomo Pharma Co. Ltd</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kirii</LastName>
        <Affiliation>Department of Animal Applied Microbiology, Okayama University Graduate School of Environmental, Life, Natural Science and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hoang Duy</FirstName>
        <LastName>Nguyen</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Hinotsu</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Ohya</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiyoshi</FirstName>
        <LastName>Yokode</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Okahisa</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruko</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshitaka</FirstName>
        <LastName>Oohashi</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Takaki</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Anorexia nervosa (AN) is a metabolic-psychiatric disorder characterized by severe weight loss, hypercortisolemia, and hypothalamic&#8211;pituitary&#8211;adrenal (HPA) axis activation. In this study, we investigated the effect of inhibiting cortisol regeneration via the enzyme 11ƒÀ-hydroxysteroid dehydrogenase type 1 (11ƒÀ-HSD1) on the pathophysiology of AN.&lt;br&gt;
Method: Female C57BL/6J mice underwent a 7-day activity-based anorexia (ABA) paradigm, involving 3&#8201;h daily feeding and free access to wheels, until 25% body weight loss or experiment completion. Mice were orally treated once daily with a potent 11ƒÀ-HSD1 inhibitor, DSOK-0011, or vehicle. Body weight, food intake, and activity transitions were recorded; plasma corticosterone and cholesterol levels were measured using a fluorometric assay; gut microbiota were analyzed using 16S rRNA sequencing; and hippocampal glial cells were analyzed using immunohistochemistry.&lt;br&gt;
Results: DSOK-0011-treated mice exhibited a modest but significant increase in postprandial wheel-running activity compared to baseline (4&#8211;5&#8201;p.m., p&#8201;=&#8201;0.018; 5&#8211;6&#8201;p.m., p&#8201;=&#8201;0.043), whereas vehicle-treated mice showed higher preprandial activity (9&#8211;10&#8201;a.m., p&#8201;=&#8201;0.0229). Gut microbiota analysis revealed increased alpha diversity in ABA mice, with a specific enrichment of the Lachnospiraceae family in the DSOK-0011 group. However, DSOK-0011 did not significantly affect body weight, food intake, corticosterone, and lipid levels, or hippocampal glial cell populations.&lt;br&gt;
Conclusion: Inhibition of 11ƒÀ-HSD1 by DSOK-0011 was associated with microbiota alterations and subtle shifts in activity timing under energy-deficient conditions. These findings suggest that peripheral glucocorticoid metabolism may influence microbial and behavioral responses in the ABA model, although its metabolic impact appears limited in the acute phase.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">11ƒÀ-HSD1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">activity-based anorexia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anorexia nervosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">corticosterone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">eating disorders</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">microbiota</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0913-8668</Issn>
      <Volume>39</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>T2 high-signal-intensity zone of the spinal cord dorsal horn in patients treated with spinal cord stimulation for herpes zoster-associated pain: a retrospective case&#8211;control study</ArticleTitle>
    <FirstPage LZero="delete">273</FirstPage>
    <LastPage>281</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kyosuke</FirstName>
        <LastName>Arakawa</LastName>
        <Affiliation>Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Pain Management Clinic, NTT Medical Center Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichiro</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Pain Management Clinic, NTT Medical Center Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Morimatsu</LastName>
        <Affiliation>Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose In patients with herpes zoster-associated pain (ZAP), magnetic resonance imaging (MRI) has revealed T2 high-signal intensity zones (MRI T2 HIZ) in the dorsal horn of the spinal cord, associated with postherpetic neuralgia (PHN). We retrospectively analyzed the relationship between PHN and MRI T2 HIZ in patients with refractory ZAP in the subacute phase who underwent temporary spinal cord stimulation therapy (tSCS).&lt;br&gt;
Methods This single-center, case&#8211;control study included patients who underwent tSCS for refractory ZAP between 2010 and 2018. MRIs were re-assessed for the presence of T2 HIZ in the dorsal horn of the spinal cord. Patients were divided into T2 HIZ(&#8201;+) and T2 HIZ(|) groups. Patients with a numerical rating score (NRS)&#8201;&#8805;&#8201;3 at the last visit were defined as PHN. The NRS values and the incidence rate of PHN were compared between the two groups.&lt;br&gt;
Results Of the 67 cases extracted, 38 were included in the analysis: 22 in T2 HIZ(&#8201;+) group and 16 in T2 HIZ(|) group. No significant differences were observed in background factors between the two groups. However, the T2 HIZ(&#8201;+) group had a significantly higher NRS at the final visit (T2 HIZ(&#8201;+):3.8&#8201;}&#8201;2.1, T2 HIZ(|):1.4&#8201;}&#8201;1.5; P&#8201;&lt;&#8201;0.05) and had significantly more patients with PHN than the T2 HIZ(|) group (T2 HIZ(&#8201;+) vs. T2 HIZ(|), 15/22 (68%) vs. 3/16 (19%); odds ratio&#8201;=&#8201;8.67; 95% confidence interval, 1.7&#8211;63.3).&lt;br&gt;
Conclusion T2HIZ is detected in more than half of refractory ZAP, and pain is more likely to remain after tSCS treatment in the T2HIZ(&#8201;+) group.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Herpes zoster</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Magnetic resonance imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Postherpetic neuralgia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Refractory zoster-associated pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Temporary spinal cord stimulation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2044-6055</Issn>
      <Volume>15</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Neurological outcomes with hypothermia versus normothermia in patients with moderate initial illness severity following resuscitation from out-of-hospital cardiac arrest: protocol for a multicentre randomised controlled trial (R-CAST OHCA)</ArticleTitle>
    <FirstPage LZero="delete">e101809</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuaki</FirstName>
        <LastName>Nishikimi</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Preventive Services, School of Public Health, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Maeyama</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeyuki</FirstName>
        <LastName>Kiguchi</LastName>
        <Affiliation>Division of Trauma and Surgical Critical Care, Osaka General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Biostatistics, School of Public Health, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeyuki</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Department of Biostatistics, School of Public Health, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Emergency and Critical Care Center, TMG Asaka Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Division of Emergency and Critical Care Medicine, Niigata University Graduate School of Medical and Dental Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taku</FirstName>
        <LastName>Iwami</LastName>
        <Affiliation>Department of Preventive Services, School of Public Health, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>JAAM R-CAST OHCA Trial Group</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction Temperature control is a fundamental intervention for neuroprotection following resuscitation from cardiac arrest. However, evidence regarding the efficacy of hypothermia in post-cardiac arrest syndrome (PCAS) remains unclear. Retrospective studies suggest that the clinical effectiveness of hypothermia may depend on the severity of PCAS. The R-CAST OHCA trial aims to compare the efficacy of hypothermia versus normothermia in improving 30-day neurological outcomes in patients with moderately severe PCAS following out-of-hospital cardiac arrest.&lt;br&gt;
Methods and analysis The multicentre, single-blind, parallel-group, superiority, randomised controlled trial (RCT) is conducted with the participation of 35 emergency and critical care centres and/or intensive care units at academic and non-academic hospitals. The study enrols moderately severe PCAS patients, defined as those with a revised post-Cardiac Arrest Syndrome for induced Therapeutic Hypothermia score of 5.5&#8211;15.5. A target number of 380 participants will be enrolled. Participants are randomised to undergo either hypothermia or normothermia within 3&#8201;hours after return of spontaneous circulation. Patients in the hypothermia group are cooled and maintained at 34‹C until 28 hours post-randomisation, followed by rewarming to 37‹C at a rate of 0.25‹C/hour. Patients in the normothermia group are maintained at normothermia (36.5‹C&#8211;37.7‹C). Total periods of intervention, including the cooling, maintenance and rewarming phases, will occur 40 hours after randomisation. Other treatments for PCAS can be determined by the treating physicians. The primary outcome is a favourable neurological outcome, defined as Cerebral Performance Category 1 or 2 at 30 days after randomisation and compared using an intention-to-treat analysis.&lt;br&gt;
Ethics and dissemination This study has been approved by the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital, Ethics Committee (approval number: R2201-001). Written informed consent is obtained from all participants or their authorised surrogates. Results will be disseminated via publications and presentations.&lt;br&gt;
Trial registration number jRCT1062220035.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Public Library of Science (PLoS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1932-6203</Issn>
      <Volume>20</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Relationship between obesity indices and cognitive function in Japanese men: A cross-sectional study</ArticleTitle>
    <FirstPage LZero="delete">e0332595</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Matsuno</LastName>
        <Affiliation>Department of Psychiatry, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Ozeki</LastName>
        <Affiliation>Department of Psychiatry, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sayaka</FirstName>
        <LastName>Kadowaki</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sayuki</FirstName>
        <LastName>Torii</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>Miyagawa</LastName>
        <Affiliation>Department of Preventive Medicine and Public Health, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Azusa</FirstName>
        <LastName>Shima</LastName>
        <Affiliation>Department of Clinical Nursing, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Itsuko</FirstName>
        <LastName>Miyazawa</LastName>
        <Affiliation>Department of Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi</FirstName>
        <LastName>Segawa</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Kadota</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>NCD Epidemiology Research Center, Shiga University of Medical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We aimed to investigate the associations among various obesity indices, including visceral (VAT) and subcutaneous adipose tissue (SAT), and cognitive function in community-dwelling Japanese men. This population-based cross-sectional study used data of 853 men who participated in the follow-up examinations of the Shiga Epidemiological Study of Subclinical Atherosclerosis. Among them, we analyzed data of 776 men who completed the Cognitive Abilities Screening Instrument (CASI) and had abdominal VAT and SAT areas measured using computed tomography. The VAT-to-SAT ratio (VSR) was calculated; participants were categorized into VSR quartiles. Using analysis of covariance, we computed crude and adjusted means of the CASI total and domain scores across VSR quartiles, adjusting for potential confounders. No significant differences were observed in total CASI scores among body mass index, VAT, or SAT quartiles. However, in the multivariable-adjusted model, participants in the lowest VSR quartile (Q1) had significantly lower CASI total scores than those in the third quartile (Q3) (Q1: 89.5, Q3: 90.9). Low VSR was independently associated with lower cognitive function in a community-based sample of middle-aged and older Japanese men. In summary, VSR may be associated with cognitive function in Japanese men, highlighting the importance of fat distribution in cognitive health and highlighting VSR as a useful indicator.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1618-1247</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Admission prognostic nutritional index predicts prolonged hospitalization in severe odontogenic deep neck infections</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyoichi</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Kikuta</LastName>
        <Affiliation>Dental and Oral Medical Center, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotaro</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>Department of Oral and Maxillofacial Anatomy, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuhisa</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Dental and Oral Medical Center, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junsei</FirstName>
        <LastName>Sameshima</LastName>
        <Affiliation>Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Tachibana</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kakogawa Central City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jingo</FirstName>
        <LastName>Kusukawa</LastName>
        <Affiliation>Dental and Oral Medical Center, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Akashi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joe</FirstName>
        <LastName>Iwanaga</LastName>
        <Affiliation>Dental and Oral Medical Center, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives Severe odontogenic deep neck infections (DNIs) can be life threatening. This study investigated the nutritional status of affected patients and evaluated the usefulness of the Prognostic Nutritional Index (PNI) at admission in helping maxillofacial surgeons identify, at presentation, those likely to require extended hospitalization.&lt;br&gt;
Methods A total of 112 patients treated for odontogenic deep neck abscesses and necrotizing soft tissue infections at five hospitals in Japan. Patients were included. Patients were categorized by length of hospitalization duration and factors associated with prolonged hospitalization were analyzed using propensity score matching to minimize bias. Spearmanfs rank correlation analysis was also performed to assess the relationship between PNI and hospitalization duration.&lt;br&gt;
Results Fifty patients (44.6%) required hospitalization for more than 14 days. Multivariate analysis identified PNI&#8201;&#8804;&#8201;41.2 (odds ratio [OR]&#8201;=&#8201;2.79) and the presence of abscesses in multiple deep neck spaces (OR&#8201;=&#8201;2.76) as significant predictors of prolonged hospitalization. Propensity score analysis confirmed the significant association between PNI and length of hospitalization duration (P&#8201;=&#8201;0.048). In addition, Spearmanfs rank correlation coefficient was r&#8201;=&#8201;|&#8201;0.471 (P&#8201;&lt;&#8201;0.001), indicating a moderate negative correlation.&lt;br&gt;
Conclusion The admission PNI may serve as a useful adjunctive indicator for predicting prolonged hospitalization in patients with severe odontogenic DNIs, as it reflects both nutritional status and systemic inflammation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Odontogenic deep neck infections</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nutrition status</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prognostic nutritional index</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prolonged hospitalization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multiple spaces with abscess</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2075-1729</Issn>
      <Volume>15</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Kidney Organoids: Current Advances and Applications</ArticleTitle>
    <FirstPage LZero="delete">1680</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Nakanoh</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naruhiko</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Haraguchi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Kidney organoids, derived from stem cells, including pluripotent stem cells and adult progenitor cells, have been reported as three-dimensional in vitro models that reflect key aspects of kidney development, structure, and function. Advances in differentiation protocols and tissue engineering have enabled the generation of organoids that exhibit nephron-like structures, including glomerular and tubular structures. Kidney organoids have been widely applied in several directions, including disease modeling and therapeutic screening, drug nephrotoxicity evaluation, and regenerative medicine. In particular, kidney organoids offer a promising platform for studying genetic kidney diseases, such as polycystic kidney disease and congenital anomalies of the kidney and urinary tract (CAKUT), by allowing patient-specific modeling for the analysis of pathophysiology and therapeutic screening. Despite several current limitations, such as incomplete maturation, lack of full nephron segmentation, and variability between protocols and cell conditions, further technological innovations such as microfluidics and bioengineering may refine kidney organoid systems. This review highlights recent advances in kidney organoid research, outlines major applications, and discusses future directions to enhance their physiological relevance, functional maturity, and translational integration into preclinical and clinical nephrology.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">kidney organoid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stem cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">disease modeling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">drug toxicity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">drug screening</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">regenerative medicine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1752-8054</Issn>
      <Volume>18</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effectiveness of Statins for Oxaliplatin]Induced Peripheral Neuropathy: A Multicenter Retrospective Observational Study</ArticleTitle>
    <FirstPage LZero="delete">e70318</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kenshi</FirstName>
        <LastName>Takechi</LastName>
        <Affiliation>Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Kawashiri</LastName>
        <Affiliation>Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Mine</LastName>
        <Affiliation>Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ushio</LastName>
        <Affiliation>Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Hida</LastName>
        <Affiliation>Department of Clinical Research and Development, Graduate School of Pharmacy, SHOWA Medical University </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Momo</LastName>
        <Affiliation>Department of Hospital Pharmaceutics, Graduate School of Pharmacy, SHOWA Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanobu</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mami</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Pharmacy, Fukuoka University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Division of Pharmacy, Ehime University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriaki</FirstName>
        <LastName>Hidaka</LastName>
        <Affiliation>Division of Pharmacy, Ehime University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Center for Clinical Research, Hamamatsu University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Faculty of Pharmaceutical Sciences, Setsunan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Pharmacy, Kansai Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misaki</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Pharmacy, Kansai Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Pharmacy, Yokohama City University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Uyama</LastName>
        <Affiliation>Department of Pharmacy, Yokohama City University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Niimura</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, University of Tokushima Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Hanai</LastName>
        <Affiliation>Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayaka</FirstName>
        <LastName>Tsuboya</LastName>
        <Affiliation>Department of Pharmacy, Kawasaki Municipal Tama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Innovation Center for Translational Research, National Center for Geriatrics and Gerontology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Kamiyama</LastName>
        <Affiliation>Asahikawa Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromi</FirstName>
        <LastName>Hagiwara</LastName>
        <Affiliation>Nagoya City University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoto</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Pharmacy Department, Yamaguchi University Hospital </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Ishizawa</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, University of Tokushima Graduate School of Biomedical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Chemotherapy-induced peripheral neuropathy, including oxaliplatin-induced peripheral neuropathy (OIPN), can have a negative impact on patient quality of life for months or even years after discontinuation of chemotherapy. Statins are commonly used for lowering cholesterol; however, evidence indicates that statins have multiple pleiotropic effects. Although statins are anticipated to exert neuroprotective actions against OIPN, no large-scale investigations have been conducted in real-world clinical settings. Our investigation aimed to determine if statins protected against OIPN. This multicentre retrospective study enrolled Japanese patients with cancer, including those with colorectal cancer (CRC), who received oxaliplatin-containing chemotherapy between April 2009 and December 2019. Propensity score matching between groups was performed to assess the relationship between the occurrence of OIPN and statin use. Among the examined 2657 patients receiving oxaliplatin, 24.7% had Grade &#8805;&#8201;2 OIPN. There was no significant difference in the incidence of OIPN between the statin and non-statin groups, even after propensity score matching. However, among the matched patients with CRC (n&#8201;=&#8201;510), statin use was associated with a significantly lower incidence of Grade &#8805;&#8201;2 OIPN than no statin use (19.8% vs. 28.3%, respectively; p&#8201;=&#8201;0.029). Our findings indicate that statins may protect against OIPN in patients with CRC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oxaliplatin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peripheral neuropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">statins</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1109-6535</Issn>
      <Volume>22</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>C1orf50 Accelerates Epithelial-Mesenchymal Transition and the Cell Cycle of Hepatocellular Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">836</FirstPage>
    <LastPage>849</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">ATSUSHI</FirstName>
        <LastName>TANAKA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">YUSUKE</FirstName>
        <LastName>OTANI</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MASAKI</FirstName>
        <LastName>MAEKAWA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ANNA</FirstName>
        <LastName>ROGACHEVSKAYA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TIRSO</FirstName>
        <LastName>PE&#209;A</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">VANESSA D.</FirstName>
        <LastName>CHIN</LastName>
        <Affiliation>UMass Chan Medical School, UMass Memorial Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHINICHI</FirstName>
        <LastName>TOYOOKA</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MICHAEL H.</FirstName>
        <LastName>ROEHRL</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ATSUSHI</FirstName>
        <LastName>FUJIMURA</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: Hepatocellular carcinoma (HCC) is a heterogeneous liver cancer with limited treatment options and a poor prognosis in advanced stages. To identify novel biomarkers and therapeutic targets, we investigated the role of chromosome 1 open reading frame 50 (C1orf50), a gene with a previously uncharacterized function in HCC.&lt;br&gt;
Materials and Methods: We performed a comprehensive transcriptome data analysis of the human hepatocellular carcinoma project from The Cancer Genome Atlas (TCGA) and subsequently validated the oncogenic roles of C1orf50 using HCC cell lines.&lt;br&gt;
Results: Using transcriptomic and clinical data from TCGA, we stratified 355 primary HCC samples based on C1orf50 expression levels. Patients with high C1orf50 expression exhibited significantly shorter overall survival, suggesting its association with aggressive tumor behavior. Differential expression and enrichment analyses revealed that C1orf50-high tumors were enriched in oncogenic pathways, including epithelial-mesenchymal transition (EMT), cell cycle activation, and stemness-related properties. Transcriptional regulatory network analysis detected 456 significantly dysregulated regulons, including ZEB1/2 and E2F2, key drivers of EMT and cell cycle, in the C1orf50-high group. In addition, we observed increased YAP1/TAZ signaling, further linking C1orf50 to stemness and therapeutic resistance. Functional data from CRISPR-based dependency screening suggested that several transcription factors up-regulated in the C1orf50-high state, such as ZBTB11 and CTCE, are essential for the survival of HCC cells. These findings indicate potential therapeutic vulnerabilities and support the rationale for targeting C1orf50-associated pathways.&lt;br&gt;
Conclusion: C1orf50 is a novel biomarker of poor prognosis in HCC and a key regulator of oncogenic features such as EMT, cell cycle progression, and stemness. This study highlights the therapeutic potential of targeting C1orf50-related networks in aggressive subtypes of liver cancer.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">C1orf50</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatocellular carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stemness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cell cycle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">epithelial&#8209;mesenchymal transition</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ovid Technologies (Wolters Kluwer Health)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2376-7839</Issn>
      <Volume>11</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Vanishing White Matter Disease With EIF2B2 c.254T &gt;A Variant</ArticleTitle>
    <FirstPage LZero="delete">e200293</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kakumoto</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Tokimura</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Tsuboyama</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasufumi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Meiko Hashimoto</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Gonoi</LastName>
        <Affiliation>Department of Radiology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives&lt;br&gt;
Typical MRI findings of vanishing white matter disease (VWM) include diffuse white matter lesions with cystic degeneration. However, mild cases may lack these typical features, posing diagnostic challenges.&lt;br&gt;
Methods&lt;br&gt;
We describe 2 of 3 individuals carrying the homozygous c.254T &gt;A variant in EIF2B2 identified at our hospital, excluding 1 previously reported case.1 Genetic analyses were performed using whole-genome sequence or whole-exome sequence analysis, and detected variants were confirmed by direct nucleotide sequence analysis. Brain MRI findings and clinical features were reviewed for the 2 individuals along with other cases in the literature with the same variant.&lt;br&gt;
Results&lt;br&gt;
A 69-year-old woman presented with recurrent transient dizziness and secondary amenorrhea. MRI of the brain revealed small T2-hyperintense lesions confined to the subcortical white matter with hyperintensities on diffusion-weighted images and mildly elevated apparent diffusion coefficient values. A 28-year-old woman presented with transient dizziness and secondary amenorrhea. MRI of the brain showed mild T2-hyperintense lesions in the cerebral white matter with frontal predominance.&lt;br&gt;
Discussion&lt;br&gt;
This report highlights the clinically mild cases of VWM with subtle abnormalities on brain MRI who had the homozygous c.254T &gt;A in EIF2B2, further expanding the clinical spectrum of VWM and underscoring the importance of genetic assessments in the diagnosis of individuals with mild clinical and MRI findings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-510X</Issn>
      <Volume>478</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Two Japanese families with adult-onset leukoencephalopathy caused by pathogenic variants in CST3</ArticleTitle>
    <FirstPage LZero="delete">123708</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Orimo</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutaka</FirstName>
        <LastName>Shiomi</LastName>
        <Affiliation>Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoji</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumiko</FirstName>
        <LastName>Kuromi</LastName>
        <Affiliation>Department of Neurology, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nozomu</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Neurology, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuaki</FirstName>
        <LastName>Kanai</LastName>
        <Affiliation>Department of Neurology, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Kurokawa</LastName>
        <Affiliation>Department of Radiology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Nomoto</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Omae</LastName>
        <Affiliation>Genome Medical Science Project, National Institute of Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Genome Medical Science Project, National Institute of Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsushi</FirstName>
        <LastName>Tokunaga</LastName>
        <Affiliation>Genome Medical Science Project, National Institute of Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>CST3 (NM_000099.4) encodes cystatin C, whose C-terminal truncating variants in this gene have recently been reported to cause adult-onset leukoencephalopathy, characterized by headaches, transient neurological symptoms, and distinct imaging findings. We present four patients from two Japanese families, including one with a novel variant (c.358-2_395del). Three patients from one family developed chronic headaches around the age of 20, whereas the patient from the other family remained asymptomatic until his fifties. mRNA analysis of the patient with c.358-2_395del revealed a splicing alteration leading to an in-frame deletion (p.Lys120_Gln133del), representing the first CST3 variant that does not result in a truncated protein. These findings broaden our understanding of the clinical and genetic spectra of CST3-related leukoencephalopathy (114 words).</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CST3</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cystatin-C</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Leukodystrophy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Leukoencephalopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Middle cerebellar peduncle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MCP</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2328-9503</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>INF2-Related Charcot&#8211;Marie&#8211;Tooth Disease in a Japanese Cohort: Genetic and Clinical Insights</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chikashi</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yujiro</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun]Hui</FirstName>
        <LastName>Yuan</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Hobara</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Risa</FirstName>
        <LastName>Nagatomo</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumikazu</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Nozuma</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Sakiyama</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Neurology, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Department of Clinical Genetics, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chinatsu</FirstName>
        <LastName>Kinjo</LastName>
        <Affiliation>Department of Clinical Genetics, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Yokochi</LastName>
        <Affiliation>Department of Pediatrics, Toyohashi Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Yamanaka</LastName>
        <Affiliation>Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nozomu</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Neurology, Fukushima Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Suichi</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, Chiba University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Hanaoka</LastName>
        <Affiliation>Department of Pediatrics, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruka</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Neurology, Tokyo Women's Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Todo</LastName>
        <Affiliation>Department of Neurology, Tokyo Women's Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Neurology, The University of Tokyo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Takashima</LastName>
        <Affiliation>Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: INF2 mutations cause focal segmental glomerulosclerosis (FSGS) and Charcot&#8211;Marie&#8211;Tooth disease (CMT). Accurate genetic diagnosis is critical, as INF2-related FSGS is typically resistant to immunotherapy yet rarely recurs after transplantation, and its associated neuropathy can mimic treatable immune-mediated disorders such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).&lt;br&gt;
Methods: We performed a multicenter study investigating 3329 Japanese patients with inherited peripheral neuropathies/CMT who underwent gene panel sequencing or whole-exome analysis between 2007 and 2024. Clinical data, including electrophysiological assessments, were obtained from the patients' medical records.&lt;br&gt;
Results: We identified six pathogenic INF2 variants in eight patients, all of which were located within the diaphanous inhibitory domain. Structural modeling revealed clustering of variants near the diaphanous autoregulatory domain-binding pocket, which is critical for INF2 autoinhibition. Clinically, all cases were sporadic, with a median age at neurological onset of 9&#8201;years. All patients exhibited lower limb weakness, and 6/8 (75%) had sensory disturbances. All patients also developed kidney dysfunction, with 7/8 (88%) progressing to end-stage renal disease at a median age of 15&#8201;years. Furthermore, all patients showed demyelinating neuropathy, and 2/8 (25%) received immunotherapy due to suspected immune-mediated neuropathy.&lt;br&gt;
Conclusion: Although INF2 variants are a rare cause of CMT in Japan, they should be considered in pediatric patients with demyelinating neuropathy and early-onset proteinuria, even in the absence of a family history. Blood and urine tests assessing renal dysfunction can provide guidance for appropriate genetic testing.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Charcot-Marie- Tooth disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">focal segmental glomerulosclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">INF2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inherited peripheral neuropathies</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neuropathy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2196-2995</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Natural Effects and Separable Effects: Insights into Mediation Analysis</ArticleTitle>
    <FirstPage LZero="delete">20</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Etsuji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Shinozaki</LastName>
        <Affiliation>Interfaculty Initiative in Information Studies, the University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Okayama University of Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose of Review We compare natural effects and separable effects under nonparametric structural equation models with independent errors, highlighting their similarities and differences. By examining their required properties and sufficient conditions for identification, we aim to provide deeper insights into mediation analysis.&lt;br&gt;
Recent Findings If certain assumptions about confounding, positivity, and consistency are met, we can identify natural direct and indirect effects under nonparametric structural equation models with independent errors. However, these effects have been criticized because they rely on a specific cross-world quantity, and the so-called cross-world independence assumption cannot be empirically verified. Furthermore, interventions on the mediator may sometimes be challenging to even conceive. As an alternative approach, separable effects have recently been proposed and applied in mediation analysis, often under finest fully randomized causally interpretable structured tree graph models. These effects are defined without relying on any cross-world quantities and are claimed to be identifiable under assumptions that are testable in principle, thereby addressing some of the challenges associated with natural direct and indirect effects.&lt;br&gt;
Summary To conduct meaningful mediation analysis, it is crucial to clearly define the research question of interest, and the choice of methods should align with the nature of the question and the assumptions researchers are willing to make. Examining the underlying philosophical perspectives on causation and manipulation can provide valuable insights.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Causality</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Counterfactuals</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cross-world independence assumption</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Directed acyclic graphs</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mediation analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nonparametric structural equation models with independent errors</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2666-1683</Issn>
      <Volume>80</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Rectal Swab&#8211;based Targeted Prophylactic Antibiotics Reduce Infectious Complications After Transrectal Prostate Biopsy: A Systematic Review and Meta-analysis of Randomized Controlled Trials</ArticleTitle>
    <FirstPage LZero="delete">57</FirstPage>
    <LastPage>65</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mehdi</FirstName>
        <LastName>Kardoust Parizi</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marcin</FirstName>
        <LastName>Miszczyk</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tam&#225;s</FirstName>
        <LastName>Fazekas</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Angelo</FirstName>
        <LastName>Cormio</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pierre I.</FirstName>
        <LastName>Karakiewicz</LastName>
        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Piotr</FirstName>
        <LastName>Chlosta</LastName>
        <Affiliation>Department of Urology, Jagiellonian University Medical College</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Alberto</FirstName>
        <LastName>Briganti</LastName>
        <Affiliation>Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shahrokh F.</FirstName>
        <LastName>Shariat</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and objective: Transperineal ultrasound-guided prostate biopsy is the recommended approach in guidelines, while transrectal ultrasound-guided prostate biopsy (TRUS-PB) is still widely used to diagnose prostate cancer (PCa); however, it is associated with a significant rate of infectious complications. We aimed to assess the efficacy of targeted prophylactic antibiotics (TPAs), based on rectal swabs, in reducing the incidence of infectious complications after TRUS-PB compared with empiric prophylactic antibiotics.&lt;br&gt;
Methods: PubMed, Web of Science, and Scopus were queried in December 2024 for randomized controlled trials (RCTs) comparing infectious complications between patients who received TPAs based on rectal swab culture before TRUS-PB and those who received empiric prophylactic antibiotics before TRUS-PB (PROSPERO: CRD42024523794). The primary outcomes were the incidence rates of febrile urinary tract infection (fUTI) and sepsis.&lt;br&gt;
Key findings and limitations: Overall, nine RCTs (n = 3002) were included in our analyses. The incidence of fUTI was approximately half as high in patients who received TPAs as in those who received empiric prophylactic antibiotics (n = 3002, 2.7% vs 5.2%, risk ratio [RR]: 0.54, 95% confidence interval [CI]: 0.36&#8211;0.81, p = 0.003). Based on these pooled incidence rates, the number of patients needed to treat to prevent fUTI after TRUS-PB was 40; however, there was no statistically significant difference in the incidence of sepsis between patients receiving TPAs and those who received empiric antibiotic prophylaxis (n = 2735, 1.3% vs 1.8%, RR: 0.74, 95% CI: 0.31&#8211;1.75, p = 0.4).&lt;br&gt;
Conclusions and clinical implications: TPAs based on rectal swab culture significantly reduces the incidence of fUTI in patients who undergo TRUS-PB for PCa diagnosis compared with that in patients who receive empiric prophylactic antibiotics; however, there is insufficient evidence to assess its effect on the risk of sepsis. We recommend, based on the clinically relevant reduction in the incidence of fUTI, performing rectal swab&#8211;based TPAs in patients undergoing TRUS-PB.&lt;br&gt;
Patient summary: We reviewed infections occurring after transrectal prostate biopsy in over 3000 patients. The use of antibiotics chosen based on a simple rectal swab decreased the rate of postbiopsy fever and urinary tract infections by half compared with the use of standard antibiotics. More research is needed to understand whether this approach also prevents the rare but serious complication of sepsis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Febrile urinary tract infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Targeted prophylactic antibiotics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Transrectal prostate biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sepsis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Utility of a Preoperative 3D Imaging Analysis System for Trigonal Meningioma</ArticleTitle>
    <FirstPage LZero="delete">387</FirstPage>
    <LastPage>392</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Omae</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichiro</FirstName>
        <LastName>Hirano</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Haruma</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshi</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Division of Radiological Technology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiyo</FirstName>
        <LastName>Higaki</LastName>
        <Affiliation>Department of Radiology, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Sugiu</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69440</ArticleId>
    </ArticleIdList>
    <Abstract>Trigonal meningiomas are rare and pose surgical challenges due to their deep location and proximity to critical neuroanatomical structures. We present the case of a 67-year-old woman with a growing trigonal meningioma successfully resected with guidance by a preoperative 3D imaging analysis system. Integration of CT and MRI including diffusion tensor imaging (DTI) enabled precise mapping of the optic radiation, guiding a middle temporal gyrus approach. Preoperative embolization reduced tumor vascularity, facilitating gross total resection with minimal blood loss. This case highlights the effectiveness of preoperative 3D imaging systems in optimizing surgical planning and improving outcomes in complex neurosurgical cases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">trigonal meningioma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">imaging analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diffusion tensor imaging</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Blood Pressure and Heart Rate Patterns Identified by Unsupervised Machine Learning and Their Associations with Subclinical Cerebral and Renal Damage in a Japanese Community: The Masuda Study</ArticleTitle>
    <FirstPage LZero="delete">369</FirstPage>
    <LastPage>379</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minako</FirstName>
        <LastName>Kinuta</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sosuke</FirstName>
        <LastName>Munetomo</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mari</FirstName>
        <LastName>Fukuda</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuhide</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Environmental Medicine and Public Health, Izumo, Shimane University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Nakahata</LastName>
        <Affiliation>Department of Health and Nutrition, The University of Shimane Faculty of Nursing and Nutrition</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyuki</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69438</ArticleId>
    </ArticleIdList>
    <Abstract>We applied unsupervised machine learning to analyze blood pressure (BP) and resting heart rate (HR) patterns measured during a 1-year period to assess their cross-sectional relationships with subclinical cerebral and renal target damage. Dimension reduction via uniform manifold approximation and projection, followed by K-means++ clustering, was used to categorize 362 community-dwelling participants (mean age, 56.2 years; 54.9% women) into three groups: Low BP and Low HR (Lo-BP/Lo-HR), High BP and High HR (Hi-BP/Hi-HR), and Low BP and High HR (Lo-BP/Hi-HR). Cerebral vessel lesions were defined as the presence of at least one of the following magnetic resonance imaging findings: lacunar infarcts, white matter hyperintensities, cerebral microbleeds, or intracranial artery stenosis. A high urinary albumin-to-creatinine ratio (UACR) was defined as the top 10% (&#8805; 12 mg/g) of the mean value from &#8805;2 measurements. Poisson regression with robust error variance, adjusted for demographics, lifestyle, and medical history, showed that the Hi-BP/Hi-HR group had relative risks of 3.62 (95% confidence interval, 1.75-7.46) for cerebral vessel lesions and 3.58 (1.33-9.67) for high UACR, and the Lo-BP/Hi-HR group had a relative risk of 3.09 (1.12-8.57) for high UACR, compared with the Lo-BP/Lo-HR group. These findings demonstrate the utility of an unsupervised, data-driven approach for identifying physiological patterns associated with subclinical target organ damage.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">blood pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">heart rate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">subclinical disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">uniform manifold approximation and projection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">unsupervised machine learning</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparison of Extraocular Muscles in Patients with Exotropia and Healthy Participants Using Anterior Segment Optical Coherence Tomography</ArticleTitle>
    <FirstPage LZero="delete">353</FirstPage>
    <LastPage>358</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Chihara</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Hamasaki</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyo</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Morisawa</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reika</FirstName>
        <LastName>Kono</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Kanenaga</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69436</ArticleId>
    </ArticleIdList>
    <Abstract>To analyze and characterize the medial and lateral rectus muscles in patients with exotropia using anterior segment optical coherence tomography (AS-OCT). This study included 24 patients with exotropia (48 eyes) and 25 healthy individuals (50 eyes). Anterior segment optical coherence tomography was used to construct the en face images. The anterior chamber angle to the extraocular muscle insertion distance, muscle width, and muscle fiber angle from the muscle insertion sites were compared between the exotropia and the control groups. The correlation between these parameters and age or angle of deviation was evaluated. The mean ages were 13.2}4.1 years for the exotropia group and 17.6}7.2 years for the control group. The lateral rectus angle was significantly more inwardly rotated in the exotropia group than in the control group (1.6}6.3‹, |1.4}4.0‹, p=0.014). With increasing angle of deviation, the width of the lateral rectus increased (p=0.002). Our results indicate that the lateral rectus angle is significantly more inwardly rotated in patients with exotropia. These findings should contribute to a deeper understanding of the extraocular muscles in patients with this condition.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">exotropia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">AS-OCT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anterior chamber angle to extraocular muscle insertion distance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">muscle width</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">muscle fiber angle</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Inhibition of Air-Exposure Stress&#8211;Induced Autolysis in Clostridium perfringens by Zn2+</ArticleTitle>
    <FirstPage LZero="delete">345</FirstPage>
    <LastPage>352</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nozomu</FirstName>
        <LastName>Matsunaga</LastName>
        <Affiliation>Department of Life Science, Faculty of Science, Okayama University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seira</FirstName>
        <LastName>Egusa</LastName>
        <Affiliation>Department of Life Science, Faculty of Science, Okayama University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Riyo</FirstName>
        <LastName>Aono</LastName>
        <Affiliation>Department of Medical Technology, Kagawa Prefectural University of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Tamai</LastName>
        <Affiliation>Department of Infectious Disease, College of Pharmaceutical Science, Matsuyama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Hitusmoto</LastName>
        <Affiliation>Department of Life Science, Faculty of Science, Okayama University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiichi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Life Science, Faculty of Science, Okayama University of Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69435</ArticleId>
    </ArticleIdList>
    <Abstract>Clostridium perfringens is a pathogenic anaerobe that causes gas gangrene and food poisoning. Although autolysin-mediated reorganization of the bacterial cell wall is crucial for cell division, excessive autolysin activity induced by stressors can lead to cell lysis. In C. perfringens, air exposure is a significant stressor that causes cell lysis, and Acp (N-acetylglucosaminidase) is known to be a major autolysin. To further facilitate C. perfringens research, a technology to prevent air-induced cell lysis must be developed. This study investigated the role of Acp in air-induced autolysis and explored potential inhibitors that would prevent cell lysis during experimental procedures. Morphological analyses confirmed that Acp functions as an autolysin in C. perfringens, as acpdeficient strains exhibited filamentous growth. The mutants exhibited negligible autolysis under air-exposure stress, confirming the involvement of Acp in the autolytic process. We also evaluated the effects of various divalent cations on Acp activity in vitro and identified Zn2+ as a potent inhibitor. Brief treatment with a Zn2+- containing buffer induced dose-dependent cell elongation and autolysis inhibition in C. perfringens. These findings demonstrate that simple Zn2+ treatment before experiments stabilizes C. perfringens cells, reducing autolysis under aerobic conditions and facilitating various biological studies, except morphological analyses.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Clostridium perfringens</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">autolysin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">zinc</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">air-exposure autolysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Current Status of Extracorporeal Membrane Oxygenation as a Treatment Strategy for Primary Graft Dysfunction after Lung Transplantation</ArticleTitle>
    <FirstPage LZero="delete">329</FirstPage>
    <LastPage>337</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Matsubara</LastName>
        <Affiliation>Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaroh</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Review</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69433</ArticleId>
    </ArticleIdList>
    <Abstract>Primary graft dysfunction (PGD) is one of the major risk factors affecting patientsf short- and long-term survival after lung transplantation. No particular management strategy has been established for PGD; supportive care is the mainstay of PGD treatment. When a supportive strategy fails, the patient may require the introduction of extracorporeal membrane oxygenation (ECMO) as the last-resort measure for severe PGD. A variety of study of ECMO as a PGD treatment was reported and the management of PGD patients developed so far. Early recognition of a patientfs need for ECMO and its prompt initiation are critical to improved outcomes. The use of venovenous-ECMO became the preferred procedure for PGD rather than venoarterial-ECMO. However, the current ECMO strategy has limitations, and using ECMO to manage patients with PGD is not sufficiently effective. Further studies are required to develop this promising technology.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">lung transplantation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">primary graft dysfunction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">extracorporeal membrane oxygenation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ex vivo lung perfusion</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2077-0383</Issn>
      <Volume>14</Volume>
      <Issue>17</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Risk Factors for Perioperative Urinary Tract Infection After Living Donor Kidney Transplantation Characterized by High Prevalence of Desensitization Therapy: A Single-Center Analysis</ArticleTitle>
    <FirstPage LZero="delete">6102</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Sekito</LastName>
        <Affiliation>Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Moto</FirstName>
        <LastName>Tokunaga</LastName>
        <Affiliation>Department of Urology, NHO Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kasumi</FirstName>
        <LastName>Yoshinaga</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Yamanoi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Risa</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Urology, NHO Okayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Edamura</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Urology, Shimane University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Limited research exists on risk factors for urinary tract infections (UTIs) in kidney transplant recipients, particularly in high-risk groups such as ABO-incompatible or donor-specific antibody (DSA)-positive cases. Early UTIs, especially within the first month post-transplant, impact on acute rejection and long-term graft outcomes, highlighting the need for risk factor identification and management. Methods: Among 157 living donor kidney transplant cases performed at our institution between 2009 and 2024, 128 patients were included after excluding cases with &gt;72 h of perioperative prophylactic antibiotics or urological complications. UTI was defined as the presence of pyuria and a positive urine culture, accompanied by clinical symptoms requiring antibiotic treatment, occurring within one month post-transplantation. Results: The median onset of UTI was postoperative day 8 (interquartile range, IQR: 6.8&#8211;9.3). No subsequent acute rejection episodes were observed. The median serum creatinine at 1 month postoperatively was 1.3 mg/dL (IQR: 1.1&#8211;1.7), and this was not significantly different from those who did not develop UTI. In univariate analysis, low or high BMI (&lt;20 or &gt;25), longer dialysis duration (&gt;2.5 years), desensitization therapy (plasmapheresis + rituximab), elevated preoperative neutrophil-to-lymphocyte ratio (NLR) (&#8805;3), and longer warm ischemic time (WIT) (&#8805;7.8 min) were significantly associated with an increased infection risk of UTI (p = 0.010, 0.036, 0.028, 0.015, and 0.038, respectively). Multivariate analyses revealed that abnormal BMI, longer dialysis duration, desensitization therapy, and longer WIT were independent risk factors for UTI (p = 0.012, 0.031, 0.008, and 0.033, respectively). The incidence of UTI increased with the number of risk factors: 0% (0/16) for zero, 10% (5/48) for one, 31% (16/51) for two, 45% (5/11) for three, and 100% (2/2) for four risk factors. Conclusions: Desensitization therapy, BMI, dialysis duration, and WIT were identified as independent risk factors for perioperative UTI. In patients with risk factors, additional preventive strategies should be considered, with extended antibiotic prophylaxis being one potential option.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">living donor kidney transplantation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">urinary tract infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">perioperative</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">desensitization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rituximab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">plasmapheresis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">body mass index</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dialysis duration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">warm ischemic time</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prophylactic antimicrobials</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>AVES YAYINCILIK A.&#350;.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2980-1478</Issn>
      <Volume>50</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Systematic Review and Meta-Analysis of Penis Length and Circumference According to WHO Regions: Who has the Biggest One?</ArticleTitle>
    <FirstPage LZero="delete">291</FirstPage>
    <LastPage>301</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hadi</FirstName>
        <LastName>Mostafaei</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fahad</FirstName>
        <LastName>Quhal</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Benjamin</FirstName>
        <LastName>Pradere</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ekaterina</FirstName>
        <LastName>Laukhtina</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Frederik</FirstName>
        <LastName>K&#246;nig</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reza Sari</FirstName>
        <LastName>Motlagh</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pawel</FirstName>
        <LastName>Rajwa</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanieh</FirstName>
        <LastName>Salehi-Pourmehr</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakineh</FirstName>
        <LastName>Hajebrahimi</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shahrokh F.</FirstName>
        <LastName>Shariat</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study aimed to perform a systematic review and meta-analysis of stretched, erect, and flaccid penis length as well as circumference according to geographic WHO regions. PubMed, Embase, Scopus, and Cochrane Library were searched for articles published until February 2024. Studies in which a healthcare professional evaluated the penis size were considered eligible. After assessing the risk of bias, a systematic review and meta-analyses were performed according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement, and the outcomes were grouped based on the WHO regions. A total of 33 studies comprising 36 883 patients were included. The risk of bias in the included studies was moderate/low. A comprehensive systematic review was done and meta-analyses performed for flaccid length [n = 28 201, mean (SE) 9.22 (0.24) cm], stretched length [n = 20 814, mean (SE) 12.84 (0.32) cm], erect length [n = 5669, mean (SE) 13.84 (0.94) cm], flaccid circumference [n = 30 117, mean (SE) 9.10 (0.12) cm], and erect circumference [n = 5168, mean (SE) 11.91 (0.18) cm]. The mean length of the stretched penis was largest in Americans [14.47 (0.90) cm]. The mean length of the flaccid penis was the largest in the Americas [10.98 (0.064) cm]. The mean flaccid penile circumference was largest in Americans [n = 29 714, mean (SE) 10.00 (0.04) cm]. Penis sizes vary across WHO regions, suggesting the need to adjust standards according to geography to better understand councilmen and their partners. These data provide a framework for discussing body image expectations and therapeutic strategies in this sensitive and emotional subject matter.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Penis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">length</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">circumference</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">world health organization</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0258-851X</Issn>
      <Volume>39</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Accuracy of Contrast-enhanced CT in Diagnosing Small-sized cT3a Renal Cell Carcinoma and Analysis of Factors Predicting Downstaging to pT1</ArticleTitle>
    <FirstPage LZero="delete">2787</FirstPage>
    <LastPage>2793</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">KENSUKE</FirstName>
        <LastName>BEKKU</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">KASUMI</FirstName>
        <LastName>YOSHINAGA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHOTA</FirstName>
        <LastName>INOUE</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">YOSUKE</FirstName>
        <LastName>MITSUI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TOMOAKI</FirstName>
        <LastName>YAMANOI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TATSUSHI</FirstName>
        <LastName>KAWADA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">YUSUKE</FirstName>
        <LastName>TOMINAGA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TAKUYA</FirstName>
        <LastName>SADAHIRA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SATOSHI</FirstName>
        <LastName>KATAYAMA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TAKEHIRO</FirstName>
        <LastName>IWATA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHINGO</FirstName>
        <LastName>NISHIMURA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">KOHEI</FirstName>
        <LastName>EDAMURA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TOMOKO</FirstName>
        <LastName>KOBAYASHI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MOTOO</FirstName>
        <LastName>ARAKI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: This study assessed the accuracy of preoperative contrast-enhanced computed tomography (CECT) scans in staging small-sized, locally advanced (cT3a) renal cell carcinoma (RCC) and identified predictors of pathological downstaging following surgery.&lt;br&gt;
Patients and Methods: Seventy-six patients who underwent radical nephrectomy for cT3aN0M0 RCC with tumors &#8804;7 cm were analyzed. Preoperative CECT evaluated features such as venous, peritumoral, or renal sinus fat, and urinary tract invasion, predictive values, and concordance index between radiological and pathological findings were calculated for these categories. The study also examined the impact of clinicopathologic factors on downstaging.&lt;br&gt;
Results: Of 76 patients with cT3 RCC, 37% were down-staged to pT1. Down-staged cases had a higher proportion of male patients and non-clear cell carcinoma (86% vs. 58%, 32% vs. 6%; p=0.02, p=0.007, respectively). Multiple cT3a factors were less common in down-staged cases (4% vs. 23%, p=0.04). Non-clear cell carcinoma was significantly associated with downstaging compared to clear cell carcinoma (75% vs. 30%, p=0.006). Multivariate analysis confirmed non-clear cell carcinoma as an independent predictor (odds ratio=8.2, p=0.01). For venous invasion, CECT sensitivity and positive predictive value were high (73.5% and 83.3%, respectively) and the degree of agreement was substantial (ƒÈ=0.62).&lt;br&gt;
Conclusion: The accuracy of preoperative CECT was acceptable for detecting venous invasion. The downstaging to pT1 occurred in 37% of cT3a RCC cases in the final pathology, with non-clear cell carcinoma being a significant predictor.&lt;br&gt;</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Contrast&#8209;enhanced CT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">staging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">T3a</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">downstaging</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Continuous glucose monitoring reveals periodontitis-induced glucose variability, insulin resistance, and gut microbiota dysbiosis in mice</ArticleTitle>
    <FirstPage LZero="delete">34768</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Moyuka</FirstName>
        <LastName>Kubota-Takamori</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Kamei-Nagata</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiko</FirstName>
        <LastName>Kiyama</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Oral Microbiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyoshi</FirstName>
        <LastName>Gotoh</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimito</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Shinoda-Ito</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Okubo</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsugumichi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Health &amp; Sports Sciences, Faculty of Education, Tokyo Gakugei University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Diabetes mellitus (DM) management has advanced from self-monitoring blood glucose (SMBG) to continuous glucose monitoring (CGM), which better prevents complications. However, the influence of periodontitis\a common DM complication\on glucose variability is unclear. This study examined glucose variability in mice with periodontitis using CGM. Periodontitis was induced in 9-week-old male C57BL/6J mice via silk ligatures around the upper second molars. Glucose levels were monitored over 14 days with CGM, validated by SMBG. On day 14, samples were collected to assess alveolar bone resorption and serum levels of tumor necrosis factor-ƒ¿ (TNF-ƒ¿), insulin, and amyloid A. Glucose tolerance test (GTT) and insulin tolerance test (ITT) were conducted to evaluate insulin resistance. Gut microbiota diversity was also analyzed. By day 10, mice with periodontitis exhibited higher mean glucose levels and time above range than controls. On day 14, serum insulin and amyloid A levels significantly increased, while TNF-ƒ¿ remained unchanged. GTT and ITT indicated insulin resistance. Microbiota analysis showed reduced alpha- and altered beta-diversity, with decreased Coprococcus spp. and increased Prevotella spp., linking dysbiosis to insulin resistance. Periodontitis disrupts glucose regulation by promoting insulin resistance and gut microbiota imbalance, leading to significant glucose variability.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Continuous glucose monitoring</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Periodontal disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Insulin resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chronic inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gut flora</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1573-7209</Issn>
      <Volume>28</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cancer-associated fibroblast-derived SOD3 enhances lymphangiogenesis to drive metastasis in lung adenocarcinoma</ArticleTitle>
    <FirstPage LZero="delete">51</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">May Wathone</FirstName>
        <LastName>Oo</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Hikita</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoha</FirstName>
        <LastName>Mashima</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Torigata</LastName>
        <Affiliation>School of Medicine, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yin Min</FirstName>
        <LastName>Thu</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Habu</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachio</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization, Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Pathophysiology and Drug Discovery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Despite advancements in diagnostic and therapeutic strategies, lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality due to its aggressive metastatic potential. Extracellular superoxide dismutase (SOD3) is an antioxidant enzyme that regulates oxidative stress and is regarded as a tumor suppressor. However, studies have demonstrated that SOD3 can either promote or inhibit cell proliferation and survival in various cancers, and its molecular mechanisms within the tumor microenvironment are poorly understood. In this study, we report a breakthrough in uncovering the role of SOD3 derived from cancer-associated fibroblasts (CAFs) in LUAD. Using LUAD xenograft models co-implanted with SOD3-overexpressing CAFs (CAFSOD3), we observe an aggressive tumor phenotype characterized by increased lymphangiogenesis and lymphatic vessel invasion (LVI) of the tumor. Additionally, LUAD patients with elevated SOD3 levels exhibit a higher incidence of LVI and metastasis. Notably, RNA sequencing of CAFSOD3 reveals that SOD3-mediated VEGF-dependent tumor progression and lymphangiogenesis are up-regulated. Furthermore, single-cell transcriptomic analysis of LUAD clinical samples confirms a strong correlation between SOD3 expression in fibroblasts and characteristics of tumor exacerbation, such as lymphangiogenesis and metastasis. These findings underscore new insights into the role of CAF-derived SOD3 in LUAD progression and highlight its potential as a biomarker and therapeutic target.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cancer-associated fibroblast</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Superoxide dismutase 3</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lymphangiogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Angiogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lung adenocarcinoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1618-1247</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Establishment of a regenerative endodontic procedures model of mature mouse teeth and evaluation of the wound healing process</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Xiuting</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Operative Dentistry, Okayama University Graduate School, Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-Ho</FirstName>
        <LastName>Tsai</LastName>
        <Affiliation>Department of Operative Dentistry, Okayama University Graduate School, Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Karin</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rahmad Rifqi</FirstName>
        <LastName>Fahreza</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Periodontology and Endodontology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>As the pulp regeneration for non-vital teeth is one of the ultimate clinical achievements, regenerative endodontic procedures (REPs) have become the most explored treatment modality. In this technique, periodontal tissue is guided from the apical region into the root canal and pulp chamber to promote attachment. It is well established that immature teeth are effective targets for treatment. However, the indications for this treatment have not yet expanded sufficiently to encompass mature teeth with closed apical apex. In the present study, a mouse model of REPs in mature teeth was established, employing the maxillary first molar mesial root. ƒÊCT analyses disclosed that the distance from the occlusal surface to the physiological apex of the maxillary first molar mesial root in mice is 2.14 mm&#8201;}&#8201;0.08 mm, and the distance from the occlusal surface to the periapical alveolar bone is 2.46 mm&#8201;}&#8201;0.10 mm. Mesial root canal was treated with several sizes of k-files, and 15# k-file was identified as the most suitable k-file for use (P&#8201;=&#8201;0.0007). During the regenerative process, spindle-shaped fibroblast-like cells, fibrous tissue formation, and mineralized tissue formation were identified on days 14 and 28. This study demonstrated that it is feasible to use the maxillary first molar mesial root as a REPs model for mature teeth and provided a detailed protocol and analysis of the healing process.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Regenerative endodontic procedures</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Establishment of protocols</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mouse experimental model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mature teeth</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ovid Technologies (Wolters Kluwer Health)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1044-3983</Issn>
      <Volume>36</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Causal Approaches to Disease Progression Analyses</ArticleTitle>
    <FirstPage LZero="delete">732</FirstPage>
    <LastPage>740</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Bronner P.</FirstName>
        <LastName>Gon&#231;alves</LastName>
        <Affiliation>Faculty of Health and Medical Sciences, University of Surrey</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Etsuji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Epidemiologic analyses that aim to quantify exposure effects on disease progression are not uncommon. Understanding the implications of these studies, however, is complicated, in part because different causal estimands could, at least in theory, be the target of such analyses. Here, to facilitate interpretation of these studies, we describe different settings in which causal questions related to disease progression can be asked, and consider possible estimands. For clarity, our discussion is structured around settings defined based on two factors: whether the disease occurrence is manipulable or not, and the type of outcome. We describe relevant causal structures and sets of response types, which consist of joint potential outcomes of disease occurrence and disease progression, and argue that settings where interventions to manipulate disease occurrence are not plausible are more common, and that, in this case, principal stratification might be an appropriate framework to conceptualize the analysis. Further, we suggest that the precise definition of the outcome of interest, in particular of what constitutes its permissible levels, might determine whether potential outcomes linked to disease progression are definable in different strata of the population. Our hope is that this paper will encourage additional methodological work on causal analysis of disease progression, as well as serve as a resource for future applied studies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">disease progression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">causal inference</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">principal stratification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">controlled direct effects</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">potential outcomes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6643</Issn>
      <Volume>17</Volume>
      <Issue>18</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Lacticaseibacillus rhamnosus Probio-M9 Alters the Gut Microbiota and Mitigates Pulmonary Hypertension in a Rat Model</ArticleTitle>
    <FirstPage LZero="delete">2927</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Zhixin</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gaopeng</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyomi</FirstName>
        <LastName>Ohmichi</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaodong</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Feiyan</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of General Medicine, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryou</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Center for Advanced Heart Failure, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Yokota</LastName>
        <Affiliation>Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhihong</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lin Hai</FirstName>
        <LastName>Kurahara</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Intestinal microbiota plays an important role in the progression of pulmonary hypertension (PH). Colostrum-derived Lacticaseibacillus rhamnosus Probio-M9 (Probio-M9) has shown protective effects against inflammation and remodeling. We investigated whether Probio-M9 supplementation could improve the pathology of PH. Methods: The monocrotaline (MCT)-induced PH model rats are created followed by Probio-M9 treatment. Microbiota and pathological analyses were performed to investigate the therapeutic effects of Probio-M9. Results: Probio-M9 significantly suppressed cardiovascular remodeling and reduced mortality in rats. Analysis of the fecal microbiota revealed that Probio-M9 significantly altered the gut microbiota of MCT model rats. Specifically, Alistipes sp009774895 and Duncaniella muris populations increased, whereas Limosilactobacillus reuteri_D, Ligilactobacillus apodeme and Monoglobus sp900542675 decreased compared to those in the MCT group. Focusing on the expression of GPNMB in macrophages and the localization of CD44, we found that the number of these cells increased in the MCT group but significantly decreased with Probio-M9 treatment. In lung tissue from PH patients, more GPNMB-positive macrophages were found than non-PH lungs, and an increase in CD44-positive cells was confirmed in the vicinity of GPNMB. Conclusions: Probio-M9 had a significant impact on the intestinal microbiota and GPNMB/CD44 positive cells in the lungs of PH rats.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">pulmonary artery remodeling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">probiotics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gut microbiota</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">macrophages</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">GPNMB</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD44</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ovid Technologies (Wolters Kluwer Health)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1536-0210</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Applicability of Effective Atomic Number (Z eff) Image Analysis of Coronary Plaques Measured With Photon- Counting Computed Tomography</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Asahara</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mana</FirstName>
        <LastName>Mitani</LastName>
        <Affiliation>Medical Support Department, Division of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Kimoto</LastName>
        <Affiliation>Department of Radiological Science, Faculty of Health Sciences, Junshin Gakuen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rina</FirstName>
        <LastName>Nishigami</LastName>
        <Affiliation>Graduate School of Medical Sciences, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Takegami</LastName>
        <Affiliation>Department of Radiological Technology, Yamaguchi University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Morimitsu</LastName>
        <Affiliation>Medical Support Department, Division of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriaki</FirstName>
        <LastName>Akagi</LastName>
        <Affiliation>Medical Support Department, Division of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kanazawa</LastName>
        <Affiliation>Faculty of Life Science, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Iguchi</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>College of Transdisciplinary Sciences for Innovation, Kanazawa University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Coronary computed tomography (CT) allows the assessment of cardiovascular risk by imaging calcified plaques in coronary arteries. Because photon-counting CT (PC-CT) can analyze the effective atomic number (Zeff) of the subject, it is expected to be applied to the analysis of plaque components. The purpose of this study was to investigate the applicability of plaque analysis based on Zeff images with continuous gradation.&lt;br&gt;
Methods: Zeff images were generated from virtual monoenergetic images (VMIs) obtained by PC-CT. Zeff values were derived from the difference between linear attenuation coefficients (ƒÊ) at low and high energies using an in-house program. Coronary CT images of 64 plaques in 10 patients were analyzed. The Zeff score, calculated as the sum of Zeff values within the plaque region, was calculated and compared with the conventional Agatston score and mean coronary artery calcium (CAC) score.&lt;br&gt;
Results: The systematic uncertainty of Zeff images was estimated to be }0.08. The Zeff score of actual patient data showed strong positive correlations with the conventional Agatston and mean CAC scores. The Zeff score uses all voxel data in the plaque area, whereas conventional scores consider only data from voxels with a CT value &gt;130. We found that the conventional scores excluded 39% of the plaque area, and the Zeff score permitted the analysis of low- and high-density plaques.&lt;br&gt;
Conclusions: Zeff imaging was shown to be applicable to plaque analysis that reflects the entire plaque volume. This study demonstrated its technical feasibility as a compositional analysis method using the Zeff image.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">effective atomic number image</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photon-counting computed tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">virtual monoenergetic images</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coronary CT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coronary plaques</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Agatston score</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1660-3397</Issn>
      <Volume>23</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel Anti-MRSA Peptide from Mangrove-Derived Virgibacillus chiguensis FN33 Supported by Genomics and Molecular Dynamics</ArticleTitle>
    <FirstPage LZero="delete">209</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Namfa</FirstName>
        <LastName>Sermkaew</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Apichart</FirstName>
        <LastName>Atipairin</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Phetcharat</FirstName>
        <LastName>Boonruamkaew</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sucheewin</FirstName>
        <LastName>Krobthong</LastName>
        <Affiliation>Center of Excellence in Natural Products Chemistry (CENP), Department of Chemistry, Faculty of Science, Chulalongkorn University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chanat</FirstName>
        <LastName>Aonbangkhen</LastName>
        <Affiliation>Center of Excellence in Natural Products Chemistry (CENP), Department of Chemistry, Faculty of Science, Chulalongkorn University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yodying</FirstName>
        <LastName>Yingchutrakul</LastName>
        <Affiliation>National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nuttapon</FirstName>
        <LastName>Songnaka</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Antimicrobial resistance (AMR) is a global health threat, with methicillin-resistant Staphylococcus aureus (MRSA) being one of the major resistant pathogens. This study reports the isolation of a novel mangrove-derived bacterium, Virgibacillus chiguensis FN33, as identified through genome analysis and the discovery of a new anionic antimicrobial peptide (AMP) exhibiting anti-MRSA activity. The AMP was composed of 23 amino acids, which were elucidated as NH3-Glu-Gly-Gly-Cys-Gly-Val-Asp-Thr-Trp-Gly-Cys-Leu-Thr-Pro-Cys-His-Cys-Asp-Leu-Phe-Cys-Thr-Thr-COOH. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) for MRSA were 8 &#181;g/mL and 16 &#181;g/mL, respectively. FN33 AMP induced cell membrane permeabilization, suggesting a membrane-disrupting mechanism. The AMP remained stable at 30&#8211;40 ‹C but lost activity at higher temperatures and following exposure to proteases, surfactants, and extreme pH. All-atom molecular dynamics simulations showed that the AMP adopts a ƒÀ-sheet structure upon membrane interaction. These findings suggest that Virgibacillus chiguensis FN33 is a promising source of novel antibacterial agents against MRSA, supporting alternative strategies for drug-resistant infections.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anionic AMP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">AMP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antimicrobial peptide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antimicrobial resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FN33</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecular dynamics simulations</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MRSA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Virgibacillus chiguensis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2079-6382</Issn>
      <Volume>13</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Unveiling a New Antimicrobial Peptide with Efficacy against P. aeruginosa and K. pneumoniae from Mangrove-Derived Paenibacillus thiaminolyticus NNS5-6 and Genomic Analysis</ArticleTitle>
    <FirstPage LZero="delete">846</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Namfa</FirstName>
        <LastName>Sermkaew</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Apichart</FirstName>
        <LastName>Atipairin</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sucheewin</FirstName>
        <LastName>Krobthong</LastName>
        <Affiliation>Center of Excellence in Natural Products Chemistry (CENP), Department of Chemistry, Faculty of Science, Chulalongkorn University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chanat</FirstName>
        <LastName>Aonbangkhen</LastName>
        <Affiliation>Center of Excellence in Natural Products Chemistry (CENP), Department of Chemistry, Faculty of Science, Chulalongkorn University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yodying</FirstName>
        <LastName>Yingchutrakul</LastName>
        <Affiliation>National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nuttapon</FirstName>
        <LastName>Songnaka</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study focused on the discovery of the antimicrobial peptide (AMP) derived from mangrove bacteria. The most promising isolate, NNS5-6, showed the closest taxonomic relation to Paenibacillus thiaminolyticus, with the highest similarity of 74.9%. The AMP produced by Paenibacillus thiaminolyticus NNS5-6 exhibited antibacterial activity against various Gram-negative pathogens, especially Pseudomonas aeruginosa and Klebsiella pneumoniae. The peptide sequence consisted of 13 amino acids and was elucidated as Val-Lys-Gly-Asp-Gly-Gly-Pro-Gly-Thr-Val-Tyr-Thr-Met. The AMP mainly exhibited random coil and antiparallel beta-sheet structures. The stability study indicated that this AMP was tolerant of various conditions, including proteolytic enzymes, pH (1.2&#8211;14), surfactants, and temperatures up to 40 ‹C for 12 h. The AMP demonstrated 4 &#181;g/mL of MIC and 4&#8211;8 &#181;g/mL of MBC against both pathogens. Time-kill kinetics showed that the AMP acted in a time- and concentration-dependent manner. A cell permeability assay and scanning electron microscopy revealed that the AMP exerted the mode of action by disrupting bacterial membranes. Additionally, nineteen biosynthetic gene clusters of secondary metabolites were identified in the genome. NNS5-6 was susceptible to various commonly used antibiotics supporting the primary safety requirement. The findings of this research could pave the way for new therapeutic approaches in combating antibiotic-resistant pathogens.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">antimicrobial peptide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antimicrobial resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bacterial genome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">biosynthetic gene cluster</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Klebsiella pneumoniae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mangrove</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mass spectrometry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">NNS5-6</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Paenibacillus thiaminolyticus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pseudomonas aeruginosa</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1751-7362</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cyanorhodopsin-II represents a yellow-absorbing proton-pumping rhodopsin clade within cyanobacteria</ArticleTitle>
    <FirstPage LZero="delete">wrae175</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masumi</FirstName>
        <LastName>Hasegawa-Takano</LastName>
        <Affiliation>Atmosphere and Ocean Research Institute, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Hosaka</LastName>
        <Affiliation>Laboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Atmosphere and Ocean Research Institute, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marie</FirstName>
        <LastName>Kurihara</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Atmosphere and Ocean Research Institute, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Ishizuka-Katsura</LastName>
        <Affiliation>Laboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomomi</FirstName>
        <LastName>Kimura-Someya</LastName>
        <Affiliation>Laboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikako</FirstName>
        <LastName>Shirouzu</LastName>
        <Affiliation>Laboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Sudo</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Yoshizawa</LastName>
        <Affiliation>Atmosphere and Ocean Research Institute, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Microbial rhodopsins are prevalent in many cyanobacterial groups as a light-energy-harvesting system in addition to the photosynthetic system. It has been suggested that this dual system allows efficient capture of sunlight energy using complementary ranges of absorption wavelengths. However, the diversity of cyanobacterial rhodopsins, particularly in accumulated metagenomic data, remains underexplored. Here, we used a metagenomic mining approach, which led to the identification of a novel rhodopsin clade unique to cyanobacteria, cyanorhodopsin-II (CyR-II). CyR-IIs function as light-driven outward H+ pumps. CyR-IIs, together with previously identified cyanorhodopsins (CyRs) and cyanobacterial halorhodopsins (CyHRs), constitute cyanobacterial ion-pumping rhodopsins (CyipRs), a phylogenetically distinct family of rhodopsins. The CyR-II clade is further divided into two subclades, YCyR-II and GCyR-II, based on their specific absorption wavelength. YCyR-II absorbed yellow light (ƒÉmax&#8201;=&#8201;570 nm), whereas GCyR-II absorbed green light (ƒÉmax&#8201;=&#8201;550 nm). X-ray crystallography and mutational analysis revealed that the difference in absorption wavelengths is attributable to slight changes in the side chain structure near the retinal chromophore. The evolutionary trajectory of cyanobacterial rhodopsins suggests that the function and light-absorbing range of these rhodopsins have been adapted to a wide range of habitats with variable light and environmental conditions. Collectively, these findings shed light on the importance of rhodopsins in the evolution and environmental adaptation of cyanobacteria.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cyanobacteria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">microbial rhodopsin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ecology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">evolution</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1758-5902</Issn>
      <Volume>18</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical Impacts of Minimally Invasive Transperineal Abdominoperineal Resection in Crohn's Disease: A Retrospective Analysis</ArticleTitle>
    <FirstPage LZero="delete">e70149</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiko</FirstName>
        <LastName>Kanaya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Inokuchi</LastName>
        <Affiliation>Research Center for Intestinal Health Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunitoshi</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Crohn's disease (CD) often leads to complex anorectal complications, posing significant challenges in surgical management. Transperineal abdominoperineal resection (TpAPR) has emerged as a minimally invasive alternative to APR. This study aims to evaluate the safety and efficacy of TpAPR compared to APR in patients with CD.&lt;br&gt;
Methods: A retrospective analysis was conducted on 19 CD patients who underwent either minimally invasive TpAPR (n&#8201;=&#8201;11) or APR (n&#8201;=&#8201;8) between 2008 and 2023 from a single institution. The primary outcomes were assessed: intraoperative blood loss, operative time, and surgical site infection (SSI) rates.&lt;br&gt;
Results: The minimally invasive TpAPR group exhibited significantly reduced intraoperative blood loss (223&#8201;mL vs. 533&#8201;mL, p&#8201;=&#8201;0.04) and a lower incidence of SSI rates (36.4% vs. 75%, p&#8201;=&#8201;0.07). Operative time and hospital stay were comparable between groups.&lt;br&gt;
Conclusion: Minimally invasive TpAPR demonstrates potential benefits over APR in reducing blood loss and SSI rates in CD patients. Further large-scale studies are warranted to confirm these findings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Crohn's disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intraoperative blood loss</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">minimally invasive surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">surgical site infection (SSI)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transperineal abdominoperineal resection (TpAPR)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japan Neurosurgical Society</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0470-8105</Issn>
      <Volume>65</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-world Experience of Embolization for Intracranial Tumors in Japan: Analysis of 2,756 Cases from Japanese Registry of NeuroEndovascular Therapy 4</ArticleTitle>
    <FirstPage LZero="delete">396</FirstPage>
    <LastPage>406</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>HARUMA</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>SUGIU</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohito</FirstName>
        <LastName>HISHIKAWA</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>SOUTOME</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>EBISUDANI</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryu</FirstName>
        <LastName>KIMURA</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisanori</FirstName>
        <LastName>EDAKI</LastName>
        <Affiliation>Department of Neurosurgery, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>KAWAKAMI</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>MURAI</LastName>
        <Affiliation>Department of Neurosurgery, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>HIRAMATSU</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>TANAKA</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsu</FirstName>
        <LastName>SATOW</LastName>
        <Affiliation>Department of Neurosurgery, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>IIHARA</LastName>
        <Affiliation>Department of Neurosurgery, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotoshi</FirstName>
        <LastName>IMAMURA</LastName>
        <Affiliation>Department of Neurosurgery, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>ISHII</LastName>
        <Affiliation>Department of Neurosurgery, Juntendo University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>MATSUMARU</LastName>
        <Affiliation>Department of Neurosurgery, Institute of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>SAKAI</LastName>
        <Affiliation>Department of Neurosurgery, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>YOSHIMURA</LastName>
        <Affiliation>Department of Neurosurgery, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuyuki</FirstName>
        <LastName>SAKAI</LastName>
        <Affiliation>Department of Neurological Surgery, Shimizu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Japanese Registry of Neuroendovascular Therapy (JR-NET) Investigators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Embolization of intracranial tumors is predominantly performed in Japan, primarily before neurosurgical resection. The Japanese Registry of NeuroEndovascular Therapy (JR-NET) Study Group, established in 2005, aims to clarify the factors influencing the outcomes of neuroendovascular treatment. Japanese Registry of NeuroEndovascular Therapy 4 is a nationwide, multicenter retrospective observational study that evaluates real-world data on intracranial tumor embolization in Japan. Japanese Registry of NeuroEndovascular Therapy 4 is based on data collected from 166 neurosurgical centers in Japan between January 2015 and December 2019. Of 63,230 patients, 2,664 (4.2%) with intracranial tumors underwent embolization. The primary endpoint was the proportion of patients with a modified Rankin scale (mRS) score of 0-2 at 30 days post-procedure. Secondary endpoints included procedure-related complications. Among the 2,664 patients, 61 records lacked sufficient data, leaving 2,603 patients (1,612 females, median age: 61 years [interquartile range 51-71]). The proportion of patients with mRS scores &#8804;2 at 30 days after the procedure was 86.9%. The overall incidence of procedure-related complications was 4.8%, with 1.8% hemorrhagic, 2.0% ischemic, and 1.0% classified as other complications. In the multivariate analysis, general anesthesia and embolization of vessels other than the external carotid artery were identified as risk factors for the development of complications. Meningioma cases had a complication rate of 4.3%, with major complications occurring in 3.5%. Hemangioblastoma cases had a 14.9% complication rate, with major complications at 9.9%. Japanese Registry of NeuroEndovascular Therapy 4 provides comprehensive real-world data on intracranial tumor embolization in Japan, identifying risk factors to inform and improve the safe practice of intracranial tumor embolization in neuroendovascular therapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">complication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intracranial tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">embolization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japanese registry</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1071-2690</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>S100A8/A9-MCAM signaling promotes gastric cancer cell progression via ERK-c-Jun activation</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Youyi</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xu</FirstName>
        <LastName>Yang</LastName>
        <Affiliation>Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Kinoshita</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nahoko</FirstName>
        <LastName>Tomonobu</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bo</FirstName>
        <LastName>Pan</LastName>
        <Affiliation>The First Affiliated Hospital, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fangping</FirstName>
        <LastName>Wu</LastName>
        <Affiliation>School of Pharmaceutical Sciences, Zhejiang Chinese Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xu</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumi</FirstName>
        <LastName>Sagayama</LastName>
        <Affiliation>Faculties of Educational and Research Management Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bei</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakiyo</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>S100 protein family members S100A8 and S100A9 function primarily as a heterodimer complex (S100A8/A9) in vivo. This complex has been implicated in various cancers, including gastric cancer (GC). Recent studies suggest that these proteins play significant roles in tumor progression, inflammation, and metastasis. However, the exact mechanisms by which S100A8/A9 contributes to GC pathogenesis remain unclear. This study investigates the role of S100A8/A9 and its receptor in GC. Immunohistochemical analysis was performed on GC tissue samples to assess the expression of the S100A8/A9 receptor melanoma cell adhesion molecule (MCAM). In vitro transwell migration and invasion assays were used to evaluate the motility and invasiveness of GC cells. Cell proliferation was assessed using a growth assay, and Western blotting (WB) was employed to examine downstream signaling pathways, including ERK and the transcription factor c-Jun, in response to S100A8/A9&#8211;MCAM interaction. S100A8/A9 stimulation enhanced both proliferation and migration through MCAM binding in GC cell lines. These cellular events were accompanied by ERK activation and c-Jun induction. Downregulation of MCAM suppressed both ERK phosphorylation and c-Jun expression, highlighting the importance of the S100A8/A9&#8210;MCAM&#8210;ERK&#8210;c-Jun axis in promoting GC progression. These findings indicate that S100A8/A9 contributes to GC progression via MCAM, which activates the ERK&#8210;c-Jun pathway. The S100A8/A9&#8210;signaling axis may represent a novel therapeutic target in GC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Gastric cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">S100 protein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MCAM</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Inflammation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metastasis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1752-8054</Issn>
      <Volume>18</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell]Derived Cardiomyocytes and FDA Adverse Events Reporting System</ArticleTitle>
    <FirstPage LZero="delete">e70325</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Yanagida</LastName>
        <Affiliation>Division of Pharmacology, National Institute of Health Sciences (NIHS)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Kawagishi</LastName>
        <Affiliation>Division of Pharmacology, National Institute of Health Sciences (NIHS)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuo</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Japan Pharmaceutical Information Center (JAPIC)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasunari</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Division of Pharmacology, National Institute of Health Sciences (NIHS)</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Recent advances in the development of anti-cancer drugs have contributed to prolonged survival of cancer patients. In contrast, drug-induced cardiotoxicity, particularly cardiac contractile dysfunction, is of growing concern in cancer treatment. Therefore, it is important to understand the risks of anti-cancer drug-induced cardiac contractile dysfunction in drug development. We have previously developed image-based motion analysis using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to assess the effect of drugs on contractility. However, the utility and predictive potential of image-based motion analysis using hiPSC-CMs for anti-cancer drug-induced cardiac contractile dysfunction have not been well understood. Here we focused on epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and investigated the correlation between the hiPSC-CMs data and clinical signals of adverse events related to cardiac contractile dysfunction. We examined the effects of the four EGFR-TKIs, osimertinib, gefitinib, afatinib, and erlotinib, on the contractility of hiPSC-CMs using image-based motion analysis. We found that osimertinib decreased contraction velocity and deformation distance in a dose- and time-dependent manner, whereas gefitinib, afatinib, and erlotinib had little effect on these parameters. Next, we examined the real-world data of the EGFR-TKIs using FDA Adverse Event Reporting System (FAERS; JAPIC AERS). Only osimertinib showed significant clinical signals of adverse events related to cardiac contractile dysfunction. These data suggest that hiPSC-CM data correlate with clinical signals in FAERS analysis for four EGFR-TKIs. Thus, image-based motion analysis using hiPSC-CMs can be a useful platform for predicting the risk of anti-cancer drug-induced cardiac contractile dysfunction in patients.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cardiomyocytes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cardiotoxicity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">contractility</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EGFR-tyrosine kinase inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FAERS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">human iPS cell</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0250-7005</Issn>
      <Volume>45</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Angiogenin-induced Osteoclastogenesis Mediates Bone Destruction in Oral Squamous Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">1025</FirstPage>
    <LastPage>1033</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">KASUMI</FirstName>
        <LastName>AOKI</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">NANA</FirstName>
        <LastName>YOSHITANI</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">NAITO</FirstName>
        <LastName>KURIO</LastName>
        <Affiliation>Department of Oral Surgery, Graduate School of Biomedical Sciences, Tokushima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">NORIE</FirstName>
        <LastName>YOSHIOKA</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">JUMPEI</FirstName>
        <LastName>TERAMACHI</LastName>
        <Affiliation>Department of Oral Function and Anatomy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MIKA</FirstName>
        <LastName>IKEGAME</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">HIROHIKO</FirstName>
        <LastName>OKAMURA</LastName>
        <Affiliation>Department of Oral Morphology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SOICHIRO</FirstName>
        <LastName>IBARAGI</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: Bone destruction caused by oral cancer severely impacts patient quality of life. This study aimed to clarify the role of angiogenin (ANG) in osteoclastogenesis and oral cancer-induced bone destruction.&lt;br&gt;
Materials and Methods: Recombinant ANG was used to assess its effects on osteoclast formation and bone resorption activity in bone marrow cultures. ANG-knockdown oral squamous carcinoma HSC-2 cells (ANG-RNAi) were transplanted into intramedullary cavities of femurs. Bone destruction was radiologically analyzed, while angiogenesis and osteoclast induction in the surrounding area of the transplanted lesion were histologically examined.&lt;br&gt;
Results: Recombinant ANG promoted osteoclast formation and bone resorption activity. Transplantation of ANG-RNAi cells significantly reduced tumor growth and bone destruction properties compared to transplantation of control cells. Histological analysis revealed lower angiogenesis and fewer osteoclast induction in the ANG-RNAi cells-transplanted group.&lt;br&gt;
Conclusion: ANG mediates oral cancer-induced bone destruction by promoting osteoclast formation and resorption. These findings suggest that ANG could be a potential therapeutic target for suppressing tumor growth, angiogenesis, and bone destruction in oral cancer therapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Angiogeninoste</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oclastogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osteoclasts</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0091-6749</Issn>
      <Volume>156</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dried blood spot proteome identifies subclinical interferon signature in neonates with type I interferonopathy</ArticleTitle>
    <FirstPage LZero="delete">473</FirstPage>
    <LastPage>479.e1</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Nihira</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Nakajima</LastName>
        <Affiliation>Department of Applied Genomics, Kazusa DNA Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazushi</FirstName>
        <LastName>Izawa</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Kawashima</LastName>
        <Affiliation>Department of Applied Genomics, Kazusa DNA Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Konno</LastName>
        <Affiliation>Department of Applied Genomics, Kazusa DNA Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoko</FirstName>
        <LastName>Higashiguchi</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiko</FirstName>
        <LastName>Nishitani-Isa</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eitaro</FirstName>
        <LastName>Hiejima</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Matsubayashi</LastName>
        <Affiliation>Department of Pediatrics, Seirei Hamamatsu General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Ishihara</LastName>
        <Affiliation>Department of Pediatrics, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Yashiro</LastName>
        <Affiliation>Department of Pediatrics, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Infection and Immunology, Aichi Childrenfs Health and Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Ohwada</LastName>
        <Affiliation>Department of Pediatrics, Dokkyo Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiichi</FirstName>
        <LastName>Tomotaki</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiko</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neonatology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Ohnishi</LastName>
        <Affiliation>Department of Pediatrics, Gifu University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Ishimura</LastName>
        <Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoi</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Morio</LastName>
        <Affiliation>Laboratory of Immunology and Molecular Medicine, Advanced Research Initiative, Institute of Science Tokyo (SCIENCE TOKYO)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Hoshino</LastName>
        <Affiliation>Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Kanegane</LastName>
        <Affiliation>Department of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (SCIENCE TOKYO)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohsuke</FirstName>
        <LastName>Imai</LastName>
        <Affiliation>Department of Pediatrics, National Defense Medical College</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuko</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pediatrics, National Defense Medical College</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeaki</FirstName>
        <LastName>Nonoyama</LastName>
        <Affiliation>Department of Pediatrics, National Defense Medical College</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Human Genetics, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>Onodera</LastName>
        <Affiliation>Department of Human Genetics, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Division of Immunology, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshinao</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Division of Immunology, National Center for Child Health and Development</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Takita</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Nishikomori</LastName>
        <Affiliation>Department of Pediatrics and Child Health, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Applied Genomics, Kazusa DNA Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Yasumi</LastName>
        <Affiliation>Department of Pediatrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Type I interferonopathy is characterized by aberrant upregulation of type I interferon signaling. The mRNA interferon signature is a useful marker for activation of the interferon pathway and for diagnosis of type I interferonopathy; however, early diagnosis is challenging.&lt;br&gt;
Objective: This study sought to identify the proteomic interferon signature in dried blood spot (DBS) samples. The aim was to evaluate the usefulness of the interferon signature for neonatal screening and to gain insight into presymptomatic state of neonates with inborn errors of immunity (IEIs).&lt;br&gt;
Methods: DBS samples from healthy newborns/adults, patients with type I interferonopathy or other IEIs as well as from neonates with viral infections, including some samples obtained during the presymptomatic neonatal period, were examined by nontargeted proteome analyses. Expression of interferon-stimulated genes (ISGs) was evaluated and a DBS-interferon signature was defined. Differential expression/pathway analysis was also performed.&lt;br&gt;
Results: The ISG products IFIT5, ISG15, and OAS2 were detected. Expression of IFIT5 and ISG15 was upregulated significantly in individuals with type I interferonopathy. We defined the sum of the z scores for these as the DBS-interferon signature, and found that patients with IEIs other than type I interferonopathy, such as chronic granulomatous disease (CGD), also showed significant elevation. Additionally, neonatal samples of type I interferonopathy and CGD patients showed high interferon signatures. Pathway analysis of neonatal CGD samples revealed upregulation of systemic lupus erythematosus&#8211;like pathways.&lt;br&gt;
Conclusion: Upregulation of the interferon pathway exists already at birth\not only in neonates with type I interferonopathy but also in other IEIs, including CGD.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Inborn errors of immunity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">interferonopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">signature</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">proteome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dried blood spot</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CGD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">WAS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">newborn</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neonate</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume>30</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Lymphadenectomy and chemotherapy are effective treatments for patients with 2023 international federation of gynecology and obstetrics stage IIC-high risk endometrial cancer in Japan</ArticleTitle>
    <FirstPage LZero="delete">144</FirstPage>
    <LastPage>156</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Tani</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masae</FirstName>
        <LastName>Yorimitsu</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Seki</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Japanese Red Cross Society Himeji Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mie</FirstName>
        <LastName>Nakanishi</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kagawa Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironori</FirstName>
        <LastName>Itou</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miyuki</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dan</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, National Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Etsuko</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background In early-stage endometrial cancer (EC), the treatment of aggressive histological subtypes (endometrioid carcinoma grade 3, serous carcinoma, clear-cell carcinoma, undifferentiated carcinoma, mixed carcinoma, and carcinosarcoma) is controversial. We aimed to investigate the treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) stage IC and stage IIC EC according to the 2023 classification.&lt;br&gt;
Methods We retrospectively identified patients with FIGO 2023 stage IC, IIC-intermediate risk (IIC-I), and IIC-high risk (IIC-H) EC who underwent adjuvant therapy or observation after surgery at eight medical institutions from 2004 to 2023. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan&#8211;Meier estimates and univariate and multivariate analyses.&lt;br&gt;
Results The PFS and OS were significantly worse in patients with FIGO 2023 stage IIC-H EC than in those with FIGO 2023 stage IIC-I EC (PFS: p&#8201;=&#8201;0.008 and OS: p&#8201;=&#8201;0.006). According to the FIGO 2023 stage IIC-H classification, lymphadenectomy and chemotherapy resulted in better prognoses regarding both PFS and OS (p&#8201;&lt;&#8201;0.001 for both) than other treatments. Our findings suggest that lymphadenectomy and chemotherapy effectively reduced vaginal stump and lymph node metastases in FIGO 2023 stage IIC-H EC (p&#8201;&lt;&#8201;0.001 and p&#8201;=&#8201;0.008, respectively). Furthermore, in the multivariate analysis, not undergoing lymphadenectomy or chemotherapy were independent predictors of recurrence and poor prognoses in patients with FIGO 2023 stage IIC-H EC (p&#8201;&lt;&#8201;0.001 and p&#8201;=&#8201;0.031, respectively).&lt;br&gt;
Conclusion Lymphadenectomy and chemotherapy resulted in better prognoses regarding both recurrence and survival in patients with FIGO 2023 stage IIC high-risk EC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Endometrial cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FIGO 2023</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Stage IIC high risk</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lymphadenectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chemotherapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association between cesarean delivery and childhood allergic diseases in a longitudinal population-based birth cohort from Japan</ArticleTitle>
    <FirstPage LZero="delete">19206</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Tamai</LastName>
        <Affiliation>Department of Epidemiology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Epidemiology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The association between cesarean delivery and childhood allergic diseases, such as atopic dermatitis, food allergy, and bronchial asthma, remains unclear, with limited evidence from Asian populations. We analyzed population-based data of 2,114 children born in Japan in 2010 from the Longitudinal Survey of Babies in the 21st Century, linked to the Perinatal Research Network Database. Comparisons were made between children born by cesarean delivery and those born vaginally. Longitudinal outcomes were atopic dermatitis, food allergy, and bronchial asthma during childhood for each age group up to 9 years of age. We performed Poisson regression analyses with robust variance, and adjusted for child and parent variables, followed by supplementary analyses using generalized estimating equations (GEE). Children born by cesarean delivery did not have a higher risk of most outcomes compared to those born vaginally. GEE analysis found no association between cesarean delivery and atopic dermatitis (adjusted risk ratio [aRR] 0.8, 95% confidence interval [CI] 0.5&#8211;1.2), food allergy (aRR 1.1, 95% CI 0.7&#8211;1.7), bronchial asthma (aRR 1.0, 95% CI 0.8&#8211;1.4), or allergic rhinoconjunctivitis (aRR 0.9, 95% CI 0.8&#8211;1.1). This study shows no clear evidence of an association between delivery mode and childhood allergic diseases in Japan.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2053-3624</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical impact of combined assessment of myocardial inflammation and fibrosis using myocardial biopsy in patients with dilated cardiomyopathy: a multicentre, retrospective cohort study</ArticleTitle>
    <FirstPage LZero="delete">e003250</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Cardiology, Nagoya City University Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko Ohta</FirstName>
        <LastName>Ogo</LastName>
        <Affiliation>Department of Pathology, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuo</FirstName>
        <LastName>Sugano</LastName>
        <Affiliation>Department of Cardiology, Keiyu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuro</FirstName>
        <LastName>Yokokawa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromitsu</FirstName>
        <LastName>Kanamori</LastName>
        <Affiliation>Department of Cardiology, Gifu University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Department of Pathology, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiaki</FirstName>
        <LastName>Hiroe</LastName>
        <Affiliation>Department of Cardiology, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kinta</FirstName>
        <LastName>Hatakeyama</LastName>
        <Affiliation>Department of Pathology, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hatsue</FirstName>
        <LastName>Ishibashi-Ueda</LastName>
        <Affiliation>Department of Pathology, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Center for Advanced Heart Failure, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Dohi</LastName>
        <Affiliation>Department of Cardiology and Nephrology, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihisa</FirstName>
        <LastName>Anzai</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Seo</LastName>
        <Affiliation>Department of Cardiology, Nagoya City University Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyoko</FirstName>
        <LastName>Imanaka-Yoshida</LastName>
        <Affiliation>Department of Pathology and Matrix Biology, Mie University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Among patients with dilated cardiomyopathy (DCM), myocardial inflammation and fibrosis are risk factors for poor clinical outcomes. Here, we investigated the combined prognostic value of these two factors, as evaluated using myocardial biopsy samples.&lt;br&gt;
Methods This retrospective and multicentre study included patients with DCM\defined as LVEF of &#8804;45% and left diastolic diameter of &gt;112% of predicted value, without evidence of secondary or ischaemic cardiomyopathy. In myocardial biopsy samples, inflammatory cells were counted using immunohistochemistry, and Massonfs Trichrome staining was performed to quantify the myocardial fibrosis as collagen area fraction (CAF). Higher myocardial inflammation was defined as leucocytes of &#8805;14/mm&#178;, including &#8804;4 monocytes/mm&#178;, with CD3+ T lymphocytes of&#8805;7/mm&#178;. Greater myocardial fibrosis was defined as CAF of&gt;5.9% by the Youdenfs index. The primary endpoint was cardiac death or left ventricular assist device implantation.&lt;br&gt;
Results A total of 255 DCM patients were enrolled (average age, 53.1 years; 78% males). Within this cohort, the mean LVEF was 28.0%, mean CAF was 10.7% and median CD3+ cell count was 8.3/mm2. During the median follow-up period of 2688 days, 46 patients met the primary endpoint. Multivariable Cox proportional hazard analyses revealed that CD3+ cell count and CAF were independent determinants of the primary endpoint. Kaplan&#8211;Meier analysis showed that patients with both higher myocardial inflammation and greater fibrosis had the worst prognosis (log-rank p&lt;0.001). When myocardial inflammation was graded as one of three degrees: T lymphocytes of &lt;13/mm&#178; (low); 13 of 13.1&#8211;23.9/mm&#178; (moderate); and T lymphocytes of &#8805;24&#8201;/mm&#178; (high), patients with moderate inflammation exhibited a superior survival rate when CAF was &#8804;5.9%, but a worse survival rate when CAF was &gt;5.9%.&lt;br&gt;
Conclusions Having both biopsy-proven higher myocardial inflammation and greater fibrosis predicted the worst clinical prognosis in patients with DCM.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>64</Volume>
      <Issue>15</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical and Genetic Analyses of SPG7 in Japanese Patients with Undiagnosed Ataxia</ArticleTitle>
    <FirstPage LZero="delete">2290</FirstPage>
    <LastPage>2294</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rimi</FirstName>
        <LastName>Hino</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Fujino</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Neurology, International University of Health and Welfare Mita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobue</FirstName>
        <LastName>K. Iwata</LastName>
        <Affiliation>Department of Neurology, International University of Health and Welfare Mita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective Spastic paraplegia 7 (SPG7) is an autosomal recessive neurodegenerative disorder caused by biallelic pathogenic variants in SPG7. It is predominantly characterized by adult-onset slowly progressive spastic paraparesis. While SPG7 presenting with ataxia with or without spasticity is relatively common in Europe and North America, it is considered rare in Japan. This study aimed to identify SPG7 patients among those with undiagnosed ataxia within the Japanese population.&lt;br&gt;
Methods We retrospectively selected 351 patients with undiagnosed ataxia, excluding those with secondary and common spinocerebellar ataxia. Whole-exome sequence analysis was conducted, and homozygosity of the identified variants was confirmed using droplet digital polymerase chain reaction (ddPCR).&lt;br&gt;
Results Among the 351 patients, 2 were diagnosed with SPG7, and homozygosity was confirmed by ddPCR. Both patients carried homozygous pathogenic variants in SPG7: c.1948G&gt;A, p.Asp650Asn, and c.1192C&gt;T, p.Arg398Ter (NM_003119.4). Clinically, both patients presented with progressive ataxia. In addition, Patient 1 exhibited partial ophthalmoplegia and spastic paraparesis, whereas Patient 2 demonstrated cerebellar ataxia without spasticity.&lt;br&gt;
Conclusion The rarity of SPG7 in Japan may be attributed to variation in the minor allele frequency of the c.1529C&gt;T, p.Ala510Val variant, which is more prevalent in Europe and North America than in other areas.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cerebellar ataxia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spastic paraparesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">whole-exome sequence analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SPG7</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0002-8177</Issn>
      <Volume>156</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The greater palatine nerve and artery both supply the maxillary teeth</ArticleTitle>
    <FirstPage LZero="delete">151</FirstPage>
    <LastPage>159.e1</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Joe</FirstName>
        <LastName>Iwanaga</LastName>
        <Affiliation>Division of Gross and Clinical Anatomy, Department of Anatomy, School of Medicine, Kurume University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Muralidharan</FirstName>
        <LastName>Anbalagan</LastName>
        <Affiliation>Department of Structural and Cellular Biology, School of Medicine, Tulane University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Binghao</FirstName>
        <LastName>Zou</LastName>
        <Affiliation>Department of Structural and Cellular Biology, School of Medicine, Tulane University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taku</FirstName>
        <LastName>Toriumi</LastName>
        <Affiliation>Department of Anatomy, School of Life Dentistry at Niigata, The Nippon Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R. Shane</FirstName>
        <LastName>Tubbs</LastName>
        <Affiliation>University of Queensland</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background. It is generally accepted that the greater palatine nerve and artery supply the palatal mucosa, gingiva, and glands, but not the bone or tooth adjacent to those tissues. When the bony palate is observed closely, multiple small foramina are seen on the palatal surface of the alveolar process. The authors hypothesized that the greater palatine nerve and artery might supply the maxillary teeth via the foramina on the palatal surface of the alveolar process and the superior alveolar nerve and artery. The authors aimed to investigate the palatal innervation and blood supply of the maxillary teeth.&lt;br&gt;
Methods. Eight cadaveric maxillae containing most teeth or alveolar sockets were selected. The mean age at the time of death was 82.4 years. The samples were examined with colored water injection, latex injection, microcomputed tomography with contrast dye, gross anatomic dissection, and histologic observation.&lt;br&gt;
Results. Through both injection studies and microcomputed tomographic analysis, the authors found that the small foramina on and around the greater palatine groove connected to the alveolar process and tooth sockets. The small foramina in the greater palatine and incisive canal also continued inside the alveolar process and the tooth sockets.&lt;br&gt;
Conclusions. The alveolar branches of the greater palatine nerve and artery as well as the nasopalatine nerve and sphenopalatine artery supply maxillary teeth, alveolar bone, and periodontal tissue via the palatal alveolar foramina with superior alveolar nerves and arteries.&lt;br&gt;
Practical Implications. This knowledge is essential for dentists when administering local anesthetic to the maxillary teeth and performing an osteotomy. Anatomic and dental textbooks should be updated with this new knowledge for better patient care.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Maxillary teeth</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dental pulp</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anatomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nerve block</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">root canal treatment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cadaver</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0815-9319</Issn>
      <Volume>39</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Long]term outcomes of endoscopic resection of superficial esophageal squamous cell carcinoma in late]elderly patients</ArticleTitle>
    <FirstPage LZero="delete">2664</FirstPage>
    <LastPage>2671</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Katsunori</FirstName>
        <LastName>Matsueda</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Fukui</LastName>
        <Affiliation>Faculty of Societal Safety Sciences, Kansai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Satomi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Inoo</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyasu</FirstName>
        <LastName>Kono</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aim: As the population ages, the number of elderly patients with superficial esophageal squamous cell carcinoma (ESCC) is increasing. We aimed to clarify the indications for endoscopic resection (ER) in late-elderly patients with ESCC in terms of life expectancy.&lt;br&gt;
Methods: Patients aged &#8805;75 years who underwent ER for ESCC at our institution from January 2005 to December 2018 were enrolled. Clinical data, including the Eastern Cooperative Oncology Group performance status, American Society of Anesthesiologists physical status (ASA-PS), Charlson comorbidity index, and prognostic nutritional index (PNI), were collected at the time of ER. The main outcome measure was overall survival (OS).&lt;br&gt;
Results: Two hundred eight consecutive patients were enrolled. The patients' median age was 78 years (range, 75&#8211;89 years). The 5-year follow-up rate was 88.5% (median follow-up period, 6.6 years). The 5-year OS rate was 79.2% (95% confidence interval [CI], 72.2&#8211;84.8), and 5-year net survival standardized for age, sex, and calendar year was 1.04 (95% CI, 0.98&#8211;1.09). In the multivariate analysis, an ASA-PS of 3 (hazard ratio, 2.45; 95% CI, 1.16&#8211;5.17) and PNI of &lt;44.0 (hazard ratio, 2.73; 95% CI, 1.38&#8211;5.40) were independent prognostic factors. When neither of these factors was met, the 5-year OS rate was 87.8% (95% CI, 80.0&#8211;92.9), and 5-year net survival was 1.08 (95% CI, 1.02&#8211;1.14).&lt;br&gt;
Conclusions: ER for ESCC in late-elderly patients may improve life expectancy. ER is recommended in patients with a good ASA-PS and PNI.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">endoscopic resection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">esophageal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">late-elderly patient</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">long-term outcome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>63</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Gastric Mucosa-associated Lymphoid Tissue Lymphoma That Relapsed after 11 Years Subsequent to Achieving Complete Remission</ArticleTitle>
    <FirstPage LZero="delete">1697</FirstPage>
    <LastPage>1702</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shoko</FirstName>
        <LastName>Inoo</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Iwamuro</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiro</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Practical Gastrointestinal Endoscopy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Ootuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A 38-year-old Japanese man was diagnosed with extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue in the stomach (gastric MALT lymphoma). Fluorescence in situ hybridization analysis revealed the absence of t (11;18) (q21;q21) translocation but the presence of extra copies of MALT1, indicating tetrasomy 18. Helicobacter pylori eradication led to complete remission (CR). However, the gastric MALT lymphoma relapsed after 11 years old. This case underscores the need for long-term observation (&gt;10 years) of patients with gastric MALT lymphoma. Further investigation is warranted to elucidate the correlation between trisomy/tetrasomy 18 and the recurrence propensity.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">gastric MALT lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">H. pylori</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">relapse</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0002-0729</Issn>
      <Volume>54</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Oestrogen replacement combined with resistance exercise in older women with knee osteoarthritis: a randomised, double-blind, placebo-controlled clinical trial</ArticleTitle>
    <FirstPage LZero="delete">afaf224</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Mitoma</LastName>
        <Affiliation>Medical Development Field, Center for Innovative Clinical Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hikaru</FirstName>
        <LastName>Ooba</LastName>
        <Affiliation>Medical Development Field, Center for Innovative Clinical Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kasumi</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Obstetrics and Gynecology, Ochiai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsunemasa</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Obstetrics and Gynecology, Ochiai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Rehabilitation Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Medical Development Field, Center for Innovative Clinical Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Medical Development Field, Center for Innovative Clinical Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jota</FirstName>
        <LastName>Maki</LastName>
        <Affiliation>Medical Development Field, Center for Innovative Clinical Medicine, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Interventions targeting physical function decline in older women with knee osteoarthritis (KOA) are vital for healthy ageing. The additive benefits of combining oestrogen replacement therapy (ERT) with resistance exercise remain unclear.&lt;br&gt;
Objective: To evaluate the additive effect of low-dose ERT on physical performance when combined with a muscle resistance exercise programme (MREP) in older women with KOA.&lt;br&gt;
Design: This is a placebo-controlled, double-blind, randomised clinical trial.&lt;br&gt;
Subjects: The subjects were community-dwelling women aged &#8805;65 years with chronic knee pain and KOA diagnosis.&lt;br&gt;
Methods: Participants completed a 3-month MREP and were randomised to receive daily low-dose transdermal ERT (oestradiol 0.54 mg/day) or placebo. Outcomes were assessed at baseline, postintervention and 12 months later. The primary outcome was change in 30-second chair stand test (CS-30) score. Secondary outcomes included muscle mass, knee extension strength, walking performance, metabolic indicators, knee pain scale and 12-item short-form health survey (SF-12). Between-group differences in CS-30 changes were analysed using a linear regression model based on the intention-to-treat principle.&lt;br&gt;
Results: Among 168 individuals screened, 75 participants (mean age 73.8 years, SD 5.8) were enrolled and randomised into an ERT group (n&#8201;=&#8201;37) or a placebo group (n&#8201;=&#8201;38). Baseline CS-30 scores were 14.81 (SD 3.95) in the ERT group and 15.58 (SD 3.48) in the placebo group. At 3 months, mean changes were 2.59 (SD 2.58) and 1.79 (SD 2.28) repetitions, respectively. The primary analysis showed no statistically significant between-group difference [regression coefficient: 0.81 (95% CI: |0.31, 1.92); P&#8201;=&#8201;.16]. Post hoc subgroup and sensitivity analyses suggested that benefits may exist among early-stage KOA participants. SF-12 mental health scores also improved significantly in the ERT group. No serious adverse events occurred.&lt;br&gt;
Conclusions: ERT did not confer significant additive benefits to resistance exercise overall but may improve outcomes in early-stage KOA and mental health domains. These exploratory findings warrant further investigation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">oestrogen replacement therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">muscle resistance exercise</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">knee osteoarthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">physical performance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">randomised controlled trial</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">older people</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Physical Therapy Association</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2189-8448</Issn>
      <Volume>27</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association Between Early Mobilization and Postoperative Pneumonia Following Robot-assisted Minimally Invasive Esophagectomy in Patients with Thoracic Esophageal Squamous Cell Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">121</FirstPage>
    <LastPage>127</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>NOZAWA</LastName>
        <Affiliation>Division of Physical Medicine and Rehabilitation, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>HARADA</LastName>
        <Affiliation>Graduate School of Health Science Studies, Kibi International University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>NOMA</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimi</FirstName>
        <LastName>KATAYAMA</LastName>
        <Affiliation>Division of Physical Medicine and Rehabilitation, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>HAMADA</LastName>
        <Affiliation>Division of Physical Medicine and Rehabilitation, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>OZAKI</LastName>
        <Affiliation>Division of Physical Medicine and Rehabilitation, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: The objective of this study was to confirm that early mobilization (EM) could reduce pneumonia in patients undergoing robot-assisted minimally invasive esophagectomy (RAMIE) for thoracic esophageal squamous cell carcinoma (TESCC). Methods: Postoperative pneumonia was defined as physician-diagnosed pneumonia using the Esophagectomy Complications Consensus Group definition of pneumonia with a Clavien&#8211;Dindo classification grade II&#8211;V on postoperative day (POD) 3&#8211;5. EM was defined as achieving an ICU Mobility Scale (IMS) &#8805;7 by POD 2. Patients were divided into EM (n = 36) and non-EM (n = 35) groups. Barriers to EM included pain, orthostatic intolerance (OI), and orthostatic hypotension. Results: The overall incidence of postoperative pneumonia was 12.7%, with a significant difference between the EM (2.8%) and non-EM (22.9%) groups (P = 0.014). The odds ratio was 0.098 in the EM group compared to the non-EM group. A significant difference was found between the two groups in terms of the barriers to EM at POD 2 only for OI, with a higher incidence in the non-EM group. Multivariate logistic regression analysis showed that patients with OI were more likely to be unable to achieve EM than those without OI (odds ratio, 7.030; P = 0.006). Conclusion: EM within POD 2 may reduce the incidence of postoperative pneumonia in patients undergoing RAMIE for TESCC. Furthermore, it was suggested that OI can have a negative impact on the EM after RAMIE.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Early mobilization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Postoperative pneumonia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Orthostatic intolerance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thoracic esophageal squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Robot-assisted minimally invasive esophagectomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0815-9319</Issn>
      <Volume>40</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-World Effectiveness and Safety of Vedolizumab in Patients &#8805;&#8201;70 Versus &lt;&#8201;70&#8201;Years With Ulcerative Colitis: Multicenter Retrospective Study</ArticleTitle>
    <FirstPage LZero="delete">1435</FirstPage>
    <LastPage>1445</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tadakazu</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taku</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Motoya</LastName>
        <Affiliation>Inflammatory Bowel Disease Center, Sapporo-Kosei General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshimitsu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reiko</FirstName>
        <LastName>Kunisaki</LastName>
        <Affiliation>Inflammatory Bowel Disease Center, Yokohama City University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Shibuya</LastName>
        <Affiliation>Department of Gastroenterology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Matsuura</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, IBD Center, Tsujinaka Hospital Kashiwanoha</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Yasuda</LastName>
        <Affiliation>Department of Gastroenterology, St. Marianna University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Gastroenterology, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noritaka</FirstName>
        <LastName>Takatsu</LastName>
        <Affiliation>Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuo</FirstName>
        <LastName>Maemoto</LastName>
        <Affiliation>Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Tahara</LastName>
        <Affiliation>Department of Gastroenterology, Saiseikai Utsunomiya Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Gastroenterology, Dokkyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Shimada</LastName>
        <Affiliation>Department of Gastroenterology, NHO Nagoya Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Kuno</LastName>
        <Affiliation>Department of Gastroenterology and Medicine, Fukuoka University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jovelle&#160;L.</FirstName>
        <LastName>Fernandez</LastName>
        <Affiliation>Japan Medical Office, Takeda Pharmaceutical Company Limited</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lisa</FirstName>
        <LastName>Hirose</LastName>
        <Affiliation>Japan Medical Office, Takeda Pharmaceutical Company Limited</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Ishiguro</LastName>
        <Affiliation>Japan Medical Office, Takeda Pharmaceutical Company Limited</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mary</FirstName>
        <LastName>Cavaliere</LastName>
        <Affiliation>Japan Medical Office, Takeda Pharmaceutical Company Limited</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Hibi</LastName>
        <Affiliation>Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Aim: Vedolizumab (VDZ) is often used in older patients with ulcerative colitis (UC) in clinical practice; however, real-world evidence is still limited, including in those with late-onset UC.&lt;br&gt;
Methods: This post hoc analysis of a multicenter, retrospective, observational chart review, enrolling 370 patients with UC receiving VDZ between December 2018 and February 2020, compared effectiveness and safety of VDZ among patients &#8805;&#8201;70 (n&#8201;=&#8201;40) versus &lt;&#8201;70&#8201;years (n&#8201;=&#8201;330), and among patients &#8805;&#8201;70&#8201;years with and without late-onset UC (age at disease onset: &#8805;&#8201;70 [n&#8201;=&#8201;13] versus &lt;&#8201;70&#8201;years [n&#8201;=&#8201;26]).&lt;br&gt;
Results: There were no differences between patients &#8805;&#8201;70 and &lt;&#8201;70&#8201;years in clinical remission rates (week 6: 57.5% vs. 47.6%, p&#8201;=&#8201;0.9174; week 14: 62.5% vs. 54.8%, p&#8201;=&#8201;0.1317; week 54: 47.5% vs. 46.4%, p&#8201;=&#8201;0.8149), primary nonresponse (10.0% vs. 15.5%, p&#8201;=&#8201;0.6248), loss of response (12.5% vs. 9.4%, p&#8201;=&#8201;0.5675), or overall safety. Among patients &#8805;&#8201;70&#8201;years, the incidence of adverse drug reactions was numerically greater in those with concomitant corticosteroids than in those without. For older patients with and without late-onset UC, week 54 remission rates were 23.1% versus 57.7% (p&#8201;=&#8201;0.0544); surgery was reported in 3/13 versus 2/26 patients and hospitalization in 5/13 versus 6/26 patients. One death was reported in patients with late-onset UC.&lt;br&gt;
Conclusions: VDZ effectiveness and safety were similar in patients &#8805;&#8201;70 and &lt;&#8201;70&#8201;years; VDZ may be a suitable treatment option for patients &#8805;&#8201;70&#8201;years with UC. Patients with late-onset UC tended to have more frequent surgery/hospitalization and lower effectiveness than those without, possibly necessitating greater caution when using VDZ.&lt;br&gt;
Trial Registration: Japanese Registry of Clinical Trials registration number: jRCT-1080225363</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">elderly</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inflammatory bowel diseases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">onset age</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vedolizumab</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Korean Association for the Study of Intestinal Diseases</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1598-9100</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Taku</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadakazu</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Motoya</LastName>
        <Affiliation>Inflammatory Bowel Disease Center, Sapporo-Kosei General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshimitsu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reiko</FirstName>
        <LastName>Kunisaki</LastName>
        <Affiliation>Inflammatory Bowel Disease Center, Yokohama City University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Shibuya</LastName>
        <Affiliation>Department of Gastroenterology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Matsuura</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Kyorin University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, IBD Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Yasuda</LastName>
        <Affiliation>Department of Gastroenterology, St. Marianna University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Gastroenterology, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noritaka</FirstName>
        <LastName>Takatsu</LastName>
        <Affiliation>Inflammatory Bowel Disease Center, Fukuoka University Chikushi Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuo</FirstName>
        <LastName>Maemoto</LastName>
        <Affiliation>Inflammatory Bowel Disease Center, Sapporo Higashi Tokushukai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Tahara</LastName>
        <Affiliation>Department of Gastroenterology, Saiseikai Utsunomiya Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Gastroenterology, Dokkyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Shimada</LastName>
        <Affiliation>Department of Gastroenterology, NHO Nagoya Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Kuno</LastName>
        <Affiliation>Department of Gastroenterology and Medicine, Fukuoka University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jovelle L.</FirstName>
        <LastName>Fernandez</LastName>
        <Affiliation>Japan Medical Office, Takeda Pharmaceutical Company Limited</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Ishiguro</LastName>
        <Affiliation>Japan Medical Office, Takeda Pharmaceutical Company Limited</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mary</FirstName>
        <LastName>Cavaliere</LastName>
        <Affiliation>Japan Medical Office, Takeda Pharmaceutical Company Limited</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisato</FirstName>
        <LastName>Deguchi</LastName>
        <Affiliation>Japan Medical Office, Takeda Pharmaceutical Company Limited</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Hibi</LastName>
        <Affiliation>Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aims The objectives of this real-world study were to determine 1-year persistence with vedolizumab in patients with ulcerative colitis and to evaluate factors contributing to loss of response.&lt;br&gt;
Methods In this multicenter, retrospective, observational chart review, patients with moderately to severely active ulcerative colitis who received &#8805; 1 dose of vedolizumab in clinical practice at 16 tertiary hospitals in Japan (from December 2018 through February 2020) were enrolled.&lt;br&gt;
Results Persistence with vedolizumab was 64.5% (n = 370); the median follow-up time was 53.2 weeks. Discontinuation due to loss of response among initial clinical remitters was reported in 12.5% (35/281) of patients. Multivariate analysis showed that concomitant use of tacrolimus (odds ratio [OR], 2.76; 95% confidence interval [CI], 1.00&#8211;7.62; P= 0.050) and shorter disease duration (OR for median duration &#8805; 7.8 years vs. &lt; 7.8 years, 0.33; 95% CI, 0.13&#8211;0.82; P= 0.017) were associated with discontinuation due to loss of response. Loss of response was not associated with prior use of anti-tumor necrosis factor alpha therapy, age at the time of treatment, disease severity, or concomitant corticosteroids or immunomodulators. Of the 25 patients with disease duration &lt; 1 year, 32.0% discontinued due to loss of response.&lt;br&gt;
Conclusions Persistence with vedolizumab was consistent with previous reports. Use of tacrolimus and shorter disease duration were the main predictors of decreased persistence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Colitis, ulcerative</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Inflammatory bowel diseases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Vedolizumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Medication persistence</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1342-1751</Issn>
      <Volume>29</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The association of fasting triglyceride variability with renal dysfunction and proteinuria in medical checkup participants</ArticleTitle>
    <FirstPage LZero="delete">920</FirstPage>
    <LastPage>927</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Matsuoka-Uchiyama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Asakawa</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Sakurabu</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shugo</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Onishi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemi</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rika</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoko</FirstName>
        <LastName>Umebayashi</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background The association between the variability of triglyceride (TG) and chronic kidney disease (CKD) progression remains unclear. We examined whether intraindividual variability in fasting TG was associated with the exacerbation of CKD.&lt;br&gt;
Methods We conducted a retrospective and observational study. 18,339 participants, who went through medical checkups and had checked their estimated glomerular filtration rate (eGFR) and semi-quantitative proteinuria by urine dipstick every year since 2017 for 4 years were registered. Variability in fasting TG was determined using the standard deviation (SD), and maximum minus minimum difference (MMD) between 2017 and 2021. The primary end point for the analysis of eGFR decline was eGFR&#8201;&lt;&#8201;60 mL/min/1.73 m2. The secondary end point for the analysis of proteinuria was the incidence of proteinuria&#8201;&#8805;&#8201;(&#8201;}) by urine dipstick.&lt;br&gt;
Results The renal survival was lower in the higher-SD, and higher-MMD groups than in the lower-SD, and lower-MMD groups, respectively (log-rank test p&#8201;&lt;&#8201;0.001, and&#8201;&lt;&#8201;0.001, respectively). Lower SD and lower MMD were significantly associated with renal survival in the adjusted model (hazard ratio (HR), 1.12; 95% confidence intervals (CI), 1.04&#8211;1.21, and HR, 1.13; 95% CI 1.05&#8211;1.23, respectively). The non-incidence of proteinuria was lower in the higher-SD, and higher-MMD groups than in the lower-SD, and lower-MMD groups, respectively (log-rank test p&#8201;&lt;&#8201;0.001 and&#8201;&lt;&#8201;0.001, respectively).&lt;br&gt;
Conclusion Fasting TG variability was associated with CKD progression in participants who went through medical checkups.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">eGFR decline</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proteinuria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Renal dysfunction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Triglyceride variability</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fasting triglyceride</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2197-1153</Issn>
      <Volume>12</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Progression of patellofemoral joint cartilage degeneration within 1 year after medial meniscus posterior root repair: A retrospective study</ArticleTitle>
    <FirstPage LZero="delete">e70139</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Furumatsu</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Japanese Red Cross Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsubasa</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: To assess postoperative progression of patellofemoral (PF) cartilage degeneration after medial meniscus posterior root (MMPR) repair and identify potential risk factors.&lt;br&gt;
Methods: Data from patients who underwent transtibial pullout repair for complete radial MMPR tears between April 2018 and October 2021 were retrospectively investigated. Patients with severe chondral lesions of the PF joint at primary surgery were excluded. All patients underwent second-look arthroscopy at 12 months postoperatively. Postoperative changes using the International Cartilage Repair Society (ICRS) grade were evaluated. Associated open magnetic resonance imaging (MRI) findings were assessed.&lt;br&gt;
Results: In total, 40 patients (30 women, 10 men; mean age: 64.0 years) were evaluated. PF joint cartilage degeneration progressed significantly postoperatively. Abnormal signal intensity (ASI) of the infrapatellar fat pad (IPFP) was observed in 15 (37.5%) patients. Arthroscopic findings in groups between IPFP with and without ASI were compared. The incidence of postoperative ICRS grade worsening (&#8805;2 grades) on the patella or trochlea was significantly higher among patients with ASI (53%) than among those without (20%, p&#8201;=&#8201;0.04). ICRS grade worsening in the medial femorotibial compartment and meniscus-healing status were comparable between the groups. Patients with ASI of the IPFP showed greater decrease in the distance between the patellar and anterior cruciate ligament insertions on knee flexion MRI (|1.5&#8201;}&#8201;0.7&#8201;mm) than that in those without (|0.2&#8201;}&#8201;0.3&#8201;mm, p&#8201;&lt;&#8201;0.01). A delayed rehabilitation protocol was a risk factor according to the logistic regression analysis (p&#8201;=&#8201;0.01).&lt;br&gt;
Conclusions: Progressive PF cartilage degeneration occurred following MMPR repair, highlighting the need for diligent postoperative PF joint management.&lt;br&gt;
Level of Evidence: Level IV case series.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">medial meniscus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">posterior root tear</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pullout repair</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rehabilitation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">second]look arthroscopy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1434-3916</Issn>
      <Volume>145</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Medial meniscus posterior root tears with advanced osteoarthritis or subchondral insufficiency fracture are good indications for unicompartmental knee arthroplasty at a minimum 2-year follow-up</ArticleTitle>
    <FirstPage LZero="delete">64</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Furumatsu</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction The outcomes of unicompartmental knee arthroplasty (UKA) in the presence and absence of medial meniscus posterior root tears (MMPRTs) have not been compared. This study compared the characteristics and clinical outcomes of patients undergoing UKA with and without MMPRTs.&lt;br&gt;
Materials and methods This study analyzed 68 patients. The presence or absence of MMPRTs was evaluated using preoperative magnetic resonance imaging. Patient characteristics, clinical scores before surgery and at the final evaluation, and imaging findings were compared between patients with and without MMPRTs. Multiple regression analysis was conducted on postoperative visual analog scale (VAS)-pain scores.&lt;br&gt;
Results MMPRTs were present in 64.7% (44/68) of patients. Patients with MMPRTs were significantly younger (67.8&#8201;}&#8201;8.2 vs. 75.0&#8201;}&#8201;7.1 years, p&#8201;&lt;&#8201;0.001) and had a shorter duration from the development of symptoms to the time of surgery than those without (6.8&#8201;}&#8201;8.4 vs. 36.1&#8201;}&#8201;38.9 months, p&#8201;&lt;&#8201;0.001). Component placement or lower-limb alignment did not significantly differ between the groups. Preoperative clinical scores were not significantly different between the groups; however, patients with MMPRTs showed significantly better postoperative VAS-pain scores than those without (10.0&#8201;}&#8201;9.0 vs. 28.2&#8201;}&#8201;26.0 points, p&#8201;= 0.026). Multiple regression analysis of postoperative VAS-pain scores revealed the significant effect of duration from the development of symptoms to the time of surgery (p&#8201;=&#8201;0.038).&lt;br&gt;
Conclusions Patients undergoing UKA with MMPRTs were younger with less radiographic osteoarthritic changes compared to those without MMPRTs, and their postoperative VAS-pain scores were significantly superior. The duration from the development of symptoms to the time of surgery significantly influenced postoperative pain in patients undergoing UKA.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Unicompartmental knee arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Meniscus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Posterior root tear</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Subchondral insufficiency fracture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Osteoarthritis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effectiveness of Pallidal Stimulation for Dystonic Storm and Subsequent Ssevere Posterior Reversible Encephalopathy Syndrome in a Patient with GNAO1 Variant</ArticleTitle>
    <FirstPage LZero="delete">293</FirstPage>
    <LastPage>297</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Saijo</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Sasada</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Hiraide</LastName>
        <Affiliation>Department of Biochemistry, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotomo</FirstName>
        <LastName>Saitsu</LastName>
        <Affiliation>Department of Biochemistry, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69156</ArticleId>
    </ArticleIdList>
    <Abstract>GNAO1 variant affects primarily the brain and neurodevelopment, leading to a range of motor disorders including seizures beginning in infancy and involuntary movements such as dyskinesia and dystonia. Our patient, a 15-year-old Japanese female, began exhibiting involuntary movements at age 4. A de novo missense mutation (NM_020988.3: c.228C&gt;G, NP_066268.1: p.(Asn76Lys)) in the GNAO1 gene was identified when the patient was 15, and during the same year she developed influenza pneumonia, accompanied by dystonic storm. She required intensive care with mechanical ventilation and underwent a tracheostomy. She also developed posterior reversible encephalopathy syndrome. Globus pallidal stimulation was administered, leading to an improvement in the dystonic storm. Early consideration of globus pallidal stimulation is recommended when treating difficult-to-manage dystonic storms.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">GNAO1 variant</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dystonic storm</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">globus pallidal stimulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">posterior reversible encephalopathy syndrome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Parieto-Occipital Disconnection for Drug-Resistant Parieto-Occipital Lobe Epilepsy: A Case Report and Surgical Technique</ArticleTitle>
    <FirstPage LZero="delete">287</FirstPage>
    <LastPage>292</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Saijo</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyohei</FirstName>
        <LastName>Kin</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Sasada</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Case Report</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69155</ArticleId>
    </ArticleIdList>
    <Abstract>We report a case of drug-resistant parieto-occipital lobe epilepsy successfully treated with parieto-occipital disconnection (POD). An 18-year-old left-handed female, who had undergone surgery for an acute subdural hematoma at 10 months of age, developed drug-resistant epilepsy at age 15. Despite antiepileptic drug treatment, her seizures remained uncontrolled, and at age 18 she was referred to our hospital for evaluation. Magnetic resonance imaging (MRI) revealed atrophy in the left occipital and parietal lobes. Ictal electroencephalography (EEG) confirmed occipital onset of seizures without temporal lobe involvement. She had pre-existing homonymous hemianopsia. POD surgery was performed, carefully preserving the temporal lobe structures. Postoperatively, she experienced transient right-sided paresis, which fully resolved, and achieved complete seizure control at 3 years without memory loss. This case demonstrates that POD, a rare surgical approach, is a viable option for parieto-occipital lobe epilepsy, effectively controlling seizures while minimizing functional impairment in the absence of temporal lobe involvement.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">parieto-occipital lobe epilepsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">parieto-occipital disconnection (POD)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Outcome of Decompression Surgery Following Rapid Neurological Deterioration in Patients with Spinal Cord Injury Without Radiographic Evidence of Trauma (SCIWORET)</ArticleTitle>
    <FirstPage LZero="delete">261</FirstPage>
    <LastPage>267</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Sugahara</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Sasada</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hayato</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Nagase</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Yasuhara</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69151</ArticleId>
    </ArticleIdList>
    <Abstract>Cervical spondylotic myelopathy (CSM) and ossification of the posterior longitudinal ligament (OPLL) increase the likelihood of spinal cord injury without radiographic evidence of trauma (SCIWORET). Opinions regarding the optimal timing for surgery in such cases vary, however. We retrospectively investigated the demographics and outcomes of patients with SCIWORET who underwent surgery shortly after experiencing rapid neurological deterioration, and we matched patients who underwent standby surgery for CSM or OPLL. Although the optimal timing of surgery for SCIWORET remains unclear, our findings suggest that early stage surgery for SCIWORET may yield favorable neurological improvements.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">spinal trauma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SCIWORET</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">timing of surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cervical spondylotic myelopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ossification of the posterior longitudinal ligament</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>79</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Organ Donation after Extracorporeal Cardiopulmonary Resuscitation: Clinical and Ethical Perspectives</ArticleTitle>
    <FirstPage LZero="delete">221</FirstPage>
    <LastPage>229</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Kosaki</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Ageta</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Tsukahara</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Review</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/69147</ArticleId>
    </ArticleIdList>
    <Abstract>Extracorporeal cardiopulmonary resuscitation (ECPR) has evolved into a life-saving therapy for select cardiac arrest patients, yet a growing body of evidence suggests it also holds promise as a bridge to organ donation in non-survivors. This review explores the clinical outcomes, ethical complexities, and evolving policies surrounding organ donation after ECPR. We summarize recent international and Japanese data demonstrating favorable graft function from ECPR donors, with the exception of lung transplantation. The ethical challenges \ particularly those involving brain death determination on extracorporeal membrane oxygenation and adherence to the dead donor rule \ are discussed in the context of Japanfs recent regulatory reforms. Additionally, we highlight the importance of structured end-of-life communication through multidisciplinary team meetings in facilitating ethically sound transitions from rescue efforts to donation pathways. Moving forward, improvements in donor management, standardized legal frameworks, and public and professional education are essential to optimizing the life-saving and life-giving potential of ECPR.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">brain death</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">end-of-life care</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ethical dilemmas</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">extracorporeal cardiopulmonary resuscitation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2589-9864</Issn>
      <Volume>31</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Investigation of the relationship between 0.5&#8211;1200&#160;Hz signal characteristics of cortical high-frequency oscillations and epileptogenicity through multivariate analysis</ArticleTitle>
    <FirstPage LZero="delete">100776</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Tsuchiya</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mari</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Matsuhashi</LastName>
        <Affiliation>Department of Epilepsy, Movement Disorders and Physiology, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuhiro</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Fast ripples (FRs) (250&#8211;500 Hz) on the electroencephalogram (EEG) are closely related to epileptogenicity and are important to determine cortical regions resected in epilepsy surgery. However, FR-related epileptogenicity may be variable, and may depend on information associated with FRs. We enrolled nine epilepsy patients who had undergone intracranial 5 kHz-sampling-rate EEG for surgical treatment and had final Engel class I outcomes. Three electrodes were selected from each epileptogenic area (EA) and the unlikely EA (the region outside the EA) in each patient. Up to 100 candidate FRs were automatically detected from interictal nocturnal EEG at each of the selected electrodes and were visually reviewed independently by two researchers. Multivariate logistic regression analysis was performed using the frequency and log-power value of the corresponding FRs, presence of concurrent spike, ripple, very-high-frequency oscillations (vHFO)1 (500&#8211;600 Hz), and vHFO2 (600&#8211;1200 Hz), and whether the timing of the spectral peak of corresponding FRs was in the peak&#8211;trough or trough&#8211;peak transition of each slow activity (0.5&#8211;1, 1&#8211;2, 2&#8211;3, 3&#8211;4, and 4&#8211;8 Hz) as independent variables. Factors significantly related to epileptogenicity were FR power, the concurrent presence of spike and vHFO2, coupling with 0.5&#8211;1 and 1&#8211;2 Hz slow waves in the peak&#8211;trough transition, and coupling with 3&#8211;4 and 4&#8211;8 Hz slow waves in the trough&#8211;peak transition. Multifactorial analysis of FRs may increase their usefulness, potentially leading to improved treatment outcomes in epilepsy surgery.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Epilepsy surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multivariate logistic regression analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phase-amplitude coupling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ripple</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Very high-frequency oscillations</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0020-7292</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Determinants of residual myometrial thickness after cesarean delivery: Comparative analysis of barbed versus conventional sutures\A sub]analysis from the SPIRAL trial</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Jota</FirstName>
        <LastName>Maki</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hikaru</FirstName>
        <LastName>Ooba</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Mitoma</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hikari</FirstName>
        <LastName>Nakato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayano</FirstName>
        <LastName>Suemori</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Kuriyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shujiro</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakurako</FirstName>
        <LastName>Mishima</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Ohira</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Eto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: This sub-analysis aimed to determine whether conventional suture-associated risk factors for cesarean scar defect show similar outcomes with barbed continuous suturing, and to identify factors influencing residual myometrial thickness when using barbed continuous sutures.&lt;br&gt;
Methods: This sub-analysis of a multicenter, parallel-group, randomized controlled trial across four Japanese obstetrics and gynecology departments included 1211 women who had their first cesarean delivery between May 2020 and March 2023. Among them, 298 women underwent a C-section, with 253 follow-up through July 2023. Singleton pregnancies were randomly assigned to receive either barbed or conventional double-layered continuous sutures in a 1:1 ratio; they were monitored from consent through their 6- to 7-month check-up. The effects of cervical ripening, facility characteristics, and surgeon experience were investigated using a two-way ANOVA.&lt;br&gt;
Results: Of the remaining 253 patients, 33 were lost to follow-up and 220 completed follow-up (110 per group). One institution enrolled the largest proportion of participants (45.9%), whereas two other institutions had more experienced surgeons. Two-way ANOVA revealed that surgeon experience (P&#8201;=&#8201;0.020) and institutional factors (P&#8201;&lt;&#8201;0.001) significantly influenced the residual myometrial thickness at 6&#8211;7&#8201;months after surgery, whereas cervical dilation during active labor did not (P&#8201;=&#8201;0.215). Additionally, a significant interaction was observed between institutional factors and suture type (barbed vs. conventional) on residual myometrial thickness (Pinteraction&#8201;&lt;0.001).&lt;br&gt;
Conclusion: Institutional factors and surgeon experience represent significant determinants of residual myometrial thickness when using barbed sutures for cesarean closure, highlighting the importance of standardized surgical protocols and training across facilities.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">barbed suture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cervical ripening</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cesarean scar defect</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cesarean scar disorder</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">niche</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">residual myometrial thickness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">risk factors</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0340-5354</Issn>
      <Volume>272</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Genetic and functional analyses of SPTLC1 in juvenile amyotrophic lateral sclerosis</ArticleTitle>
    <FirstPage LZero="delete">36</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">So</FirstName>
        <LastName>Okubo</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroya</FirstName>
        <LastName>Naruse</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Sudo</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kayoko</FirstName>
        <LastName>Esaki</LastName>
        <Affiliation>Department of Biotechnology and Life Sciences, Faculty of Biotechnology and Life Sciences, Sojo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Satake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Peter</FirstName>
        <LastName>Greimel</LastName>
        <Affiliation>Laboratory for Cell Function Dynamics, RIKEN Centre for Brain Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanoka</FirstName>
        <LastName>Shingai</LastName>
        <Affiliation>Division of Applied Life Science, Graduate School of Engineering, Sojo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Oya</LastName>
        <Affiliation>Department of Neurology, National Center of Neurology and Psychiatry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeo</FirstName>
        <LastName>Yoshikawa</LastName>
        <Affiliation>Laboratory of Molecular Psychiatry, RIKEN Center for Brain Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder of the motor system. Pathogenic variants in SPTLC1, encoding a subunit of serine palmitoyltransferase, cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), and have recently been associated with juvenile ALS. SPTLC1 variants associated with ALS cause elevated levels of sphinganines and ceramides. Reports on ALS associated with SPTLC1 remain limited. This study aimed to investigate the frequency of SPTLC1 variants in ALS and relevant clinical characteristics.&lt;br&gt;
Methods We analyzed whole-exome and whole-genome sequence data from 40 probands with familial ALS and 413 patients with sporadic ALS without previously identified causative variants. Reverse transcription polymerase chain reaction (RT-PCR) analysis and droplet digital PCR (ddPCR) were used to assess splicing and mosaicism, respectively. Plasma sphingolipid levels were quantified to analyze biochemical consequences.&lt;br&gt;
Results The heterozygous c.58G&gt;A, p.Ala20Thr variant was identified in a 21-year-old Japanese female patient presenting with symmetric weakness which slowly progressed over 15 years. RT-PCR analysis showed no splice defects. Plasma sphingolipid levels in the patient were significantly increased compared to her asymptomatic parents. ddPCR revealed that the asymptomatic father harbored a mosaic variant with 17% relative mutant allele abundance in peripheral blood leukocytes.&lt;br&gt;
Conclusions We identified a pathogenic c.58G&gt;A, p.Ala20Thr SPTLC1 variant in a patient with juvenile ALS, likely inherited from an asymptomatic parent with mosaicism. Lipid analysis results are consistent with previous findings on SPTLC1-associated ALS. Further studies are necessary to determine the clinical effect of mosaic variants of SPTLC1.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Juvenile amyotrophic lateral sclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SPTLC1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sphingolipids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mosaicism</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>64</Volume>
      <Issue>14</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Wilson's Disease Preceded by Schizophrenia-like Symptoms with Frontal-dominant Leukoencephalopathy</ArticleTitle>
    <FirstPage LZero="delete">2240</FirstPage>
    <LastPage>2244</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryoji</FirstName>
        <LastName>Miyano</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satomi</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Koyama</LastName>
        <Affiliation>Department of Radiology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yudai</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Department of Radiology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akatsuki</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Sakuishi</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We herein report a 26-year-old man diagnosed with Wilson's disease (WD), initially treated for schizophrenia for 11 years. At 26 years old, he was admitted because of status epilepticus. Brain magnetic resonance imaging revealed frontal-dominant leukoencephalopathy with cystic changes and basal ganglia atrophy. The diagnosis of WD was confirmed based on neuropsychiatric symptoms, Kayser-Fleischer rings, abnormal copper metabolism, and a genetic analysis of ATP7B. Psychotic symptoms in WD can precede neurological manifestations, and extrapyramidal signs may be mistaken for drug-induced Parkinsonism. WD should be considered in patients presenting with progressive Parkinsonism preceded by schizophrenia-like psychiatric symptoms.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Wilsonfs disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">leukoencephalopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">brain MRI</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ATP7B</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">schizophrenia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Informa UK Limited</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1179-1322</Issn>
      <Volume>17</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Predictive Value of Tumor ERCC1 Expression for Treatment Outcomes After Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer</ArticleTitle>
    <FirstPage LZero="delete">1477</FirstPage>
    <LastPage>1486</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of General Thoracic Surgery, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Saisho</LastName>
        <Affiliation>Department of General Thoracic Surgery, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Soh</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norihito</FirstName>
        <LastName>Okumura</LastName>
        <Affiliation>Department of Thoracic Surgery, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshige</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of General Thoracic Surgery and Breast and Endocrine Surgery, Department of Surgery, Faculty of Medicine, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Date</LastName>
        <Affiliation>Department of Thoracic Surgery, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: To evaluate the predictive value of tumor expression of the excision repair cross-complementation group 1 gene (ERCC1) for the treatment outcomes after platinum-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer (NSCLC).&lt;br&gt;
Methods: In this study, we conducted immunohistochemical analysis using a mouse monoclonal anti-ERCC1 antibody (clone 8F1) of operative specimens obtained from 238 patients enrolled in the SLCG0401 study which compared paclitaxel plus carboplatin (CBDCA+PTX) with uracil-tegafur (UFT) as adjuvant chemotherapy for stage IB-IIIA NSCLC. The overall survival (OS) of the patients was compared according to the ERCC1 expression status and adjuvant chemotherapy employed.&lt;br&gt;
Results: Of the 238 specimens, 102 (42.9%) showed a positive result for ERCC1 expression. There were no significant differences in the patient characteristics or OS between the tumor ERCC1-positive and -negative patient groups. Among the patients with ERCC1-negative tumors, there was no significant difference in the survival between patient groups treated with CBDCA+PTX and UFT (HR=0.932, 95% CI: 0.52&#8211; 1.67, p=0.814). However, among the patients with ERCC1-positive tumors, CBDCA+PTX treatment tended to yield an inferior outcome, in terms of the OS, as compared with UFT treatment (HR=1.852, 95% CI: 0.92&#8211; 3.73, p=0.080). Multivariate analysis showed that ERCC1 expression was not an independent predictor of the OS following CBDCA+PTX treatment in completely resected NSCLC patients.&lt;br&gt;
Conclusion: In completely resected NSCLC patients with positive tumor ERCC1 expression, adjuvant CBDCA+PTX treatment tended to yield an inferior outcome as compared with UFT treatment in terms of the OS. However, immunohistochemical analysis with the 8F1 antibody cannot be used for clinical decision making at this point.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">non-small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">postoperative adjuvant chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">platinum-based chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">excision repair crosscomplementation group 1 gene</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">survival</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1434-5161</Issn>
      <Volume>69</Volume>
      <Issue>12</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association study of GBA1 variants with MSA based on comprehensive sequence analysis -Pitfalls in short-read sequence analysis depending on the human reference genome-</ArticleTitle>
    <FirstPage LZero="delete">613</FirstPage>
    <LastPage>621</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Orimo</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Nomoto</LastName>
        <Affiliation>Institute of Medical Genomics, International University of Health and Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Omae</LastName>
        <Affiliation>Genome Medical Science Project, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Genome Medical Science Project, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsushi</FirstName>
        <LastName>Tokunaga</LastName>
        <Affiliation>Genome Medical Science Project, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>NCBN Controls WGS Consortium</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by various combinations of autonomic failure, parkinsonism, and cerebellar ataxia. To elucidate variants associated with MSA, we have been conducting short-read-based whole-genome sequence analysis. In the process of the association studies, we initially focused on GBA1, a previously proposed susceptibility gene for MSA, to evaluate whether GBA1 variants can be efficiently identified despite its extraordinarily high homology with its pseudogene, GBA1LP. To accomplish this, we conducted a short-read whole-genome sequence analysis with alignment to GRCh38 as well as Sanger sequence analysis and compared the results. We identified five variants with inconsistencies between the two pipelines, of which three variants (p.L483P, p.A495P&#8211;p.V499V, p.L483_M489delinsW) were the results of misalignment due to minor alleles in GBA1P1 registered in GRCh38. The miscalling events in these variants were resolved by alignment to GRCh37 as the reference genome, where the major alleles are registered. In addition, a structural variant was not properly identified either by short-read or by Sanger sequence analyses. Having accomplished correct variant calling, we identified three variants pathogenic for Gaucher disease (p.S310G, p.L483P, and p.L483_M489delinsW). Of these variants, the allele frequency of p.L483P (0.003) in the MSA cases was higher than that (0.0011) in controls. The meta-analysis incorporating a previous report demonstrated a significant association of p.L483P with MSA with an odds ratio of 2.85 (95% CI; 1.05 &#8211; 7.76, p = 0.0400).</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Spandidos Publications</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2049-9450</Issn>
      <Volume>23</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association of the expression of 5&#8209;FU biomarkers with aging and prognosis in elderly patients with lung cancer treated with S&#8209;1 adjuvant chemotherapy: Follow&#8209;up results of the Setouchi Lung Cancer Group Study 1201</ArticleTitle>
    <FirstPage LZero="delete">79</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Soh</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromasa</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norihito</FirstName>
        <LastName>Okumura</LastName>
        <Affiliation>Department of Thoracic Surgery, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Chest Surgery, Fukushima Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of General Thoracic Surgery, Kawasaki Medical School Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiya</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenicehi</FirstName>
        <LastName>Gemba</LastName>
        <Affiliation>Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Hiroshima 720&#8209;0001, Japan; 8Department of Respiratory Surgery, Japanese Red Cross Nagasaki Genbaku Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isao</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Department of Respiratory Surgery, Japanese Red Cross Nagasaki Genbaku Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuji</FirstName>
        <LastName>Fujinaga</LastName>
        <Affiliation>Department of General Thoracic Surgery, National Hospital Organization Nagara Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Surgery and Respiratory Center, Okayama Saiseikai General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Terasaki</LastName>
        <Affiliation>Department of Respiratory Surgery, Saga Medical Center Koseikan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobukazu</FirstName>
        <LastName>Fujimoto</LastName>
        <Affiliation>Department of Medical Oncology and Respiratory Medicine, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kosaka</LastName>
        <Affiliation>Department of Thoracic Surgery, Shimane Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Inokawa</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization Yamaguchi&#8209;Ube Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaaki</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Thoracic Surgery, Shimonoseki City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshige</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of General Thoracic Surgery, Tottori University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Thoracic Surgery, National Hospital Organization Kure Medical Center and Chugoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidejiro</FirstName>
        <LastName>Torigoe</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshige</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Thoracic Oncology, Kansai Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keitaro</FirstName>
        <LastName>Matsuo</LastName>
        <Affiliation>Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Tokai Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Date</LastName>
        <Affiliation>Department of Thoracic Surgery, Kyoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of Thoracic Surgery, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Managing elderly patients presents several challenges because of age&#8209;related declines; however, age should not be the sole determinant for adjuvant treatment decisions in patients with non&#8209;small cell lung cancer (NSCLC). Moreover, age may affect the expression of 5&#8209;fluorouracil (5&#8209;FU) biomarkers. The present study assessed: i) The effect of age on the expression levels of 5&#8209;FU biomarkers by analyzing a public database; and ii) the ability of these biomarkers to predict clinical outcomes in elderly patients with NSCLC who underwent complete resection in the Setouchi Lung Cancer Group Study 1201 (SCLG1201) followed by S&#8209;1 adjuvant chemotherapy. Changes in gene expression levels across age groups were assessed by analyzing The Cancer Genome Atlas (TCGA) database. The expression of 5&#8209;FU biomarkers, including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase, epidermal growth factor receptor (EGFR) and excision repair cross&#8209;complementation group 1 (ERCC1), were assessed via quantitative reverse&#8209;transcription PCR assays in 89 elderly patients (&#8805;75 years) with NSCLC who received adjuvant chemotherapy with oral fluoropyrimidine prodrug S&#8209;1 in the SLCG1201 trial. TCGA database analysis (n=955) showed that TS expression decreased significantly with aging, especially in the age group &#8805;75. In the SCLG1201 trial, univariate analysis revealed that EGFR upregulation and TS downregulation were correlated with favorable recurrence&#8209;free survival (RFS) and overall survival (OS), respectively. Multivariate analysis demonstrated that pathological stage was an independent prognostic factor for both RFS and OS. EGFR mutations were associated with upregulation of DPD and EGFR, and downregulation of TS and ERCC1. In conclusion, although pathological stage is an independent prognostic factor for survival, EGFR upregulation and TS downregulation may be a greater predictor of clinical outcomes in elderly patients with NSCLC treated with S&#8209;1 adjuvant chemotherapy. The age&#8209;related decrease in TS expression supports the potential benefit of 5&#8209;FU therapies in elderly patients. Nonetheless, further research is warranted to validate these results.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">non&#8209;small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">elderly patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">adjuvant chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">S&#8209;1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EGFR</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OPRT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ERCC1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DPD</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0003-4975</Issn>
      <Volume>120</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparable Clinical Outcomes Between Segmentectomy and Lobectomy for NSCLC With Unsuspected N1/N2: A Multicenter Real-World Data Study</ArticleTitle>
    <FirstPage LZero="delete">87</FirstPage>
    <LastPage>98</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ryuko</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Okazaki</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suzawa</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiya</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mototsugu</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Inokawa</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiko</FirstName>
        <LastName>Misao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidejiro</FirstName>
        <LastName>Torigoe</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Washio</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Tao</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Okutani</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makio</FirstName>
        <LastName>Hayama</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Uomoto</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Kurosaki</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Yaginuma</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eito</FirstName>
        <LastName>Niman</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kawamata</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nishikawa</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Yoshikawa</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuro</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Okayama University Thoracic Surgery Study Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Segmentectomy for lung cancer has been increasingly performed. However, evidence regarding the necessity of additional surgical resection after the diagnosis of unsuspected N1 or N2 lymph node metastasis is limited.&lt;br&gt;
Methods We conducted a multicenter, real-world data study of patients with any clinical T and N0 non-small cell lung cancer (NSCLC) who underwent lobectomy or segmentectomy between 2012 and 2021 and who subsequently received a diagnosis of pathologic N1 or N2 lymph node metastasis. Patients were categorized into lobectomy and segmentectomy groups. We analyzed overall survival (OS), recurrence-free survival (RFS), cumulative recurrence rates, and recurrence patterns using both unadjusted and propensity score&#8211;adjusted cohorts.&lt;br&gt;
Results A total of 736 patients were in the lobectomy group, and 70 were in the segmentectomy group. In the unadjusted cohort, segmentectomy-treated patients were older, had a lower preoperative percentage of vital capacity, had smaller tumors, and received less postoperative adjuvant chemotherapy. The 5-year OS was significantly worse in the segmentectomy group (P = .011), with no significant differences in 5-year RFS or cumulative recurrence rates. In the propensity score&#8211;adjusted cohort, there were no significant differences in OS, RFS, or recurrence rates; however, the segmentectomy group had a higher rate of local recurrence.&lt;br&gt;
Conclusions In patients with unsuspected N1 or N2 NSCLC, analysis using a cohort adjusted for patient background with propensity scores revealed no differences in OS, RFS, or cumulative recurrence rates between segmentectomy and lobectomy. This finding suggests that additional resection of the remaining segments may not be necessary for these patients. However, the higher rate of local recurrence in the segmentectomy group warrants careful consideration.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2589-5370</Issn>
      <Volume>86</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Global trends in mortality related to pulmonary embolism: an epidemiological analysis of data from the World Health Organization mortality database from 2001 to 2023</ArticleTitle>
    <FirstPage LZero="delete">103389</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ko</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Division of Hematology and Oncology, Mayo Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sayoko</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michio</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Graduate School of Human Sciences, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Niimura</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Osaki</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Quynh Thi</FirstName>
        <LastName>Vu</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mariko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Sako</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuaki</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Center for Education in Medicine and Health Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Koyama</LastName>
        <Affiliation>Department of Health Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Pulmonary embolism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mortality</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">WHO</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Global trends</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2040-1116</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Relationship between maternal body composition changes and heavy for date infants in pregnant women with diabetes</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Eto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Kirino</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Kuriyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Syujiro</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hikari</FirstName>
        <LastName>Nakato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakurako</FirstName>
        <LastName>Mishima</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Ohira</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims/Introduction: Maternal hyperglycemia is associated with heavy for date (HFD) infants. Considering the association between body composition and hyperglycemia, we investigated the changes in maternal body composition and their relationship with HFD infants in pregnant women with diabetes.&lt;br&gt;
Materials and Methods: Body composition was measured during pregnancy using a bioelectrical impedance analysis system. This retrospective study included 151 pregnant women; 27 women had type 1 diabetes mellitus (DM), 21 had type 2 DM, 101 were diagnosed with gestational DM, and 2 had overt DM. The number of HFD infants was 40.&lt;br&gt;
Results: In the non-type 1 DM group, change in fat mass (ƒ¢FM) (P&#8201;&lt;&#8201;0.01) and pre-pregnancy BMI (P&#8201;&lt;&#8201;0.05) were risk factors for HFD. In the insulin group, ƒ¢FM, pre-pregnancy BMI, and age (all P&#8201;&lt;&#8201;0.05) were risk factors for HFD. The area under the curve was 0.813 for the predictive model combined with ƒ¢FM and pre-pregnancy BMI in the non-type 1 DM group and 0.818 for the model combined with ƒ¢FM, pre-pregnancy BMI, and age in the insulin group.&lt;br&gt;
Conclusions: The combination of body composition parameters and clinical data may predict HFD in pregnant women with diabetes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Fat mass gain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heavy for date</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Maternal body composition</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1432-0533</Issn>
      <Volume>150</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Biallelic variants in DNAJC7 cause familial amyotrophic lateral sclerosis with the TDP-43 pathology</ArticleTitle>
    <FirstPage LZero="delete">19</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Yokota</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Ousaka</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hongming</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Haraguchi</LastName>
        <Affiliation>Department of Neurology, National Hospital Organisation Minami-Okayama Medical Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ricardo Satoshi</FirstName>
        <LastName>Ota-Elliott</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohito</FirstName>
        <LastName>Kawano</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanae</FirstName>
        <LastName>Nakashima-Yasuda</LastName>
        <Affiliation>Department of Psychiatry, Zikei Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Fukui</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Morihara</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Hosono</LastName>
        <Affiliation>Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seishi</FirstName>
        <LastName>Terada</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Takaki</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive degeneration of motor neurons. ALS pathology primarily involves the failure of protein quality control mechanisms, leading to the accumulation of misfolded proteins, particularly TAR DNA-binding protein 43 (TDP-43). TDP-43 aggregation is a central pathological feature of ALS. Maintaining protein homeostasis is critical and facilitated by heat shock proteins (HSPs), particularly the HSP40 family, which includes co-chaperones such as DNAJC7. Here, we report a family with three siblings affected by ALS who carry a homozygous c.518dupC frameshift variant in DNAJC7, a member of the HSP40 family. All three patients exhibited progressive muscle weakness, limb atrophy, bulbar palsy, and respiratory failure. Pathological examination revealed degeneration of both upper and lower motor neurons, with phosphorylated TDP-43-positive neuronal cytoplasmic inclusions in the frontal and temporal cortices. Immunoblot analysis were consistent with a type B pattern of phosphorylated TDP-43 in the precentral gyrus. Immunohistochemistry and RNA sequencing analyses demonstrated a substantial reduction in DNAJC7 expression at both the protein and RNA levels in affected brain regions. In a TDP-43 cell model, DNAJC7 knockdown impaired the disassembly of TDP-43 following arsenite-induced stress, whereas DNAJC7 overexpression suppressed the assembly and promoted the disassembly of arsenite-induced TDP-43 condensates. Furthermore, in a zebrafish ALS model, dnajc7 knockdown resulted in increased TDP-43 aggregation in motor neurons and reduced survival. To the best of our knowledge, this study provides the first evidence linking biallelic loss-of-function variants in DNAJC7 to familial ALS with TDP-43 pathology.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Amyotrophic lateral sclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heat shock protein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DNAJC7</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TDP-43</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Live-cell imaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Zebrafish disease model</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-5042</Issn>
      <Volume>10</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mycobacterium tuberculosis bacillus induces pyroptosis in human lung fibroblasts</ArticleTitle>
    <FirstPage LZero="delete">e00110-25</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takemasa</FirstName>
        <LastName>Takii</LastName>
        <Affiliation>Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Mycobacterium Reference and Research, the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chihiro</FirstName>
        <LastName>Motozono</LastName>
        <Affiliation>Department of Molecular Immunology, Research Institute for Microbial Diseases, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Molecular Immunology, Research Institute for Microbial Diseases, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jordi B.</FirstName>
        <LastName>Torrelles</LastName>
        <Affiliation>Texas Biomedical Research Institute and International Center for the Advancement of Research &amp; Education (I&#8226;CARE)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joanne</FirstName>
        <LastName>Turner</LastName>
        <Affiliation>Texas Biomedical Research Institute and International Center for the Advancement of Research &amp; Education (I&#8226;CARE)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aoi</FirstName>
        <LastName>Kimishima</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, &#332;mura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihiro</FirstName>
        <LastName>Asami</LastName>
        <Affiliation>Laboratory of Applied Microbial Chemistry, &#332;mura Satoshi Memorial Institute, Kitasato University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Oral Microbiology, Graduate School of Medicine, Density and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeaki</FirstName>
        <LastName>Hida</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Cell Signaling, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kikuo</FirstName>
        <LastName>Onozaki</LastName>
        <Affiliation>Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We previously reported that live, but not dead, virulent Mycobacterium tuberculosis (Mtb) H37Rv bacilli induce cell death in human lung fibroblast cell lines, MRC-5, MRC-9, and TIG-1. Here, using two distinct Mtb strains from two different lineages (HN878 lineage 2 and H37Rv lineage 4), we confirmed cell death at day 2 after infection with a device that measures cell growth/cytotoxicity in real time (Maestro-Z [AXION]). Mtb bacilli uptake by the fibroblast was confirmed with a transmission electron microscope on day 2. Expressions of inflammatory cytokines and interleukin (IL)|1ƒÀ, IL-6, and IL-8 were observed when exposed to live, but not dead bacteria. The cell death of fibroblasts induced by both Mtb strains tested was prevented by caspase-1/4 and NLRP3 inflammasome inhibitors, but not by caspase-3 and caspase-9 inhibitors. Therefore, we classified the fibroblast cell death by Mtb infection as pyroptosis. To investigate the biological and pathological relevance of fibroblast cell death by Mtb infection, we performed dual RNA-Seq analysis on Mtb within fibroblasts and Mtb-infected fibroblasts at day 2. In Mtb bacilli tcrR, secE2, ahpD, and mazF8 genes were highly induced during infection. These genes play roles in survival in a hypoxic environment, production of a calcium-binding protein-inducing cytokine, and regulation of transcription in a toxin-antitoxin system. The gene expressions of IL-1ƒÀ, IL-6, and IL-8, caspase-4, and NLRP3, but not of caspase-3 and caspase-9, were augmented in Mtb bacilli-infected fibroblasts. Taken together, our study suggests that Mtb bacilli attempt to survive in lung fibroblasts and that pyroptosis of the host fibroblasts activates the immune system against the infection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Mycobacterium tuberculosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pyroptosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">caspase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RNA-Seq</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cytokine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibroblasts</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2198-4034</Issn>
      <Volume>10</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Implant-supported fixed prostheses with cantilever: a systematic review and meta-analysis</ArticleTitle>
    <FirstPage LZero="delete">57</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Clinical Guideline Task-Force Members (2018-), Japanese Society of Oral Implantology (JSOI)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Clinical Guideline Task-Force Members (2018-), Japanese Society of Oral Implantology (JSOI)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Minakuchi</LastName>
        <Affiliation>Department of Oral Rehabilitation and Implantology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Horimai</LastName>
        <Affiliation>The Library, School of Dentistry, Nihon University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuo</FirstName>
        <LastName>Kuboki</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Faculty of Medicine Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>JSOI Clinical Guideline Working Group collaborators</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose This systematic review (SR) aimed to investigate whether the presence of a cantilever affects the results of implant treatment for partial edentulism, including an analysis of the anterior and posterior regions of the dental arches.&lt;br&gt;
Methods An electronic search was performed, and original articles published between 1995 and November 2023 were included. The outcomes were the implant survival rate, patient satisfaction, occurrence of mechanical complications, and marginal bone loss around the implants. Two SR members independently examined the validity of the studies, extracted evidence from the included studies, and performed risk of bias assessment, comprehensive evidence evaluation, and meta-analysis.&lt;br&gt;
Results Nine studies met our inclusion criteria. Implant survival rate tended to be lower in the cantilever group, and marginal bone loss tended to be higher in the cantilever group; however, there was no significant difference. There was no significant difference in patient satisfaction based on the presence or absence of a cantilever. Moreover, the incidence of mechanical complications was significantly higher in the cantilever group. According to the analysis of anterior and posterior regions, implant survival rate tended to be lower in the cantilever group of the posterior region, and marginal bone loss around the implants tended to be higher in the cantilever group of the anterior region.&lt;br&gt;
Conclusion Implant-supported fixed prostheses with cantilevers did not negatively affect implant survival rate, marginal bone loss, or patient satisfaction. However, the incidence of mechanical complications significantly increased in the cantilever group.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cantilever</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fixed prostheses</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Implants</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Partial edentulism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Systematic review</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2304-6767</Issn>
      <Volume>12</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Coronal Cementum and Reduced Enamel Epithelium on Occlusal Surface of Impacted Wisdom Tooth in a Human</ArticleTitle>
    <FirstPage LZero="delete">348</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Horie</LastName>
        <Affiliation>Division of Reconstructive Surgery for Oral and Maxillofacial Region, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Division of Regenerative Medicine, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhito</FirstName>
        <LastName>Minamida</LastName>
        <Affiliation>Division of Oral and Maxillofacial Surgery, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Nagayasu</LastName>
        <Affiliation>Division of Oral and Maxillofacial Surgery, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Shimo</LastName>
        <Affiliation>Division of Reconstructive Surgery for Oral and Maxillofacial Region, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Industrial Technology and Environment Research Development, Hokkaido Research Organization</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetsugu</FirstName>
        <LastName>Tsujigiwa</LastName>
        <Affiliation>Department of Life Science, Faculty of Science, Okayama University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youssef</FirstName>
        <LastName>Haikel</LastName>
        <Affiliation>Department of Biomaterials and Bioengineering, Institut National de la Sant&#233; et de la Recherche m&#233;dicale Unit&#233; Mixte de Recherche (INSERM UMR) _S 1121, University of Strasbourg</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: There is only limited research on the coronal cementum of a tooth, and the mechanisms of its forming process are not well-defined. This report presents a coronal cementum on the occlusal surfaces of enamel in an impacted wisdom tooth in a human, which is not nearly the cervical portion. Materials and Methods: The tooth (Tooth #1) was derived from a 46-year-old female. Histological analysis, including hematoxylin and eosin (HE) and toluidine blue (TB) staining, and Scanning Electron Microscopy and Energy Dispersive X-ray Spectrometer (SEM-EDS) analysis of the extracted tooth were conducted. Radiographic examination showed that Tooth #1 was horizontally impacted in the maxilla and had the apex of a single root placed between the buccal and palatal roots of Tooth #2. Results: Coronal cementum was distributed widely on the enamel, and reduced enamel epithelium was also found with enamel matrix proteins histologically. The formation of acellular cementum was observed to be more predominant than that of the cellular cementum in Tooth #1. SEM showed that the occlusal cementum connected directly with enamel. Calcium mapping revealed an almost similar occlusal cementum and enamel. In addition, the spectrum of elements in coronal cementum resembled the primary cementum according to SEM-EDS. Discussion: Thus, coronal cementogenesis in impacted human teeth might be related to the existence of reduced enamel epithelium.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">coronal cementum</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">human</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reduced epithelium</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">impacted tooth</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0021-8820</Issn>
      <Volume>77</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Synthesis and biochemical characterization of naphthoquinone derivatives targeting bacterial histidine kinases</ArticleTitle>
    <FirstPage LZero="delete">522</FirstPage>
    <LastPage>532</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Teruhiko</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Graduate School of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Eguchi</LastName>
        <Affiliation>Department of Science and Technology on Food Safety, Faculty of Biology-Oriented Science and Technology, Kindai University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Igarashi</LastName>
        <Affiliation>Institute of Microbial Chemistry (BIKAKEN)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihide</FirstName>
        <LastName>Okajima</LastName>
        <Affiliation>SANKEN (The Institute of Scientific and Industrial Research), Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Mita</LastName>
        <Affiliation>Graduate School of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Graduate School of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaho</FirstName>
        <LastName>Sumikura</LastName>
        <Affiliation>Graduate School of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisei</FirstName>
        <LastName>Okumura</LastName>
        <Affiliation>Graduate School of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuna</FirstName>
        <LastName>Tabuchi</LastName>
        <Affiliation>Graduate School of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chigusa</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Institute of Microbial Chemistry (BIKAKEN)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Martina</FirstName>
        <LastName>Pasqua</LastName>
        <Affiliation>Istituto Pasteur Italy, Department of Biology and Biotechnology, gC. Darwinh, Sapienza University of Rome</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marco</FirstName>
        <LastName>Coluccia</LastName>
        <Affiliation>Istituto Pasteur Italy, Department of Biology and Biotechnology, gC. Darwinh, Sapienza University of Rome</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gianni</FirstName>
        <LastName>Prosseda</LastName>
        <Affiliation>Istituto Pasteur Italy, Department of Biology and Biotechnology, gC. Darwinh, Sapienza University of Rome</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bianca</FirstName>
        <LastName>Colonna</LastName>
        <Affiliation>Istituto Pasteur Italy, Department of Biology and Biotechnology, gC. Darwinh, Sapienza University of Rome</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chie</FirstName>
        <LastName>Kohayakawa</LastName>
        <Affiliation>Department of Lead Exploration Units, Graduate School of Pharmaceutical Sciences, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiyoshi</FirstName>
        <LastName>Tani</LastName>
        <Affiliation>Compound Library Screening Center, Graduate School of Pharmaceutical Sciences, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun-ichi</FirstName>
        <LastName>Haruta</LastName>
        <Affiliation>Department of Lead Exploration Units, Graduate School of Pharmaceutical Sciences, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryutaro</FirstName>
        <LastName>Utsumi</LastName>
        <Affiliation>SANKEN (The Institute of Scientific and Industrial Research), Osaka University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Waldiomycin is an inhibitor of histidine kinases (HKs). Although most HK inhibitors target the ATP-binding region, waldiomycin binds to the intracellular dimerization domain (DHp domain) with its naphthoquinone moiety presumed to interact with the conserved H-box region. To further develop inhibitors targeting the H-box, various 2-aminonaphthoquinones with cyclic, aliphatic, or aromatic amino groups and naphtho [2,3-d] isoxazole-4,9-diones were synthesized. These compounds were tested for their inhibitory activity (IC50) against WalK, an essential HK for Bacillus subtilis growth, and their minimum inhibitory concentrations (MIC) against B. subtilis. As a result, 11 novel HK inhibitors were obtained as naphthoquinone derivatives (IC50: 12.6&#8211;305&#8201;&#181;M, MIC: 0.5&#8211;128&#8201;&#181;g&#8201;ml|1). The effect of representative compounds on the expression of WalK/WalR regulated genes in B. subtilis was investigated. Four naphthoquinone derivatives induced the expression of iseA (formerly yoeB), whose expression is negatively regulated by the WalK/WalR system. This suggests that these compounds inhibit WalK in B. subtilis cells, resulting in antibacterial activity. Affinity selection/mass spectrometry analysis was performed to identify whether these naphthoquinone derivatives interact with WalK in a manner similar to waldiomycin. Three compounds were found to competitively inhibit the binding of waldiomycin to WalK, suggesting that they bind to the H-box region conserved in HKs and inhibit HK activity.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2666-1683</Issn>
      <Volume>73</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Incidence, Management, and Prevention of Gynecomastia and Breast Pain in Patients with Prostate Cancer Undergoing Antiandrogen Therapy: A Systematic Review and Meta-analysis of Randomized Controlled Trials</ArticleTitle>
    <FirstPage LZero="delete">31</FirstPage>
    <LastPage>42</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Robert J.</FirstName>
        <LastName>Schulz</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ekaterina</FirstName>
        <LastName>Laukhtina</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pierre I.</FirstName>
        <LastName>Karakiewicz</LastName>
        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shahrokh F.</FirstName>
        <LastName>Shariat</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and objective: In patients with prostate cancer treated with antiandrogen monotherapy, gynecomastia and breast pain are relatively common. In the setting of androgen receptor pathway inhibitors (ARPIs), the incidence of these adverse events (AEs) remains unclear. In addition, the effect of prophylactic treatment on gynecomastia remains uncertain. We aimed to evaluate the incidence of gynecomastia and breast pain in prostate cancer patients treated with ARPIs compared with androgen deprivation therapy (ADT) and the effect of prophylactic treatment for these AEs due to antiandrogen therapy.&lt;br&gt;
Methods: In June 2024, we queried four databases\PubMed, Scopus, Web of Science, and Embase\for randomized controlled trials (RCTs) investigating prostate cancer treatments involving antiandrogen therapy. The endpoints of interest were the incidence of these AEs due to ARPIs and the effect of prophylactic treatment for these.&lt;br&gt;
Key findings and limitations: Eighteen RCTs, comprising 5036 patients, were included in the systematic review and meta-analysis. ARPIs included enzalutamide, darolutamide, and apalutamide. The results indicated that patients who received ARPI monotherapy had a significantly higher incidence of gynecomastia than those who received ADT monotherapy (risk ratio [RR]: 5.19, 95% confidence interval [CI]: 3.58&#8211;7.51, p &lt; 0.001). There was no significant difference in the incidence of gynecomastia between ARPI plus ADT therapy and ADT monotherapy (RR: 1.27, 95% CI: 0.84&#8211;1.93, p = 0.2). Prophylactic tamoxifen or radiotherapy reduced significantly the incidence of gynecomastia and breast pain caused by bicalutamide monotherapy.&lt;br&gt;
Conclusions and clinical implications: We found that ARPI monotherapy increases the incidence of these AEs significantly compared with ADT. In contrast, ARPI plus ADT therapy did not result in a higher incidence of AEs. The use of either tamoxifen or radiotherapy was effective in reducing the incidence of these AEs due to bicalutamide monotherapy. These prophylactic treatments could reduce the incidence of AEs due to ARPI monotherapy. However, further studies are needed to clarify their efficacy.&lt;br&gt;
Patient summary: Although androgen deprivation therapy (ADT) improves overall survival in patients with prostate cancer, it is associated with several complications. Androgen receptor pathway inhibitor (ARPI) monotherapy has emerged as a promising strategy for improving oncological outcomes in these patients. However, ARPI monotherapy increases gynecomastia and breast pain in prostate cancer patients compared with ADT, while ARPI plus ADT did not result in a higher incidence of adverse events.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Antiandrogen therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Androgen deprivation therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Androgen receptor pathway inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Breast pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gynecomastia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0962-8819</Issn>
      <Volume>33</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Generation and characterization of cerebellar granule neurons specific knockout mice of Golli-MBP</ArticleTitle>
    <FirstPage LZero="delete">99</FirstPage>
    <LastPage>117</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Haruko</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Nishioka</LastName>
        <Affiliation>Department of Experimental Genome Research, Research Institute for Microbial Diseases, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Yamanaka</LastName>
        <Affiliation>Laboratory of Structural Neuropathology, Graduate School of Brain Science, Doshisha University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Abe</LastName>
        <Affiliation>Department of Animal Model Development, Brain Research Institute, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukio</FirstName>
        <LastName>Imamura</LastName>
        <Affiliation>Laboratory of Structural Neuropathology, Graduate School of Brain Science, Doshisha University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Miyasaka</LastName>
        <Affiliation>Faculty of Life and Medical Sciences, Doshisha University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuto</FirstName>
        <LastName>Kakuda</LastName>
        <Affiliation>Faculty of Life and Medical Sciences, Doshisha University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshitaka</FirstName>
        <LastName>Oohashi</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomomi</FirstName>
        <LastName>Shimogori</LastName>
        <Affiliation>Laboratory for Molecular Mechanisms of Brain Development, RIKEN Center for Brain Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Yamakawa</LastName>
        <Affiliation>Laboratory for Neurogenetics, RIKEN Center for Brain Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahito</FirstName>
        <LastName>Ikawa</LastName>
        <Affiliation>Department of Experimental Genome Research, Research Institute for Microbial Diseases, Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuyuki</FirstName>
        <LastName>Nukina</LastName>
        <Affiliation>Laboratory of Structural Neuropathology, Graduate School of Brain Science, Doshisha University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Golli&#8211;myelin basic proteins, encoded by the myelin basic protein gene, are widely expressed in neurons and oligodendrocytes in the central nervous system. Further, prior research has shown that Golli&#8211;myelin basic protein is necessary for myelination and neuronal maturation during central nervous system development. In this study, we established Golli&#8211;myelin basic protein-floxed mice to elucidate the cell-type-specific effects of Golli&#8211;myelin basic protein knockout through the generation of conditional knockout mice (Golli&#8211;myelin basic proteinsfl/fl; E3CreN), in which Golli&#8211;myelin basic proteins were specifically deleted in cerebellar granule neurons, where Golli&#8211;myelin basic proteins are expressed abundantly in wild-type mice. To investigate the role of Golli&#8211;myelin basic proteins in cerebellar granule neurons, we further performed histopathological analyses of these mice, with results indicating no morphological changes or degeneration of the major cellular components of the cerebellum. Furthermore, behavioral analysis showed that Golli&#8211;myelin basic proteinsfl/fl; E3CreN mice were healthy and did not display any abnormal behavior. These results suggest that the loss of Golli&#8211;myelin basic proteins in cerebellar granule neurons does not lead to cerebellar perturbations or behavioral abnormalities. This mouse model could therefore be employed to analyze the effect of Golli&#8211;myelin basic protein deletion in specific cell types of the central nervous system, such as other neuronal cells and oligodendrocytes, or in lymphocytes of the immune system.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Golli-MBP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cerebellar granule neuron</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CRISPR/Cas9</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Conditional knockout</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0168-0102</Issn>
      <Volume>218</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Alteration of perineuronal nets and parvalbumin interneurons in prefrontal cortex and hippocampus, and correlation with blood corticosterone in activity-based anorexia model mice</ArticleTitle>
    <FirstPage LZero="delete">104922</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hoang Duy</FirstName>
        <LastName>Nguyen</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruko</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Takaki</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshitaka</FirstName>
        <LastName>Oohashi</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Anorexia nervosa (AN) is an eating disorder characterized by restricted energy intake, severely underweight status, and frequent hyperactivity. Previous research has shown structural and functional alterations in the medial prefrontal cortex (mPFC) and hippocampus of AN patients. To investigate the pathological mechanism of AN, we analyzed the expression and distribution of parvalbumin (PV) interneurons and perineuronal nets (PNNs), which are implicated in the pathology of neuropsychiatric disorders, in the mPFC and hippocampus dorsal (HPCd) and ventral (HPCv) using an activity-based anorexia (ABA) mouse model. We found that PNN expression and density increased in the mPFC, with minor alterations in the HPCd and HPCv of ABA mice. The expression and distribution of PV neurons were unchanged in the brains of ABA mice, except for a regional decrease in PV-expressing neuron density in the HPCd. Co-localization analysis showed an increased number of PNNs enwrapping PV-negative neurons in the mPFC of ABA mice. Furthermore, the upregulation of PNN expression in the mPFC was positively correlated with elevated blood corticosterone levels, a well-known stress indicator, in ABA mice. Our findings suggest that the increased expression and distribution of PNNs surrounding PV-negative neurons in the mPFC may indicate the pathological mechanisms of AN.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anorexia nervosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">activity-based anorexia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">perineuronal nets</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">parvalbumin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">corticosterone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prefrontal cortex</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hippocampus</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>JMIR Publications Inc.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2561-326X</Issn>
      <Volume>9</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Usefulness of Interventions Using a Smartphone Cognitive Behavior Therapy Application for Children With Mental Health Disorders: Prospective, Single-Arm, Uncontrolled Clinical Trial</ArticleTitle>
    <FirstPage LZero="delete">e60943</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinichiro</FirstName>
        <LastName>Nagamitsu</LastName>
        <Affiliation>Department of Pediatrics, Faculty of Medicine, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Sakuta</LastName>
        <Affiliation>Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Department of Pediatrics &amp; Child Health, Kurume University, School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenshi</FirstName>
        <LastName>Koyanagi</LastName>
        <Affiliation>Nagasaki Prefectural Center of Medicine and Welfare for Children</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chizu</FirstName>
        <LastName>Habukawa</LastName>
        <Affiliation>Department of Pediatric Allergy, Minami Wakayama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>L2B Inc</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Kanie</LastName>
        <Affiliation>National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoko</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tasuku</FirstName>
        <LastName>Kitajima</LastName>
        <Affiliation>Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Matsubara</LastName>
        <Affiliation>Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chie</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshie</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Neuropsychiatry, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuyuki</FirstName>
        <LastName>Kakuma</LastName>
        <Affiliation>Biostatistics Center, Kurume University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Horikoshi</LastName>
        <Affiliation>National Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: The prevalence of mental health disorders among children in Japan has increased rapidly, and these children often show depressive symptoms and reduced quality of life (QOL). We previously developed a smartphone-based self-monitoring app to deliver cognitive behavioral therapy (CBT), implemented it in healthy children, and reported its effectiveness for health promotion.&lt;br&gt;
Objective: This study aims to examine the usefulness of the CBT app for improvement in depressive symptoms and QOL in children with mental health disorders.&lt;br&gt;
Methods: The participants were 115 children with mental health disorders (eg, school refusal, orthostatic hypotension, eating disorders, developmental disorders, among others) and aged 12]18 years. The CBT app&#8211;based program comprised 1 week of psychoeducation followed by 1 week of self-monitoring. After reading story-like scenarios, participants created a self-monitoring sheet with 5 panels: events, thoughts, feelings, body responses, and actions. All participants received regular mental health care from physicians in addition to the app-based program. To evaluate the participantsf depressive symptoms and QOL, Patient Health Questionnaire for Adolescents (PHQ-9A), Depression Self-Rating Scale for Children (DSRS-C), and Pediatric Quality of Life Inventory (PedsQL) were measured at the beginning of the intervention, and at 2 and 6 months thereafter. Questionnaire for Triage and Assessment with 30 items (QTA30), and Rosenberg Self-Esteem Scale (RSES) were also used to measure their health and self-esteem. Participants were divided into 4 groups on the basis of the PHQ-9A score (above or below the cutoff; PHQ-9A&#8805;5 or PHQ-9A&lt;5) and completion or noncompletion of the CBT app&#8211;based program (app [+] or app [-]). The primary outcome was improvement in the DSRS-C score, and secondary outcomes were improvement in other psychometric scales including PedsQL, QTA30, and RSE. A paired-samples t test was used for statistical analysis. The Medical Ethics Committee of Fukuoka University Faculty of Medicine (approval U22-05-002) approved the study design.&lt;br&gt;
Results: There were 48, 18, 18, and 7 participants in the PHQ-9A&#8805;5 app (+), PHQ-9A&#8805;5 app (-), PHQ-9A&lt;5 app (+), and PHQ-9A&lt;5 app (-) groups, respectively. A total of 24 participants dropped out. No improvement in the DSRS-C score was observed in all groups. However, PedsQL scores improved significantly at 2 and 6 months in the PHQ-9A&lt;5 app (+) group (t17=6.62; P&lt;.001 and t17=6.11; P&lt;.001, respectively). There was a significant positive correlation between the PHQ-9A scores and the number of self-monitoring sheets completed.&lt;br&gt;
Conclusions: The CBT app was useful for improving PedsQL scores of children with mental health disorders. However, a higher-intensity CBT program is necessary for more severely depressed children.&lt;br&gt;
Trial Registration: University Hospital Medical Information Network Clinical Trials Registry UMIN000046775; center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053360</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">smartphone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cognitive behavioral therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">application</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">adolescent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">youth</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">teen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pediatric</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mental health</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psychoeducation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">self-monitoring</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">questionnaire</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">depressive symptoms</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">effectiveness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">statistical analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">single-arm uncontrolled study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mobile phone</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1099-5129</Issn>
      <Volume>27</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>SCN5A variant type-dependent risk prediction in Brugada syndrome</ArticleTitle>
    <FirstPage LZero="delete">euaf024</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Aizawa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeru</FirstName>
        <LastName>Makiyama</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hai</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine , 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507 ,</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiko</FirstName>
        <LastName>Imamura</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Megumi</FirstName>
        <LastName>Fukuyama</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Sonoda</LastName>
        <Affiliation>Medical Genome Center, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hisamatsu</LastName>
        <Affiliation>Department of Public Health, Dentistry and Pharmaceutical Science, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pediatrics, Tsuchiura Kyodo General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Hoshino</LastName>
        <Affiliation>Department of Cardiology, Saitama Childrenfs Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Ozawa</LastName>
        <Affiliation>Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazushi</FirstName>
        <LastName>Yasuda</LastName>
        <Affiliation>Department of Pediatric Cardiology, Aichi Childrenfs Health and Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisaaki</FirstName>
        <LastName>Aoki</LastName>
        <Affiliation>Department of Pediatric Cardiology, Osaka Womenfs and Childrenfs Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kurita</LastName>
        <Affiliation>Division of Cardiovascular Center, Kindai University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Division of Pediatric Cardiology and Electrophysiology, Osaka City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsugutoshi</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Division of Pediatric Cardiology and Electrophysiology, Osaka City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihide</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Division of Pediatric Cardiology and Electrophysiology, Osaka City General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiharu</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Division of Cardiology, Hyogo Prefectural Kobe Childrenfs Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Yamagami</LastName>
        <Affiliation>Department of Cardiology, Tenri Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Cardiovascular Therapeutics, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Fukuda</LastName>
        <Affiliation>Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidekazu</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiko</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Cardiology and Clinical Examination, Faculty of Medicine, Oita University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiko</FirstName>
        <LastName>Ohno</LastName>
        <Affiliation>Medical Genome Center, National Cerebral and Cardiovascular Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihisa</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koh</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Horie</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims The variant in SCN5A with the loss of function (LOF) effect in the cardiac Na+ channel (Nav1.5) is the definitive cause for Brugada syndrome (BrS), and the functional analysis data revealed that LOF variants are associated with poor prognosis. However, which variant types (e.g. missense or non-missense) affect the prognoses of those variant carriers remain unelucidated.&lt;br&gt;
Methods and results We defined SCN5A LOF variants as all non-missense and missense variants that produce peak INa &lt; 65% of wild-type previously confirmed by patch-clamp studies. The study population consisted of 76 Japanese BrS patients (74% patients were male and the median age [IQR] at diagnosis was 28 [14&#8211;45] years) with LOF type of SCN5A variants: 40 with missense and 36 with non-missense variants. Non-missense variant carriers presented significantly more severe cardiac conduction disorder compared to the missense variant carriers. During follow-up periods of 9.0 [5.0&#8211;14.0] years, compared to missense variants, non-missense variants were significant risk factors of lifetime lethal arrhythmia events (LAEs) (P = 0.023). When focusing only on the missense variants that produce no peak INa, these missense variant carriers exhibited the same clinical outcomes as those with non-missense (log-rank P = 0.325). After diagnosis, however, both variant types were comparable in risk of LAEs (P = 0.155).&lt;br&gt;
Conclusion We identified, for the first time, that SCN5A non-missense variants were associated with higher probability of LAE than missense variants in BrS patients though it did not change significantly after diagnosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Brugada syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SCN5A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lethal arrhythmia event</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Variant type</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Loss of function</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1328-8067</Issn>
      <Volume>67</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Avoidant/restrictive food intake disorder prognosis and its relation with autism spectrum disorder in Japanese children</ArticleTitle>
    <FirstPage LZero="delete">e70040</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chie</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mana</FirstName>
        <LastName>Hanzawa</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshie</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makiko</FirstName>
        <LastName>Horiuchi</LastName>
        <Affiliation>Clinical Psychology Section, Department of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Tsukahara</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: There is a lack of reported clinical factors associated with the outcomes of children and adolescents with avoidant/restrictive food intake disorder (ARFID) in Japan. This study aimed to identify these clinical factors and explore the relationship between ARFID and autism spectrum disorder (ASD).&lt;br&gt;
Methods: This retrospective study analyzed data from 48 Japanese children and adolescents with ARFID who visited Okayama University Hospital between January 2011 and March 2022. Clinical characteristics were assessed using medical records and natural history questionnaires. The study compared patients with good and poor prognosis groups and used multiple logistic regression analysis to determine factors influencing prognosis.&lt;br&gt;
Results: The study included 33 patients with good prognoses and 15 with poor prognoses. Comorbid ASD was more prevalent in the poor prognosis group (60%) compared to the good prognosis group (21%). Additionally, more than half of the ARFID patients with comorbid ASD were initially undiagnosed. Multivariate analysis revealed that older age at first visit (p&#8201;=&#8201;0.022) and comorbid ASD (p&#8201;=&#8201;0.022) were statistically significant factors associated with poor prognosis in ARFID patients. There were no significant differences in body mass index standard deviation score and maximal weight loss between the two groups.&lt;br&gt;
Conclusions: The poor prognosis group had a higher prevalence of comorbid ASD diagnoses. Therefore, it is crucial to evaluate patient's developmental characteristics early in treatment and consider these characteristics throughout the course of care.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">autism spectrum disorder</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">avoidant/restrictive food intake disorder</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">children</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">feeding and eating disorders</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">outcome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1471-2431</Issn>
      <Volume>24</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Body weight and eating attitudes influence improvement of depressive symptoms in children and pre-adolescents with eating disorders: a prospective multicenter cohort study</ArticleTitle>
    <FirstPage LZero="delete">551</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Pediatrics, Fukushima Medical University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichiro</FirstName>
        <LastName>Nagamitsu</LastName>
        <Affiliation>Department of Pediatrics, Fukuoka University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuoki</FirstName>
        <LastName>Eshima</LastName>
        <Affiliation>Department of Pediatrics, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoko</FirstName>
        <LastName>Otani</LastName>
        <Affiliation>Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Sakuta</LastName>
        <Affiliation>Child Development and Psychosomatic Medicine Center, Dokkyo Medical University Saitama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Iguchi</LastName>
        <Affiliation>Department of Pediatrics, Hoshigaoka Maternity Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Department of Pediatrics and Child Health, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soh</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Karamun`S Forest Children`S Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kitayama</LastName>
        <Affiliation>Himeji City Center for the Disabled</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenshi</FirstName>
        <LastName>Koyanagi</LastName>
        <Affiliation>Nagasaki Prefectural Center of Medicine and Welfare for Children</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Pediatrics, National Hospital Organization Mie National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshino</FirstName>
        <LastName>Sumi</LastName>
        <Affiliation>Mental and Developmental Clinic for Children gElm Treeh</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shizuo</FirstName>
        <LastName>Takamiya</LastName>
        <Affiliation>Takamiya Psychiatry Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Pediatrics/Child Psychosomatic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimitsu</FirstName>
        <LastName>Fukai</LastName>
        <Affiliation>Department of Pediatrics, St. Lukefs International Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Pediatric patients with eating disorders in a multicenter joint study on 11 facilities were enrolled and prospectively investigated to determine whether improvement in body weight, eating attitudes, and psychosocial factors in children with eating disorders would also improve depressive symptoms.&lt;br&gt;
Methods In this study, 91 patients were enrolled between April 2014 and March 2016. The severity of underweight was assessed using the body mass index-standard deviation score (BMI-SDS), eating behavior was assessed using the children's eating attitude test (ChEAT26), the outcome of childhood eating disorders was assessed using the childhood eating disorder outcome scale, and depressive symptoms were assessed using the Children's Depression Inventory (CDI) score.&lt;br&gt;
Results After 12 months of treatment, depressive symptoms were evaluated in 62 of the 91 cases where it was evaluated at the initial phase. There was no difference in background characteristics between the included patients and the 29 patients who dropped out. A paired-sample t-test revealed a significant decrease in CDI scores after 12 months of treatment (p&#8201;&lt;&#8201;0.001, 95% CI: 2.401&#8211;7.373) and a significant increase in the BMI-SDS (p&#8201;&lt;&#8201;0.001, 95% CI:&#8201;|&#8201;2.41973&#8211;1.45321). Multiple regression analysis revealed that BMI-SDS and ChEAT26 scores at the initial phase were beneficial in CDI recovery. In addition, BMI-SDS at the initial phase was useful for predicting BMI-SDS recovery after 12 months of treatment.&lt;br&gt;
Conclusions Depressive symptoms in children with eating disorders improved with therapeutic intervention on body weight and eating attitudes.&lt;br&gt;
Trial registration The Clinical Trial Number for this study is UMIN000055004.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Eating disorders</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anorexia nervosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Body mass index-standard deviation score</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Eating attitudes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Childrenfs depression inventory</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Chemical Society (ACS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2575-9108</Issn>
      <Volume>7</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Rethinking Thin-Layer Chromatography for Screening Technetium-99m Radiolabeled Polymer Nanoparticles</ArticleTitle>
    <FirstPage LZero="delete">2604</FirstPage>
    <LastPage>2611</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kathrin</FirstName>
        <LastName>Schorr</LastName>
        <Affiliation>Department of Pharmaceutical Technology, University of Regensburg</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xinyu</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Nuclear Medicine, Faculty of Medicine, University of Augsburg</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anahi Paula</FirstName>
        <LastName>Arias-Loza</LastName>
        <Affiliation>Department of Nuclear Medicine and Comprehensive Heart Failure Center, University Hospital W&#252;rzburg</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Johannes</FirstName>
        <LastName>Lang</LastName>
        <Affiliation>Department of Pharmaceutical Technology, University of Regensburg</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Achim</FirstName>
        <LastName>Goepferich</LastName>
        <Affiliation>Department of Pharmaceutical Technology, University of Regensburg</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Thin-layer chromatography (TLC) is commonly employed to screen technetium-99m labeled polymer nanoparticle batches for unreduced pertechnetate and radio-colloidal impurities. Although this method is widely accepted, our findings applying radiolabeled PLGA/PLA&#8211;PEG nanoparticles underscore its lack of transferability between different settings and its limitations as a standalone quality control tool. While TLC profiles may appear similar for purified and radiocolloid containing nanoparticle formulations, their in vivo behavior can vary significantly, as demonstrated by discrepancies between TLC results and single-photon emission computed tomography (SPECT) and biodistribution data. This highlights the urgent need for a case-by-case evaluation of TLC methods for each specific nanoparticle type. Our study revealed that polymeric nanoparticles cannot be considered analytically uniform entities in the context of TLC analysis, emphasizing the complex interplay between nanoparticle composition, radiolabeling conditions, and subsequent biological behavior.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">polymer nanoparticles</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">direct 99mTc-labeling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">single-photon emission computed tomography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radio-thin layer chromatography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiocolloids</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1467-3045</Issn>
      <Volume>47</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Artificial Intelligence Approach in Machine Learning-Based Modeling and Networking of the Coronavirus Pathogenesis Pathway</ArticleTitle>
    <FirstPage LZero="delete">466</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shihori</FirstName>
        <LastName>Tanabe</LastName>
        <Affiliation>Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sabina</FirstName>
        <LastName>Quader</LastName>
        <Affiliation>Innovation Centre of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Division of Cellular and Molecular Toxicology, Center for Biological Safety and Research, National Institute of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi Y.</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihisa</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Mechanical Systems Engineering, Graduate School of Systems Design Tokyo Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Surgical Pathology, Kyoto Prefecture University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Edward J.</FirstName>
        <LastName>Perkins</LastName>
        <Affiliation>US Army Engineer Research and Development Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Horacio</FirstName>
        <LastName>Cabral</LastName>
        <Affiliation>Department of Bioengineering, Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The coronavirus pathogenesis pathway, which consists of severe acute respiratory syndrome (SARS) coronavirus infection and signaling pathways, including the interferon pathway, the transforming growth factor beta pathway, the mitogen-activated protein kinase pathway, the apoptosis pathway, and the inflammation pathway, is activated upon coronaviral infection. An artificial intelligence approach based on machine learning was utilized to develop models with images of the coronavirus pathogenesis pathway to predict the activation states. Data on coronaviral infection held in a database were analyzed with Ingenuity Pathway Analysis (IPA), a network pathway analysis tool. Data related to SARS coronavirus 2 (SARS-CoV-2) were extracted from more than 100,000 analyses and datasets in the IPA database. A total of 27 analyses, including nine analyses of SARS-CoV-2-infected human-induced pluripotent stem cells (iPSCs) and iPSC-derived cardiomyocytes and fibroblasts, and a total of 22 analyses of SARS-CoV-2-infected lung adenocarcinoma (LUAD), were identified as being related to ghumanh and gSARS coronavirus 2h in the database. The coronavirus pathogenesis pathway was activated in SARS-CoV-2-infected iPSC-derived cells and LUAD cells. A prediction model was developed in Python 3.11 using images of the coronavirus pathogenesis pathway under different conditions. The prediction model of activation states of the coronavirus pathogenesis pathway may aid in treatment identification.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coronavirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">coronaviral infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pathway analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">predictionmodel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecular network</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecular pathway image</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">network analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2076-3417</Issn>
      <Volume>15</Volume>
      <Issue>13</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Protective Effects of the Ethyl Acetate Fraction of Distylium racemosum Against Metabolic Dysfunction-Associated Steatohepatitis</ArticleTitle>
    <FirstPage LZero="delete">7238</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Young-Hyeon</FirstName>
        <LastName>Lee</LastName>
        <Affiliation>Department of Clinical Laboratory Science, Catholic University of Pusan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Min-Ho</FirstName>
        <LastName>Yeo</LastName>
        <Affiliation>Department of Clinical Laboratory Science, Catholic University of Pusan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyung-Soo</FirstName>
        <LastName>Chang</LastName>
        <Affiliation>Department of Clinical Laboratory Science, Catholic University of Pusan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Weon-Jong</FirstName>
        <LastName>Yoon</LastName>
        <Affiliation>Clean Bio Business Division, Biodiversity Research Institute (JBRI), Jeju Technopark (JTP)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hye-Sook</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Department of International Infectious Diseases Control, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jongwan</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Department of Anatomy, College of Medicine, Dongguk University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hye-Ran</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Department of Biomedical Laboratory Science, Dong-Eui Institute of Technology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as non-alcoholic steatohepatitis (NASH), which is a progressive non-alcoholic fatty liver disease, is accompanied by hepatic steatosis, inflammation, and fibrosis. Despite its increasing prevalence, available treatment options for MASH are limited. Here, we investigated the protective effects of the Distylium racemosum ethyl acetate fraction (DRE) using MASH models and explored its key physiologically active components. Palmitic acid (PA)-induced AML12 hepatocytes and high-fat methionine- and choline-deficient-fed C57BL/6 mice were used as MASH models. Lipid accumulation was evaluated via triglyceride measurement, oil red O staining, and histological analysis. Lipid accumulation, inflammation, and fibrosis-associated gene expression were evaluated via real-time polymerase chain reaction. The physiologically active components of DRE were identified via high-performance liquid chromatography. Lipid accumulation and triglyceride levels were significantly reduced in PA-treated AML12 cells following DRE treatment. Additionally, DRE inhibited the expression of genes involved in lipogenesis (FAS and SREBP1c), inflammation (CD68, IL-6, and MCP-1), and fibrosis (COL1A1, COL1A2, and TIMP1). DRE reduced the liver weight, liver-to-body weight ratio, and hepatic steatosis in MASH model mice. It increased carnitine palmitoyltransferase-1 levels and decreased CD36 and transforming growth factor-ƒÀ levels in the MASH mouse liver. High-performance liquid chromatography revealed that the extract contained rutin flavonoid family members. Overall, DRE was involved in lipid metabolism, inflammation, and fibrosis regulation, exerting potent hepatoprotective effects partly attributed to rutin and serving as a potential preventive candidate for MASH.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">metabolic dysfunction-associated steatohepatitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Distylium racemosum</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ethyl acetate fraction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">extract</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume>30</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Percutaneous cryoablation versus robot-assisted partial nephrectomy for small renal cell carcinoma: a retrospective cost analysis at Japanese single-institution</ArticleTitle>
    <FirstPage LZero="delete">1621</FirstPage>
    <LastPage>1630</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mayu</FirstName>
        <LastName>Uka</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Iguchi</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Yamanoi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideo</FirstName>
        <LastName>Gobara</LastName>
        <Affiliation>Division of Medical Informatics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Umakoshi</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kawabata</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Tomita</LastName>
        <Affiliation>Department of Radiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Hiraki</LastName>
        <Affiliation>Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: No direct cost comparison has been conducted between percutaneous cryoablation (PCA) and robot-assisted partial nephrectomy (RAPN) for clinical T1a renal cell carcinoma (RCC) in Japan. This study aimed to compare their costs.&lt;br&gt;
Methods: We retrospectively analyzed data from 212 PCAs (including 155 with transcatheter arterial embolization) and 119 RAPN cases performed between December 2017 and May 2022.&lt;br&gt;
Results: PCA patients were older with higher American Society of Anesthesiologists scores, Charlson Comorbidity Index, and history of previous RCC treatment, cardiovascular disease, and antithrombotic drug use than RAPN patients. PCA was associated with a significantly shorter procedure time and hospitalization duration with fewer major complications than those associated with RAPN. While PCA incurred a slightly lower total cost (1,123,000 vs. 1,155,000 yen), it had a significantly higher procedural cost (739,000 vs. 693,000 yen) and markedly worse total (| 93,000 vs. 249,000 yen) and procedural income-expenditure balance (| 189,000 vs. 231,000 yen) than those of RAPN. After statistical adjustment, PCA demonstrated significantly higher total (difference: 114,000 yen) and procedural costs (difference: 72,000 yen), alongside significantly worse total (difference: | 358,000 yen) and procedural income-expenditure balances (difference: | 439,000 yen). The incremental cost-effectiveness ratio was more favorable for PCA than for RAPN.&lt;br&gt;
Conclusion: For high- risk patients, PCA demonstrated a safer option with shorter hospitalization duration than those of RAPN. Although PCA was more cost-effective, its higher procedural cost and unfavorable income-expenditure balance require careful evaluation, especially for large tumors that require three or more needles.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Renal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cryoablation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Robot-assisted partial nephrectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cost</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cost effectiveness</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy</ArticleTitle>
    <FirstPage LZero="delete">27163</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Fukuokaya</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumasa</FirstName>
        <LastName>Komura</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Tsujino</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Maenosono</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Urology, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuhisa</FirstName>
        <LastName>Nukaya</LastName>
        <Affiliation>Department of Urology, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lan</FirstName>
        <LastName>Inoki</LastName>
        <Affiliation>Department of Urology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Department of Urology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Urology, Tokyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Hirasawa</LastName>
        <Affiliation>Department of Urology, Tokyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Edamura</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Tominaga</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Yamanoi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kasumi</FirstName>
        <LastName>Yoshinaga</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuma</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Takamoto</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyohei</FirstName>
        <LastName>Kurose</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito</FirstName>
        <LastName>Azuma</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Shiroki</LastName>
        <Affiliation>Department of Urology, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutoshi</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Urology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Ohno</LastName>
        <Affiliation>Department of Urology, Tokyo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Immune checkpoint inhibitors (ICIs) are a key component of first-line treatment for metastatic renal cell carcinoma (mRCC). However, predicting treatment-related adverse events (TRAEs) remains challenging. This study investigated the utility of eosinophil-related biomarkers as predictors of Common Terminology Criteria for Adverse Events grade&#8201;&#8805;&#8201;3 TRAEs in mRCC patients undergoing ICI combination therapy. In this retrospective analysis across 21 hospitals in Japan, we examined 180 patients treated with ICI/ICI therapy and 216 patients treated with ICI/tyrosine kinase inhibitor (TKI) therapy. Grade&#8201;&#8805;&#8201;3 TRAEs occurred in 39.4% and 31.9% of patients in the ICI/ICI and ICI/TKI groups, respectively. An elevated eosinophil proportion of&#8201;&#8805;&#8201;2.0% (odds ratio [OR]: 2.36; 95% CI [confidence interval] 1.23&#8211;4.54, p&#8201;=&#8201;0.01) and a low neutrophil/eosinophil ratio (NER) of&#8201;&#8804;&#8201;40.0 (OR: 2.78, 95% CI 1.39&#8211;5.53, p&#8201;=&#8201;0.004) were significant predictors of severe TRAEs in the ICI/ICI group. However, no significant associations were found in the ICI/TKI group. These findings may help identify patients who suffer from grade&#8201;&#8805;&#8201;3 TRAEs and help determine individualized treatment strategies in patients with mRCC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune checkpoint inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ICI</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Eosinophil</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune-related adverse event</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Treatment-related adverse event</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1471-2490</Issn>
      <Volume>25</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of concomitant medications on the oncologic efficacy of systemic therapy in patients with advanced or metastatic urothelial carcinoma: a systematic review and meta-analysis</ArticleTitle>
    <FirstPage LZero="delete">107</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mehdi Kardoust</FirstName>
        <LastName>Parizi</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marcin</FirstName>
        <LastName>Miszczyk</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tam&#225;s</FirstName>
        <LastName>Fazekas</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Robert J</FirstName>
        <LastName>Schulz</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ekaterina</FirstName>
        <LastName>Laukhtina</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pawel</FirstName>
        <LastName>Rajwa</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katharina</FirstName>
        <LastName>Oberneder</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Piotr</FirstName>
        <LastName>Chlosta</LastName>
        <Affiliation>Department of Urology, Medical College, Jagiellonian University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pierre I.</FirstName>
        <LastName>Karakiewicz</LastName>
        <Affiliation>Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shahrokh F.</FirstName>
        <LastName>Shariat</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Immune checkpoint inhibitors (ICI) and chemotherapy, including antibody-drug conjugates, are widely used for the treatment of patients with advanced unresectable or metastatic urothelial carcinoma (UC). The majority of elderly patients receive concomitant medications to address various comorbidities. We aimed to evaluate the impact of concomitant medications on oncological outcomes in patients with advanced unresectable or metastatic UC treated with systemic therapy.&lt;br&gt;
Material &amp; methods: In August 2024, three datasets were queried for studies evaluating concomitant medications in patients with advanced unresectable or metastatic UC. The review protocol was registered in PROSPERO (CRD42024547335). The primary outcome was overall survival (OS). A fixed- or random-effects model was used for meta-analysis depending on the heterogeneity.&lt;br&gt;
Results: We identified 16 eligible studies (3 prospective and 13 retrospective) comprising 4,816 patients. Most reported concomitant medications included proton pump inhibitors (PPIs), antibiotics, steroids, and opioids. The use of concomitant PPIs, antibiotics, steroids or opioids during ICI therapy was associated with worsened OS (PPIs: HR: 1.43, 95% CI: 1.31&#8211;1.57, p&#8201;&lt;&#8201;0.001; antibiotics: HR: 1.2, 95% CI: 1.04&#8211;1.38, p&#8201;=&#8201;0.01; steroids: HR: 1.45, 95% CI: 1.25&#8211;1.67, p&#8201;&lt;&#8201;0.001; and opioids: HR: 1.74, 95% CI: 1.46&#8211;2.07, p&#8201;&lt;&#8201;0.001). Concomitant use of antibiotics during chemotherapy did not impact OS (HR: 1.01, 95% CI: 0.67&#8211;1.51).&lt;br&gt;
Conclusions: When treating advanced unresectable or metastatic UC with ICI therapy, we need to pay attention to concomitant medications, such as PPIs and antibiotics to avoid reducing the efficacy of ICI therapy. The mechanism of action of these drugs on ICI efficacy requires further examination.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Concomitant medications</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Proton pump inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Antibiotics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">steroids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Opioids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Histamine type-2 receptor antagonists</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune checkpoint inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Urothelial carcinoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0919-8172</Issn>
      <Volume>32</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Postoperative infections after robotic]assisted radical prostatectomy in a single large institution: Effect of type and duration of prophylactic antibiotic administration</ArticleTitle>
    <FirstPage LZero="delete">258</FirstPage>
    <LastPage>263</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Sadahira</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takanori</FirstName>
        <LastName>Sekito</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: We evaluated the incidence of and risk factors for postoperative infections after robotic-assisted radical prostatectomy (RARP) according to the type and duration of prophylactic antibiotic administration.&lt;br&gt;
Methods: A total of 1038 patients underwent RARP at our institution from 2010 to 2021; 1026 patients (201 in the cefazolin [CEZ] group and 825 in the ampicillin/sulbactam [ABPC/SBT] group) were analyzed, and 12 who used other antibiotics were excluded. The primary endpoint was the incidence of urinary tract infection (UTI), surgical site infection (SSI), and remote infection (RI). T-tests, propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were performed. Multivariate logistic regression analysis was performed to evaluate the effect of type and duration of prophylactic antibiotic administration.&lt;br&gt;
Results: The incidence of UTI was 2.5% (5/201) in the CEZ group and 3.2% (26/825) in the ABPC/SBT group, with no significant difference between groups (p&#8201;=&#8201;0.622). The rates of SSI and RI were comparable between groups (p&#8201;=&#8201;0.680 and 0.906, respectively). Although the duration of antimicrobial therapy was longer in the ABPC/SBT group (p&#8201;&lt;&#8201;0.001), there was no significant difference in the incidence of UTI/SSI/RI after PSM and IPTW (all p&#8201;&gt;&#8201;0.05). Multivariate logistic regression analysis showed that neither the type of antibiotic nor the duration of administration affected the incidence of UTI/SSI/RI.&lt;br&gt;
Conclusion: The risk of postoperative UTI/SSI/RI after RARP did not change with the type and duration of antimicrobial therapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cefazolin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">postoperative infections</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prophylactic antibiotics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prostate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">robotic-assisted radical prostatectomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ovid Technologies (Wolters Kluwer Health)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1044-3983</Issn>
      <Volume>36</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>L or M1\Critical Challenges in Mediation Analysis</ArticleTitle>
    <FirstPage LZero="delete">686</FirstPage>
    <LastPage>689</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Etsuji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Methods for causal mediation analysis have developed dramatically over the past few decades.1&#8211;7 In the causal mediation literature, several causal quantities\or estimands\have been proposed, including natural direct and indirect effects, interventional direct and indirect effects, and separable direct and indirect effects. As another possible causal estimand, Chen and Lin8 proposed separable path-specific effects, which is an extension of the separable effects framework to cases that involve multiple ordered mediators. In this commentary, I briefly discuss the newly proposed method from a broader perspective on causal mediation analysis. For readers less familiar with common causal mediation approaches, please see related literature.1&#8211;3,9&#8211;11</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1999-4923</Issn>
      <Volume>17</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development of an Antimicrobial Coating Film for Denture Lining Materials</ArticleTitle>
    <FirstPage LZero="delete">902</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kumiko</FirstName>
        <LastName>Yoshihara</LastName>
        <Affiliation>National Institute of Advanced Industrial Science and Technology (AIST), Health and Medical Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeru</FirstName>
        <LastName>Kameyama</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Nagaoka</LastName>
        <Affiliation>Dental School, Advanced Research Center for Oral and Craniofacial Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukinori</FirstName>
        <LastName>Maruo</LastName>
        <Affiliation>Department of Prosthodontics, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Biomaterials and Bioengineering, Faculty of Dental Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bart</FirstName>
        <LastName>Van Meerbeek</LastName>
        <Affiliation>BIOMAT, Department of Oral Health Sciences, KU Leuvem</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Okihara</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Denture hygiene is essential for the prevention of oral candidiasis, a condition frequently associated with Candida albicans colonization on denture surfaces. Cetylpyridinium chloride (CPC)-loaded montmorillonite (CPC-Mont) has demonstrated antimicrobial efficacy in tissue conditioners and demonstrates potential for use in antimicrobial coatings. In this study, we aimed to develop and characterize CPC-Mont-containing coating films for dentures, focusing on their physicochemical behaviors and antifungal efficacies. Methods: CPC was intercalated into sodium-type montmorillonite to prepare CPC-Mont; thereafter, films containing CPC-Mont were fabricated using emulsions of different polymer types (nonionic, cationic, and anionic). CPC loading, release, and recharging behaviors were assessed at various temperatures, and activation energies were calculated using Arrhenius plots. Antimicrobial efficacy against Candida albicans was evaluated for each film using standard microbial assays. Results: X-ray diffraction analysis confirmed the expansion of montmorillonite interlayer spacing by approximately 3 nm upon CPC loading. CPC-Mont showed temperature-dependent release and recharging behavior, with higher temperatures enhancing its performance. The activation energy for CPC release was 38 kJ/mol, while that for recharging was 26 kJ/mol. Nonionic emulsions supported uniform CPC-Mont dispersion and successful film formation, while cationic and anionic emulsions did not. CPC-Mont-containing coatings maintained antimicrobial activity against Candida albicans on dentures. Conclusions: CPC-Mont can be effectively incorporated into nonionic emulsion-based films to create antimicrobial coatings for denture applications. The films exhibited temperature-responsive, reversible CPC release and recharging behaviors, while maintaining antifungal efficacy, findings which suggest the potential utility of CPC-Mont-containing films as a practical strategy to prevent denture-related candidiasis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">antimicrobial</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">denture liner</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cetylpyridiniumchloride</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">drug release</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">drug recharge</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Trends in the incidence of severe fever with thrombocytopenia syndrome in Japan: an observational study from 2013 to 2022</ArticleTitle>
    <FirstPage LZero="delete">20715</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of General Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of General Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Koyama</LastName>
        <Affiliation>Department of Health Data Science, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We aimed to determine the 10-year trend in the incidence of Severe fever with thrombocytopenia syndrome (SFTS) in Japan. This retrospective observational study used a publicly available national database. Trends in the incidence of SFTS with annual percent changes (APC) were examined using Joinpoint regression analysis with stratification by patient age, season, and region. The association between disease incidence and environmental factors was investigated using Spearmanfs rank correlation. Between 2013 and 2022, there were 803 notified cases (397 males and 406 females) of SFTS, with 79.5% aged&#8201;&#8805;&#8201;65 years. The annual incidence rate increased continuously with an APC of 9.6%. The incidence peaked between May and June, with 80.8% of cases observed between May and October. The incidence was predominantly higher in western Japan, and the mean annual incidence rate was the highest in Miyazaki prefecture, with 0.89 per 100,000 people. Correlations between the SFTS incidence rates and environmental factors were observed in western Japan, with forest area (correlation coefficient, 0.80), followed by agricultural population rate (0.70). SFTS incidence is continuously increasing in Japan, especially among the elderly population. Environmental factors such as broader forest areas and increased agricultural population were possibly associated with the incidence.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Epidemiology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Severe fever with thrombocytopenia syndrome (SFTS)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tick-borne infectious disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Joinpoint regression analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1109-6535</Issn>
      <Volume>22</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>C1orf50 Drives Malignant Melanoma Progression Through the Regulation of Stemness</ArticleTitle>
    <FirstPage LZero="delete">510</FirstPage>
    <LastPage>524</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">YUSUKE</FirstName>
        <LastName>OTANI</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MASAKI</FirstName>
        <LastName>MAEKAWA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ATSUSHI</FirstName>
        <LastName>TANAKA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TIRSO</FirstName>
        <LastName>PE&#209;A</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">VANESSA D.</FirstName>
        <LastName>CHIN</LastName>
        <Affiliation>UMass Chan Medical School, UMass Memorial Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ANNA</FirstName>
        <LastName>ROGACHEVSKAYA</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHINICHI</FirstName>
        <LastName>TOYOOKA</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MICHAEL H.</FirstName>
        <LastName>ROEHRL</LastName>
        <Affiliation>Department of Pathology, Beth Israel Deaconess Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">ATSUSHI</FirstName>
        <LastName>FUJIMURA</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: Recent advancements in omics analysis have significantly enhanced our understanding of the molecular pathology of malignant melanoma, leading to the development of novel therapeutic strategies that target specific vulnerabilities within the disease. Despite these improvements, the factors contributing to the poor prognosis of patients with malignant melanoma remain incompletely understood. The aim of this study was to investigate the role of C1orf50 (Chromosome 1 open reading frame 50), a gene previously of unknown function, as a prognostic biomarker in melanoma.&lt;br&gt;
Materials and Methods: We performed comprehensive transcriptome data analysis and subsequent functional validation of the human Skin Cutaneous Melanoma project from The Cancer Genome Atlas (TCGA).&lt;br&gt;
Results: Elevated expression levels of C1orf50 correlated with worse survival outcomes. Mechanistically, we revealed that C1orf50 plays a significant role in the regulation of cell cycle processes and cancer cell stemness, providing a potential avenue for novel therapeutic interventions in melanoma.&lt;br&gt;
Conclusion: This study is the first to identify C1orf50 as a prognostic biomarker in melanoma. The clinical relevance of our results sheds light on the importance of further investigation into the biological mechanisms underpinning C1orf50fs impact on melanoma progression and patient prognosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">C1orf50</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">melanoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer stem cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">YAP/TAZ</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0021-9258</Issn>
      <Volume>301</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A repertoire of visible light&#8211;sensitive opsins in the deep-sea hydrothermal vent shrimp Rimicaris hybisae</ArticleTitle>
    <FirstPage LZero="delete">110291</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Nagata</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Institute for Extra-Cutting-Edge Science and Technology Avant-Garde Research (X-Star), Japan Agency for Marine-Earth Science and Technology (JAMSTEC)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Research Center for Bioscience and Nanoscience (CeBN), Research Institute for Marine Resources Utilization, Japan Agency for Marine-Earth Science and Technology (JAMSTEC)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Tanioka</LastName>
        <Affiliation>School of Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Yamanaka</LastName>
        <Affiliation>School of Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Yoshizawa</LastName>
        <Affiliation>Atmosphere and Ocean Research Institute, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kuto</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Obayashi</LastName>
        <Affiliation>Department of Biology, Graduate School of Science, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisao</FirstName>
        <LastName>Tsukamoto</LastName>
        <Affiliation>Department of Biology, Graduate School of Science, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Takai</LastName>
        <Affiliation>Institute for Extra-Cutting-Edge Science and Technology Avant-Garde Research (X-Star), Japan Agency for Marine-Earth Science and Technology (JAMSTEC)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideyo</FirstName>
        <LastName>Ohuchi</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Biophysics, Graduate School of Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Sudo</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Unlike terrestrial environments, where humans reside, there is no sunlight in the deep sea. Instead, dim visible light from black-body radiation and bioluminescence illuminates hydrothermal vent areas in the deep sea. A deep-sea hydrothermal vent shrimp, Rimicaris hybisae, is thought to detect this dim light using its enlarged dorsal eye; however, the molecular basis of its photoreception remains unexplored. Here, we characterized the molecular properties of opsins, universal photoreceptive proteins in animals, found in R. hybisae. Transcriptomic analysis identified six opsins: three Gq-coupled opsins, one Opn3, one Opn5, and one peropsin. Functional analysis revealed that five of these opsins exhibited light-dependent G protein activity, whereas peropsin exhibited the ability to convert all-trans-retinal to 11-cis-retinal like photoisomerases. Notably, all the R. hybisae opsins, including Opn5, convergently show visible light sensitivity (around 457&#8211;517 nm), whereas most opsins categorized as Opn5 have been demonstrated to be UV sensitive. Mutational analysis revealed that the unique visible light sensitivity of R. hybisae Opn5 is achieved through the stabilization of a protonated Schiff base by a counterion residue at position 83 (Asp83), which differs from the position identified in other opsins. These findings suggest that the vent shrimp R. hybisae has adapted its photoreceptive devices to dim deep-sea hydrothermal light by selectively maintaining a repertoire of visible light&#8211;sensitive opsins, including the uniquely tuned Opn5.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">rhodopsin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">opsin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">G protein&#8211;coupled receptor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">signal transduction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photoreceptor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vision</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photobiology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vent shrimp</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">deep sea</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecular evolution</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0361-8609</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Midori Filiz</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Haratake</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Nishikori</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Remi</FirstName>
        <LastName>Sumiyoshi</LastName>
        <Affiliation>The Research Program for Intractable Disease by Ministry of Health, Labor and Welfare, Castleman Disease, TAFRO and Related Ddisease Research Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Ujiie</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Koga</LastName>
        <Affiliation>The Research Program for Intractable Disease by Ministry of Health, Labor and Welfare, Castleman Disease, TAFRO and Related Ddisease Research Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masao</FirstName>
        <LastName>Ueki</LastName>
        <Affiliation>School of Information and Data Sciences, Nagasaki University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dorottya</FirstName>
        <LastName>Laczko</LastName>
        <Affiliation>Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eric</FirstName>
        <LastName>Oksenhendler</LastName>
        <Affiliation>Department of Clinical Immunology, H&#244;pital Saint-Louis</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">David C.</FirstName>
        <LastName>Fajgenbaum</LastName>
        <Affiliation>Center for Cytokine Storm Treatment and Laboratory, Division of Translational Medicine and Human Genetics, Perelman School of Medicine, University of Pennsylvania</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Frits</FirstName>
        <LastName>van Rhee</LastName>
        <Affiliation>Myeloma Center, University of Arkansas for Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Kawakami</LastName>
        <Affiliation>The Research Program for Intractable Disease by Ministry of Health, Labor and Welfare, Castleman Disease, TAFRO and Related Ddisease Research Group</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuharu</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder classified into three recognized clinical subtypes\idiopathic plasmacytic lymphadenopathy (IPL), TAFRO, and NOS. Although clinical criteria are available for subtyping, diagnostically challenging cases with overlapping histopathological features highlight the need for an improved classification system integrating clinical and histopathological findings. We aimed to develop an objective histopathological subtyping system for iMCD that closely correlates with the clinical subtypes. Excisional lymph node specimens from 94 Japanese iMCD patients (54 IPL, 28 TAFRO, 12 NOS) were analyzed for five key histopathological parameters: germinal center (GC) status, plasmacytosis, vascularity, hemosiderin deposition, and gwhirlpoolh vessel formation in GC. Using hierarchical clustering, we visualized subgroups and developed a machine learning-based decision tree to differentiate the clinical subtypes and validated it in an external cohort of 12 patients with iMCD. Hierarchical cluster analysis separated the IPL and TAFRO cases into mutually exclusive clusters, whereas the NOS cases were interspersed between them. Decision tree modeling identified plasmacytosis, vascularity, and whirlpool vessel formation as key features distinguishing IPL from TAFRO, achieving 91% and 92% accuracy in the training and test sets, respectively. External validation correctly classified all IPL and TAFRO cases, confirming the reproducibility of the system. Our histopathological classification system closely aligns with the clinical subtypes, offering a more precise approach to iMCD subtyping. It may enhance diagnostic accuracy, guide clinical decision-making for predicting treatment response in challenging cases, and improve patient selection for future research. Further validation of its versatility and clinical utility is required.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">clinical subtype</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">histopathological criteria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">idiopathic multicentric castleman disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lymphoproliferative disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine-learning</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume>64</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Novel De Novo Variant in KCNH5 in a Patient with Refractory Epileptic Encephalopathy</ArticleTitle>
    <FirstPage LZero="delete">759</FirstPage>
    <LastPage>762</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Mitsutake</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuhiko</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Department of Rheumatology and Allergy, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keishi</FirstName>
        <LastName>Fujio</LastName>
        <Affiliation>Department of Rheumatology and Allergy, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Fujishiro</LastName>
        <Affiliation>Department of Pediatric Surgery, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Harushi</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Radiology, School of Medicine, Jichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Morishita</LastName>
        <Affiliation>Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We herein report a novel de novo KCNH5 variant in a patient with refractory epileptic encephalopathy. The patient exhibited seizures at 1 year and 7 months old, which gradually worsened, leading to a bedridden status. Brain magnetic resonance imaging (MRI) showed cerebral atrophy and cerebellar hypoplasia. A trio whole-exome sequence analysis identified a de novo heterozygous c.640A&gt;C, p.Lys214Gln variant in KCNH5 that was predicted to be deleterious. Recent studies have linked KCNH5 to various epileptic encephalopathies, with many patients showing normal MRI findings. The present case expands the clinical spectrum of the disease, as it is characterized by severe neurological prognosis, cerebral atrophy, and cerebellar hypoplasia.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">epileptic encephalopathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">whole-exome sequencing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KCNH5</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">de novo variant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Internal Medicine</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-2918</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Two Cases of Autosomal Recessive Spinocerebellar Ataxia-8 Showing Two Novel Variants of SYNE1 in Japanese Families</ArticleTitle>
    <FirstPage LZero="delete">5602-25</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Taijun</FirstName>
        <LastName>Yunoki</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chika</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Osakada</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Fukui</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mami</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Morihara</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Autosomal recessive spinocerebellar ataxia-8 (SCAR8) is a neurodegenerative disorder caused by the biallelic pathogenic variants of SYNE1. It is characterized by slowly progressive cerebellar ataxia and atrophy. We identified two SCAR8 families using exome analyses and two novel variants, c.2127delG (p.Met709Ilefs) and c.15943G&gt;T (p.Gly5315*), in SYNE1 (NM_182961.4). Pathogenic variants of SYNE1 cause various symptoms, including cerebellar ataxia, pyramidal tract disorders, and joint disorders, and the pathogenic variants discovered in this study were located in a region prone to cerebellar ataxia.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">SCAR8</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SCAR</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cerebellar ataxia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">whole-exome sequencing analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2054-345X</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>In-frame deletion variant of ABCD1 in a sporadic case of adrenoleukodystrophy</ArticleTitle>
    <FirstPage LZero="delete">5</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Sudo</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kakumoto</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Hao</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Kainaga</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hyangri</FirstName>
        <LastName>Chang</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Mano</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Mitsui</LastName>
        <Affiliation>Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Morishita</LastName>
        <Affiliation>Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Adrenoleukodystrophy (ALD), an X-linked leukodystrophy caused by pathogenic variants in ABCD1, exhibits a broad range of phenotypes from childhood-onset cerebral forms to adult-onset adrenomyeloneuropathy (AMN). We report a rare in-frame ABCD1 deletion c.1469_71delTGG (p.Val490del) in a man with AMN. Although this variant has been interpreted as euncertain significancef in ClinVar, biochemical analysis along with clinical evaluation confirmed the pathogenicity of this variant, underscoring the importance of functional assessment of in-frame deletions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
</ArticleSet>
